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SUMMARY
Sepsis and septic shock are clinical conditions resulting from infections, 
mediated through a complex interplay of mediators and receptors. It is known that 
lipopolysaccharide (LPS) is primarily responsible for stimulating cells of the immune 
system including monocytes and macrophages play a pivotal role in immune 
modulation. Monophosphoryl lipid A (MPL), a modified form of LPS, has been 
shown to exert immunomodulatory effects similar to LPS, but relatively non-toxic. The 
present study was designed to compare the immunomodulatory effects of LPS and 
MPL on human monocytes in vitro. In addition, the development of tolerance in vitro 
by various agents or in vivo in sepsis and septic shock has been examined. Results
show that MPL stimulates monocytes to release equal amounts of superoxide (O2O and 
higher amounts of hydrogen peroxide (H2O2) compared to LPS whereas MPL-
pretreated and challenged monocytes showed greater hyporesponsiveness in releasing 
these radicals than that seen by LPS. Data suggest that MPL stimulates monocytes via
similar but limited pathways than LPS, and O2 and H2O2 release in LPS- and MPL-
stimulated monocytes are regulated differently. MPL-stimulated monocytes are found 
to release nitric oxide (NO) through a novel mechanism that has yet to be determined. 
MPL-stimulated cells release lower levels of cytokines compared to that released by 
LPS. Variable degrees of phagocytosis-related activities and receptor expression are 
observed in LPS- and MPL-stimulated monocytes, suggesting the existence of a time- 
and dose-dependent "compensatory" mechanism. Both LPS and staphylococcal 
enterotoxin B (SEB) can induce tolerance in vitro to specific antigens or non-specific 
stimuli, indicating the existence of cross-tolerization. Sepsis and septic shock are found
to induce hyporesponsiveness in vivo to O2 and cytokine release in response to
different activating stimuli in vitro, suggesting a generalized immune suppression in 
sepsis and septic shock. It is concluded that MPL is less toxic than LPS and yet is a 
potent immune modulator. Sepsis- and septic shock-induced tolerance that includes an 
attenuated reactive oxygen radical and cytokine release is a non-specific phenomenon 
and this tolerance may be disadvantageous for the host.
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INTRODUCTION
1.1 General
Sepsis results from an infection and is manifested clinically by fever or 
hypothermia, increased heart and respiratory rates, abnormal white blood cell (WBC) 
count, and evidence of systemic hypoperfusion. It is accompanied by a number of 
cellular and biochemical changes in the immune system. Septic shock is a condition 
that usually develops as a complication of overwhelming sepsis. It is manifested by 
decreased blood pressure which persists despite fluid resuscitation and requires 
vasopressor therapy. During shock, release of a variety of mediators and changes in 
cellular immune function lead to immune and metabolic disorders, the severity of which 
depends upon the stage of the disease process, the host’s underlying health problems, 
treatments, and causes of the disease. Worldwide statistics on sepsis or septic shock are 
not known. However, sepsis is the 13th leading cause of death in the USA (National 
Center for Health Statistics, 1989) and accounts for $5 -10  billion of health-related 
costs annually (Wenzel, 1985). A study of sepsis and septic shock between 1979 - 
1987 has demonstrated a progressive increase in their incidence despite the development 
of more potent antibiotics, supportive therapy and critical care medicine (Center for 
Disease Control, 1990; Rackow and Astiz, 1993; Solomkin and Fink, 1994). Although 
precise recent data are not available, it was estimated that 100,000 to 400,000 patients 
develop sepsis annually in the United States (Martin, Wenzel and Gorelick, 1991; 
reviewed in Shapiro and Gelfand, 1993); half of these patients develop septic shock 
with a mortality rate ranging between 2 0 % and 80% depending upon the definition of 
the syndrome (Knaus et a l, 1992; Parrillo, 1993; Rackow and Astiz, 1993). More 
than 70 - 80% of all cases of septic shock were caused by gram-negative organisms. 
However, recent trends show an increase in the incidence of gram positive bacteria (30 
- 40%), virus- and fungi-related sepsis which previously were considered to be 
minority causes of sepsis. The major predisposing factors for the development of 
septic shock appear to be impairment of host defense mechanism(s) due to underlying 
disease, the age of the patients, the use of immunosuppressive drugs or chemo­
therapeutic agents and other iatrogenic factors.
At the turn of the century, physicians focused only on the microorganisms 
responsible for overwhelming infections. It was believed that either pyrogenic or toxin- 
producing organisms were required for such infections or sepsis. In the late 1920s, it 
was discovered that the host also responds to microbes or microbial products. This 
drew the attention of scientists to the immune status of the host. Later, in the 1950s, it 
was suggested that the endotoxin of gram-negative bacteria was a major causative factor 
of sepsis. Through subsequent work in the 1970s by various investigators, a 
consensus was reached that complement and neutrophil activation play a major role in 
the pathogenesis of this disease. During the next 10 years, a large number of 
publications presented evidence of the involvement of a number of mediators, 
particularly cytokines and metabolites of arachidonic acid in the pathogenesis of sepsis
and septic shock. It was not until later that it was postulated that the pathological sequel! 
of these endotoxin-mediated syndromes primarily involve monocytes and macrophages 
(MPs) (from reviews by Morrison and Ryan, 1987; Fong and Lowry, 1990; Danner et 
al., 1991; Rackow and Astiz, 1991; Shapiro and Gelfand, 1993).
Once MPs are exposed to a stimulus, they respond by releasing a number of 
mediators and activating other immune mechanisms. These mediators include, but are 
not limited to, metabolites of arachidonic acid (prostaglandins, leukotrienes), products 
of respiratory burst activity (superoxide, hydrogen peroxide, nitric oxide), complement 
proteins (Cl - C5, factor B, D), coagulation factors, enzymes and inhibitors, and 
cytokines (interleukin (IL)-l, IL-6 , IL-10, tumor necrosis factor (TNF), transforming 
growth factor). These events progress by accompanying modulation of monocytes' 
surface receptor expression (clusters of differentiation (CD )ll, CD 14, CD 16, CD 18, 
CD54, receptors of the major histocompatibility complex (MHC) class II) leading to 
amplification of responses in other cells such as neutrophils, lymphocytes, and 
platelets. Through this cascade, monocytes become activated and amplify host 
responses to a degree that either eliminates the stimulus or damages host tissues, 
leading to shock.
The pleiotropic stimulus in sepsis and septic shock for MPs and other cells of 
the immune and inflammatory systems (both in vitro and in vivo) is endotoxin or 
lipopolysaccharide (LPS). This is a complex glycolipid comprising the major 
component of the outermost membrane of the gram-negative bacterial cell wall. LPS 
causes the extraordinary array of pathophysiologic events seen in humans and animals 
which lead to endotoxic or septic shock (from reviews by Rietschel et al., 1982; 
Morrison and Ryan, 1987; Bone, 1991; Cohen and Glauser, 1991; Rackow and Astiz, 
1991; Raetz et a l, 1991; Vogel, 1992).
1.2 Sepsis and septic shock
1.2.1 Definitions and clinical features
Sepsis is defined by a systemic inflammatory response (SIR) in the presence of 
an infection, using increases in temperature, heart rate, respiratory rate, and WBC 
count as criteria. Presence of an identifiable source of infection, or a positive blood or 
body fluid culture is considered to be a proof of infection. Severe sepsis is defined by 
sepsis associated with hypoperfusion or hypotension. Septic shock is defined by 
hypoperfusion or hypotension not responding to fluids, thereby requiring the use of 
pharmacologic cardiovascular support to maintain arterial pressure (Rackow and Astiz, 
1993). However, decreases in body temperature may also be involved in the SIR. The
range of values normally accepted are: temperature >38°C or <36°C; heart rate>100 
beats/minute; respiratory rate > 2 0  breaths/minute or tachypnea or hyperventilation, as 
indicated by a <PaC0 2  30 mm Hg; and WBC <4.0 x lOfyml or >12 x 106/ml or the 
presence of 10% immature neutrophils. Also, thrombocytopenia (<100,000 
platelets/mm3) is considered sometimes as an indication of SIR. Hypoperfusion is
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indicated by an increase in the arterial lactate concentration >2 mmol/L with at least one 
other sign of organ dysfunction such as (a) altered mentation; (b) decreased urine output 
(<30 ml/hour); hypotension (systolic arterial blood pressure <90 mm Hg). Sepsis- 
induced hypotension is defined by the presence of a systolic blood pressure <90 mm 
Hg or its reduction by 40 mm Hg or more from baseline in the absence of other causes 
for hypotension. In order to consider these cases as septic shock, it was suggested that 
refractoriness should persist for more than one hour and not respond to intravenous 
fluid administration or pharmacologic intervention (Bone et a l, 1992; Knaus et al., 
1992; Shapiro and Gelfand, 1993).
Other clinical features include mild hypoxemia with a respiratory acidosis. A 
metabolic acidosis unrelated to lactic acid accumulation also may be present. 
Hyperglycemia may be seen although hypoglycemia is a terminal event in severe sepsis 
(Rackow and Astiz, 1993). The most frequent organisms associated with sepsis are 
found to be Escherichia coli, Enterobacter spp., Pseudomonas aeruginosa, Klebsiella 
spp., and Staphylococcus spp. and Streptococcus pneumoniae (Stevens, Bryant and 
Hackett, 1992; Rackow and Astiz, 1993) *
1.2.2 Pathophysiology
In patients under 40 years of age, sepsis is rarely complicated by shock. 
Impairment of the host defense system predisposes towards the development of septic 
shock, especially in patients whose sepsis is associated with trauma, diabetes, cancer, 
cirrhosis, bums or treatment with immunosuppressive and chemotherapeutic agents. 
Indirectly, due to the systemic response, endotoxin has been shown to activate the 
coagulation cascade, the kinin system, plasma phospholipase, the release of cytokines, 
(3-endorphins, platelet activating factor, prostaglandins and leukotrienes. Directly, 
endotoxin has been shown to activate complement, the fibrinolytic pathway, 
neutrophils, MPs, endothelial cells and other mediator systems (reviewed in Morrison 
and Ryan, 1987; Rackow and Astiz, 1991; Shapiro and Gelfand, 1993).
Although endotoxin directly triggers the release/activation of these mediators, it 
has been established that the systemic manifestations of severe sepsis and septic shock 
are related to the release of a number of cytokines. Cytokines appear early in the 
sequence of reactions and play a major role in amplifying the subsequent release of 
other soluble mediators and the activation of different plasma cascade systems (for 
review see Rackow and Astiz, 1991,1993). Indeed, others suggest a role for 
endothelium-derived nitric oxide (NO) in cytokine-induced hypotension (Kilboum and 
Belloni, 1990). In more severe cases, multiple organ failure (MOF) occurs which, in 
the majority of patients, leads to death. A smaller portion of septic shock patients die of 
progressive cardiac failure with hypodynamie circulatory shock. A significant number 
of patients suffer a severe vasodilatation and hypotension which is refractory to 
vasopressor drug therapy (Rackow and Astiz, 1991). The organ failure evolves as a 
result of microvascular injury sustained by the local and systemic immune response. 
Following trauma and the onset of infection, endotoxin in the portal circulation 
stimulates liver macrophages (Kupffer cells) which release different cytokines and
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mediators. LPS directly stimulates the classical pathway of the complement cascade 
that releases anaphylatoxin which is a potent stimulator of polymorphonuclear cells 
(PMNs) (reviewed in Morrison and Ryan, 1987; Redl and Schlag, 1990). The 
activation of the PMNs, cytokine release and endothelial cell stimulation up-regulates 
the expression of adherence molecules for leukocytes, such as E-selectin and 
intercellular adhesion molecule (ICAM)-1 (CD54), with subsequent expression of 
CD 18 on PMNs and other cells. These events increase adhesion of PMNs (and 
possibly monocytes) to endothelium. This causes the release of different mediators 
which in turn damages the endothelium, resulting in increased permeability of the 
vascular epithelium. LPS-induced endothelial injury was shown to be potentiated by 
mononuclear cells in vitro (Jones, Brigham and Meyrick, 1987) via cytokine release, 
and enhanced adhesiveness of PMNs and monocytes to the endothelium (Bevilacqua et 
al., 1985) or interaction between PMNs and monocytes (Panush, 1983). Increased 
vascular permeability allows MPs to migrate to the tissues and these potentiate tissue 
damage through the release of mediators such as oxygen radicals, thromboxanes, and 
leukotrienes (reviewed by Redl and Schlag, 1990).
Oxygen radicals generated as a result of monocyte and neutrophil activation are 
propagated through lipid peroxidation. Free radicals attack proteins, nucleic acids, 
membrane lipids and the extracellular matrix by hydrogen abstraction and radical 
addition or electron transfer. Free radicals attack sulphydryl-containing amino acids 
(methionine, cystine) or enzymes (calmodulin and calcium adenosine triphosphatase) 
and extracellular proteins like immunoglobulin (Ig)G, and albumin. The radical 
addition to the nucleic acid base pairs leads to chromosomal deletions, mutation or cell 
death. Alternatively, through a series of changes in the membrane lipids, oxygen 
radicals alter membrane permeability and fluidity, damaging cells and organelle integrity 
and leading to cell death. Free radicals are known to increase intracellular free calcium 
which activates protein kinases and phosphatases, causing cell damage (reviewed by 
Tew and Jones, 1994).
1.2.3 Immunopathology
The sequence of events leading to sepsis and septic shock begins with the 
introduction of a stimulus. MPs play an important role in recognition (cognitive phase) 
and activation of the specific immune response as well as a pivotal role in innate 
immunity. In their cognitive function, MPs act as antigen presenting cells (APCs) 
which process foreign substances (including LPS) in a way conducive to recognition by 
antigen-specific T-cells. A chain of events occurs which includes binding, 
phagocytosis, and the release of a number of mediators (primarily reactive oxygen or 
nitrogen intermediates) causing containment and finally destruction of the particles. 
During antigen processing and presentation, macrophages express a number of 
secretory and membrane proteins that promote T-cell activation and differentiation 
(Auger and Ross, 1992). This requires cellular expression of the processed antigen in 
association with a glycoprotein coded for by the class II genes of the MHC, (human 
leukocyte associated antigens (HLA)-DR, -DP, or -DQ). This results in a regulatory
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signal (interleukin-1) being given to the responding T-cells causing their activation, 
growth and differentiation. In response to the processed antigen and signal from the 
macrophages, the T-cells show increased expression of IL-2 receptors and secrete IL-2 
followed by the release of (primarily) IL-1, IL-2 and interferon (IFN)-y, which activate 
monocytes.
The process of monocyte activation is complex and the systemic sequelae 
depend upon the state of monocyte differentiation and the presence of other stimuli. 
Macrophages are activated directly by LPS or by the mediators secreted by T-cells. 
However, lymphokines secreted from activated lymphocytes also contribute to 
monocyte activation and differentiation. The activated monocytes, in turn, secrete 
cytokines (primarily IL-1, IL-6 , granulocyte-macrophage colony stimulating factor 
(GM-CSF) and TNF), which may alter the secretion of lymphokines and affect their 
subsequent effects on monocytes. In their effector phase, the autocrine action of these 
lymphokines results in increased production of a variety of cytokines, receptors and 
receptor antagonists from the macrophages which cause T-cell activation and B-cell 
proliferation (Morrison and Ryan, 1987; Redl and Schlag, 1990; Tracey and Lowry, 
1990; Dofferhoff et al., 1991; reviewed by Lynn and Golenbock, 1992). However, in 
the case of an overwhelming response to LPS or other stimulus (as in sepsis or septic 
shock), the cytokine-cell-receptor-antagonist cascade mechanisms become exacerbated 
causing cellular adhesion, cell death, shock and multiple organ failure (Redl and 
Schlag, 1990; Schlag, Redl and Halldtrom, 1991).
In addition to the expression of IL-1, IL-2, IL-6 , TNF, GM-CSF and IL-2 
receptor (IL2r), anti-inflammatory cytokines, pleiotropic cytokines or other mediators 
are also released by MPs. These include IL-10, transforming growth factor p (TGFp), 
prostaglandin (PG)F^, and soluble cytokine receptors, primarily IL-1 receptor 
antagonist (IL-lra) (Tracey and Lowry, 1990; Dinarello 1991; Ertel et al., 1991; Kang 
et al., 1992; Miller-Graziano et al., 1991; Bogdan and Nathan 1993; Pinsky et al., 
1993; Lin et al., 1994; Marchant et a l, 1994). The cell surface receptors involved in 
this process are up-regulated or down-regulated depending on the stage and magnitude 
of the disease process. The notable receptors are GDI 1, CD 14, CD 16, CD 18, CD54, 
CD64 and HLA-DR that modulate the immune response (Appel et a l, 1989; Hershman 
et a l, 1990; Munoz et a l, 1991; Faist et a l, 1992; Fingerle et a l, 1993; Lin et al, 
1993). Most of these cytokines and receptors will be discussed in detail later (Sections
1.11 - 1.14).
1.3 Monocytes and macrophages
Monocytes and macrophages belong to a group of cells which comprise the 
"mononuclear phagocyte system". Monocytes derive from hematopoedc stem cells in 
the bone marrow and after passing through the developmental stages (monoblast, 
promonocyte) are released as monocytes into the circulation. Upon migration into the 
tissues, monocytes differentiate into macrophages. These are a heterogenous group of 
cells which include free macrophages in bone marrow, lymph nodes, pleural and
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peritoneal cavities and fixed cells such as histiocytes of connective tissues, Kupffer 
cells of the liver, alveolar macrophages of the lungs and microglial cells of the central 
nervous system. MPs play an important role in innate immunity, particularly with 
respect to the control of microbial growth and phagocytosis. Besides their scavenging 
activities, the cells of the mononuclear phagocyte system (MPS) can initiate and amplify 
immune responses through antigen presentation and synthesis of various products. 
Monocytes and macrophages can produce more that 100 products and a partial list of 
these products is presented in Table 1.1.
1.3.1 Origin, development and differentiation
Monocytes derive from the myelomonocytic progenitor cells in the bone 
marrow. These progenitor cells, the colony forming unit-granuolocyte-macrophage 
(CFU-GM), are thought to be common to both monocytes and neutrophils. Indeed, 
studies in vitro have shown that the CFU-GM gives rise to colonies of monocytes and 
neutrophils in semi-solid marrow cultures. Also, the human promyelocytic leukemia 
cell line, HL-60, differentiates into MPs in the presence of certain phorbol esters, but 
into neutrophils in the presence of dimethyl sulphoxide (DMSO), suggesting a common 
origin and stimulation-dependent differentiation of these cells (Koeffler and Golde, 
1980; reviewed in Auger and Ross, 1992).
The progenitor cells give rise to monoblasts which are positive for lysozyme, 
non-specific esterase (low level) and Fc receptors for IgG. They are able to 
phagocytose red blood cells (RBCs) coated with IgG, but not complement (C)3b, and 
only rarely ingest opsonized bacteria. Each monoblast divides into two pro-monocytes. 
These cells, in addition to the morphologic and functional characteristics of monoblasts, 
have peroxidase-positive granules and can ingest opsonized bacteria. Each 
promonocyte gives rise to two monocytes. The newly formed monocytes remain in the 
bone marrow for less than 24 hours before entering the peripheral circulation. They 
circulate in the blood for 34 - 120 hours (half-life 70 hours) before they migrate into the 
tissues where they differentiate into friacrophages. The macrophages in different tissues 
acquire different characteristics. It has been shown that approximately 5% of 
macrophages in tissues and body cavities derive from local division of MPs that have 
left the bone marrow within the previous 24 hours, before completion of cell division. 
In the tissue, macrophages can live for several months. However, during an acute 
inflammatory reaction, the kinetics of monocytopoiesis change; the number of 
circulating monocytes increases briefly, and they rapidly migrate to the tissue site of 
inflammation (Auger and Ross, 1992).
1.3.2 Histochemical characteristics
Promonocytes measure 12-18 um in diameter and are characterized by several 
immature and mature azurophilic granules, and deeply indented, irregularly-shaped 
nuclei. Peripheral blood monocytes (PBMs) are 12-15 um in diameter, uniformly 
rounded cells with an eccentrically placed nucleus occupying at least 50% of the cell
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Table 1.1. Secretory products of mononuclear phagocytes
Binding proteins 
Transferrin 
Fibronectin 
Laminin
Lipid transfer protein
Reactive oxygen intermediates 
Superoxide 
Hydrogen peroxide
Hydroxyl radical 
Hypohalous acid
Cytokines and hormones 
Interleukin (IL)-la, IL-lp 
IL-6 , IL-8 , IL-10 
Tumor necrosis factor a  (TNFa) 
Interferon (IFN) a  and p 
Chemotactic factors for
T- lymphocytes 
Neutrophils 
Fibroblasts 
Granulocyte-macrophage colony
stimulating factor (GM-CSF) 
Granulocyte-colony stimulating 
factor (G-CSF)
Macrophage colony stimulating
factor (M-CSF) 
Transforming growth factor 
(TGF) a and p 
la, 25-Dihydroxy vitamin D3
Nucleosides and metabolites 
Uric acid 
Lactic acid 
Nitrites and nitrates 
Neopterin
Bioactive lipids
Arachidonic acid metabolites 
Prostaglandins E2 , F^a
Prostacyclin
Thromboxane
Leukotrienes B4 , C, D and E 
Platelet activating factors
Coagulation factors
Factors III, V, VII, VIII, IX, 
X and tissue factor 
Prothrombin
Complement components 
C l, C4, C2, C3 and C5 
Factor B, factor D 
Cl inhibitor, C3b inactivator
Enzyme inhibitors 
a2-macroglobulin
Plasmin inhibitor 
Plasminogen inhibitor
Proteases, lipases, collagenase 
arginase
Modified from Oppenheim and Leonard, (1989)
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area. The nucleus may be kidney shaped, round or irregular with fine chromatin 
granules. The cytoplasm contains clear vacuoles, and both fine and large azurophilic 
granules (Goldman, 1989) and the plasma membrane is ruffled (Douglas and Hassan, 
1990; reviewed by Auger and Ross, 1992). Freshly isolated monocytes adhered to 
plastic or glass surfaces appear flattened and spread. The cell size may increase with 
corresponding increase in the cytoplasm to nuclear ratio, and the number of granules 
and lipid inclusions may also increase. Macrophages are generally large, irregularly- 
shaped cells measuring about 25-50 um. They often have an eccentrically placed, 
round or kidney-shaped nucleus with one or two prominent nucleoli and finely 
dispersed nuclear chromatin. Also, they frequently contain clearly defined juxtanuclear 
Golgi complexes in an abundant cytoplasm that contains fine granules and multiple 
large, azurophilic granules. Cytoplasmic vacuoles are frequently seen at the cell 
periphery, and the surface of these cells appears ruffled (Douglas and Hassan, 1990).
Various hydrolytic enzymes have been isolated from MPs, namely, acid 
phosphatase, p-glucuronidase, N-acetyl-glucosaminidase, lysozyme, non-specific 
esterase, and peroxidase. Macrophages are generally periodic acid-Schiff (PAS)- 
negative, but following phagocytosis, they may show globular PAS-positive 
intracytoplasmic deposits (Schmalzl and Braunsteiner, 1970). Non-specific esterases 
are enzymes on the external surface of the plasma membrane of monocytes and 
macrophages. There are two forms of esterase that are primarily found in monocytes 
and macrophages: a-naphthyl acetate esterase (a-NAE) and a-naphthyl butyrate 
esterase (a-NBE). These enzymes are used most commonly as cytochemical markers to 
distinguish monocytes from lymphocytes (Augur and Ross, 1992). However, human 
monocytes are heterogenous for a-NAE activity, probably reflecting the number and 
composition of lysosomes that contain this enzyme (Kaplow, 1975) which may reflect 
their stage of differentiation (Cook and Eales, 1994).
Peroxidase activity is found in 90% of human monocytes in their primary 
lysosomes. It has been found that during in vitro culture, lysosome-associated 
peroxidase is lost; the enzyme reappearing in association with the nuclear envelope and 
rough endoplasmic reticulum. The latter distribution is thought to be associated with 
mature, resident macrophages (Bos et al., 1988).
1.3.3 Functional and phenotypical properties
Macrophages are the early reacting sentries of the body’s defense system. As 
discussed in Section 1.2.3, in response to a microbial invasion, macrophages ingest 
and kill the invader, and initiate a battery of reactions that greatly increase the defense 
capability of the host such as: (a) elaborate tissue factors on the macrophage surface that 
promotes local clotting and trapping of microorganisms; (b) secrete leukotriene which 
stimulates endothelial cells to produce platelet activating factor which in turn enhances 
leukocyte adhesion; (c) secrete chemoattractant that recruits leukocytes to the site of 
injury; (d) start antigen processing and presentation (first step in the development of a 
specific immune response); (e) secrete a number of cytokines (Oppenheim and 
Leonard, 1989). All these functions are accompanied by simultaneous expression of
receptors on the monocyte and macrophage surface that characterizes that functional and 
maturation stages of these cells.
1.3.3.1 Functional properties
Monocytes in vitro go through a series of morphological as well as functional 
changes as they mature to macrophage-like cells. Freshly prepared monocytes secrete
high levels of superoxide (O2O and hydrogen peroxide (H2O2) stimulated with phorbol
esters or zymosan but release of both O2 and H2O2 declines with time in culture. This
decrease was correlated with decreased antimicrobial ability of monocytes. Similarly, 
freshly isolated monocytes generally do not produce cytokines. Activation of these 
cells leads to synthesis of mRNA and new protein, such as IL-1 (3, IL- 6  and TNFoc, 
which was first detected in the cytosol and subsequently in the extracellular matrix. A 
list of cytokines released by activated monocytes is presented in Table 1.2. Freshly 
prepared monocytes produce more IL-1 than mature monocytes (Elias et al., 1985). 
Mature macrophages stimulated with LPS do not induce IL- 6  receptor (EL-6 r) mRNA or 
increase secretion of IL- 6  (Bauer et a l, 1989). However, monocytes stimulated with 
LPS increase release of IL-lra but macrophages do not (Poutsiaka et a l, 1991; Kline, 
Monick and Hunninghake, 1992). LPS- or phorbol myristate acetate (PMA)-stimulated 
monocytes produced a large amount of IL-1 in vitro that correlated with an increase in 
size and maturity. However, the release was found to decline over time. Decreased 
ability of IL -1 secretion and HLA-DR expression by monocytes have been correlated 
with diminished capacity of these cells to act as accessory cells in the generation of 
proliferative responses of T-cells against both antigens and mitogens. On the other 
hand, monocytes in culture have been shown to increase cytolytic activity against 
murine or human target cell lines compared to freshly prepared cells. Since release of 
reactive oxygen intermediates (ROIs) was found to decrease in culture, it was suggested 
that target cell killing by monocytes may be independent of ROIs release (from reviews 
by Dougherty and McBride, 1989; te Velde, 1994). The involvement of NO in 
cytolysis has been proposed. It has been shown that monocyte NO release increased 
over time in culture and this was correlated with tumor cell killing activity of monocytes 
(Martin and Edwards, 1993).
1.3.3.2 Surface antigen expression (phenotypes)
A majority of circulating monocytes express CD 14 which has been used widely 
as a characteristic marker for monocytes (Todd, Nadler and Schlossman, 1981; 
Bernstein and Self, 1984). The expression of CD 14 decreases in cultures without 
serum, but remains constant in the presence of serum or on differentiated macrophages 
(Andreesen et a l, 1990).
Virtually all monocytes express CD 18, the p chain of the CD11 integrin 
complex, on their surface. The integiins are a family of structurally related hetero­
dimers, which mediate cellular adhesion, a vital process in cell migration and many
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Table 1.2. Cytokine released by activated monocytes
Name Biologic properties
IL -la and p Immunostimulatory, mediator of inflammation and shock
IL- 6 Induction of acute phase response, regulation of hematopoiesis and
immune response
IL-8 Chemoattractant for granulocytes and T-cells
IL-10 Suppress IL -la  and p, IL-6 , IL-8 , TNFa, GM-CSF, G-CSF and
monocyte/macrophage antigen presenting function
TNFa Immunostimulatory, cytotoxicity, mediator of inflammation and shock
G-CSF Proliferation, differentiation and prolongation survival of neutrophilic
granulocytes, and enhance antibody dependent phagocytosis
M-CSF and Induction of monocyte migration, growth and differentiation factor.
GM-CSF potentiate survival and effector function of monocytes/macrophages
TGFp Acts on cell proliferation, fibrosis, healing, angiogenesis, hemo­
poiesis and suppresses IL-1, IL- 6  and TNFa release
IL-1 receptor Binds and blocks IL-1 effects, potent inhibitor of inflammation
antagonist
Modified from te Velde (1994); Sherry and Cerami, (1988); Nicola and Vadas, 
(1984); Begley et al., (1986); Arend, (1991); Dinarello and Wolff, (1993)
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immune functions (reviewed in Springer et aL, 1987). Valentin et a i, (1991) reported 
that 80 - 95% of the human monocytes reacted with antibodies to the CD1 la and 
C D llb  integrins. Over 60% of the isolated human monocytes adherent to plastic were 
shown to express C D llb  and CD l ie  (Bennett et al., 1992). ICAM-1 (CD54) is the 
ligand for CD l ia  (LFA-1, leukocyte functional antigen-1) (Marlin and Springer, 1987) 
and CD 1 lb/CD 18 (Diamond et aL, 1990). ICAM-1 is expressed on a wide variety of 
cells including monocytes and the expression of this molecule is up-regulated by 
inflammatory cytokines. Adhesion, subsequent stretching and migration of monocytes 
to, and over, the luminal surface of vascular endothelial cells (EC) are essential steps in 
the emigration of monocytes from the circulation into tissues at the site of inflammation 
(Beekhuizen et aL, 1992). CD11 a/CD 18- and CD1 lb/CDl8-dependent migration of 
monocytes through EC have been demonstrated in vivo (Issekutz, 1995) and in vitro 
(Meerschaert and Furie, 1995).
The molecules primarily responsible for the discrimination between self and 
non-self in a host system are a group of surface glycoproteins coded for by the genes of 
the MHC. The two classes of MHC molecules, class I and class H, primarily function 
during antigen presentation. Class II molecules (HLA-DR, DP, DQ) are expressed by 
APCs, i.e., monocytes, macrophages, dendritic and B-cells, and activated T-cells in 
humans. Expression of Class II molecules on isolated monocytes increases 
significantly during the first 12-24 hours of culture in vitro (Wahl et aL, 1987; 
Andreesen et aL, 1990).
Monocytes also express receptors for the Fc portion of IgG called the Fey 
receptors (FcyR). Three major classes of FcyR have been identified in humans, 
namely, FcyRI (CD64), FcyRII (CD32) and FcyRHI (CD16) (Valentin et aL, 1991; 
reviewed in Fanger et aL, 1989; van de Winkel and Anderson, 1991,1993; Unkeless, 
Scigliano and Freedman, 1988). These have been shown to play an important role in 
the immune response by providing a link between the humoral and cellular branches of 
the immune system. All three receptors are expressed by MPs. However, controversy 
exists regarding the expression of CD 16 on monocytes. Valentin et aL, (1991) 
indicated that it is not expressed on monocytes whereas others indicated that a subset of 
monocytes express CD16 (in reviews by Fanger et aL, 1989; van de Winkel and 
Anderson, 1991; van de Winkel arid Capel, 1993). However, the expression of CD16 
was shown to be found on monocytes culture for 2 days (Valentin et aL, 1991). FcyRI 
binds to monomeric human IgG with high affinity and was shown to be an effective 
cytotoxic trigger molecule on different types of cells. In MPs, FcyRIII are low affinity 
IgG receptors while FcyRII have intermediate affinity for IgG (Fleit, Wright and 
Unkeless, 1982).
1.4 Lipopolysaccharide
Lipopolysaccharide is a bacterial product with an ability to stimulate a multitude 
of biologic responses in humans. It is produced in the cytoplasmic membrane but 
remains exclusively in the external layer of the outer membrane of gram-negative 
bacteria. As an exposed component of the bacteria, LPS of the non-capsulated bacteria
stimulates the production of antibacterial antibodies by the immune cells predominantly 
directed against its determinants (from Rietschel et aL, 1982).
1.4.1 Structure and properties of LPS
LPS is a macromolecular glycolipid composed of a polysaccharide and a lipid 
chain (Figure 1). The former composes a core polysaccharide and an O-specific chain 
which differ in their chemical and biologic properties. The O-specific polysaccharide 
which is a polymer of oligosaccharide molecules carries the main serologic specificity 
of the bacterium. The nature and sequence of the individual monosaccharide residues 
within a repeating unit, and the type of linkage between them is characteristic of a given 
bacterium and its LPS. The structural variability in the core oligosaccharide of different 
gram-negative bacteria is very slight. It is covalently linked through the 2-keto, 3- 
deoxyoctonates to the lipid A (ketosidic bond) (from Rietschel et aL, 1982; Ribi and 
Takayama, 1985).
The biologic properties of LPS reside in the lipid A portion of the molecule 
which comprises a diglucosamine backbone linked to six long-chain fatty acids. In 
addition two phosphate groups are attached, one at each end of the disaccharide, at 
positions 1 and 4. Lipid A is the most conserved and least variable structural element of 
LPS; only minor differences exist in this structure from taxonomically remote bacteria. 
However, Lipid A must contain all three of the following components in order to be 
toxic (1) a glucosamine disaccharide, (2) a sugar-1-phosphate, and (3) a fatty acid 
(Takayama et aL, 1984). Lipopolysaccharides are not secreted, rather released after 
bacterial disintegration, and are heat-resistant (Westphal, 1984). In humans, lipid A (or 
LPS) elicits a variety of distinct biological effects such as fever, hypotension, 
disseminated intravascular coagulation (DIC), changes in WBC counts and lethal shock 
caused by the mediators released from host cells, such as MPs (reviewed by Rietschel 
et aL, 1982). It has also been shown to enhance non-specific resistance to microbial 
pathogens and tumor in animals and humans (reviewed by Ribi, 1984; Oettgen et aL, 
1984).
1.4.2 Mechanisms of action of LPS
As early as 1940, it was hypothesized that LPS interacts primarily with the 
cellular components of the host when specific cell components were not identified. 
Later, it was shown by others that LPS causes differentiation and proliferation of B- 
cells and fibroblasts. Further work led to the suggestion that interaction of LPS with 
certain host cells may lead to the secretion of particular endogenous mediators which, in 
turn, are responsible for the observed effects of LPS in vivo (from Rietschel et aL, 
1982). Data accumulated in recent years have supported this postulation.
Although the exact intracellular events that mediate LPS responses are not 
completely understood, a few hypotheses exist. A signal transduction mechanism via 
phospholipase C (PLC) that results in the hydrolysis of phosphatidylinositol 4,5- 
bisphosphate (PIP2 ) to inositol 1 ,4,5-trisphosphate (IP3) and diacylglycerol (DG) has
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Figure 1.1. Structures of lipopolysaccharide (LPS).
Figure A represents a schematic structure of a Salmonella LPS. The wavy lines 
at the lipid A region represent the fatty acid residues, the hexagons represent 
sugar residues, the bullets represent phosphate molecules, and the tadpoles 
represent phosphorylethanolamine (from Rietschel et aL, 1984).
Figure B indicates the chemical structure of LPS from S. minnesota Re 595 that 
lacks the O-polysaccharide and some portion of the core oligosaccharide (contains 
only 3-deoxy-D-mannooctulosonic acid, KDO, as the sugar constituent of the 
core) (adapted from Rietschel et aL, 1984; Ulrich and Myers, 1995).
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been proposed. The IP3 stimulates the release of intracellular Ca2+ and the DG
modifies the phospholipid layer of the membrane which, by the action of the protein 
kinase C (PKC), phosphorylates a number of proteins including the NADPH oxidase 
system in the plasma membrane (Klein, 1990). It has been demonstrated that a rapid 
tyrosine phosphorylation and the involvement of protein tyrosine kinase (PTK) is 
caused by LPS (Weinstein, June and DeFranco, 1993; Shapira et aL, 1994; Ulevitch 
and Tobias, 1994; Herrera-Velit and Reiner, 1996). Because LPS stimulation did not 
significantly increase intracellular level of DG and inhibiting this PKC activator did not 
affect LPS-stimulated TNFa secretion, a DG-independent pathway has been suggested 
(Shapira et aL, 1994). While these authors found this mechanism was not dependent 
on CD 14, others demonstrated it otherwise (Herrera-Velit and Reiner, 1996).
1.4.2.1 Lipid binding proteins
Serum proteins that bind to LPS may modify the physical, chemical and 
biological properties of LPS. LPS can bind to serum lipoproteins that can cause 
detoxification of LPS. By contrast, addition of serum markedly enhances LPS binding 
and subsequent activation of MPs. Later it was found that these apparently opposite 
effects of LPS in the presence of serum involve a serum protein, called lipid binding 
protein (LBP). LBP is a 60 kDa serum glycoprotein synthesized by hepatocytes and is 
an acute phase protein found in humans and animals. It binds with high affinity and 
with a 1:1 stoichiometry to lipid A, forming a LBP-LPS complex which facilitates 
binding of LPS to CD 14. LPB also binds to gram-negative bacteria via LPS in the 
outer membrane and facilitates attachment of the bacteria to CD 14 on monocytes. The 
attachment of LPS to membrane-bound CD 14 causes monocyte activation (Wright et 
aL, 1989; Wright et aL, 1990; Ulevitch, 1993; reviewed in Ulevitch and Tobias, 1994; 
Jack et aL, 1995). Recognition of LPS on the cell surface is required for LPS uptake 
or initiation of transmembrane signaling (Ulevitch and Tobias, 1994). The binding of 
the LBP-LPS complex to CD 14 causes rapid phosphorylation of tyrosine, through 
CD 14 itself or through a transmembrane tyrosine kinase causing activation of an 
intracellular tyrosine kinase. These events lead to the transcription and translation of a 
group of genes resulting in cellular activation accompanied by the expression of various 
receptors and cytokines. Although the LBP-LPS complex mediates binding of LPS to 
CD 14, LPS can stimulate MPs in the absence of LBP (Wright et aL, 1990; Chen et aL, 
1992; Hailman et aL, 1996). These findings suggest the existence of more than one 
specific LPS receptor on monocytes; although this phenomenon may be explained by 
the hydrophobic interaction of the LPS with lipid bilayers of the cell membrane.
Another serum protein called bactericidal/permeability-increasing protein (BPI) 
secreted from PMNs is involved in the modulation of LPS function. BPI, a 50 kDa 
protein, binds to LPS or bacteria containing LPS via lipid A and transfers the lipid A 
moiety to lipoproteins, especially low density lipoprotein (LDL), and appears to 
ameliorate the affects of LPS. BPI complexes with LPS and prevents the formation of 
the LPS-LBP complex, thus reducing the effects of LPS (Heumann et aL, 1993; Jahr et
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al., 1995). When LBP binds to intact bacteria, it acts as an opsonin whereas BPI is 
directly bactericidal (from Ulevitch and Tobias, 1994). LBP may also transfer LPS to 
high density lipoprotein (HDL) with or without the help of sCD14 that may result 
inactivation of LPS (Wurfel, Hailman and Wright, 1995; from Fearon and Locksley, 
1996).
1.4.2.2 LPS receptors
Several LPS receptors, both membrane bound and soluble forms, have been 
suggested that recognize LPS and initiate cell activation (Lynn and Golenbock, 1992; 
Ulevitch and Tobias, 1994). However, to date, only CD 14 has been definitely shown 
to be an LPS receptor that mediates cell activation and LPS uptake (Ulevitch and 
Tobias, 1994). It is a phosphatidyl inositol (GPI)-anchored membrane glycoprotein 
present in monocytes, macrophages, and some PMNs. Its distribution and role in LPS- 
mediated monocyte activation is described in Section 1.14.3. CD14 also exists in a 
soluble form that lacks the GPI anchor (Bazil et aL, 1986; Fearon and Locksley, 1996). 
However, its role in monocyte activation is not clearly understood. Similar to 
membrane bound CD 14, soluble CD 14 (sCD14) binds both to LPS and LPS-containing 
bacteria. sCD14 has been shown to mediate rapid uptake of isolated LPS (Gallay et aL, 
1993) and intact gram-negative bacteria by monocytes in vitro (Jack et aL, 1995) and it 
was suggested that it may help rapid elimination of the bacteria. In a recent review, 
Fearon and Locksley, (1996) indicated that sCD14 binds LPS and enhances the activity 
of LPS by 100 - 10,000 times. However, Haziot et aL, (1995) demonstrated that, 
despite its agonist activity, sCD14 prevented mortality in mice that was associated with 
reduced TNFa release.
The existence of a 70 - 80 kDa membrane protein in murine splenocytes with an 
affinity for lipid A or LPS has been reported. Later, it was found in human 
macrophages as evidenced by activation of these cells by a monoclonal antibody (mAb) 
against this protein. However, the ability of this protein to bind peptidoglycan of gram- 
negative bacteria has raised questions about the specificity of this protein. Data on 
structure and other biological functions of this protein is not available (reviewed by 
Lynn and Golenbock, 1992; Ulevitch and Tobias, 1994).
In their review, Lynn and Golenbock (1992) indicated that CD 18 may function 
as an LPS receptor in phagocytic leukocytes. It has been found to be involved in the 
non-opsonic recognition of LPS in gram-negative bacterial cell walls and later, an anti- 
CD 18 mAb has been shown to block the binding of gram-negative bacteria to 
macrophages. In addition, LDL in MPs has been found to bind and detoxify LPS and 
is considered to be a potential LPS receptor.
An 80 kDa membrane protein in monocytes and endothelial cells has been 
demonstrated to bind LPS through sCD14 and LPS-binding protein (Schletter et aL, 
1995). Certain receptors on tissue macrophages referred to as scavenger receptors are 
found to be involved in adhesion of microbes and clearance of LPS (Fearon and 
Locksley, 1996). However, whether these receptors are in fact LPS receptors needs to 
be determined.
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1.4.3 LPS effects in vivo and in vitro
The systemic manifestations of LPS in humans and animals are postulated to 
result from the activation of complement components (from reviews by Lynn and 
Golenbock, 1992; Shapiro and Gelfand, 1993), humoral and cellular mediated systems 
(Schlag, Redl and Hallstrom, 1991; Morrison and Ryan, 1987) and the release of 
cytokines (Morrison and Ryan, 1987; Michie et aL, 1988; Bone, 1991). It is well 
known that LPS activates complement and that complement receptors play an important 
role in monocyte activation. Human monocytes not only possess the complement 
receptor (CR)3, but also secrete the complement component C3. LPS independently, 
or in concert with IFNy and GM-GSF, stimulates MPs resulting in increased surface 
expression of MHC class II molecules. This is followed by expression of surface 
receptors for antibodies and certain complement proteins resulting in enhanced 
opsonization (coating) and phagocytosis of particles. Infusion of LPS in humans 
reproduces many of the clinical manifestations of sepsis, and serum endotoxin levels 
correlate with the severity Of infection during septic shock (Michie et aL, 1988; van 
Deventer et aL, 1988; Suffredini et aL, 1989; Danner et aL, 1991). In addition, 
increased serum levels of cytokines (Michie et aL, 1988; Damas et aL, 1989; Calandra 
et aL, 1991; Lin et aL, 1994) or complement components (Lin et aL, 1993), increased 
or decreased surface antigen expression (Appel et aL, 1989; Birkenmaier, Hong and
Horn, 1992; Ertel et aL, 1993; Lin et üL, 1993a) and increased serum NO2VNO3-
(Ochoa et aL, 1991; Evans et aL, 1993) in septic patients have been related to MPs 
activity in vivo.
Observations in vitro using whole blood or isolated PBMs from normal or 
septic humans or animals, revealed a body of evidence which parallels the clinical 
reports. Increased or decreased production of ROIs (Halliwell, 1987; Leon et aL,
1992; Lynn and Golenbock, 1992; Kono et aL, 1995), reactive nitrogen intermediates 
(RNIs) (Schutt, Schilling and Kruger, 1991; Shultz and Raij, 1992; Kitajima et aL, 
1995), phagocytic activity (Leon et aL, 1992), complement production (Hogasen, 
Hestdal and Abrahamsen, 1993), cell surface receptor and antigen expression 
(Hershman et aL, 1990; Wright, 1991; Marchant et aL, 1992), and release of cytokines 
(Matic and Simon, 1991; Ayala et aL, 1992) have been reported following LPS 
stimulation.
1.5 Staphylococcal enterotoxin B (SEE)
SEE is a cell wall component of gram-positive bacteria of the genus 
Staphylococcus. It belongs to a group of bacterial proteins that stimulate a large 
proportion of T-cells, i.e., it exhibits superantigen activity (Marrack and Kappler,
1990). This toxin has been found to be associated with food poisoning, fever, 
microvascular injury, organ failure and shock (Marrack and Kappler, 1990; reviewed in 
Stevens, Bryant and Hackett, 1992).
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1.5.1 Structure and properties of SEB
SEE is a glycoprotein with a molecular weight of 26 - 28 kDa. It stimulates 
host cell cytokine synthesis, global T-cell stimulation, and PMNs adhesion (reviewed in 
Stevens, Bryant and Hackett, 1992) as well as activation of monocytes and B-cells 
(Miethke et aL, 1993). SEB binds to MHC class II molecules in the order of affinity 
HLA-DR > HLA-DQ > HAL-DP (reviewed in Miethke et al., 1993). It stimulates 
monocytes to release EL-1 and IE- 6  (Salamon et aL, 1992) and peripheral blood 
mononuclear cells (PBMCs) to produce TNFa, IL-1, IE-2 and EE- 6  (Krakauer, 1995).
1.5.2 Mechanisms of action of SEB
SEB activates T-cells by binding to the MHC class II (3 chain on APCs and to 
the Vp chain of the T-cell receptor (TCR), forming a trimolecular (SEB-MHC class II- 
TCR) complex. Since it binds outside the antigen binding groove of the T-cells, 
probably close to the CD4 binding sites, SEB does not require intracellular processing 
to be presented to a T-cell (Dellabona et aL, 1990). In addition, SEB can activate 
monocytes without T-cell help by directly binding to the constant region of HLA-DR 
class II molecules on the monocyte surface (Fraser, 1989; Trede, Geha and Chatila, 
1991). SEB has been shown to induce PTK and PKC activities in monocytes in vitro 
(Palkama and Hurme, 1993; Zheng et al., 1993; 1995). In an experiment with mice 
deficient in MHC class II antigen, the mice were found to be resistant to SEB and it was 
concluded that SEB action is dependent on the MHC class II antigen (Stiles et aL,
1993).
1.5.3 SEB effects in vivo and in vitro
SEB has been shown to induce cytokine release, fever, hypotension, shock and 
multiple organ failure in humans. In vitro, through its interactions with T-cells, it has 
been shown to induce the production of IL-1, TNF and IFN-y by T-cells and MPs 
(Marrack and Kappler, 1990; Johnson, Russell and Pontzer, 1991). SEB has been 
shown to bind directly to the HLA-DR molecule with high affinity and induced EL-ip 
release in human monocytes in vitro (Trede, Geha and Chatila, 1991; Palkama and 
Hurme, 1993). It was also found to stimulate human monocytes to release NO in vitro 
(Essery et aL, 1994). Recently, human PBMCs stimulated with SEB in vitro have been 
shown to release IE-ip, EL-2 EL-6 , and IFNy. IE-10 release was not detected; 
however, addition of EL-10 to the cells attenuated the release of these cytokines 
(Krakauer, 1995).
1.6 Immunologic approach to sepsis and septic shock therapy
Despite using new broad-spectrum antibiotics, advanced hemodynamic 
monitoring, and increased understanding of the pathophysiology of septic shock, the 
mortality associated with this syndrome has not decreased. In an attempt to reduce 
mortality from this ailment, newer approaches have been adapted, aiming at interrupting 
the pathophysiology of septic shock. Mainly, two different approaches are being
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investigated that will complement the traditional treatment regimens. Firstly, the 
immunologic approach to overcome the endotoxin-macrophage interactions. Secondly, 
the pharmacologic approach aimed to inhibit the synthesis of the secondary mediators of 
septic shock. The first approach uses antibodies to endotoxins and the second, uses the 
modulation of cytokine synthesis or actions.
Pollack et aL, (1983) demonstrated that the survival rate of patients with 
P. aeruginosa septicemia was higher for those who had elevated levels of circulating 
antibodies (anticore IgG or IgM) to Escherichia coli. This finding led to the belief that 
antibodies to LPS can be used to treat sepsis and septic shock. Polyclonal antisera to 
rough strains of O-polysaccharide-deficient bacteria, E. coli J5 and S. minnesota R595 
have been found to be protective against heterologous endotoxins in animal models. 
However, in human trials, core-specific antiserum treatment produced inconsistent 
results. Since the inconsistencies among studies have never been reconciled, this 
approach of treatment has not received wide acceptance (reviewed in Corriveau and 
Danner, 1993).
E5 is a murine monoclonal antibody, raised in mice immunized with E. coli J5, 
that has been reported to bind an epitope on lipid A (heterologous smooth LPS). 
Differing degrees of success in different studies have been reported with this antibody 
in vitro and in animal studies; however, marginal benefits have been found in human 
trials. Results from a multi-center trial indicate that this agent can reduce the mortality 
in septic patients (gram-negative) without shock and reverse conditions such as acute 
renal failure and adult respiratory distress syndrome (Greenman et aL, 1991; Corriveau 
and Danner, 1993).
HA-Ia is a human IgM mAb derived from a heterohybridoma created from the 
spleen cells of a patient who had been vaccinated with E. coli J5 before splenectomy. 
This mAb has been reported to bind lipid A in the fluid phase as well as to gram- 
negative bacteria, gram-positive bacteria, fungi, and lipoproteins, and thus raised 
doubts about its specificity (Warren et tz/., 1992). Ziegler et aL, (1991) reported that 
HA-Ia reduced mortality in patients with gram-negative bacteremia and septic shock by 
24%; however, an in depth scrutiny by the Food and Drug Administration (FDA) has 
concluded that this mAb has marginal benefit in improving mortality. Further studies 
are being conducted to determine whether these agents can be used for therapy in sepsis 
and septic shock.
It is widely accepted that cytokine levels, specifically IL-1, EL- 6  and TNFa, are 
elevated in infection and LPS infusion, but clinical studies often have failed to 
document this finding (reviewed by Lowry, 1993). Since these mediators are assumed 
to exert significant pathophysiologic influences in septic and critically ill patients, it was 
thought reasonable to use antibodies to ameliorate the detrimental effects of these 
mediators (reviewed in Fong et aL, 1990a). The deleterious effects of TNF and IL-1 
have been blocked by using mAbs in baboons (Tracey et aL, 1987). EL-Ira has been 
shown to be elevated in bacterial infections or experimental endotoxemia (Granowitz et 
aL, 1991; Fischer et aL, 1992) and septic shock (Fischer et aL, 1992a; Fisher et aL,
1994). Administration of IL-Ira has been shown to ameliorate the septic syndrome in
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experimental endotoxemia (Ohlsson et aL, 1990; Fischer et aL, 1992) and in humans 
(Fisher et aL, 1994). However, 100 - 10,000 fold more of this agent was necessary to 
achieve the potential benefits (Arend et aL, 1990; Dinarello, 1991; McIntyre et aL,
1991). Following experimental endotoxemia, the concentration of EL-Ira was found to 
increase in parallel with the increase in IL-1 p in human volunteers (Granowitz et aL,
1991). Initial results showed a dose-dependent increase in survival in patients with 
these ailments (Fisher et aL, 1994). However, the recent report on the efficacy of IL- 
Ira therapy indicated that it increases the survival time only in patients with predicted 
risk of mortality >24%. Nevertheless, an alternative risk model assessment using 
APACHE m  showed an overall survival benefit with EL-Ira therapy for all patients 
(reviewed in Knaus et aL, 1996).
Data from animal studies have shown that lipopolysaccharide receptors can be 
blocked by LPS analogues like lipid X or fragment IA that are lipid A precursors with 
minimal agonist activities (Golenbock et aL, 1987; Proctor et aL, 1986). Non-steroidal 
anti-inflammatory drugs that inhibit the IL-1 converting enzyme have shown some 
benefits in experimental toxemia and are being investigated (reviewed by Shapiro and 
Gelfand, 1993). Initial evaluations of antitoxin therapies have not been proven 
beneficial. Some recent trials of anti-TNF therapy were indicated to be harmful (Knaus 
et aL, 1996); nevertheless/it is currently under investigation.
1.7 Monophosphoryl lipid A (MPL)
MPL is a detoxified form of the lipid A portion of LPS ; a phosphate group 
having been removed from the reducing end of the molecule (Takayama et aL, 1984; 
Johnson et aL, 1987). It retains most of the properties of LPS but only shows toxic 
effects (in humans and animals) in relatively large doses.
1.7.1 Structure and properties of MPL
MPL is usually prepared from the refined cell wall of polysaccharide-deficient 
Re mutant strains of Salmonella typhimurium and S. minnesota. This endotoxin 
consists of only the simple sugar (KDO) and lipid A (Figure 1.2). The KDO moiety is 
selectively removed under mildly acidic conditions resulting in the formation of 
diphosphoryl lipid A (DPL). Treatment of DPL with dilute acid at low pH selectively 
removes a phosphate group. The resulting molecule, the MPL form of lipid A, bears 
the same molecular structure as.DPL except that it lacks the acid-labile phosphate group 
at the reducing end of the glucosamine disaccharide unit. Further, alkaline hydrolysis 
of this molecule removes a base-labile fatty acyl residue, yielding deacylated MPL. It 
still retains the capacity to enhance synergistically the ability of the mycobacterial cell 
wall skeleton to regress tumor and establish Systemic anti-tumor immunity (Ribi, 1984; 
Ulrich and Myers, 1995).
MPL has been demonstrated to be less toxic than LPS in equivalent doses 
measured by the Chick Embryo Lethal Dose test, pyrogenicity test, the dermal 
Shwartzman reaction and cytokine release in vivo and in vitro (Takayama et aL, 1984;
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Figure 1.2. Structure of monophosphoryl lipid A (MPL).
Figure represents the chemical structure of MPL from Salmonella minnesota 
Re 595. It is prepared by acid hydrolysis of S. minnesota Re 595 LPS that 
cause the loss of the glycosidic phosphate at the 1 position and the inner 
core residues attached via the 6 ' position (the KDO) resulting in 4'-mono- 
phosphoryl lipid A. Further alkaline treatment removes the base-labile fatty 
acyl residue attached to the 3 position yielding 3-O-deacylated MPL.
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Rudbach et a l, 1994; Astiz et a l, 1995; Ulrich and Myers, 1995). MPL is, at least 
1 ,0 0 0  times less toxic than its parent molecules as determined by in vivo studies in 
rabbits and chick embryos (Takayama et aL, 1984; Ribi, et aL, 1986). Johnson et aL, 
(1987) reported that the average LD50 for chick embryos was approximately 0.005 ug
for LPS whereas it was 10 ug for MPL, i.e., 2000 times less toxic. However, Johnson 
et aL, (1991) demonstrated that the LD50 in mice was 225 times that of the native LPS
molecule. It was later reported by Henricson et aL, (1993) that MPL was 100 - 1,000 
times less potent than LPS in inducing inflammatory gene expression in mouse 
macrophages.
1.7.2 Mechanisms of action of MPL
The mechanism(s) by which MPL exerts its immunomodulatory functions is not 
known. Heumann et aL, (1994) while trying to quantify LBP in human plasma, found 
that MPL binds with LBP as well as with BPI. However, MPL neither enhanced TNF 
production in human monocytes in vitro in the presence of LBP or BPI and nor 
prevented the MPL-mediated production of TNF (Jahr et aL, 1995). These data 
indicate that MPL may form complexes with these proteins in vivo but whether MPL 
activate monocytes through similar receptors as LPS is yet to be determined. Several 
factors have been reported to be responsible for the activities (adjuvant properties) of 
MPL. It is mitogenic for bone marrow-derived precursors of antibody-forming cells or 
B-cells; activates peritoneal macrophages; stimulates the production of IL-1; and 
promotes granulopoiesis through the release of an endogenous colony-stimulating 
factor (CSF) (Ribi et aL, 1986). MPL stimulation of human monocytes to produce IL- 
1 is reported to be via the production of CSF. It has been shown to stimulate murine 
peritoneal macrophage phagocytosis and enhanced antibody responses to sheep RBCs 
and ovalbumin (Ribi and Takayama, 1985).
1.7.3 MPL effects in vivo and in vitro
Human and animal studies have indicated the beneficial effects of MPL in 
modulating the lethal effects of LPS (reviewed by Rudbach et aL, 1994; Gustafson, 
Rhodes and Hegel, 1995; Ulrich and Myers, 1995). In animal models, MPL has been 
shown to induce non-specific resistance to a wide spectrum of infectious agents and 
tumors, produce hyporesponsiveness to microbial toxins, and modulate cytokine 
responses (Astiz etaL, 1989,1991,1994; Rackow etaL, 1989; Rudbach etaL, 1993; 
1994; Gustafson, Rhodes and Hegel, 1995). MPL also has been shown to prevent the 
LPS-stimulated elevation of cytokines in mice (Henricson, Benjamin and Vogel, 1990), 
induce tolerance to endotoxic shock in pigs (Carpati et aL, 1992) and mice (Astiz et aL,
1993), and decrease infarct size and neutrophil infiltration in dogs (Yao et aL, 1993, 
1993a). In humans, MPL has been demonstrated to suppress the LPS-induced 
elevation of cytokine release (Astiz et al., 1995) and the systemic response (Rudbach et 
al., 1995) and it was concluded that MPL may be useful for prevention or amelioration 
of the severe consequences of sepsis.
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MPL has been shown in vitro to increase bactericidal activities of human 
peritoneal macrophages (Carozzi et aL, 1989). In vitro experiments with murine 
peritoneal macrophages showed a suppression of LPS-stimulated IFNy (Gustafson and 
Rhodes, 1992,1994) and TNFa (Henricson et dl., 1992) release by MPL. The 
majority of the studies proposed that MPL treatment resulted in the development of 
tolerance to the lethal effects of LPS. Ribi et aL, (1986) indicated that factors that 
contribute to the immunomodulatory activities of MPL might include the activation of 
macrophages, stimulating the production of IL-1, and promoting granulopoiesis 
through the release of CSF. In an extensive review regarding the use of MPL as an 
adjuvant, Ulrich and Myers (1995) concluded that MPL stimulates both cellular and 
humoral immunity through activation of macrophages, and mediates T- and B-cell 
interaction, resulting in cytokine release.
1.8 Immunologic tolerance
As early as 1973, Beeson and his colleagues (reported by Rietschel et al., 1982) 
demonstrated that a single or repeated injections of a sublethal dose of LPS rendered 
animals and humans relatively non-responsive to a subsequent LPS challenge. This 
phenomenon is referred to as endotoxin tolerance. Tolerance can be induced to the 
lethal, metabolic and pyrogenic effects of LPS. Tolerance to pyrogenic and toxic 
effects of LPS was shown to develop within 48 hours of a single LPS injection in 
humans (Johnston and Greisman, 1985). The early refractory stage, which is termed 
"early phase" tolerance, develops within a few hours after LPS administration. This 
phase is transient and requires closely spaced or continuous exposure to LPS. The 
tolerance that occurs several weeks after the initial exposure to LPS is called "late 
phase" tolerance. This tolerance in vivo has been correlated with the appearance of 
circulating anti- 0  antibodies, but the underlying mechanism(s) for early phase tolerance 
is not known (Johnston and Greisman, 1985). Macrophages from LPS-desensitized 
animals were shown to be refractory to LPS challenge (Haslberger et aL, 1988). 
Regulation of LPS tolerance in vitro has been suggested to be mediated by 
transcriptional and post-transcriptional events (Virca et aL, 1989; Zuckerman et al,
1989; Haas era/., 1990).
The exact mechanism of endotoxin tolerance is not known. The down- 
regulation of cytokine production in LPS refractory macrophages may be caused by the 
suppression of TNFa mRNA induction (Virca et aL, 1989; Haas et aL, 1990). 
Similarly, Takasuka, Takunaga and Akagawa, (1991) reported that murine 
macrophages pre-exposed to small doses of LPS inhibit TNFa mRNA but not IL-lp 
mRNA production. By contrast, Zuckerman et aL, (1989) indicated post- 
transcriptional suppression of TNFa production in LPS-tolerant macrophages; 
however, a later study with murine peritoneal macrophages revealed that tolerance is 
associated with transcriptional regulation of both TNF and IL-1 (Zuckerman and Evans,
1992). This conclusion was based on the observations that both diminished serum 
TNF and EL-1 levels were correlated with significant reduction of TNF and IL-1 mRNA 
accumulation in macrophages that was also correlated with decreased levels of the
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transcription regulator, NF-kp (nuclear factor-kp). The discrepancies between studies 
may be dependent on the species studied, the state of macrophage differentiation, the 
involvement of other soluble mediators such as IL-10 (Frankenberger, Pechumer and 
Ziegler-Heitbrock, 1995), and the in vivo or in vitro environment.
Fahmi and Chaby (1993) induced tolerance in murine macrophages by 
pretreating the cells with LPS or closely related structures of MPL. Tolerance was 
measured by decreased cytokine release, however, no correlation was found between 
down-regulation of LPS binding sites and tolerance. Labeta et aL, (1993) studied the 
mechanisms of tolerance in the Mono Mac 6  cell line and reported that tolerance 
precedes CD 14 down-modulation and operates by decreasing the receptor affinity for 
LPS through alteration of the PKC signaling pathway. However, tolerance may be 
seen without down-regulation of CD 14, but may even be increased in the number of 
receptors at the cell surface. Tolerance may be mediated through up-regulation of some 
gene product, such as p50 of NF-kB, TNF receptor type II, and IL-10, upon secondary 
stimulation (Haas et aL, 1990; Frankenberger, Pechumer and Ziegler-Heitbrock, 1995; 
Ziegler-Heitbrock, Frankenberger and Wedel, 1995; reviewed in Ziegler-Heitbrock, 
1995).
1.9 The respiratory burst
Antimicrobial activities of monocytes and other phagocytes have been broadly 
categorized into oxygen-independent or oxygen-dependent systems. The oxygen- 
independent system causes killing of organisms by secretory products, such as 
proteases, enzymes, acid hydrolyses and cytokines, to name a few of the over 1 0 0  
products secreted by monocytes (Oppenheim and Leonard, 1989). A partial list of 
these products is presented in Table 1.1 (page 7). The oxygen-dependent system 
includes the production of ROIs and RNIs. The ROIs include the hydroxyl radical
(•OH), hydroxyl ion (OH-), O2 , singlet oxygen (IO2), peroxide radical (HO) and
H2O2 . The RNIs include NO, nitrite (NO2") and nitrate (NO3"). The coordinated
sequence of reactions in various stimulated cells leading to the production of these 
intermediates is known as the respiratory or oxidative burst.
The respiratory burst of phagocytic cells occurs in response to binding of 
particles to cell surface receptors and complement activation. However, it is not a 
necessary component of the phagocytic process and is not activated by particle 
engulfment alone (Elsbach and Weiss, 1983; Wright and Silverstein, 1983; Nathan and 
Hibbs, 1991). The respiratory burst can be initiated in vitro by soluble stimulants such 
as cytokines, PMA, or LPS (Segal, 1989; Baggiolini and Wymann, 1990; Satriano et 
aL, 1993) or in humans during pathological conditions by a variety of agents, including 
prostaglandins and catecholamines (reviewed in Tew and Jones, 1994). The products 
of the respiratory burst, besides killing bacteria, play a prominent role in many of the 
cytotoxic reactions of macrophages including killing of parasites (Smith et aL, 1990), 
tumor cells and possibly extracellular lysis of erythrocytes (Segal, 1989).
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1.9.1 Mechanisms of 0%" and H2O2 production
Upon attachment of opsonized particles to the receptors on their surface, 
monocytes consume a large amount of oxygen, increase utilization of glucose through 
the hexose monophosphate shunt, and then release O2 metabolites. Within the
monocytes the toxic oxygen metabolites are converted to less toxic intermediates 
through the NADPH-oxidase respiratory complex. This system is composed of a series 
of electron-transporting molecules including cytochrome b-245 and at least one 
flavoprotein that occurs in the plasma membrane and the wall of the phagocytic 
vacuoles. On activation, the cyanide-resistant NADPH oxidase system transfers 
electrons from cytosolic NADPH (via the hexose monophosphate shunt) across the
membrane to O2 which is reduced to O2 . The resulting O2 is then converted to H2O2 
either spontaneously (one molecule of O2 oxidizes another) or catalyzed by superoxide 
dismutase (SOD). The addition of further electrons, one at a time, to H2O2  leads to the 
formation of the OH- anion and the OH radical, and finally to O2  and H2O by the
enzyme catalase (Segal, 1989). Blood monocytes possess myeloperoxidase (MPO) 
which mediates the halogénation of microbial proteins producing hypochlorous acid and 
chloramines; both increase the bactericidal power of ROIs (reviewed in Elsbach and 
Weiss, 1983). Recently, it has been reported that MPO may interact with H2O2 to form
hypohalous acids that also increase the defense armature of the monocytes (Miller and 
Britigan, 1995).
The production of ROIs is limited to the plasma membrane and the wall of the 
phagocytic vacuoles. However, during activation through cytokines or phagocytosis, 
the ROIs are released into the extracellular matrix. ROIs production and release have 
been shown to be regulated by cytokines; TGFpl is the first cytokine demonstrated to 
decrease H2O2 release by murine macrophages in vitro. Exposure of human monocytes 
to IL-10 or IL-4 or monocytes from patients receiving IL-4 therapy also showed 
decreased ROIs release (Niiro et aL, 1992; reviewed in Bogdan and Nathan, 1993).
1.9.2 Superoxide production in vitro and in vivo
Oxidative metabolites have been implicated in many human diseases, namely 
rheumatoid arthritis, ischemia, reperfusion injury, and immune injury to the lungs and 
kidney (reviewed by Halliwell, 1987). Increased free radical production has also been 
associated with sepsis and shock and the use of antioxidants has been found to improve 
conditions in animals and humans (reviewed in Tew and Jones, 1994), but the relative 
contribution of monocytes and macrophages in these conditions has not been assessed.
LPS- and MPL-stimulated release of O2 and H2O2 by different types of cells
are summarized and presented in Table 1.3. Increased O2 production has been
demonstrated in mouse peritoneal macrophages (Pabst and Johnston, 1980; Leon et aL,
1992) and human monocytes (Pabst et al., 1982) exposed to small amounts of LPS.
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Table 1.3. 0% and H2 O 2 release by different types of cells in vitro
Treatments Systems Findings References
LPS hMono Î 0 2- Pabst etaL, (1982)
LPS hMono T o 2- Pabst etaL, (1988)
LPS, Lipid A hMono T o 2- Landmann et aL, (1995)
LPS Mono Mac Î0 2 - Aepfelbacher et aL, (1992)
LPS Elicited mPM i  H20 2 Johnston, Adams and Hamilton,
(1985)
LPS Resident mM 1 H202 Ding and Nathan, (1987)
LPS+IFNy Resident mM, 1 h 2o 2 Ding, Nathan and Stuehr,
Elicited mPM (1988)
LPS hMDM T h 20 2 Padgett and Pruett, (1992)
LPS hMDM, mPM 4- H2 O2, 4- 0 2 Rellstab and Schaffner, (1989)
MPL hMDM NC02-
LPS, MPL mPM T o 2- ,T h 2o 2 Chen, Solem and Johnson,
(1991)
MPL mPM T % Elliott, Welty and Kuo, (1991)
MPL hMDM NC in H2O2
LPS mPM T o 2- Pabst and Johnston, (1980);
Leon et aL, (1992)
LPS, MPL mPM T h 2o 2, n c o 2- Johnson et aL, (1991)
LPS = lipopolysaccharide; MPL = monophosphoryl lipid A; m = mouse; h = human; 
PM = peritoneal macrophages; Mono = monocytes; Mono Mac = Mono Mac 6  
monocytic cell line; M = macrophages; MDM = monocyte-derived macrophages;
NC = no change. Most of the studies used priming agents and PMA or zymosan 
stimulation, details in the text.
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Later, Pabst et al., (1988) demonstrated that priming of human monocytes with small 
amount of LPS or IFNy for 48 hours increased O2 release in response to PMA that 
was associated with increased phagocytosis. Aepfelbacher et aL, (1992) demonstrated 
that LPS treatment caused a dose- and time-dependent increase in PMA-sdmulated Co­
production by human monocytic Mono Mac 6  cells. They reported that LPS-treated 
cells produced 20-fold more 0% compared to the untreated cells. By contrast, Rellstab
and Schaffner, (1989) demonstrated a dose-dependent decrease in CO and H2O2
production by human monocyte-derived macrophages pretreated with different types of 
LPS and challenged with either opsonized particles or PMA. MPL pretreatment did not 
cause any suppression. Effective half-maximum concentrations (EC50) of LPS were
reported to be from 0.49 to 2.14 ng/ml for LPS whereas it was >1000 ng/ml for MPL. 
The authors demonstrated the same phenomenon with non-elicited mouse peritoneal 
macrophages, suggesting that LPS may have impaired the formation of ROIs. Since 
LPS down-regulated ROIs release, it was also speculated that LPS-mediated down- 
regulation of ROIs release may be a part of an auto-regulatory system of MPs for the 
control of excessive production of potentially harmful oxidants.
Peritoneal macrophages collected 2 days after mice were treated with MPL
showed increased O2 production when compared to LPS-treated or control animals
(Chen, Solem and Johnson, 1991). Similarly, in a D-galactosamine-sensitized murine
model, MPL treatment has been shown to increase PMA-stimulated O2 release by
peritoneal macrophages (Elliott, Welty and Kuo, 1991).
Landmann et aL, (1995) demonstrated that non-adherent human monocytes in
the presence of serum showed increased O2 release in response to different types of
LPS and Lipid A in a dose- and time-dependent manner. Peak release was achieved at 
30 minutes with 1 -100 ng/ml depending upon the toxin used. Since the monocytes 
did not release significant amounts of O2 in the absence of serum and in the presence
of anti-LBP antibody or Polymyxin B (an inhibitor of LPS), it was concluded that LPS 
in association with LBP directly stimulates human monocytes via CD 14.
1.9.3 Hydrogen peroxide production in vitro and in vivo
The present understanding of the mode and pattern of H2O2 release by human 
monocytes is mostly extrapolated from cell line or murine studies, due to the lack of 
literature in this area. While only one study reported an MPL-mediated increase in 
H2O2 release (Johnson et aL, 1991), a majority reported decreased H2O2 release with 
LPS treatment. LPS- and MPL-stimulated release of H2O2 by different types of cells 
are presented in Table 1.3.
Rellstab and Schaffner, (1989) found a dose-dependent decrease in H2O2
production by both human monocytes and mouse peritoneal macrophages treated with
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LPS. By contrast, others reported increased H2O2 release by human monocyte-derived 
macrophages in response to PMA (Padgett and Pruett, 1992).
Comparative data on LPS- arid MPL-stimulated H2O2 release by human 
monocytes have not been reported. Peritoneal macrophages from mice treated with 
MPL showed increased H2O2 production when compared to LPS-treated or control 
animals (Chen, Solem and Johnson, 1991). Similarly, Johnson etaL, (1991) 
demonstrated that peritoneal macrophages isolated from mice injected with MPL 
produced increased amounts of H2O2 compared to LPS whereas no difference was
found in O2 production. It was speculated that this difference between LPS and MPL
may be related to the presence of an oligosaccharide moiety in the LPS molecule.
Recently, selective deactivation of human monocyte functions in vitro has been 
documented. Monocytes cultured for 72 hours in the presence of TGFp failed to release
H2O2 in response to a stimulating dose of PMA while O2 production was unaffected.
Since evidence of increased catalase production and phagocytic activity was not found,
the existence of a differential modulation of O2 and H2O2 in these cells was suggested
(Warwick-Davies, Lowrie and Cole, 1995). Although a considerable amount of data 
on H2O2 release by in v/fro-primed monocytes has been generated, the state of
functional integrity of in vivo primed monocytes remains unknown. Monocytes 
obtained from surgical patients stimulated with PMA in vitro have been shown to 
release increased amounts of H2O2 . However, patients with sepsis complications
produced increased amounts of H2O2 compared to those who did not develop
complications (Kono et aL, 1995).
1.9.4 Mechanisms of NO production
Nitric oxide is produced from an NADPH-dependent oxidation of L-arginine 
catalyzed by NO synthase (NOS) that leads to the formation of L-citrulline and NO in
equimolar amounts. NO is spontaneously oxidized to NO2" and NO3* very quickly
(half-life of NO is a few seconds) in oxygenated physiological solutions. While the
interaction of NO with O2 results in NO2" and NO3 ', its interaction with O2 forms
peroxynitrite, nitrogen dioxide or hydroxy radicals, which are potentially toxic to target 
cells (Nathan and Hibbs, 1991; reviewed in Billiar, 1995; Griffith and Stuehr, 1995).
The NO synthesis pathway is not well characterized. However, it is known 
that NO synthesis is mediated through the up-regulation of NOS that requires molecular 
O2 and NADPH as co-substrates. Flavin mononucleotide (FMN), flavin adenine 
dinucleotide (FAD), heme, and tetrahydrobiopterin (BH4 ) are cofactors required for the 
synthesis of NO (reviewed in Kolb and Kolb-Bachofen, 1992; Nathan, 1992; 
Furchgott, 1996). Initially, three distinct forms of NOS have been identified and 
isolated: constitutive NOS (cNOS) from endothelium, cNOS from central nervous
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system, and inducible NOS (iNOS) from hepatocytes. Later, NOS was found to exist 
constitutively (cNOS) in a variety of cells including MPs, and iNOS in these cells is 
induced by stimulation (reviewed in Billiar, 1995). However, conflicting data 
regarding the expression of iNOS in human monocytes exists (Griffith and Stuehr, 
1995). It has been reported that LPS and cytokines induce iNOS and iNOS mRNA in 
monocytes (Reiling etaL, 1994; Dugas etaL, 1995; Weinberg etaL, 1995). Although 
iNOS mRNA was detected by a reverse transcriptase-polymerase chain reaction by both 
Reiling et aL, (1994) and Weinberg et aL, (1995), the latter authors could not detect it
by northern analysis or RNAse protection assay. The cNOS is Ca2+/calmodulin 
dependent; in the presence of elevated Ca2+, calmodulin binds to NOS and activates it.
The iNOS is independent of Ca2+/calmodulin where calmodulin remains tightly bound 
to NOS at all times, thus maintaining the enzyme in a tonically activated state (Nathan, 
1992; Billiar, 1995).
The RNIs exert their bactericidal activities by directly inactivating and 
degrading iron-sulfur groups of the organisms or by synergizing with ROIs. Toxicity 
may involve NO itself or in combination with 0% which forms peroxynitrite. This
decomposes to -OH and -NO^ free radicals which are more reactive and toxic than NO
(reviewed in Snyder, 1992; Nathan, 1992). Cytotoxicity caused by high concentrations 
of NO by MPs is non-specific, and therefore, excessive production of NO is believed to 
be a major factor in the pathology of acute inflammatory disease such as sepsis and 
septic shock (Drapier, Wietzerbin and Hibbs, 1988; reviewed in Pastor and Billiar,
1995).
NO production by macrophages is believed to be regulated by cytokines 
through negative feedback modulation of NOS (reviewed in Griffith and Stuehr, 1995; 
Griscavage, Hobbs and Ignarro, 1995) possibly by binding of NO to NOS (Wang et 
aL, 1994). IL-4 has been shown to be a potent inducer or inhibitor of NO production 
by human monocytes in vitro depending upon the activation state of these cells 
(Mautino et aL, 1994). TGFp, a potent inhibitor of iNOS synthesis, has been shown to 
reduce iNOS mRNA without affecting the transcription of iNOS mRNA by decreasing 
protein stability in mouse macrophages. Decreased iNOS protein was found to result 
from decreased iNOS mRNA translation and increased protein degradation (Vodovotz 
etaL, 1993).
1.9.5 Nitric oxide production in vitro and in vivo
NO is the pharmacologically active part of the endothelium-derived relaxing 
factor produced by vascular endothelium and macrophages and NO2" and NO3" are the
stable and measurable end products of NO metabolism. They are found to be released 
in a ratio of 3:2 and follow a lag period of 6  -12 hours for the synthesis of these 
metabolites (Stuehr and Marietta, 1985,198,7). It is reported to be produced at high 
levels by activated macrophages and neutrophils (Ding, Nathan and Stuehr, 1988;
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Drapier, Weitzerbin and Hibbs, 1988) and described as an activation marker and an 
essential mediator of macrophage cytotoxic activity (Adams et aL, 1990; Denis, 1991; 
Green, Nacy and Meltzer, 1991). NO-mediated killing or growth inhibition of many 
pathogenic organisms by MPs in vitro and in vivo has been reviewed and found to 
range from viruses to helminths (De Groote and Fang, 1995). NO acts as a 
neurotransmitter and an inhibitor of platelet aggregation, and as a major defense against 
parasites, tumor cells and intracellular bacteria (in reviews by Kolb and Kolb-Bachofen, 
1992; Quinn et aL, 1995). However, it is not completely understood whether these 
effects in vivo are due to NO itself or related to its reactive intermediates.
NO has been shown to activate guanylate cyclase that promotes formation and 
accumulation of intracellular cyclic guanosine 3'5'-monophosphate (cGMP) resulting in 
vasodilatation (reviewed in Furchgott, 1996). The increase in cGMP leads to relaxation 
of smooth muscle by mechanisms that are not yet known. It has been suggested that it 
involves the activation of cGMP-dependent protein kinase, causing a reduction in
intracellular Ca2+ and/or a reduced sensitivity of the contractile proteins to Ca2+.
The ability of mammalian cells, including human macrophages, to produce NO 
after appropriate stimuli is well recognized. However, evidence of NO release by 
human monocytes is equivocal (reviewed in Denis, 1994; Dugas et aL, 1995). NO 
production in vitro by different cell types is summarized and presented in Table 1.4. 
Monocytes isolated from alcoholics were shown to release significantly higher amounts 
of NO in vitro in response to LPS (Hunt and Goldin, 1992). Leibovich et aL, (1994) 
found that LPS stimulates NO release by human monocytes in culture for 48 hours. 
Mautino et aL, (1994) demonstrated that human donors are heterogeneous in relation to 
spontaneous NO release by monocytes in culture; monocytes from 75% of the
population produced very low levels of NO2" (<10 nM) while others produced high 
levels (10 -110 nM). IL-4 that induces NO2" release, inhibited NO2" release in the 
high producer group while it stimulated NO release in the low producers, suggesting an 
auto-regulatory mechanism of NO release. In addition, spontaneous release of NO2" by
monocyte-derived macrophages correlated with tumor cell cytotoxicity (Martin and 
Edwards, 1993).
De Maria et aL, (1994) presented convincing proof that human monocytes 
produce NO. Monocytes incubated for 18 hours either with LPS or antibody to CD69 
(a member of the natural killer gene family, which is also found in other activated 
leukocytes, that generates an intracellular signal after cross linking) showed that LPS 
did not stimulate NO release whereas cross-linking of the CD69 receptor by anti-CD69
Ab released significant amounts of NO. This release was inhibited by L-MG- 
monomethyl arginine, a known inhibitor of iNOS.
Zembala et aL, (1994) reported that human monocytes produced NO2" only 
when co-cultured with the human colorectal carcinoma cell line, DeTa cells. However,
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Table 1.4. Nitric oxide (NO) release by different cell types in vitro
Treatments Systems Findings References
LPS Mono în c> 2- Hunt and Goldi, (1992)
IL-4 Mono ÎNQr Kolb et aL, (1994)
LPS Mono T NO2 - Leibovich et aL, (1994)
LPS Mono No NO2 ' De Maria et aL, (1994)
Anti-CD69 Ab î n o 2"
DeTa cell Mono Î N 0 2 - Zembala et aL, (1994)
LPS, IFNy Mono No NO2" Konur et aL, (1996)
LPS, TNFa Mono, MDM No NO2 ' Schneemann et aL, (1993)
LPS+INFy MDM No N 02- Reiling et aL, (1994)
LPS, cytokines Mono No NO2 ' Weinberg et aL, (1995)
LPS mMac T NO2-/NO3- Stuehr and Marietta, (1985)
gp 120 HIV MDM ÎN O Pietraforte et aL, (1994)
Spontaneous MDM ÎN02- Martin and Edwards, 
(1993,1994)
LPS RAW 264.7 TN02-/N03- Iyengar, Stuehr and Marietta,
J774 C3C Î  N02-/N03- (1987)
J774.16 T N0 2 -/N0 3 -
LPS, IFNy mMac î  N0 2 -/N0 3 " Ding, Nathan and Stuehr, 
(1988)
Various toxins rBMM ÎN O 2- Keller, Keist and Toiler, (1994)
NO2" = nitrite; NO3" = nitrate; Mono = monocytes; MDM = monocyte-derived 
macrophages; mMac = mouse macrophages; rBMM = rat bone marrow macrophages
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these authors were unable to stimulate the monocytes cultured for 36 hours to produce 
NO2" with LPS, TNF or IFNy. Later, it was found that thé increased NO release by
these cells was inhibited by and-MHC class I and anti-HLA DR antibodies. It was 
postulated that these receptors are involved in the DeTa cell-stimulated NO release of 
human monocytes (Siedlar, Marcinldewicz and Zembala, 1995). By contrast, 
Schneemann et aL, (1993) found that human peripheral or peritoneal MPs cultured from 
2 - 1 2  days did not produce a significant amount of NO after stimulation with LPS, 
IFNy, GM-CSF, TNFa or bacteria and in the presence of BH4 (human phagocytes do
not synthesize BH4). NOS activity in the subcellular fractions of these cells was not
up-regulated, even in the presence of exogenous cofactors such as BH4 and NADPH.
Similarly, Reiling et aL, (1994) found that human monocytes cultured for 7 days do not 
release measurable NO. These authors, using reverse transcription polymerase chain 
reaction (RT-PCR), demonstrated that unstimulated monocyte-derived macrophages 
express cNOS mRNA that disappears with the appearance of iNOS mRNA induced by 
LPS-IFNy stimulation. Weinberg et aL, (1995) using a similar technique, also could 
not demonstrate NO release by monocytes cultured for 3 - 4 days. While none of the 
13 stimuli including LPS, TNFa, IFNy and PMA, with different doses and 
combinations, was effective in the NO release, increased NOS activity as well as iNOS 
mRNA was found with LPS and IFNy treatment. It was concluded that human 
mononuclear phagocytes can produce iNOS mRNA and protein but are unable to 
produce high amounts of NO.
High plasma NO2 /NO3" levels have been reported in septic patients which
correlated with high endotoxin levels in blood (Ochoa et aL, 1991). High serum levels 
of these metabolites were also reported in septic patients that correlated with the degree
of hypotension (Evans et aL, 1993). High levels of NO2YNO3- were found in rat
serum and urine after a single injection of LPS and it was concluded that LPS stimulates 
endogenous production of NO (Shultz and Raij, 1992; Kitajima et aL, 1995).
Suppression of NO synthesis during experimental endotoxemia has been 
shown to be detrimental (Minnafd et aL, 1994). All rats receiving E. coli -LPS at a 
dose of 25 mg/kg body weight and a NO inhibitor, N-nitro-L-arginine methyl ester,
died compared to 87% survival in the control group. The serum level of NO2 '  was
decreased compared to the control group. Similar results were also found with murine 
macrophages in vitro.
Studies with non-elicited mouse peritoneal macrophages revealed that LPS or
MPL treatment caused increased NO2" production. However, a 100-fold higher
concentration of MPL was required to elicit the half-maximum response compared to 
LPS (Gustafson and Rhodes, 1992). Palacios, Knowles and Moncada, (1992) 
demonstrated that LPS treatment but not MPL, increased NOS in rat lung in vivo 
whereas in vitro experiments with lung tissue showed an increased NO production by 
both LPS and MPL compared to control. These authors also reported that LPS caused
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increased NO synthesis in the murine monocytic cell line J774 and in rat peritoneal 
macrophages. However, no non-specific resistance to infection was found to develop 
in the rats treated with MPL.
1.10 Phagocytosis and related activities
1.10.1 Mechanisms of phagocytosis
Phagocytosis is one of the earliest events in the immune response involving 
monocytes and macrophages which are sometimes referred as the "sentries" of the 
defense system. Phagocytosis by these cells generally follows a chain of events with 
specific requirements, i.e., opsonization, attachment and engulfment (Klein, 1990). 
Opsonization facilitates binding and engulfment of the particles (Fearon and Wong, 
1983). However, opsonin-independent mechanisms (phagocyte-receptors interact 
directly with the structural determinants on the surface of the target) also exist, which 
are principally mediated by oligosaccharide-containing moieties on the surface of 
bacteria, or other organisms (reviewed by Greenberg and Silverstein, 1994). There are 
three major classes of opsonihs present in humans, namely: members of the IgG 
family, the third component of the complement (C3) and acute phase reactants.
Particles coated with opsonins bind to the specific receptors of the phagocytic cells, 
i.e., the Fc receptors for the Fc portion of the IgG, complement receptors for the C3b 
(CRI), C3bi (CR3) fragments of complement, and lectin receptors for 
mannose/fucose/n-acetylglucosamine residues of glycoproteins (Ezekowitz, 1992). 
Binding of gram-negative bacteria through phosphocholine residues with acute phase 
reactant, C-reactive protein, also facilitates bacterial interaction with phagocytes. Not 
all particles forming complexes with the surface receptors are internalized. The CR, in 
its inactive form, may bind to its ligand but does not initiate phagocytosis (Wright and 
Silverstein, 1982). The exact mechanisms by which phagocytes are rendered 
"competent for phagocytosis" is not known, but for phagocytosis to occur, the cells 
must be activated by other mediators, possibly cytokines (Greenberg and Silverstein,
1994).
Mononuclear phagocytes are known to express three classes of Fc receptors 
(FcR), FcyRI (CD64), FcyRII (CD32) and FcyRIII (CD 16) (reviewed in Ravetch and 
Kinet, 1991). When an FcyR interacts with Ig, a variety of biological responses are 
triggered which include phagocytosis, endocytosis, antibody-dependent cellular
cytotoxicity (ADCC), enhancement of antigen presentation, O2 production and release
of inflammatory mediators (reviewed by van de Winkel and Capel, 1993; Casado et aL, 
1994; Greenberg and Silverstein, 1994).
After the entry of bacteria or other antigens in the body, or bloodstream, these 
antigens become opsonized with antibody and complement which facilitates their 
attachment to the phagocyte cell surface receptors. This contact initiates changes in the 
plasma membrane of the phagocytic cells via degradation of the membrane lipid,
causing increased intracellular Ca2+ and cytosolic pH of these cells. These changes
lead to the stimulation of diverse and seemingly unrelated pathways including oxidative
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or respiratory burst. The involvement of PKC in this process was demonstrated by 
Park et aL, (1993). COS-1 cells, a fibroblast-derived cell line with cellular machinery 
for phagocytic function, treated with PMA inhibited phagocytosis but did not affect 
IgG-sensitized RBC binding, suggesting that a PKC-dependent pathway inhibits 
phagocytosis.
Following attachment (that initiates intracellular signaling pathways leading to 
submembrane actin filament assembly), the particles are engulfed by clustering, 
assembly and cross-linking of the actin filaments of the phagocytic cells, and 
pseudopod formation. The pseudopod is formed by the phagocytes surrounding the 
particle forming a vesicle known as phagosome. This is followed by fusion of the 
membrane, possibly through a process known as the "Zipper hypothesis". These 
phagosomes fuse with the intracellular lysosomes, a constitutive product of the 
mononuclear phagocytes, forming phagocytic lysosomes or phagolysosomes causing 
digestion of the ingested particles. The cycle is completed by expulsion of the digested 
materials to the extracellular matrix (known as exocytosis) and preparing the cell for the 
next cycle.
1.10.2 Cell mediated cytotoxicity
1.10.2.1 Antibody-dependent cellular cytotoxicity
Cells of the MPS also have the ability to destroy target cells without engulfing 
them, i.e., extracellularly, a phenomenon largely credited to natural killer (NK) cells 
and cytotoxic lymphocytes. This is carried out by releasing toxic materials or initiating 
complex cell-mediated mechanisms. The complete mechanism used by these cells to 
carry out this process is not completely understood. Several different mechanisms have 
been implicated: humoral mechanisms i.e., lysis mediated by antibody and complement; 
ADCC; or cellular mechanisms involving direct recognition and cytotoxicity by the 
effector cells (Benjamin! and Leskowitz, 1991; te Velde and Figdor, 1992).
Mononuclear phagocytes can kill or destroy antibody-coated targets through a 
process known as ADCC. It is performed by a variety of other cells also and requires 
the binding of antibody on the target by Fc receptors on the effector cell. The efficiency 
of ADCC is influenced by such factors as state of activation of the effector cells, species 
and isotype of the antibody, the nature of the target cell, and the specificity or density of 
coating of the anti-target-cell antibody. The Fc portion of the Ig molecule which coats 
the particle binds to antigen receptors on the surface of macrophages. Lysis occurs 
following occupancy and cross-linking of the Fc receptors, which initiates the secretion 
of lytic mediators by macrophages. ROIs, especially H2O2 , play a key role in
cytolysis, but other mediators are also important, such as complement, neutral 
proteases, TNF (reviewed by Auger and Ross, 1992) and RNIs (Martin and Edwards,
1993). Additionally, the spectrum of signals generated by the engagement of the cell 
surface receptors includes generation of superoxide anion, PCs and membrane 
depolarization (Suzuki, 1991). In another review Kurzrock, Gutterman and Talpaz
(1991) indicated that augmented ADCC of macrophages correlates with the up-
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regulation of FcR and HLA-DR expression, and the increased release of oxygen 
radicals, IFN, and lysosomal enzyme.
Although various experiments have shown that cytotoxicity is due to soluble 
factors released by MPs, direct contact between target and effector cell is required in 
order to initiate the release of these factors (Eggen, Bakke and Hammerstrom, 1983; 
Johnson, Whisnant and Adams, 1981). In general, monocytes must be activated to 
carry out ADCC. That can be performed in two steps: (a) target recognition and 
binding; (b) target cytolysis. The involvement of the receptors and mediators in this 
process has been reviewed by Adams and Hamilton, (1984). It was indicated that 
binding of antibody-coated targets by macrophages results from interaction between 
antibodies and the Fc receptors. In one study, inhibition of FcRI or FcRII inhibited 
binding by 50%; inhibition of FcRI reduced subsequent cytolysis by 80% whereas a 
20% reduction was found with inhibition of FcRC. This implies that both the receptors
are involved in the ADCC but that the FcRI is more efficient. The involvement of 0%,
H2O2 and -OH in cytolysis has been indicated. Since the engagement of Fc receptors 
stimulates profuse release of H2O2 from macrophages, the involvement of this radical 
in cytolysis is emphasized.
Liesveld et ah, (1991) using human monocytes, demonstrated that 
macrophages exhibited ADCC towards the human colon cancer cell line (SW1116) 
which reached a maximum at 5 - 7 days. Cytotoxicity in the presence of human Fc 
receptors was inhibited significantly only by anti-FcRin antibody, indicating the 
involvement of this receptor in ADCC.
Connor, Shen and Fanger, (1990) demonstrated that lysis of erythrocytes, as 
demonstrated by formation of lytic plaques by human monocytes, significantly 
increased in the presence of antibody. It has been shown that the ADCC was also 
increased when the monocytes were incubated with IFNy and GM-CSF, but not with 
IL-6  or TNFa. It was suggested that the monocyte ADCC is influenced by factors 
which affect monocyte activation and differentiation.
Keller, Keist, and Joller, (1994) observed that tumor cell lysis by rat bone 
marrow macrophages was enhanced by a variety of gram-negative and gram-positive 
bacteria and their toxins, with the exception of LPS , despite increased expression of
low and high affinity Fc receptors (FcyR I and III), release of TNFa, IL-1 and NO2".
1.10.2.2 Antibody-independent cellular cytotoxicity
As indicated above, Ab-independent cellular cytotoxicity also occurs in MPs 
primarily mediated by complement components. C3- coated target cells are killed 
following binding to the macrophage through their CRs. The receptors that are 
involved in this process are found to be CR1 for C3b and CR3 for C3bi. Following 
binding, cytotoxicity is carried out with the help of various enzymes and proteases, and 
by different cytokines, primarily TNF. It has been reported that LPS may trigger this 
process through CD 14 where LBP acts as an opsonin (Wright et a l, 1989). Changes
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in intracellular pH through an increase in cytosolic Ca2+ allow optimum functioning of 
some cationic proteins. Although not fully understood, they are believed to damage the 
bacterial cell membrane by neutral proteases (cathepsin G), defensins and lactofemn 
(reviewed by Segal, 1989).
TNF-dependent cytotoxic activity in a human histiocytic cell line, U937 cells, 
was reported by van de Loosdrecht et aL, (1993). Nakabo et aL, (1993) reported that 
peripheral blood monocyte-derived macrophages activated by LPS and IFNy lysed two 
different lines of leukemia cells m vitro. The lytic activity was completely inhibited by 
anti-TNF antibody. Since the culture supernatant did not show any lytic activity, it was 
suggested that cell-associated TNF plays a role in this activity. By contrast, a lack of 
enhanced cytolytic activity of mouse peritoneal macrophages in the presence of 
recombinant TNFa and a NO donor was found to negate this notion (Li et aL, 1995).
Senescent erythrocytes and other cells in the circulation are primarily eliminated 
through the complement-coated and complement receptor-mediated phagocytosis.
1.10.3 Non-opsonic phagocytosis and cellular adhesion
The process of non-opsonic phagocytosis is complex and depends upon the 
physical and chemical characteristics of the bacterial surface and complementary 
macrophage receptors. The bacterium which is not opsonized, must first make contact 
with the macrophage membrane before it can be phagocytosed. As reviewed by Speert,
(1992), phagocytosis of a K12 strain of E. coli by human monocyte-derived 
macrophages is mediated in concert by three adhesion-promoting receptors, i.e., LFA- 
1, CR3 and p150,95 with LPS being identified as the bacterial ligand for the 
macrophage receptors. This form of phagocytosis was described as "non-specific 
phagocytosis". Mannosyl/fucosyl receptors have also been reported to play a critical 
role in non-opsonic phagocytosis by macrophages. It has been demonstrated that 
phagocytosis of P. aeruginosa by human macrophages in vitro is facilitated by mannose 
receptors since the phagocytosis was inhibited by D-mannose (Speert et aL, 1988). 
Similarly, uptake of un-opsonized Candida species by macrophages was reported to be 
mediated primarily through mannose receptors (Marodi, Korchak and Johnston, 1991) 
and was enhanced by IFNy (Marodi and Johnston, 1993). Many bacteria, especially 
the encapsulated bacteria or bacteria containing the lipid A moiety, may contact 
monocytes and macrophages directly and initiate the process.
However, not all particles forming complexes with the surface receptor will be 
phagocytosed. The CRs in an inactive form may bind to the ligand but do not initiate 
phagocytosis (Wright and Silverstein, 1982).
1.10.4 Phagocytosis in vitro and in vivo
The decreased functionability of phagocytosis-promoting receptors has been 
associated with a variety of diseases (Greenberg and Silverstein, 1994), but information 
on sepsis-related modulation of phagocytic activity is not known. Very low 
concentrations of LPS greatly increase the phagocytic activity of MPs in vitro (Morland
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and Kaplan, 1977). Vecchiarelli et a l, (1989) found that human PBMs increased 
Candida albicans killing after being stimulated with LPS. Aepfelbacher et a l, (1992) 
demonstrated that Mono Mac 6  cells, when treated with LPS, showed increased 
phagocytosis of Staphylococcus aureus after 72 hours. It was reported that 56% of the 
cells ingested 10 or more bacteria compared with 24% in the control group.
Masihi et a l, (1986) demonstrated that phagocytosis of freshly prepared 
fluorescent beads by adherent peritoneal mouse macrophages was enhanced by LPS or 
MPL stimulation; however, the increment by MPL was significantly lower than that of 
the LPS treatment. Zymosan-induced chemofluorescent activity of splenic cells was 
found to be similar in both the LPS and MPL treatment groups at lower doses, but 
higher doses of MPL (100 ug/ml) increased chemofluorescent activity compared to 
either the control or LPS.
In a study where peritoneal macrophages were collected 2 days after the mice 
were treated with LPS or MPL, a greater increase in phagocytic activity in vitro 
(measured by Candida killing) was seen in the MPL-treated group than in the LPS 
group (Chen, Solem and Johnson, 1991). However, LPS was shown to increase 
phagocytosis by mouse peritoneal macrophages in vitro measured by phagocytosis of 
C. albicans (Leon et a l, 1992). Impaired clearance of IgG-sensitized erythrocytes has 
been documented in cirrhosis patients. The degree of impairment correlated with liver 
insufficiency and presence of infection (Gomez, Ruiz and Schreiber, 1994).
1.11 Cytokines and their modulation by LPS and MPL
The cytokines are glycoproteins (or polypeptide hormones of approximately 
15-50 kDa) produced principally by leukocytes in response to both exogenous and 
endogenous stimulations. Cytokines have autocrine, paracrine and endocrine actions, 
and they play a central role in the development, maturation, differentiation and 
functioning of the cells of the immune system. They interact synergistically, 
antagonistically or in cascade mechanisms with each other, and with their receptors and 
receptor antagonists on the cells of the immune system. Among more than 25 
cytokines, receptors and their antagonists discovered to date, the discussion will be 
restricted to IL-la, IL-1 (3, IL-6 , IL-10, TNFa, GM-CSF, G-CSF, and TGFp, 
considering their significant and potential involvement in the pathophysiology of sepsis, 
and their relation to LPS and MPL.
LPS-induced activation of monocytes is a complex, multi-step event resulting 
in cytokine production. The exact mechanisms and the sequence of the events are not 
yet understood clearly. Many of the effects of LPS leading to septic shock syndrome in 
humans and animals are the result of overproduction of cytokines. It is accepted that 
systemic changes occur in response to cytokines produced by macrophages, such as IL- 
1, EL- 6  and TNFa, as a result of stimulation by LPS (Akira et a l, 1990; van Deventer 
et a l, 1990; Beutler and Cerami, 1987,1989; Hancock et a l, 1992). Also see reviews 
by Tracey and Lowry, (1990); Lowry, (1993) (IL-1, TNFa); Kang et a l, (1992) (IL- 
1, TNF, GM-CSF, M-CSF); Fong and Lowry, (1990); Ayala et a l, (1992) (IL-1, IL- 
6 , TNF); Marchant, (1994) (EL-10); Bogdan and Nathan, (1993) (IL-10, TGFp). The
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elevated circulating cytokine levels in sepsis and septic shock have been found to be 
associated with increased mortality in humans (Debets et al., 1989; Waage et a i, 1989; 
Damas et al., 1989; Marks et a l, 1990; Marano et a l, 1990; Calandra et a l, 1991). 
Also, it has been shown that non-survivors who died of sepsis, had significantly higher 
serum cytokine levels (Damas et al., 1989; Calandra, 1991; Pinsky et al., 1993). 
However, a review of literature by Lowry (1993) indicates that serum levels of 
cytokines in sepsis and septic shock do not correlate with mortality or with the severity 
of the disease. Nevertheless, it was demonstrated that the persistence of elevated serum 
levels of cytokines, especially IL- 6  and TNF, rather than peak levels of cytokines, 
predicts a poor outcome in patients with shock (Pinksy et al., 1993).
1.11.1 Interleukin-1
There are two types of IL-1 (IL- loc and IL-ip) produced primarily by MPs, 
epithelial cells and some cells of the central nervous system (Oppenheim, et a l, 1986; 
Dinarello and Wolff, 1993). IL-1 is considered to be pro-inflammatory (Le and Vilcek, 
1987; Dinarello, 1991,1991a) and is released in response to injury or infection (Damas 
et a l, 1989) and by activated cells (Oppenheim, et a l, 1986). However, IL-1 is not 
usually detected in mild inflammation but has been detected in serum of septic or 
severely infected patients (Michie et a l, 1988; Cannon et a l, 1990; Fong et al., 1990; 
Fischer et a l, 1992a; Martich et a l, 1991). Both IL -la and IL-lp bind to the same 
receptor and appear to have identical functions (Oppenheim, et a l, 1986). IL -la is the 
membrane-bound form and IL-lp the secreted form which is found in high 
concentration in the extracellular matrix.
IL-1 has pleiotropic effects on a variety of cells and has been implicated as one 
of the preeminent mediators of acute inflammation. Prominent among the effects of IL- 
1 is pyrogenic activity, stimulation of hepatocytes to produce acute phase proteins, T- 
and B-cell activation, B-cell proliferation and maturation, and induction or suppression 
of other interleukins (Pike and Nossal, 1985; Le and Vileck, 1987; Dinarello, 1991; 
Dinarello and Wolff, 1993). *
LPS was shown to increase IL-1 (Réllstab and Schaffner, 1989) by cultured 
human monocytes within 36 hours whereas Bing et a l, (1992) showed that freshly 
harvested human PBMCs increased IL-1 production following LPS stimulation within 
5 hours. A dose-dependent increase in IL-lp production by human PBMCs incubated 
with 0.1 to 100 ng/ml LPS for 24 hours has been documented (Poutsiaka et a l, 1991). 
Later, a similar dose-dependent increase in both IL-la and IL-lp by LPS-stimulated 
monocytes was shown by Conti et a l, (1992).
Increased release of IL-1 in response to LPS or sepsis as well as the 
development of tolerance to LPS in animals and humans has been documented (Lepe- 
Zuniga, 1990; Mathison et al, 1990; Ayala et a l, 1992; Dehoux et a l, 1994; Li et a l,
1994). Ayala et a l, (1992) showed that peritoneal macrophages from septic mice 
spontaneously released EL-1 in vitro but further stimulation by LPS did not augment 
already elevated IL-1 release. It was also shown that macrophages from the control 
mice did not produce detectable amounts of IL-1 whereas LPS stimulation produced
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comparable amounts of IL-1 to that of the septic mice. LPS pretreatment was shown to 
decrease IL-1 release following LPS challenge in rabbits (Mathison et al., 1990). IL-1 
release has been shown to be increased by LPS stimulation in murine macrophages, but 
by contrast, the release was augmented after a second stimulus with LPS in vitro (Li et 
al., 1994).
IL-1 release in vitro has been shown to be increased by human monocytes in 
response to LPS but found to attenuate after the second stimulus (Lepe-Zuniga, 1990). 
IL -la and p mRNA expression was shown to be up-regulated in human PBMCs with 
LPS (Kaspar and Gehrke, 1994). Faist et al,, (1992) reported that human PBMCs 
from septic patients suppressed LPS-stimulated release of IL-1 in vitro, suggesting an 
altered behavior of monocytes following injury and infection. Similarly, alveolar 
macrophages from patients with pneumonia have been shown to produce increased 
amounts of IL-lp spontaneously, but attenuate the release in response to LPS (Dehoux 
etal., 1994).
1.11.2 Interleukin-6
IL- 6  is a polypeptide cytokine produced mainly by MPs, T-cells, fibroblasts 
and endothelial cells which performs several biologic functions, sharing its activity with 
IL-1. It influences the proliferation, activation and differentiation of B-cells (into Ig- 
secreting plasma cells), T-cells, hepatocytes and stem cells. It also induces hepatic 
acute phase protein synthesis and increases albumin gene expression. IL- 6  is 
considered to be an endogenous pyrogen. Its primary physiological role is presumably 
to act as a messenger between damaged tissue and the liver. IL- 6  works synergistically 
with EL-1 on T-cell proliferation, synthesis of Ig by B-cells and promoting B-cell
growth. IL-1 and TNF (alone or in combination with IFNy), platelet-derived growth
factor and GM-CSF were shown to induce EL-6  production in various cell types and its 
role in infection is well demonstrated (Van Snick, 1990; Lingerie et al., 1993). EL-6  
production is regulated by a variety of signals including LPS, EL-1 and TNF and its 
effects on different cells vary considerably (reviewed by Hirano et al., 1990; van Snick,
1990). It is one of the major acute immune responses to an infection (van Snick,
1990). A recent review indicated that IL- 6  also has anti-inflammatory properties; it has 
been shown to induce secretion of IL-lra and soluble TNF receptor (sTNFr) (Klein and 
Brailly, 1995). However, it is not clear yet whether IL-6  production is beneficial or 
harmful for the host.
Plasma IL- 6  levels were elevated in humans infused with a bolus injection of 
E. coli endotoxin (van Deventer et al., 1990). Elevated levels of IL- 6  are associated 
with many disease conditions including sepsis and septic shock (reviewed by Hack et 
al., 1989; Dofferhoff et al., 1991). It has been detected in the serum, cerebrospinal and 
synovial fluid of patients with bacterial infections, sepsis and septic shock (Damas et 
«/., 1989; Hack et al., 1989; Helfgott et al., 1989; Waage et al., 1989; Pinsky et a l, 
1993; Lin et a l, 1994). The serum level of IL- 6  in sepsis has been correlated with 
TNFa, APACHE II score and mortality (Damas et a l, 1989). The elevated EL- 6  and
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TNFa has been correlated with the fatal outcome in sepsis patients (Hack et al., 1989; 
Waage etal., 1989).
Calandra et a l, (1991) reported that the IL-6  level was higher in patients who 
died of fulminant septic shock compared to either patients who survived or patients 
during transient reversal of shock. Similar findings were reported by Pinsky et al.,
(1993). Later, Lin et al., (1994) found that patients suffering from severe sepsis had 
significantly elevated levels of IL- 6  compared to normal controls.
In vitro, endotoxin has been shown to induce gene expression and secretion of 
IL-6  by MPs (Ritchie and Fuller, 1983). Breuninger et al., (1994) found that human 
monocytes incubated with LPS under different conditions released varying amounts of 
IL-6 . It was concluded that length of monocyte culture and adherence may alter LPS- 
induced IL- 6  release. Recently, Otterlei et al., (1995) demonstrated that the production 
of IL-6  by LPS-stimulated human monocytes is enhanced by antibody to CD 18, 
indicating a role of adhesion molecules in IL-6  release. Monocytes isolated from septic 
shock patients were shown to release increased amounts of IL- 6  in vitro spontaneously 
or in response to IFN or muramyl dipeptide, a stimulator of certain cell function (Miller- 
Graziano et a l, 1990).
Increased IL- 6  production by murine peritoneal macrophages in experimental 
sepsis (Ayala et al., 1992) and in LPS-stimulated cells (Li et al., 1994) has been 
documented. Pretreatment with LPS decreased IL- 6  release by these cells, indicating a 
tolerance phenomenon (Mengozzi et al., 1991a; Leon et al. 1992; Zingarelli et al.,
1995). Alveolar macrophages from patients with pneumonia have been shown to 
produce increased amounts of IL- 6  spontaneously but the release was attenuated in 
response to LPS (Dehoux et ah, 1994).
Pretreatment with MPL has also been shown to suppress IL-6 , IFN and TNF 
release in LPS challenged mice (Henricson, Benjamin and Vogel, 1990; Astiz et ah,
1993) and humans (Astiz et al., 1995).
1.11.3 Interleukin-10
IL-10 is a 35 kDa noncovalently-linked homodimeric pleiotropic peptide 
initially described as "cytokine synthesis inhibitory factor" produced by lymphocytes 
(Fiorentino et ah, 1989) and MPs (de Waal Malefyt et al., 1991) (reviewed in Moore et 
al., 1993.). It acts on different cell types, including lymphocytes (MacNeil et al., 1990; 
Fiorentino et al., 1991), mast cells (Thompson-Snipes et al., 1991) and MPs 
(Fiorentino etal., 1991,1991a; Bogdan and Nathan, 1993). It is inhibitory to 
monocyte cytokine synthesis and antigen-presentation. The latter function results from 
the decreased expression of MHC class II molecules on monocytes (de Waal Malefyt et 
al., 1991a). In contrast to these findings, an amplification of IgG-coated ox RBCs, and 
binding and ingesting of opsonized bacteria or latex beads in vitro by monocytes and 
the U937 cell line was reported (Spittler et al., 1995).
LPS has been shown to activate monocytes to release IL-10 in vivo and in vitro 
following the peak release of TNF (de Waal Malefyt et a l, 1991; reviewed in Docke et
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al., 1994). Monocytes have been shown to release significant amounts of IL-10 in 
vitro within 7 hours, reaching maximum release within 24 - 48 hours of culture, with a 
subsequent decrease reaching near-control levels by 98 hours (de Waal Malefyt et al.,
1991).
It was reported that IL-10 strongly inhibited macrophage IL-10 mRNA 
synthesis after 24 hours incubation with LPS, but, in the presence of neutralizing anti- 
IL-10 mAb, increased the expression of the mRNA. The existence of an auto- 
regulatory mechanism for IL-10 has been suggested; it was described as the first 
cytokine exhibiting a negative feedback mechanism of its own production. IL-10 also 
was found to inhibit the synthesis of IL-la, IL-lp, IL-6 , IL-8 , TNFa, GM-CSF, G- 
CSF at the transcriptional level and to down-modulate MHC class II molecules 
following activation by LPS. In addition, inhibition of T cell proliferation and IFN-y 
production by lymphocytes was reported to be mediated through the decreased MHC 
class II expression and other monocyte-dependent mechanisms, respectively (reviewed 
by Docke et al., 1994). IL-10 has been found to prevent macrophage cytotoxic activity 
by inhibiting both cytokine and nitric oxide release (Bogdan, Vodovotz and Nathan,
1991). Recently, IL-10 injected into human volunteers has been shown to suppress the 
production of pro-inflammatory cytokines and exert inhibitory effects on T cells 
(Chemoff et al., 1995). However, release of anti-inflammatory sTNFa receptor and 
IL-lra were not suppressed, rather sTNFa release was increased. It was suggested that 
IL-10 treatment may be detrimental for the host. Subsequent animal studies have 
shown that inhibiting biological activity of IL-10 by using anü-IL-10 serum improved 
bacterial clearance and prolonged survival (Greenberger et ah, 1995).
IL-10 has been detected in plasma after administration of LPS to animals 
(Durez et al., 1993) and in patients with sepsis and septic shock (Lin et al., 1994; 
Marchant et al., 1994; Derkx et al., 1995; Gomez-Jimenez et al., 1995). IL-10 was 
elevated in human volunteers infused with LPS, peaking at 3 hours, and reaching the 
baseline level at 6  hours (van der Poll et al., 1996). It was shown to suppress LPS- 
induced production of IL-la, IL-la, and TNFa in murine macrophages by increasing 
degradation of the mRNA (Bogdan et al., 1992). By contrast, IL-10 has been shown 
to enhance phagocytosis of IgG-sensidzed ox erythrocytes, and to bind and ingest 
opsonized E. coli or latex beads (Spittler et a l, 1995).
1.11.4 Tumor necrosis factor a
To date, two different forms of TNF have been identified, each of which is 
synthesized by different cells. TNFa, the predominant and active form, is produced by 
MPs, mast cells and endothelial cells whereas TNFp is secreted by T-lymphocytes. 
TNFa (also known as cachecdn) is a 17 kDa non-glycosylated protein synthesized, as a 
26 kDa transmembrane precursor, primarily upon activation by LPS, IL-1, IFN-y or 
TNFa (Beutler and Cerami, 1989; Cord et al., 1992).
TNFa exerts a diverse effects including cytotoxicity of tumor or virus-infected 
cells, modulation of the immune and inflammatory response, and metabolite formation 
resulting in hyperlipemia, bone resorption and muscle glycogenolysis leading to
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cachexia (reviewed by Sherry and Cerami, 1988). Increased levels of TNF have been 
demonstrated in many disease conditions and are believed to be a key mediator in 
endotoxic shock (Tracey and Lowry, 1990). It is generally accepted that the lethal 
activities of LPS are induced via endogenous mediators formed by the interactions of 
LPS with the cellular targets. This is believed to be mediated mainly through TNFa 
(Beutler and Cerami, 1987,1989; Tracey and Lowry 1990). While its involvement in 
sepsis and septic shock is undisputed, the significance of the serum level of this 
cytokine in predicting the outcome in septic shock is debatable.
Increased serum levels of TNF have been observed in patients with septic 
shock (Damas et al., 1989) and normal subjects infused with LPS (van Deventer et al., 
1990). Offner et al., (1990) found that serum TNFa levels were high in sepsis patients 
compared to control, and survivors were found to have lower TNFa levels. Calandra 
et al., (1990) observed that increased TNFa and IL-lp were associated with poor 
outcome in septic shock, and patients with higher levels of these cytokines eventually 
did not survive. Although Cannon et al., (1990) reported slightly elevated plasma 
levels of TNFa and IL-lp in patients with septic shock, they found higher levels of IL- 
lp in the survivor than in the non-survivor. Leroux-Roels et al., (1990) observed 
slightly elevated plasma levels of TNFa in a similar group of patients that persisted 
longer than comparable normals. It was suggested that the toxic effects of TNFa may 
not depend as much on the concentration as on its persistence within the body. Later, 
Pinsky et al., (1993) clearly demonstrated that TNFa and IL- 6  levels increased 
significantly in patients with sepsis and septic shock and that nonsurvivors had higher 
levels of these cytokines compared to normals. It was also documented that persistent 
increased levels of these cytokines correlated better with outcome than the peak levels 
during the acute stage. Although APACHE II scores did not correlate with serum
TNFa levels, significantly increased TNFa in septic shock patients has been reported
(Lin et al., 1994).
In a review, Sherry and Cerami, (1988) indicated that LPS induces TNF 
release by stimulating macrophages both in vivo and in vitro. Increased levels of 
TNFa were found in normal volunteers administered with LPS (Michie et al., 1988; 
Van Zee et al., 1995; van der Poll et aL, 1996). It was demonstrated that TNFa was 
released after LPS infusion followed by the TNF receptor (TNFr)-l, however, TNFa 
came to the baseline within 3 hours, although TNFa levels remained high for 
approximately 24 hours (Van Zee et al., 1995). Increased TNFr in patients with sepsis 
and septic shock has been reported earlier (Lowry, 1993).
Rellstab and Schaffner, (1989) and Lee et al., (1990) showed that monocytes
produced increased levels of TNF following LPS stimulation. Later, this was
confirmed by Bing et al., (1992) showing that cultured mononuclear cells stimulated by
LPS produced an increased level of TNF production within 5 hours. Similar results
from monocytes were reported by Otterlei et al., (1995). In addition, these authors
demonstrated that antibody to CD 18 enhanced TNFa release from these cells. Since
CD 14 expression increased concurrently, it was suggested that CD18 regulates CD14
expression and participates in LPS-induced TNFa production. Matic and Simon,
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(1992) stimulated monocyte-derived macrophages in a series of different protocols and 
consistently found that LPS increases TNF release by these cells. Unstimulated cells 
did not produce significant amounts of TNF, regardless of the length of incubation. 
However, monocytes isolated from septic shock patients were found to release 
increased levels of TNFa either spontaneously or in response to IFN and muramyl 
dipeptide (Miller-Graziano et a l, 1990).
Pretreatment with LPS in experimental sepsis decreased serum TNFa in mice 
(Henricson et aL, 1990; Mengozzi, 1991a; Astiz et aL, 1993) and rabbits (Mathison et 
ai., 1990) in vivo, and in mouse peritoneal macrophages (Haslberger et aL, 1988; 
Mengozzi, 1991; Henricson et al., 1992; Leon, et al., 1992) and human PBMs (Matic 
and Simon, 1991) or monocyte-derived macrophages (Lepe-Zuniga, 1990; Matic and 
Simon, 1992) in vitro. Similarly, LPS stimulation in vitro has been shown to increase 
TNFa release, but a second stimulation attenuated its release in human monocyte- 
derived macrophages, indicating the development of tolerance in these cells by LPS pre­
exposure (Lepe-Zuniga, 1990). A similar behavior of TNFa release in pneumonia 
patients (Dehoux et aL, 1994) has been seen as described for IL- 6  in Section 1.11.2.
Kiener et aL, (1988) demonstrated in an in vivo mouse model of sepsis that 
peak serum levels of TNF were lower in MPL-treated mice compared to those treated 
with LPS. Henricson, Benjamin and Vogel (1990) indicated that MPL pretreatment in 
mice caused the release of less TNF and IL- 6  in response to LPS challenge when 
compared to an LPS-pretreated group. Similarly, Henricson et aL, (1992) 
demonstrated that MPL inhibits TNFa release from thioglycolate-elicited macrophages 
in vitro. Later, it was confirmed that MPL pretreatment reduces the LPS-induced 
elevation of TNFa in vivo in mice (Astiz et aL, 1993) and in humans (Astiz et aL,
1995).
1.11.5 Granulocyte-macrophage colony stimulating factor
GM-CSF is a member of the CSF family that includes IL-3, M-CSF, G-CSF 
and GM-CSF. GM-CSF was found to be produced by macrophages, monocytes, 
activated T-cells and fibroblasts (Vellenga etal., 1988; Groopman, Molina and 
Scadden, 1989; Lee et aL, 1990; Bing et aL, 1992). GM-CSF is a 14kDa polypeptide 
with multipotential,‘ hemopoietic growth factor activity in vitro that is similar to IL-3 
(Gillan, Plunkett and Cairo, 1993).
GM-CSF generates macrophages and granulocytes from progenitor cplls by 
clonal proliferation and differentiation (Vellenga et al., 1988; Lee et aL, 1990; Bing et 
aL, 1992). These cytokines are also considered to be stimulators of MPs as 
demonstrated by the increased expression of MHC class II molecules (Alvaro-Gracia, 
Zvaifler and Firestein, 1989; Jansen ef aL, 1989) and adherence to the endothelium 
(Gamble et aL, 1989). GM-CSF and M-CSF increase the monocyte-macrophage 
production of other cytokines (Sisson et aL, 1988; Young, Lowe and Clark, 1990), 
activate their killing of bacteria, possibly through the generation of RNIs (Smith et aL, 
1990; Denis, 1991) and enhance ADCC by human monocyte-derived macrophages 
(Young, Lowe and Clark, 1990; Liesveld et aL, 1991). GM-CSF has been reported to
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prime the functional activation of monocytes in vitro (Khwaja et aL, 1992) for enhanced 
ability to kill intracellular parasites (Ho et aL, 1990), and induce growth inhibition of 
Mycobacterium avium-M. intracellulare (Blanchard et aL, 1991) and Aspergillus 
fumigatus (Roilides et aL, 1996). It has also been shown to increase cellular 
expression of FcyRI in 3-day old monocytes (Buckle et aL, 1990) whereas decreased 
expression of this receptor was reported in monocytes cultured for 14 days in vitro. 
Since the FcyRIII expression was found to be unchanged, the latter authors suggested 
that expression of these receptors is regulated independently.
There is little agreement between investigators regarding the mode of secretion 
of this cytokine. Lee et al., (1990) demonstrated that freshly isolated, adherent 
monocytes produce GM-CSF after stimulation with LPS, but become refractory to LPS 
stimulation when in culture for 24 hours. Similarly, human monocytes in suspension 
have been shown to release high quantities of GM-CSF with LPS stimulation but 
become refractory to further stimulation with the same class of LPS (Sullivan et aL, 
1983).
Golde and Cline, (1975) found that, in humans, blood levels of GM-CSF 
begin to rise within 1 -2  hours following LPS stimulation, reach a peak concentration 
at about 24 - 36 hours arid return to resting levels at 48 - 72 hours without further 
stimulation. Hogasen, Hestdal and Abrahamsen (1993) demonstrated that GM-CSF 
(10 ng/ml or higher doses) inhibited the production of C3 by monocytes in vitro. It 
was also shown to abrogate the LPS -induced elevation of C3 and factor B production 
by GM-CSF, implicating its role in inflammation.
In vitro GM-CSF was shown to be produced by both unstimulated and 
stimulated mononuclear cells within 5 hours of their attachment to latex beads. By 
contrast, others reported that unstimulated human monocytes did not release GM-CSF 
but that it was produced by LPS-stimulated cells incubated for 18 hours (Hamilton et 
al., 1992) and M. avium-M. intracellulare-sûmxi\&teà monocytes within 2 days 
(Blanchard et aL, 1991) in vitro.
Data on the effects of MPL on GM-CSF release by human monocytes are not 
available, however, Henricson, Benjamin and Vogel (1990) indicated that LPS and 
MPL induced comparable amounts of CSF by mouse peritoneal macrophages.
1.11.6 Granulocyte-colony stimulating factor
G-CSF is another member of the CSF family with a molecular weight of 
18-22 kDa produced from MPs and fibroblasts (Vellenga et aL, 1988; Weisbart et aL, 
1989; Gillan, Plunkett and Cairo, 1993). Found in humans, it received its name due to 
its ability to sustain proliferation and differentiation of colonies consisting primarily of 
neutrophilic granulocytes (Metcalf, 1989). It has been shown to stimulate the 
production and functional activation of neutrophilic granulocytes both in vivo and in 
vitro. In addition, it is now recognized that G-CSF has a variety of effects on mature 
granulocytes, including prolongation of survival in vitro, augmentation of ADCC and 
enhancement of phagocytosis. However, most of the functions of the G-CSF overlap 
with that of GM-CSF (Nicola and Vadas, 1984; Begley et aL, 1986).
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Though the kinetics and pathophysiologic effects of G-CSF in humans have 
not been clearly understood, increased levels of G-CSF in serum was reported in 
persons with hematological and infectious disorders (Kawakami et aL, 1990,1992; 
Shirafuji etal., 1989; Watari, et aL, 1989; Kawakami, 1994). In vitro stimulation of 
monocytes has also been shown to release significant amounts of G-CSF within 18 
hours incubation (Hamilton et aL, 1992). In vivo experiments have shown that G- 
CSF increased the number of neutrophils in mice infected with P. aeruginosa and 
increased survival (Yasuda et aL, 1990). Later, in a canine model of sepsis and septic 
shock, G-CSF has been shown to increase peripheral neutrophil number and improve 
survival (Eichacker et aL, 1994). By contrast, no relationship has been found with 
serum level of G-CSF and total WBC count or peripheral neutrophil count in human 
patients with infections (Kawakami et aL, 1990,1992; Kawakami, 1994). In the latter 
two studies, the serum levels of G-CSF were found to be higher during acute infections 
and lower during recovery. It was also found that patients with repeated infections had 
lower levels of this cytokine. This finding implies that with repeated infections patients 
develop tolerance to infection-induced G-CSF release.
1.11.7 Transforming growth factor-p
TGFp represents a family of proteins designated as TGFpl through TGFpS. 
These are disulfide-linked homodimers and are produced by a number of cell types 
including fibroblasts, monocytes, chondrocytes, astrocytes and endothelial cells. These 
proteins are synthesized as larger, inactive protein precursors. The biologically latent 
form remains as a complex with a latency-associated protein. Subsequent to secretion 
from the cell, activation must occur to release the biologically active dimer form. 
Whereas acidification can release the TGFp dimer in vitro, in vivo activation is still a 
controversy.
TGFp is constitutively present in monocytes (Assoian et aL, 1987; de Waal 
Malefyt et aL, 1991) and releases after monocyte activation (Assoian et al., 1987). It is 
also produced by activated macrophages and depresses monocyte cytokine release and 
HLA-DR expression (reviewed in Docke et aL, 1994). Monocytes alone can produce
only a marginal level of active TGFp, however, in the presence of IFN-y, they are
shown to process exogenous latent TGFp from platelets (Twardzik et aL, 1990).
TGFp is a pluripofent cytokine which has been known for its role in wound 
healing; it inhibits the proliferation of many cell types and strongly simulates matrix 
formation. The role of TGFp may be stimulatory or inhibitory depending upon the 
stage of activation of the cell and the triggering stimulus. It stimulates monocyte cyto­
kine release, inhibits ROIs release and stimulates fibroblast proliferation (Corradin et 
aL, 1993; reviewed in Rifkin et aL, 1993). TGFp was shown to suppress LPS-induced 
production of IL-la, IL-lp, and TNFa by murine macrophages (Bogdan et aL, 1992).
Miller-Graziano et aL, (1990,1991) demonstrated that monocytes isolated 
from immunocompromised patients including sepsis patients secreted significantly 
increased amounts of TGFp. These authors indicated that TGFp may be a key inducer
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of the immunosuppression associated with trauma and sepsis.
1.12 Cytokine receptors and their antagonists
Cytokines work upon binding to the receptors expressed on the surface of the 
cells and, in certain cases, with soluble receptors. Soluble receptors sometimes work 
as inhibitors and confer an auto-regulatory mechanism. For many cytokines, soluble 
receptors have been found which retain their ligand binding ability and compete with the 
membrane receptors, thus acting as antagonists (reviewed in Femandez-Botran, 1991). 
In addition, these receptors also have been shown to act as transport proteins which 
protect the corresponding cytokines from proteolytic damage (Femandez-Botran and 
Vitetta, 1991). Some receptors, such as those for IL-1, EL-2, IL-6 , and receptor 
antagonist, IL-lra, are implicated in septic shock and are discussed here.
1.12.1 Soluble IL-2 receptors
The IL-2 receptors (IL-2r) are induced receptors expressed on a variety of 
cells, including monocytes and activated lymphocytes. These receptors are expressed 
on lymphocytes upon presentation of processed antigens by the APCs. The interaction 
between T-cell receptors and the antigens induce the expression of EL-2r that can bind 
IL-2. Monocytes express these receptors after being stimulated, especially by IL-2 
(reviewed in Smith, 1989). These receptors consist of a low affinity a  chain (55 kDa 
peptide) and an intermediate affinity p chain (75 kDa peptide) which together form the 
p55-p75 high affinity receptor. The low affinity p55 is also known as CD25 and will 
be discussed later (Section 1.14.5). Recently, a third form of IL-2ry (p58 - p64 kDa 
protein) has been found in human monocytes that was reported to be constitutive 
(Epling-Bumette et aL, 1995). EL-2 binds to high affinity receptors resulting in signal 
transduction; it may also result from binding to p75 alone, however, it is 100 times less 
potent (reviewed by Smith, 1989). The high affinity receptors are stable components 
on lymphocyte, monocyte and macrophage membranes whereas the low affinity 
subunits are absent in monocytes but can be induced by cellular activation (Smith,
1989; Scheibenbogen et aL, 1992). Following stimulation, a part of the 55 kDa subunit 
is released from the membrane, becoming the sIL-2r, which has been considered a 
circulating marker of cell activation. This released form of EL-2r has a molecular weight 
of 45 kDa, lacking the transmembrane and cytoplasmic portion of the cell surface- 
expressed EL-2r chain (Robb and Kutny, 1987). Although both proteolytic cleavage of 
the surface IL-2r p55 or differential splicing of this chain encoding the mRNA have 
been suggested as a possible mechanism for this receptor release (reviewed by 
Anderson, 1982), data from thé studies by Robb arid Kutny (1987) support the 
proteolytic cleavage mechanism for this receptor release. Later, Kniep, Strelow and 
Lohmann-Matthes, (1992) demonstrated that sIL-2r is produced in the cytoplasm and 
secreted as preformed protein in human monocytes.
sEL-2r has been demonstrated in the supernatant of activated PBMCs, T- and 
B-cell line (Rubin et aL, 1985). Increased sIL-2r has been shown to occur in bum
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patients (Teodorczyk-Injeyan et al., 1991,1992) and in the supernatant of LPS- 
stimulated monocytes (Holter et al., 1987; Valitutti et aL, 1989; Kniep, Strelow and 
Lohmann-Matthes, 1992). Studies with human PBMCs indicate that sIL-2 receptors 
are released either spontaneously in small quantities, or in increased quantities 
following LPS stimulation (Holter ef aL; 1987; Valitutti et aL, 1989). The LPS- 
stimulated response appeared to be augmented by a co-stimulation with IFNy (Holter et 
aL, 1987). By contrast, sIL-2r release by monocytes was not found even after 24 
hours in vitro. However, increased release of sIL-2r was demonstrated by 7-day old 
macrophages stimulated with LPS (Scheibenbogen et aL, 1992). It was suggested that 
the release of sIL-2r was independent of CD25 expression on the cell surface, 
suggesting an active secretion of this peptide from macrophages rather than a simple 
shedding.
Kniep, Strelow and Lohmann-Matthes, (1992) demonstrated that LPS 
stimulation of monocytes produced large quantities of sIL-2r within 48 hours. Further 
investigation of the mode of secretion and location of this receptor revealed that it was 
present in the cytoplasm within 24 hours of stimulation and did not increase further 
with longer incubation. Fractionation of the monocytes and examination of the 
presence of receptor in different fractions of the cells revealed that the main portion of 
this receptor was present in the cytoplasm. It was postulated that, in monocytes, the 
cell-associated IL-2 receptors are not necessarily attached to the membrane, but freshly 
produced and subsequently secreted.
1.12.2 Soluble IL-6 receptors
The membrane receptors of IL-6  consist of two glycoprotein chains; the a  (80 
kDa) and the p (130 kDa). The former is cleaved to yield the circulating 55 kDa soluble 
IL- 6  receptor (sIL-6 r) (Hibi ef aL, 1990). IL-6  binds to IL-6 ar to form a binary 
complex which then binds to two molecules of IL-6 pr, causing its phosphorylation.
The homodimer of IL-6 pr is responsible for signal transduction (Ip et aL, 1992; Yin et 
aL, 1993).
sIL-6 r was initially thought to be essential for the final maturation of B-cells 
into antibody-forming cells (reviewed in Kishimoto and Hirano, 1988). sIL-6 r was 
found in the body fluid of normal individuals, however, increased production was 
found in T-cell abnormality and AIDS, or in stimulated PBMCs in vitro (Honda et aL, 
1992). Bauer et aL, (1989) have reported that EL-6 r was present in human monocytes 
and LPS stimulation down-regulated its expression in vitro as measured by decreased 
levels of IL-6 r mRNA, indicating their role in the inflammatory process. This process 
was found to be inversely proportional to the expression of IL- 6  mRNA. IL- 6  was also 
found to suppress IL-6 r at higher concentrations. Oh the other hand, IL-6 r was up- 
regulated in hepatocytes by IL-1 and IL-6 . Repression of monocyte EL-6r and 
stimulation of hepatocyte IL-6r synthesis was thought to be a shift of the IL-6  tissue 
target under inflammatory conditions.
Direct evidence of the presence of sEL-6  receptors in cell culture supernatants is 
scant, however, some investigators reported the presence of IL- 6  receptors on T-cells,
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activated B-cells, plasma cell lines, histiocyte cell line U937, and the promyelocytic cell 
line HL60 (Taga et aL, 1987; Horiuchi et aL, 1994).
1.12.3 IL-1 receptor antagonist
IL-1 receptor antagonist (IL-lra) is a secreted ligand (also considered as a 
cytokine) from various cells, notably from tissue macrophages and stimulated 
monocytes and has no agonist activity (Arend et al., 1990; Arend, 1991; Hannum et aL, 
1990; Schur et aL, 1990; Poutsiaka et aL, 1991; Dinarello and Wolff, 1993). It shows 
homology with IL-lp, binds and blocks IL-1 receptors (IL-lr), and was shown to be a 
potent inhibitor of inflammation (Hannum et aL, 1990; Ohlsson et aL, 1990; Granowitz 
et aL, 1992; Dinarello and Wolff, 1993). Inhibitory action of IL-lra results from 
competitive binding of IL -la or p receptors, and the binding of IL-lra to these receptors 
does not induce signal transduction (Dripps et aL, 1991; Granowitz, et aL, 1992).
Later, it was shown that there are two types of IL-lr: type I and type n. IL-lra binds to 
IL-lr type I that blocks the binding of IL-la or p with IL-lr on cells, thus blocks the 
effects of IL-1. Binding of IL-1 to thé type II receptor does not transduce the 
intracellular signal (reviewed by Debets and Savelkoul, 1994). O'Nuallain et aL, (1995) 
found increased levels of plasma IL- Ira and IL-lp in patients who have undergone 
surgery but could not demonstrate the presence of IL-lra in PBMCs or PMNs cell- 
lysate of these patients. It was, thus, suggested that these cells are not the source of IL- 
lra. Others suggested that macrophages, not monocytes, are the producer of IL-lra 
(Janson, Hance and Arend, 1991; Tilg et aL, 1994). IL-lra has been shown in vitro to 
inhibit LPS-stimulated release of IL-la and p (Conti et ai., 1992), and IL-lp and TNFa 
(Marsh et al., 1994) by human PBMCs.
In animal models, IL-lra has been shown to prevent the lethal effects of LPS 
or septicemia (Ohlsson etal., 1990; Alexander etal., 1991; Mengozzi et aL, 1991; 
Wakabayashi et aL, 1991; Fischer et aL, 1992). It has been shown to be effective in 
preventing lethal effects of LPS- or E. co/z’-induced shock in rabbits and baboons 
(Ohlsson et aL, 1990, Wakabayashi et aL, 1991), and in mice (Alexander et aL, 1991). 
In the latter study serum TNF levels and in vitro toxicity were not modulated. These 
findings were interpreted as evidence that the LPS effect was mediated through IL-1. 
Similarly, Mengozzi et aL, (1991) showed that administration of IL-lra protected the 
mice from lethal effects of IL-1 including the blocking of IL-6  secretion.
Fischer et aL, (1992) demonstrated a clear relationship between endotoxemia 
and IL-lra in humans and animals, both clinically and experimentally. IL-lra was 
found to increase in critically ill patients and £. co/Z-induced septic shock in non-human 
primates. In animals the fatal outcome of septic shock was thought to be due to the lack 
of adequate IL-lra release to block the effects of IL-lp. It was suggested that IL-lra 
may play a role in mediating the systemic host response to non-lethal disease by altering 
the balance between cytokines and their antagonists. LPS or sepsis-modulated release 
of IL-lra in humans and animals is summarized and presented in Table 1.5.
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Table 1.5. IL-1 receptor antagonist release in vivo and in
vitro by human cells
Treatments Systems Findings References
Surgery PBMCs, PMNs Not detected O'Nuallian et aL, (1995)
Plasma Î
Critically ill Plasma Î Fischer et al., (1992a)
Critically ill Plasma Î Fisher et aL, (1994)
Exp. endotox Serum T van der Poll et aL, (1996)
LPS Mac Î Kline, Monock and Hunninghake,
Monocytes I (1992)
LPS Mac No change Janson, Hance and Arend, (1991)
LPS PBMCs T Poutsiaka et aL, (1991)
MPL Serum Î Astiz et al., (1995)
Exp. endotox = experimental endotoxemia; PBMCs = peripheral blood mononuclear 
cells; PMNs = polymorphonuclear cells; Mono = monocytes; Mac = macrophages; 
AM = alveolar macrophages.
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In humans, IL-lra was found to be increased in experimental endotoxemia 
(Granowitz et aL, 1991) and in patients those who have undergone surgery without 
detectable LPS in the plasma (O'Nuallain et aL, 1995). It was suggested that it is an 
early-response cytokine in response to trauma which may be induced in the absence of 
an infection. IL-lra was also elevated in human volunteers infused with LPS (van der 
Poll et aL, 1996). Serum IL-lra level peaked at 3 hours and reached the baseline level 
at 6  hours. LPS administration in humans has been shown to increase plasma levels of 
IL-lra 100 times over the levels of IL-lp (Granowitz et aL, 1991). Later, Lin et aL, 
(1994) in a study with human subjects comprising of normal volunteers, critically ill 
non-sepdc, septic and severely septic patients, did not find any significant difference in 
IL-lra level in serum.
Kline, Monick, and Hunninghake (1992) demonstrated a down-regulation of 
monocyte IL-lra released by LPS but not in macrophages. Janson, Hance and Arend, 
(1991) indicated that macrophages in culture constitutively produce IL-lra but did not 
respond further to LPS stimulation. By contrast, when human PBMCs were stimulated 
with LPS and incubated for 24 hours, the culture supernatant showed a dose-dependent 
increase in IL-lra production reaching approximately 16000 pg/ml (Poutsiaka et aL, 
1991), however, a decreased release was seen when the cell-cell contact was prevented 
by constant shaking of the culture plates. It was suggested that the cell adherence 
which stimulates the differentiation of monocytes to macrophages (Janson, Joslin and 
Arend, 1990; Kumagi et aL, 1979) may have been the reason for the lack of LPS 
response to IL-lra production by monocytes (Poutsiaka et aL, 1991; Kline, Monick and 
Hunninghake, 1992).
Recently, Astiz et aL, (1995) demonstrated that serum IL-lra was significantly 
increased in human volunteers injected with MPL, indicating a possible role of this 
inhibitor in modulating cytokine responses.
1.13 Other soluble mediators
Other soluble mediators involved in sepsis and septic shock include the 
products of the arachidonic acid metabolism, complement products (C3a and C5a), 
histamine, serotonin, platelet activating factor, and members of the coagulation cascade 
system (Morrison and Ryan, 1987; Shapiro and Gelfand, 1993). Arachidonic acid 
from the cells, after appropriate stimulation, can be metabolized to prostaglandins and 
leukotrienes, which may modulate the host response in sepsis and septic shock (from 
Gallin, 1994).
1.13.1 Prostaglandins
Prostaglandins or eicosanoids are produced by a variety of cells including 
macrophages, monocytes and platelets. The products of the arachidonic acid
metabolism include prostaglandins, such as PGE2 , PGFia , prostacyclin-I^ (PGI2) and 
thromboxane-A2  (TXA2 ) in the cycloxygenase pathway. The leukotrienes are
synthesized via the lipoxoygenase pathway. Some products of arachidonic acid can be
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oxygenated through cytochrome p450. There is considerable evidence that the 
prostaglandins play a pivotal role in the regulation of immune response. PGE2 has
been known as a local mediator which is currently considered as an anti-inflammatory 
mediator of sepsis and septic shock.
Increased PGE2 levels have been associated with depressed antigen presenta­
tion, depressed T-cell activation and proliferation, decreased phagocytic function, and 
depressed primary antibody response (Miller-Graziano et aL, 1988; Ogle et aL, 1989; 
reviewed in Faist et al., 1989). It was demonstrated that stimulation of FcyRI receptor 
by cross-linking resulted increased PGE2 production (Miller-Graziano et aL, 1988,
1990).
Mouse peritoneal macrophages stimulated with LPS have been shown to 
release significant amounts of PGE2 and PGF2CC within 3 hours of incubation with a 
dose as low as 0.1 ug/ml (reviewed in Rietschel et aL, 1982). Increased plasma levels 
of TxB2  (a stable metabolite of TxA2 ), PGFia  and various leukotrienes were found in
experimental endotoxemia and sepsis in animals. The relative levels of these metab­
olites were influenced by the route, and frequency, of LPS administration; the levels 
paralleled the severity of the sepsis or septic shock (reviewed in Cook et aL, 1993).
Increased PGE2 release by either stimulated or unstimulated monocytes in vitro
was found in patients with sepsis (Takayama, Miller and Szabo, 1990) or in monocytes 
from normal subjects (Scatter et al., 1995). Similarly, Miller-Graziano et aL, (1990,
1991) demonstrated that monocytes isolated from immunocompromised patients 
including those with sepsis secreted significantly increased amounts of PGE2 . A 
positive correlation was found between PGE2 and TGFp, suggesting that these 
mediators causing immunosuppression contributed to the development of sepsis. It 
was also demonstrated that increased PGE2  release was associated with increased 
expression of monocyte FcyRI.
As with cytokines, LPS-mediated attenuation of PGs release has also been 
reported by some authors. Although LPS has been shown to release increased amounts 
of PGE2 in vitro, the release after a second stimulus was found to be variable in
monocyte-derived macrophages (Matic and Simon, 1992), but increased in murine 
peritoneal macrophages (Li et aL, 1995). Zingarelli et aL, (1995) demonstrated that 
LPS stimulated mouse peritoneal macrophage to release 6 -keto-PGFla (a stable product 
of prostacyclin metabolism), but the release was attenuated when the mouse was 
pretreated with LPS, suggesting a tolerance phenomenon.
1.14 Cell surface receptor expression
Receptors on the monocyte or macrophage surface determine the control of 
their own activities, such as growth, differentiation, activation, recognition, 
endocytosis, migration, and secretion. These cells are known to express a number of 
surface proteins which play an important role both in non-specific and specific immune 
responses. The most important markers for MPs include CD 14, GDI la, CD 11b,
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CD1 le, CD 18, and HLA-DR of the class H MHC molecule. Other receptors, namely 
CD32 and CD64, are also found on monocytes whereas CD 16 (Fc^RlII receptors) 
CD25, CD45, CD54 and CD71 arç believed to be expressed on activated monocytes 
and macrophages, suggesting their roles in immune responses.
1.14.1 CD 11b
This is a 165 kDa antigen receptor, one of the three leukocyte integrins 
belonging to the LFA-l/CR3/pl50,95 or CD 11/CD 18 family. These three leukocyte 
molecules have distinct a  chains but share a common p chain. CD l ib  is present on 
neutrophils, mature monocytes and NK cells and forms the Mac-1 integrin in 
association with CD 18 (in Ross, Walport and Hogg, 1989).
Each of the CD11/CD 18 family members performs a range of functions that are 
mediated through cellular adhesion. Adhesions occur through specific ligand-binding 
sites believed to be present primarily on the a-chains with different specificities for 
distinct ligands (Ross, Walport and Hogg, 1989). CD1 lb, which is the a  chain of the 
CR3 (iC3b receptor), contains three distinct binding sites, namely: (1) iC3b-binding 
site which plays a role in adhesion and phagocytosis of iC3b-coated particles (Wright 
and Silverstein, 1982); (2) p-glucan receptor; and (3) binding sites for LPS (Wright 
and Jong, 1986). In addition, C D llb  plays a central role in binding to endothelium and 
subsequent migration of monocytes to tissue through the endothelium of blood vessels 
(Meerschaert and Furie, 1995).
Many pro-inflammatory functions are mediated through this heterodimer 
(Amaout, 1990). Trezzini et aL, (1991) showed that antibody to CD11/CD 18 
decreased oxidative burst in monocytes. It has been demonstrated in vitro that 
monocytes migrate through binding of CD 11 a/CD 18 with CD54 in unstimulated human 
vascular endothelial cells (HVEC) (Amaout, Lanier and Faller, 1988) whereas both 
CD11 a/CD 18 and CDllb/CD18 bind to IL-ip-stimulated HVEC (Meerschaert and 
Furie, 1995). Similar results on rat monocyte adhesion to rat microvascular endothelial 
cells in vitro were also reported (Issekutz, 1995). By contrast, expression of 
CD1 lb/CD 18 in a soluble form has been implicated as an anti-inflammatory agent 
shown by inhibition of binding of PMNs to the activated endothelium (Dana et aL,
1991). An in vivo study in rats demonstrated that both CD11 a/CD 18 and CD 1 lb/CD 18 
are important in adhesion and monocyte migration, but CD1 lb/CD 18 plays a more 
important role. Engagement of CD lla, CD llb, and CD 18 receptors with respective 
antibodies has been shown to produce TNFa from whole blood or isolated monocytes 
in vitro (Wright et aL, 1990; Couturier et aL, 1992).
Although the physiological role of these receptors in sepsis and septic shock 
has been known for some time, consistent data regarding its expression on MPs is 
lacking. Fingerle et aL, (1993) observed decreased CD1 lb expression in CD14/CD16- 
positive monocytes in septic patients. Interestingly, a decreased number of CD 1 lb- 
positive monocytes, but an unchanged receptor density in these cells from septic and 
septic shock patients has been reported by Ertel et aL, (1993). Monocyte expression of 
C D llb  was found to be unchanged in septic patients with or without MOF compared to
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control subjects (Gawaz et aL, 1995).
1.14.2 CD18
GDI8 , also known as the p chain of LFA-1 family or p integrins, is covalently 
linked to C D lla, C D llb  or CD11c. It is present on leukocytes, especially in large 
amounts, and on macrophages and performs a similar function to CD1 lb  except that 
CD 18 is involved in the nonspecific recognition of antigen by phagocytic leukocytes 
(Golenbock et aL, 1990; Wright et aL, 1989a). It was suggested that the mechanisms 
of LPS binding to cells depend on the physical state of the LPS (Golenbock et aL,
1990). It is extremely difficult to delineate the functions of CD 18 independent of 
CDU. A detailed description, function and its involvement with LPS has been 
indicated above with C D llb  (Section 1.14.1). It has been shown that gram-negative 
bacteria and LPS-coated erythrocytes bind to macrophages through an interaction of 
LPS with different members of the integrin family including CD 18 (Wright and Jong, 
1986).
The observations that mAb to CD 18 stimulates TNFa release in whole blood 
preparation and monocytes (Wright etal., 1990; Couturier et aL, 1992) and that binding 
of a CD 18 mAb immobilized on plastic, which may mimic cross-linking of CD 18, did 
not induce TNFa or IL-lp production (Webb et aL, 1990) indicate the involvement of 
CD 18 in cytokine release. Recently, Otterlei et aL, (1995) demonstrated that anti-CD 18 
mAbs increased IL-6  and TNFa production from LPS-stimulated monocytes in vitro.
A parallel increase was observed in CD 14 expression, and anti-CD 14 antibody inhibited 
the LPS-stimulated expression of CD 14 and IL-6  and TNFa release in these cells.
Thus, it was suggested that CD 18 receptors are involved in LPS-stimulated cytokine 
production and in regulation of CD 14 expression on monocytes.
1.14.3 CD14
CD 14 is a 55 kDa phosphoinositol (Pl)-linked single-chain surface membrane 
glycoprotein present on 70 - 90% of normal PBMs. It is also found on macrophages, 
and on some granulocytes, but in these cells the expression is weak as compared with 
monocytes or macrophages. CD 14 is a stable monocyte marker and frequently used to 
define human PBMs (Dimitriu-Bona et al., 1983; Todd, Nadler and Schlossman, 1981; 
Bernstein and Self, 1984).
These receptors serve as LPS receptors, controlling cell activation under 
physiological conditions (Wright et aL, 1990; Ulevitch, 1993; Ulevitch and Tobias, 
1994). LPS in the circulation binds with LBP, and then the LPS-LBP complex binds 
to the cell surface receptor molecule (Tobias et aL, 1989), which was identified as 
CD 14 (Wright et aL, 1990; reviewed in Ulevitch and Tobias, 1994). Binding of the 
LPS-LBP complex to CD 14 is postulated to trigger protein tyrosine phosphorylation 
(Weinstein, June and DeFranco, 1993) and to release cytokines including TNFa 
(Wright et aL, 1990; Grey et aL, 1993; Weinstein, June and DeFranco, 1993). It was 
postulated that binding of LPS to CD 14 causes shedding of CD 14 from the membrane
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of activated monocytes, resulting in a decreased ability of the cells to be stimulated by a 
local excess of the LPS. A low level of the soluble form of CD 14 has been found to be 
produced spontaneously by cultured monocytes (Bazil et al., 1989).
It has been demonstrated that phagocytosis of LBP-coated gram-negative 
bacteria can be mediated through CD14 (Wright ef al., 1989; reviewed in Wright, 1991; 
Grunwald et al., 1996). It may have a role in the oxidative burst, antigen presentation 
and host response to particulate or soluble antigen (reviewed by Ulevitch and Tobias, 
1994). Schutt et al., (1992) indicated that LPS stimulates human monocytes to release 
sCD14 in the culture supernatant in a dose-dependent manner, however, it was not 
detectable until the seventh day of culture. The addition of sCD14 to culture containing 
LPS suppressed respiratory burst activity, suggesting that sCD14 acts as a receptor for 
the LBP-LPS complex. Subsequent demonstration that purified human sCD14 
prevented binding of LPS to bovine monocytes in vitro supported this hypothesis 
(Grunwald, Kruger and Schutt, 1993). There is a general consensus that LPS and 
sepsis cause down-regulation of CD 14 expression in monocytes. However, increased 
expression has been reported by some. Review of the literature indicates that these 
variations may be related to the degree of stimulation and time of exposure to LPS. The 
findings of various studies are summarized and presented in Table 1.6.
Grey et al., (1993) demonstrated that low doses of LPS down-regulate the 
expression of CD 14 on monocytes as early as 4 hours after stimulation. These authors 
found that the percentages of CD 14-positive cells decreased from 90% to 50% at 24 
hours, confirming the earlier reports (Wright, 1990; Bazil and Strominger, 1991). By 
contrast, Otterlei et al., (1995) reported that monocytes decreased expression of CD 14 
after 30 minutes to 4 hours of LPS treatment, but increased expression in overnight 
culture. It was also shown that the decreased expression resulted from the reduction of
the CD14+/CD16+ subset whereas ah increase was seen in both CD14+/CD16+ and
CD14+/CD16~ populations. In addition, these authors observed a relationship between 
LPS-stimulated cytokine secretion and CD 14 expression, and indicated that LPS- 
stimulated cytokine release is mainly CD14-dependent.
Stimulation of whole human peripheral blood in vitro with very small doses of 
LPS, up-regulated the CD 14 expression in monocytes in a dose-dependent manner 
(Marchant et al., 1992). Increased expression was associated with increased binding of 
LPS to monocytes. Aepfelbacher et al., (1992) also reported an up-regulation of CD 14 
expression in Mono Mac 6  cells stimulated with small amounts of LPS. However, 
studies with septic blood stimulated with LPS in vitro showed a decreased expression 
of CD 14 by monocytes. Recently, Landmann gf al., (1996) demonstrated that LPS, 
heat-killed E. coli, lipoteichoic acid and S. aureus cell wall extract up-regulated CD 14 in 
human monocytes in vitro and it was further enhanced in LPS primed cells. However, a 
transient decrease in the expression of CD 14 was reported to be found between 6 -1 5  
hours after incubation with LPS.
Inconsistent data on the expression of CD 14 in human monocytes in response 
to LPS in vitro or in sepsis and septic shock exist in the literature. Increased CD14-
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Table 1.6. Expression of CD14 on human monocytes in vivo
and in vitro
Treatments Systems Findings References
LPS Mono I Bazil and Strominger, (1991)
LPS Mono i Payne, Nichols and Peluso, 
(1992)
LPS Mono i Schutt et al., (1992)
LPS Mono 4 Grey et al., (1993)
LPS Mono I Breuninger et al., (1994)
LPS Mono IT Otterlei etal., (1995)
LPS Mono T . Landmann et a l, (1996)
LPS Mono Mac T Aepfelbacher et al., (1992)
LPS Sepsis WB 4 .
LPS WB Î Marchant et a l, (1992)
No treatment Sepsis WB T Faist et a l, (1992)
No treatment Sepsis WB T Fingerle et a l, (1992)
No treatment Sepsis WB 4 Heinzelmann et a l, (1996)
No treatment Sepsis/SS WB 4 Lin et a l, (1993a)
No treatment Sepsis/SS WB 4 . Ertel et a l, (1993)
Mono = monocytes; Mono Mac = Mono Mac 6  cell line; WB = monocyte expression of 
CD 14 from whole blood preparation; SS = septic shock.
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positive cells in trauma and severe sepsis patients compared to control was reported by 
Faist et al., (1992). By contrast, Lin et a l, (1993a) reported that CD 14-positive cells 
were lower in all infected patients compared to critically ill non-infected patients. 
Decreased CD 14 was also reported in cultured monocytes in response to LPS 
stimulation (Schutt et al., 1992; Bazil and Strominger, 1991). Fingerle et al., (1993) 
reported that the number of CD 14-positive cells increased in septic patients compared to 
normal volunteers. This increase was correlated with increased expression of MHC 
class II antigens, serum levels of IL-6 , and decreased C D llb  expression in septic 
patients. By contrast, Ertel et al., (1993) demonstrated that CD 14 expression (both 
percentage positive cells and mean fluorescence) decreased in monocytes from sepsis 
and septic shock obtained at various times up to 10  days post infection compared to 
control subjects. In addition, LPS-stimulated cytokine mRNA expression in vitro (IL- 
lp, IL-6 , TNFa) between these groups was not different. It was suggested that LPS- 
induced activation of monocytes from sepsis and septic shock patients may occur 
through direct binding of LPS to other receptors in monocytes, possibly through 
CD ll/CD 18, and that the LBP-LPS complex to CD 14 may not play a central role in 
sepsis. A recent study with severely injured patients demonstrated that monocyte CD14 
expression was decreased following injury and remained low for 30 days (Heinzelmann 
et al., 1996). The CD 14 expression was correlated with clinical outcome; the non­
survivors had significantly lower level of expression than the survivors!
1.14.4 CD16
CD 16 (FcyRIII) is a 50-70 kDa phosphoinositol-linked (Pi-linked) transmem­
brane antigen receptor present on MPs, granulocytes, NK cells, and a small population 
of lymphocytes (15%). FcyRIII was found in a sub-population of human monocytes 
(FcyRIIIa, 10 - 40%) (reviewed in Unkeless, Scigliano and Freedman, 1988; Passlick, 
Flieger and Ziegler-Heitbrock, 1989; van de Winkel and Anderson, 1991). Fcylll 
receptors are actively involved in ADCC and enhance respiratory burst activity when 
cross-linked (van de Winkel and Anderson, 1991). They also play an important role in 
the clearance of immune complexes (reviewed in Unkeless et al., 1989). FcyRIII 
functions in collaboration with FcyRI and FcyRII in the recognition and killing of 
microorganisms as well as the clearance of immune complexes. They are extremely 
mobile on the cell surface, permitting large numbers of FcyRIII to aggregate rapidly at 
the site of contact with an IgG-coated particle (Ross, Walport and Hogg, 1989).
FcyRIII can be induced by IFNy, G-CSF, and GM-CSF suggesting that they 
are readily modulated receptors (Buckle, Jayaram and Hogg, 1990). LPS increases the 
expression of this receptor in rat bone marrow macrophages in vitro (Keller, Keist, and 
Toiler, 1994) and rIFNy increases FcR expression in monocytic cell lines (HL-60 and 
U937) and human monocytes (Guyre, Morganelli and Miller, 1983). Although, Jungi 
and Hafner, (1986) reported that freshly isolated monocytes express FcyR and can bind 
and phagocytose RBCs opsonized with IgG, involvement of the specific receptors was 
not reported. Blockade of FcyRIII by an anti-FcyRIII mAb was shown to inhibit the 
clearance of opsonized peripheral blood cells in vivo, confirming the role of this
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receptor in the removal of immune complex (Clarkson et al., 1986; 1986a). A subclass 
of FcyRIII, FcyRIIIa has also been reported to mediate the LPS binding (reviewed by 
van de Winkel and Capel, 1993).
CD 16 antigen has been demonstrated to be a prerequisite for Fc receptor- 
dependent binding of immune complexes to human monocytes (Klaassen et al., 1990). 
It plays a role in the activation and ADCC in phagocytic cells (reviewed in van de 
Winkel and Anderson, 1991). Antibodies to CD 11/CD 18 did not influence ADCC, but 
antibody to only FcyRIII decreased ADCC of the human colon cancer cell line by 
human monocyte-derived macrophages in vitro (Liesveld et al., 1991). It was 
suggested that CD 16 is involved in the ADCC of colon cancer cells.
Gomez, Ruiz and Schreiber, (1994) found that clearance of IgG-sensitized 
autologous red cells was decreased significantly in alcoholic liver cirrhosis patients 
compared to normal subjects. Furthermore, it was lower in patients who developed 
infections when compared to those who did not. Since the clearance of the heat-killed 
or unsensitized cells did not correlated with HLA haplotype, or the presence of 
circulating immune complexes, these authors suggested the existence of an impairment 
of the FcyR in these patients. The specific FcyR responsible for this impairment was 
not determined in this study. Nevertheless, Fingerle et al., (1993) reported that the 
number of CD 16-positive cells expanded in septic patients.
1.14.5 CD25
As mentioned earlier (Section 1.12.1), CD25 is the 55 kDa low affinity (a 
chain) EL-2r which has a minor cytoplasmic portion, also known as Tac antigen or IL- 
2r. These low-affinity receptors are absent in freshly prepared monocytes and can be 
induced by certain stimuli (Valitutti et al., 1989; Scheibenbogen et al., 1992; Grey et 
al., 1993). They are expressed on activated B-cells, T-cells and MPs and involved in 
T-cell growth (Holter et al., 1987; Uchiyama, Broder and Waldman, 1981).
Holter et al., (1987) showed that human monocytes stimulated in vitro with 
LPS express these receptors within 24 hours. This response was augmented by co- 
incubating the cells with IFNy. LPS up-regulates the expression of p75 (intermediate- 
affinity (3 chain of IL-2r) and effectively induces surface expression of CD25 on human 
monocytes within 18 hours (Scheibenbogen et a l, 1992). IL-2 binding studies using 
biotinylated IL-2 revealed that functional high-affinity receptors are present on 
monocytes, indicating that LPS stimulates the induction of these receptors and increases 
the number of binding sites per cell. It was also revealed that CD25 expression de­
creased as the monocytes differentiated into macrophages in a time-dependent manner. 
Kniep, Strelow and Lohmann-Matthes, (1992) demonstrated that CD25 can be induced 
in monocytes with LPS stimulation within 24 hours of culture while the high affinity 
sIL-2r are not secreted into the supernatant until 48 hours of incubation. Later, Grey et 
al., (1993) showed that CD25 was expressed on 87% of freshly prepared human 
monocytes stimulated with LPS (10 ug/ml) after 8 hours of stimulation.
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1.14.6 CD45
CD45, a transmembrane protein known as the leukocyte common antigen 
(LCA), is an 180 - 220 kDa antigen receptor of the T200 family that represents a family 
of protein tyrosine phosphatases. It is also known as Ly-5 or B220 on B-cells and 
10% of the lymphocyte cell surface is occupied by member of the LCA family. It has 
been found on T-cells, B-cells, granulocytes and MPs (Pulido et a l, 1988). CD45 
molecules are known to play a critical role in the regulation of T-cell and B-cell 
function. There are four isoforms which are abundantly expressed on all human 
leukocytes including monocytes. The gene encoding for the CD45 family maps to 
chromosome 1. Monoclonal Abs that recognize CD45 can be divided into 2 groups; 
some recognize common epitopes while others recognize restricted epitopes (CD45R) 
which are generated by alternate splicing of the exons 4, 5, 6  or A, B, C; accordingly 
they are named RA, RB, RC and RO. CD45RA is relatively immunodominant in 
humans (Shevach, 1995). The natural ligand(s) of CD45 and its receptor function are 
not clearly understood, but it appears to have a role in the signal transduction involving 
tyrosine phosphatase (Thomas, 1989; Tonks et al., 1988). Engagement of CD45 by 
anti-CD45 mAbs has been shown to both inhibit and augment T-cell proliferation 
(Shevach, 1995). Limited information regarding the function of CD45 in monocytes 
and macrophages exists in the literature.
Studies showed that engagement of the surface CD45 antigen by specific 
antibodies immobilized on a plastic surface induced TNFa and IL-lp release from 
human monocytes, suggesting a role for GD45 in inducing the release of these 
cytokines (Webb et al., 1990). Later, Gruber et al., (1992) demonstrated that mAb to 
CD45 could trigger M-CSF secretion by human monocytes. The secretion was 
augmented by co-stimulation with LPS or IL-lp within 8 hours and peaked at 48 hours, 
implying that CD45 is an important first signal in monocyte activation.
Liles et a l, (1995) demonstrated that CD45 modulates activation of the 
inducible respiratory burst in normal human phagocytes including monocytes. It has 
been shown that cross-linking CD45 significantly increased monocyte respiratory burst 
in vitro, an effect that was enhanced by LPS, TNFa and GM-CSF. Although 
monocyte tyrosine phosphorylation was not determined in that study, based on 
neutrophil data it was postulated that CD45 may mediate the coupling of specific cell 
surface receptors to downstream tyrosine kinase-dependent signal-transduction 
pathway(s) in activated phagocytes.
1.14.7 CD71
CD71 is a 95 kDa homodimer present on activated T-cells, B-cells, 
macrophages and other proliferating cells. It is also known as T9 or the transferrin 
receptor, a classical cell activation marker. CD71 is not generally expressed on freshly 
isolated monocytes and was found in mature macrophages (Hirata et al., 1986). Later, 
increased expression of CD71 was found in macrophages in patients who have 
undergone peritoneal dialysis (Hart, Jones and Finely-Jones, 1992).
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This receptor plays a role in iron metabolism and cell growth. Many important 
functions of MPs, including generation of ROIs and arachidonic acid metabolites, are 
dependent on a supply of iron. Since the ferric ion is taken up by cells bound to 
transferrin, it was suggested that it might play an important role in performing these 
functions in monocytes (Dougherty and McBride, 1989). Gessani et a i, (1993) 
reported a time-dependent increase in transferrin receptor expression in human 
monocytes-macrophages in vitro but they did not examine whether LPS would enhance 
the receptor expression.
1.14.8 HLA-DR
All three members of the MHC class II antigen family (HLA-DR, -DQ, -DP) 
play a central role in T-cell activation by accessoiy cells, such as activated MPs and 
dendritic cells (King and Katz, 1990). HLA-DR is a 28 - 33 kDa dimer present on B- 
cells, activated T-cells, MPs and other APCs. While 75 - 94% of monocytes express 
HLA-DR, only 25 - 50% of these cells express HLA-DQ and HLA-DP. HLA-DR 
plays an important role in MPs antigen presentation and host response (Gonwa et al., 
1983; Gonwa and Stobo, 1984; Sorg, 1991).
In vitro studies have demonstrated that LPS induces HLA-DR expression in 
monocytes within 1 -2  hours of stimulation (McLeish, Wellhausen and Dean, 1987; 
McLeish et al., 1989; Schmittel, Scheibenbogen and Keilholz, 1995). Because this 
expression was found to be independent of protein synthesis, it was suggested that 
enhanced HLA-DR expression results from redistribution of the molecules from the 
intracellular pool (McLeish, Wellhausen and Dean, 1987).
Decreased macrophage MHC II antigen expression is associated with defective 
antigen presentation to T-cells in animals and is believed to be predictive of patient 
outcome after major trauma and sepsis. Trauma and sepsis appear to reduce monocyte 
HLA-DR expressionand antigen presentation in vivo and in vitro (Polk et al., 1986; 
Appel et al., 1989; Cheadle et al., 1991; Volk et al., 1991; Gardiner et al., 1994).
Direct correlation between HLA-DR depression and development of infection in 
transplant patients receiving immunosuppressive therapy has been documented (Docke 
e ta l ,  1994).
Studies with surgical patients showed that qualitative and quantitative 
expression of HLA-DR on PBMs was lower in infected patients compared to uninfected 
patients. Severely infected non-surgical patients were found to have significantly lower 
expression compared to that of the normal volunteers, and the survivors had higher 
HLA-DR expression than the non-survivors as assessed by mean fluorescent intensity
of HLA-DR on CD 14+ cells (Cheadle et a l, 1991). Wakefield et a l, (1993), later 
found that monocytes from patients following surgery expressed lower levels of HLA- 
DR than the pre-operative levels, but in the patients who developed sepsis, the level 
remained low. In another study, Appel et a l, (1989) incubated monocytes from septic 
patients for 1 - 2 hours with various doses of LPS in vitro and examined the
fluorescent intensity of HLA-DR expression in CD 14+ cells. They found that
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expression was significantly increased in septic patients who survived compared to 
those did not. Similar results were also reported by Hershman et al., (1990).
Fingerle et al., (1993) reported that class II antigen expression was increased in 
CD 14/CD 16-positive monocytes in septic patients. In contrast, studies of populations 
comprising non-septic critically ill, septic, and septic shock patients revealed that 
monocyte HLA-DR expression was decreased in patients with severe sepsis compared 
to those of normal controls (Lin et al., 1993a, 1994).
Studies with monocytes from patients with inflammatory bowel syndrome 
showed that the percentage and the mean fluorescence of cells that expressed HLA-DR 
antigen were lower than the control (Gardiner et al., 1994). The percentage of 
monocytes displaying HLA-DR decreased from 79 to 50% in patients with ulcerative 
colitis. Those requiring surgical intervention had only 52% positive cells whereas 
patients needing only medical treatment had 81% positive cells. Recently, monocytes 
from surgical patients those developed septic complications showed decreased 
expression of this antigen compared to patients who did not (Kono et al., 1995). •
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1.15 AIMS OF PROJECT
Review of the existing literature reveals very little data comparing the 
modulation of MPs function by LPS and MPL. This study was designed to compare 
the effects of LPS and MPL in isolated monocytes (eliminating the other cell-mediated 
influences) from healthy human volunteers in vitro. The aspects that will be examined
are; (1). activation and effector cell function of monocytes as measured by O2 ', H2O2
and NO production; (2). role of these cells in cell-mediated cytotoxicity, extracellular 
lysis and phagocytosis; (3). secretory capability of these cells as measured by the 
release of cytokines, soluble cytokine receptors and a receptor antagonist; and (4). state 
of monocyte activation and the involvement of different cell surface receptors and 
antigens as measured by expression of these molecules on the cell surface. In addition, 
development of tolerance in vitro by various agents or in vivo due to sepsis and septic 
shock is examined.
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MATERIALS AND METHODS
2.1 Preparation of reagents and solutions
Phenol-chloroform-petroleum ether-extracted LPS from rough strain of 
S. minnesota Re 595 was purchased from Sigma Chemical Co. (St. Louis, MO, USA) 
as lyophilized powder. MPL, also from S. minnesota Re 595, was obtained from Ribi 
Chemicals (Hamilton, MT, USA). Following extraction as above, the phosphate group 
was removed by hydrolysis with 0.1 N HC1 (Johnson et a l, 1987).
Both LPS and MPL were dissolved in phosphate buffered saline (PBS) to 
which 2 ul triethylamine (Sigma Chemical Co.) per mg of LPS or MPL was added to 
increase solubility and stability. The LPS and MPL concentrations were 3.3 mg/ml and
2.0 mg/ml, respectively and were kept at 8 °C. They were found to be stable up to one
year. The toxins were dissolved by sonicating the solution at 37°C for 30 minutes.
This procedure was followed every time a dilution was made. The solutions were 
diluted as needed in the same media in which the experiments were performed.
All other reagents were purchased from Sigma Chemical Co. unless indicated. 
Complete RPMI-1640 medium (RPMIc) containing 300 mg/dl L-glutamine (Gibco 
BRL, Grand Island, NY, USA), 10 ml/dl heat inactivated fetal calf serum (PCS)
(Gibco BRL or HyClone Labs, Logan, UT, USA) and 5 mg/dl Kanamycin was made 
in small quantities and was not used later than three weeks after it was made. For some 
assays it was filtered using 0.2 um PTFE-F filters, specially for H2O2 and 
phagocytosis assays.
Phorbol 12-myristate 13-acetate (PMA) was dissolved in ethyl alcohol (95%) 
to a solution of 1 mM and it was kept frozen at -70°C. It was found to be stable for 
approximately 6  months at this temperature. Polymyxin B was dissolved in low 
endotoxin ( < 6  pg/ml) tissue culture water (Gibco BRL) and kept at -20°C until use. It 
was used within one month of preparation.
Superoxide dismutase (SOD) was dissolved in low-endotoxin tissue culture 
water (Gibco BRL) to an initial concentration of 18,750 units/ml. This was diluted to
4.000 units/ml with complete phenol red-free RPMI-1640 culture medium (Gibco BRL
or Sigma Chemical Co.) and stored at -70^C in freezer vials. Ferricytochrome C (FC; 
from horse heart) was also dissolved in low-endotoxin tissue culture water (Gibco 
BRL) to 1 mM concentration. Aliquots (1.6 ml) were dispensed into vials and stored at 
-700C.
Horseradish peroxidase (HRPO) type II was dissolved in hon-pyrogenic H2O
to a concentration of 1000 units/ml. One milliliter aliquots were stored at -70°C until 
use. Phenol red solution was prepared freshly before each experiment. It contained 
816 mg sodium chloride, 99 mg DL (+) glucose, 20 mg phenol red (sodium salt of
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phenolsulfonapthalein), 1000 units HRPO, and 100 ml potassium phosphate buffer. 
This solution was kept at 8 °C and used within a week of preparation.
Nicotinamide adenine dinucleotide phosphate (NADP), reduced NAD? 
(NADPH), BH4 (L-biopterin dihydro chloride; ICN, Costa Mesa, CA, USA) and a
keto glutarate (ICN) were dissolved in DPBS. Glutamate dehydrogenase and nitrate 
reductase were dissolved in potassium phosphate buffer.
Sheep RBCs in Alsever’s solution (1:1) were obtained from Accurate
Chemicals (Westbury, NY, USA). They were kept at 8®C and used within 4 weeks of 
collection. Diaminofluorene (DAP) solution was dissolved in 90% acetic acid. This 
solution was kept at -20^C. The stock solution contained 10 mg/ml DAF in 90% acetic
acid. It was kept at 8^C in the dark. This dark-green solution was found to be stable 
for approximately 4 weeks.
2.2 Mononuclear cell isolation
2.2.1 Cell isolation from buffy coat
Mononuclear cells were isolated from the freshly drawn venous blood of 
apparently healthy volunteers obtained by the New York Blood Bank, New York. The 
cell collection medium contained 70 ml citrate phosphate dextrose adenine -1 (CPDA-1) 
per bag for 450-500 ml whole blood. Each 70 ml CPDA-1 contained 209 mg citric 
acid anhydrous, 155 mg sodium monophosphate, 2.23 gm dextrose monohydrate,
USP, and 19.3 mg adenine. Blood was collected in the morning, processed (New 
York Blood Bank) and the buffy coat transported to the laboratory in the afternoon. 
Mononuclear cell isolation using a slightly modified method of Boyum, (1968) 
commenced within 6  hours of collection. In short, immediately after emptying the 
contents of the bag (approximately 40 ml), 400 ul ethylene diamine tetraacetic acid 
(EDTA, 10% solution) was added to the buffy coat to reduce adhesion of the 
monocytes during isolation. The buffy coat was diluted 2 .5  times with m in im u m
endotoxin ( < 6  pg/ml), Ca2+- and Mg2+-free, Dulbecco’s phosphate-buffered saline 
(DPBS; Gibco BRL). Twenty-four milliliters of the diluted, leukocyte-rich solution 
was layered over 12 ml of NycoPrep (density = 1.077; Gibco BRL) and centrifuged for
20 minutes at 700 g and 21° C using a refrigerated centrifuge (Jouan Inc., Model #
CR4 22). The mononuclear cells were harvested and washed once for 8 minutes (700 
g; 21° C) with approximately 30 ml of incomplete low endotoxin (< 6  pg/ml) RPMI- 
1640 (Gibco BRL). The supernatant was discarded, the pellet resuspended in 30 ml 
DPBS and centrifuged again for 8 minutes (160 g; 21° C). After the final wash, the 
supernatant was discarded and the pellet resuspended in RPMIc.
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2.2.2 Cell isolation from sepsis and septic shock patients, and 
normal volunteers
Monocytes were isolated from the blood following a slight modification of the 
method described for buffy coat cells. Venous blood (30 ml) was drawn in vacutainer 
tubes (Becton Dickinson, Rutherford, NJ, USA) containing 1.5 ml adenine-citrate- 
dextrose (ACD) solution. The cells from the normal volunteers and patients were 
processed within 30 minutes of collection. The blood was diluted 1:1 with DPBS and 
the rest of the method was same as that described above.
2.2.3 Cell isolation from critically ill patients
Monocytes were collected from critically ill, non-septic patients using Percoll 
(Pharmacia, Piscataway, NJ, USA) as described by Haslett et a l, (1985). Briefly, 18 
ml of venous blood with 2 ml sodium citrate (5%) was centrifuged at 300 g for 20 
minutes. The platelet-rich plasma was collected and centrifuged at 2500 g for 10 
minutes to obtain platelet-poor plasma (PPP). The pellet containing the blood cells was 
resuspended with 40 ml of 0.75% Dextran (500 kD) in 0.9% saline and allowed to 
stand for 30 minutes at room temperature. The leukocyte-rich supernatant was 
collected, centrifuged at 280 g for 6  minutes and the pellet resuspended in 3 ml PPP. 
Then the suspension was underlayered with 42% and 52% Percoll gradient in PPP.
The gradient was centrifuged at 280 g for 10 minutes. The mononuclear cells at the 
42% interface were collected, washed first with Krebs-Ringer phosphate buffer
containing 0.2% dextrose and 10% PCS (700 g; 8  minutes at 21° C) and then with 
DPBS (160 g) as above. The cells were resuspended in RPMIc, counted and ■ 
concentration adjusted as required (Please see Section 3.5.).
2.3 Cell count
Cell concentration and viability was determined by a modified Trypan blue dye 
exclusion method (Sigma Chemical Company's literature, Product # T8154 and 
T6146). Briefly, 20 ul of the cell suspension was mixed with an equal volume of 0.1% 
trypan blue dye in PBS (w/v) (Sigma Chemical Co.) and placed on a Neubaur 
hemocytometer (Hausser Scientific, Horsham, PA, USA). Cells were examined under 
the microscope at lOOx. The cells that took up the dark blue stain were considered to be 
dead. With this procedure <2.0% of the cells were found to be non-viable. Results of 
5 experiments show that 1.9 ± 0.4% cells were non-viable (range 0.8 - 3.4%). The cell
concentration was adjusted to 12.5 x 106 mononuclear cells/ml with RPMIc.
A differential count was done using a Coulter counter, (Microdiff, Model # 
MD16, Coulter Corp.) or Mascot Hematology Systems counter (CDC Technology, 
Oxford, CT, USA). A balanced electrolyte solution and a coulter lytic reagent were 
used for the coulter counter and Hema-set solutions were used for the Hematology 
systems. Differential counts were made, following the standard procedures of the 
manufacturers. The results of 5 experiments showed a correlation between visual count
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and the Coulter count of mononuclear cells (r2 = 0.97). Student's t-tests demonstrated 
no significant difference between these two methods (p = 0.86). The isolated cells 
contained an average of 15% monocytes (9 - 23%), 12% granulocytes and 74% 
lymphocytes. Red blood cell and platelet contamination were minimal. For some 
studies, the cells were stained using Wright-Giemsa staining using Wright-Giemsa 
Stain Pak (Baxter Scientific Products, Edison, NJ, USA) and the differential count was 
made using a microscope. At least 100 cells were counted and they contained an 
average of 37% monocytes 56% lymphocytes, 6 % neutrophils and <1% other cells. 
The purity of monocytes after adherence was determined to be greater than 95% using 
the same technique.
2.4 Monocyte separation
Culture-plate-adherent monocytes were obtained by following a standard 
method (Rosenwasser, 1986). The cells were plated in Falcon 96 well, U-bottom 
tissue culture plates (Primaria, Baxter Scientific Products). The volume added to each 
well was 200, 150, 100 and 60 ul corresponding to 2.5xl06, 1.87xl06, 1.25xl06 and
0.75xl0& mononuclear cells/well, respectively. The fluid volume in each well was 
adjusted to 200 ul with RPMIc. The plates were incubated in a water-jacketed 
humidified incubator (Precision Scientific, Model # 5430) at 37° C with 5% CO2 for 2
hours. At the end of the incubation period, the plates were washed twice: first with 
200 ul pre-warmed incomplete RPMI-1640 (RPMI) containing 5% FCS (HyClone 
Laboratories, or Gibco BRL) and subsequently with 200 ul DPBS at room temperature. 
The liquid was discarded and the identity of the cells remaining adhered to the plate was 
confirmed using flow cytometry.
Cells were retrieved using EDTA and cold shock (described in Section 2.14.1) 
and the composition of the cell preparation was determined. Flow cytometric analysis 
(n = 5) showed an average of 85 ± 6 % purity (range 79 - 95%) using CD 14 as the 
positive marker, and trypan blue dye exclusion tests showed an average of 92% 
viability.
The isolated monocytes were treated with different doses of LPS or MPL (0.01 
-100 ug/ml) and incubated for 18 hours before assays were performed. For some 
experiments assays were performed immediately or 1 2  hours after separating and 
treating the monocytes.
2.5 Superoxide assay
The measurement of O2 is based on an SOD-inhibitable reduction of ferri-
cytochrome C (FC) as assayed by the increased absorption by media at 550 nm 
following a slightly modified method described by Pick andMizel (1981).
One vial of the FC solution (1 mM; Section 2.1) was thawed at room temper­
ature and diluted with phenol red-free RPMIc (PR" RPMIc) to a final concentration of
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160 uM. Monocytes in microtiter plates were obtained as described in Section 2.4 and 
180 ul of the diluted FC solution was added to each well. Twenty microliters of SOD 
solution was added to one column of wells (final concentration 400 units/ml) and other 
stimulants (LPS, MPL, PMA) were added to other columns as appropriate. A well 
containing only 200 ul FC solution and no cells acted as the plate blank. The wells 
containing cells and FC solution without stimulants served as an indicator of
spontaneous generation of O2 by the cells (control). The volume of each well was
adjusted using the media when necessary.
The plates were read at 30,60,90,120 and 150 minutes using a Bio-Tek 
ELISA reader (Model EL311; Highland Park, Winooski, VT, USA). Results were 
calculated as follows:
A Absorbance 550 (Absorbance f c  - Absorbance f c +SOd ) x 12.29.
The multiplication factor 12.29 was used, as opposed to 15.87, because the 
length of light passing through 200 ul medium in the U-bottom plate is 7.75 mm in 
contrast to the 3.0 mm (100 ul medium) reported by Pick (1986). The results are 
expressed in nmole/mg protein or nmole per specific number of cells. The 
multiplication factor was adjusted when a different types of microplate or volume were 
used which resulted in a different lightpath length.
The viability of the cells was assessed at the end of the 0% assays. The fluid
was discarded and 100 ul of 0.1% trypan blue dye was added to each well. After a 
few seconds, the trypan blue dye was discarded leaving the cells in the well. Cells 
were observed under an inverted phase microscope at 160x. One hundred cells were 
counted randomly and the percentage cell viability determined. It was found to be 
greater than 97% (n = 3).
Since the precise number of monocytes per well was not known, protein
contents of the wells were measured and final 0 % production was expressed in
nmole/mg protein. Marginal means of the protein contents for each cell concentration 
were used for this purpose. ,
2.6 Protein assay
At the end of the 0 2 * assay, the fluid from the plate was discarded and the 
plate washed once with 200 ul DPBS. Two hundred microliters of 1 M NaOH was 
added to each well and the protein digested overnight in an oven at 60° C. The protein 
was measured by a slight modification of Lowry's micro-method using a Sigma protein 
assay kit (Cat. # 690-A, Sigma Chemical Company literature). In short, the standard 
bovine albumin stock solution was diluted to contain 3.12, 6.25, 12.5, 25 and 50 ug 
protein/ml with distilled deionized water (DDH2O). One hundred microliters of these
standards was added to empty wells and 100 ul DDH2O was added to two additional 
empty wells which served as the blank. Ten microliters deoxycholate (DOC; 1.5
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mg/ml) solution was added to each well and the plate was incubated on a shaker 
(Virion, Wuerzburg, Germany) at room temperature for 10 minutes. Then, due to the 
presence of a very small amount of protein in each well, the contents of two adjacent 
wells with the same cell concentration were combined. Following this procedure, 10 ul 
trichloroacetic acid (TCA; 72%) solution was added to each well and mixed. The plate 
was centrifuged at 210 g for 5 minutes and the supernatant discarded without 
dislodging the pellet. To each well, 100 ul Lowry reagent was added, mixed by 
tapping, and incubated at room temperature for 20 minutes. At the end of the 
incubation period, 50 ul Folin and Ciocalteu’s phenol reagent was added to each well 
and incubated again at room temperature for 30 minutes. The absorbance was read at 
620 nm and the protein content was calculated by interpolation from the standard curve 
and expressed as ug protein/well.
2.7 Hydrogen peroxide assay
The H2O2 assay is based on the HRPO-dependent oxidation of phenol red 
which is indicated by the increased absorbance at 600 - 620 nm. This assay was 
performed following the method described by Pick and Mizel (1981). To each well 
containing monocytes, 180 ul phenol red solution (Section 2.1) was added.
To all wells containing cells and to one additional column of wells without any 
cells, 180 ul phenol red solution was added. In one column of wells, 20 ul 1 M NaOH 
was added to induce cell death which served as the negative control. The plates were
incubated at 37°C (5% CO2) for 30, 60, 90 or 120 minutes. At the end of the 
incubation period, H2O2 (30%, Sigma Chemical Co.) standards ranging from 1.0 to 25
nM were added to empty wells with an appropriate volume of PR solution. The plate 
was incubated again for 5 minutes. After this incubation period, 20 ul 1 M NaOH was 
added to each well except the wells where 10 ul NaOH had already been used; to these 
wells 10 ul NaOH was added. The contents were mixed by placing the plate on the 
shaker for 10 seconds and the absorbance was read at 610 nm, 5 minutes after the 
addition of NaOH. The H2O2 level was determined from the standard curve. In some 
experiments the absorbance was measured at 600 nm and H2O2 contents were
determined by using the extinction coefficient of 19.8 x 103 M"1 cm'l as described for
O2 (Pick, 1986). The multiplication factor was adjusted when a different type of
microplate or volume was used which resulted in a different lightpath length. The 
protein contents of the samples were determined on parallel plates as described earlier. 
The result was expressed as nmole/mg protein, or nmole per specific number of cells.
2.8 Nitrite assay
Since NO is very unstable with a half-life of about 5 seconds, the more stable 
end product of NO metabolism, NO2: was measured (reviewed in Snyder, 1992). This
assay was performed using the Griess reagent by following a method described by
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Ding, Nathan and Stuehr, (1988) where sodium nitrite was used as the standard. The 
Griess reagent contained: 1 gm sulphanilamide, 100 mg N-(napthyl) ethylene diamino 
dihydrochloride, 2.5 gm phosphoric acid (H3PO4 ) (Fisher Scientific), and 96.75 ml
DDH2O. Since this reagent tends to be oxidized at room temperature, it was kept in a
tightly closed bottle at 8°C.
Culture supernatants were thawed and vortexed, then 100 ul of sample was 
placed in a 96-well, flat-bottom, enzyme-linked-immunosorbant assay (ELISA) plate 
(Baxter Scientific Products). To each sample and standard, 100 ul Griess reagent was 
added. The plate was incubated for 10 minutes at room temperature and the absorbance 
was read at 550 nm using the ELISA reader. The concentrations were calculated by 
interpolation from the standard curve. The results were expressed as uM per well or 
per specific number of cells.
2.9 Nitric oxide synthase assay
2.9.1 Enzymatic method
iNOS was isolated and quantitated by modifications of the previously described 
methods (Forstermann et al., 1994; Hevel and Marietta, 1994). Briefly, 2 x 107 
mononuclear cells in 2  ml medium were added to tissue culture plates (65 x 15 mm; 
Primaria, Baxter Scientific Products) and the adherent cells were obtained as described 
in Section 2.4. To these cells was added 100 ug/ml of LPS or MPL in RPMI and the 
cells were incubated for 12 hours as before. Following incubation, the monocytes were 
washed once with 2 ml DPBS, then 1 ml of ice cold iNOS isolation buffer was added to 
each plate. The isolation buffer contained 10 mM K2HPO4 (pH 7.5), 0.5 mM L-
arginine, 10 ml/dl glycerol (Fisher Scientific), 20 ug/ml phenylmethylsulfonyl fluoride, 
1 ug/ml leupeptin, 5 ug/ml pepstadn A and 5 ug/ml aprotenin. The cells were 
homogenized for 30 seconds with a probe sonicator (Sonicator XL, Heat Systems, 
Farmingdale, NY) and subjected to 3 cycles of rapid freeze-thawing. The cell
homogenates were centrifuged at 100,000 g (34,000 rpm) at 4° C for 60 minutes in an 
ultracentrifuge (Model L7, Beckman Instruments, Palo Alto, CA, USA).
One hundred microliter aliquots of the supernatant were placed in 1.5 ml 
Eppendorf tubes, (the remaining supernatant being discarded). The pellets were 
resuspended in 100 ul of the iNOS isolation buffer and quantitatively transferred to 
another set of the Eppendorf tubes. The following reagents (10 ul, final concentration) 
were added to the supernatants and pellets: p-NADPH, 1 mM; NADP, 0.25 mM; NaCl, 
15 mM; tetrahydrobiopterin (BH4 ), 4 uM (ICN). The solutions were mixed and
incubated for 30 minutes at room temperature. The conversion of NO3" to NO2" was
initiated by adding 20 ul of 600 mU nitrate reductase and was terminated after a 30- 
minute incubation at room temperature by adding 200 mU L-glutamate dehydrogenase, 
100 mM NH4CI and 4 mM freshly prepared oc-ketoglutarate (ICN) (10 ul, final
concentration). The mixture was incubated at room temperature for 10 minutes to
67
eliminate any excess NADPH. Following the incubation, NO2" was measured in the 
reaction mixture in duplicate as described above (Section 2.8). Results were expressed 
as iNOS arbitrary units/10^ monocytes. The calculation was based on the assumption 
that 1 unit of iNOS converts 1 nmole of L-arginine to citrulline and NO per minute.
2.9.2 Immunofluorescent microscopy method
iNOS expression was measured by a method developed in this laboratory by the 
author. Cells were isolated and the cell concentrations were adjusted to 1 x 107 cells/ml 
as described earlier (Sections 2.4 and 2.9.1). Cells were adhered to cover slips 
(diameter, 18 mm) in 12-well (diameter 22 mm) tissue culture plates (Baxter Scientific) 
allowing monocytes to adhere both to cover slips and culture plates. The cover slips 
were prepared for tissue culture by immersing them in 95% ethyl alcohol for 2 days, 
washing 5 times with DPBS and then steam sterilizing. The cover slips were rinsed 
again with DPBS before using. One milliliter of the cell suspension was added to each 
well in which cover slips were placed and the adherent monocytes were obtained as 
described above. The monocytes were treated with MPL or LPS (100 ug/ml) and 
incubated for 12 hours as indicated earlier. Following the incubation period, the 
monocytes were washed once with DPBS and labeled with mouse anti-macrophage 
iNOS mAb-FITC using the supplier’s protocol (Transduction Laboratories, Lexington, 
KY, USA). In short, the monocytes were fixed by adding 500 ul of methanol : acetone
(1:1) to each well and kept at -20° C for 10 minutes. The fixing solution was discarded 
and the plate was air dried. Five hundred microliters of bovine serum albumin (BS A, 
0.2% in DPBS) was added to each well containing the cover slips and incubated for 10 
minutes at room temperature. After discarding the BSA, 350 ul of anti-iNOS-FITC 
mAb (2.0 ug/ml, diluted in 0.2% BSA) was added to the wells and incubated again for
45 minutes at 3 7 ® C. A matching isotype control was used in each experiment. The 
cells were washed for 5 minutes with DPBS three times. CD14-PE mAb was added to 
monocytes along with iNOS-FITC in some experiments. The cover slips were then 
removed from the wells (the monocytes in the wells were saved for flow cytometry)
and placed on microscopic slides with 10  ul of mounting media containing 0 .1% p-
phenylenediamine and 50% glycerol in DPBS. The monocytes were observed under 
visible and fluorescent light at 400x magnification. An average of 150 cells were 
counted and result was reported as percentage ± SEM of positive cells.
2.9.3 Flow cytometry method
After recovering the cover slips, the remaining cells in the wells were prepared 
for immunofluorescent staining; the DPBS was discarded and 0.5 ml of 
paraformaldehyde (0.5% in DPBS) was added to each well. The monocytes remaining 
in the wells were removed by scraping with cell scrapers (Baxter Scientific) and 
transferred to flow cytometry tubes. The data were acquired by FACScan Research
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software and analyzed by PcLysys (Becton Dickinson, Mountainview, CA, USA) 
following methods described previously (Loken et al., 1990; Lin et al., 1993a).
2.10 Phagocytosis assay
This assay is based on the principle that pseudoperoxidase of hemoglobin 
oxidizes DAF, forming fluorehe blue (FB), which is a linear function of erythrocyte 
concentration. Assays were performed following a slight modification of the method 
described by Gebran et al., (1992) that heeded coating the RBCs with IgG before 
presenting to the monocytes (see Section 2.10.3 for detail). To determine the amount 
of IgG (antibody) needed to cause optimal phagocytosis, the concentration (or dilution) 
of antibody at which agglutination of RBCs occurred was first determined by 
hemagglutination assay.
2.10.1 Hemagglutination assay
One milliliter of 50% sheep RBCs in Alsever’s solution (Cedarlane 
Laboratories, Hornby, Ontario, Canada) was added to 9.0 ml DPBS in a 15 ml Falcon 
polypropylene tube (Baxter Scientific Products). The suspension was centrifuged at
180 g for 7 minutes at 21°C and the supernatant discarded. This washing was repeated 
at least four times with 10 ml DPBS until the supernatant became clear. The cells were 
counted using a Neubaur hemocytometer and the cell concentration was adjusted to 2.5
x 107 RBC/ml with RPMIc. *
A 2-fold dilution series of rabbit-anti-sheep RBC antibody (Accurate Chemical 
Co., Westbury, NY, USA) was,made with DPBS ranging from 1:80 to 1:5120. One 
hundred microliters of each concentration of diluted antibody was added to 2  wells of a 
96-well V-bottom microtiter plate (Costar, Cambridge, MA, USA). Two wells 
containing 100 ul DPBS served as the control. To each well was added 100 ul RBC
suspension and the plate was incubated for 45 minutes at 37°C in a humidified 
atmosphere. At the end of the incubation period the hemagglutination was determined 
visually. Three different lots of antibody were used in these experiments. The dilution 
at which the hemagglutination occurred was 1:640 to 1:1280. The results of these 
assays are presented in Table 2.1.
2.10.2 RBC opsonization
Fifty milliliters of the washed, diluted RBC suspension (12.5 x 1 0^ cells/ml in 
RPMIc) was divided into two equal halves. Using the hemaglutination results 
described in Section 2.10.1, the calculated amount of anti-sheep RBC was added to one
half of the RBC suspension and both portions were incubated at 37® C for 30 minutes.
The sub-agglutinating antibody dilution used in these experiments was either 
1:320 or 1:640 depending on the antibody lot used. At the end of the incubation period, 
both tubes (containing opsonized and non-opsonized RBCs) were centrifuged for 5
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Table 2.1. Hemagglutination assay
Antibody dilutions
1:80 1:160 1:320 1:640 1:1280 1:2560 1:5120 Control
Lot# 1 + ++ 4- - - -
Lot # 2 + ++ + - -
Lot# 3 - + ++ +
Sheep red blood cells at 2.5 x 106 per well were used. The double (++) signs indicate 
the dilution at which optimum hemagglutination occurred. Lot # indicates the batches 
of antibody used.
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minutes at 180 g at 21°C. The supernatants were discarded and cells were resuspended 
in RPMIc. The cells were counted again to confirm that the cell concentration did not 
change due to lysis or loss during the washing procedure.
2.10.3 Measurement of phagocytosis and related activities
Since this assay was based on the principle that the hemoglobin (Hb) content of 
the solution is directly proportional to the number of RBCs, the RBCs were lysed and 
the Hb content was measured. The pseudoperoxidase activity of Hb oxidized DAF to 
FB and the absorbance of the blue color of the FB was measured.
Monocytes were isolated and incubated as described in Section 2.2.1 - 2.4. At 
the end of the 18-hour incubation, the supernatant was either collected for other assays 
or discarded. The cells were washed gently with 200 ul DPBS at room temperature and 
the liquid was discarded by inverting the plate. Two hundred microliters of RBC 
suspension (coated or uncoated) was added to respective wells with one column of 
wells containing RPMIc. These wells served as the cell blank since the cells may 
produce certain amounts of myeloperoxidase which may react with the reagents to yield 
a false-positive reading. To another column of wells (without any cells) 200 ul of the 
RBC suspension was added which served as the indication of spontaneous lysis of 
RBCs, if any, or the reagent-RBC background. The remaining RBC suspensions were 
saved for later use as standards. Following addition of the RBCs to the wells, the 
plates were centrifuged for 30 seconds at 210 g to facilitate settling of the RBCs and 
contact with the cells adhered to the plate. The plates were then incubated for 60 or 90 
minutes at 37° C in a humidified incubator with 5% CO2 .
At the end of the incubation, the plates were centrifuged at 210 g for 5 minutes. 
One hundred microliters supernatant from each well was withdrawn very carefully 
without disturbing the RBC pellet and transferred to a 96-well flat bottom ELISA plate 
(Baxter Scientific Products). This portion of the assay represents the extracellular lysis 
of RBCs by the monocytes. The remaining fluid was discarded by inverting the plate 
and the cells were washed gently with 200 ul DPBS twice to remove any unbound 
RBCs from the wells. To each well, 200 ul 0.2% NaCl was added and the plate was 
incubated for 3 minutes at room temperature to lyse the extracellular RBCs. An aliquot 
(1 0 0  ul) of the supernatant was withdrawn and transferred to another flat-bottom 
ELISA plate; this portion of the assay represents the adherence of RBCs to the cells 
which did not lyse or phagocytose.
The remaining fluid was discarded and the plate was washed twice with 200 ul 
DPBS as before. To each well 200 ul 0.2 M Tris-HCl containing 6  M urea (Tiis-HCl- 
urea buffer) was added to lyse the monocytes and to expose the internalized RBCs. 
Each 100 ml Tns-HCl-urea buffer contained: 3.15 gms Trizma HC1; 36.04 gms urea; 
and approximately 80 ml DDH2O. At this point the standards were prepared by 5-fold
dilution of the RBC suspensions with DPBS and added to the plate. Standards using 
both Ab-coated and uncoated RBCs were prepared. The plate was centrifuged as 
before and 100 ul supernatant was transferred to another flat-bottom ELISA plate. This
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portion of the experiment represents the actual phagocytosis. The supernatant and the 
RBC pellets from the standard wells were also transferred quantitatively to the plate.
One milliliter of DAF solution (10 mg/ml in 90% acetic acid) was added to 9.0 
ml Tris-HCl-ürea buffer to which 100 ul H2O2 (30%) was added (DAF working
solution). This solution was freshly prepared immediately before the assay. Initial 
experiments revealed that the reaction was very rapid. In order to decrease the speed of 
color development, the prepared solution was diluted 2x with Tris-HCl-urea buffer. 
One hundred milliliters of this diluted DAF working solution was added to each well 
containing the supernatant and the absorbance was read with the ELISA reader at 620 
nm exactly at 5 minutes.
2.11 Cytokine assays
All cytokines were assayed using commercial ELISA kits. All samples were 
diluted using the appropriate diluents and the concentrations were calculated from the 
absorbance values by best fitting binomial regression curves using the StatView 
statistical and graphics program on a Macintosh computer.
2.11.1 Interleukin-la
This was performed using IL -la  ELISA kits (Quantikine human EL-la, R & D
systems, Minneapolis, MN, USA) according to the standard procedures. In short, 100 
ul samples or 200 ul standards were added to anti-DL-la mAb pre-coated plates and 
incubated for 2 hours at room temperature. After washing, HRPO-conjugated 
polyclonal antibody specific for IL -la was added to the wells and incubated again for 1 
hour. Following washing to remove the unbound antibody-enzyme conjugate, an equi- 
volume mixture of H2O2 and tetramethyl benzidine solution (TMB) was added (as
substrate) to develop color. The plate was incubated for 20 minutes. After adding the 
stop reagent (1M H2SO4), the absorption was read at 450 nm with wavelength
correction at 550 nm using the Bio-Tek ELISA reader. The sensitivity and limit of the 
assay were 0.2 pg/ml and 250 pg/ml, respectively. The sample volume was adjusted 
appropriately when needed using the standard diluent provided. Recombinant human
IL -la  was used as the standard.
2.11.2 Interleukin-1(3
This was performed by using the IL-Ip ELISA kits (Quantikine human IL-lp, 
R & D  Systems). The procedure was similar to the IL -la assay except that it used 
specific mAb and standards for the EL-Ip. The sensitivity and limit of this assay were 
0.3 pg/ml and 250 pg/ml, respectively.
2.11.3 Interleukin-6
This 4 membrane solid phase ELISA assay was performed using human IL-6
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ELISA kits (Cytoscreen hIL-6 ) from BioSource International (Camarillo, CA, USA) 
according to the standard procedures. This method was similar to the IL -la assay 
except that it used 2 conjugates: biotinylated monoclonal anti-IL-6  antibody and 
streptavidin-peroxidase conjugate which required one additional washing. The 
substrate used was O-phenylenediamine (OPD) or TMB and the absorbance was read at 
490 nm. Fifty microliters of standards and 50 ul of 4-fold diluted samples were used in
this assay and the plates were incubated at 37°C. The sensitivity and limit of the assay
were 2 pg/ml and 500 pg/ml, respectively. Recombinant human IL- 6  was used as the 
standard.
2.11.4 Interleukin-10
Serum IL-10 was assayed using a specific DL-10 antibody pre-coated solid 
phase sandwich ELISA (Cytoscreen IL-10 kit, BioSource International) similar to that 
described for the IL-6  assay. The sensitivity and limit of the assay were 5.0 pg/ml and
500 pg/ml, respectively. Recombinant human IL-10 was used as the standard.
2.11.5 Tumor necrosis factor a
This was assayed using human TNFa ELISA kits (Cytoscreen hTNFa, 
Innogenetics, Antwerp, Belgium). This method was similar to that of the IL- 6  assay 
except that TMB was used as the substrate and the absorbance was read at 450 nm. 
Fifty microliter of standards and 50 ul of 2-fold diluted samples were used in this 
assay. The sensitivity and limit of the assay were 25 pg/ml and 800 pg/ml,
respectively. Recombinant human TNFa was used as the standard.
2.11.6 Granulocyte macrophage-colony stimulating factor
This was assayed using Cytoscreen Innotest h-GM-CSF ELISA kits 
(Innogenetics) following the standard protocol. This procedure was similar to that of 
the TNFa assay. The substrate used in these kits was TMB and the absorbance was 
read at 450 nm. The sensitivity and limit of this assay were 8 pg/ml and 320 pg/ml,
respectively. Recombinant human GM-CSF was used as the standard.
2.11.7 Granulocyte-colony stimulating factor
This assay was performed using the human G-CSF ELISA kits ( R & D  
Systems, Minneapolis, MN, USA) which was similar to IL-la assay kits except that it 
used TMB as substrate. The absorbance was read at 450 nm. The sensitivity and limit 
of the assay were 7.2 pg/ml and 5,000 pg/ml, respectively. Recombinant human
G-CSF was used as the standard.
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2.11.8 Transforming growth factor p
Since in the absence of acidification TGFpl levels were undetectable total 
activated TGFpl was assayed after acidification of the serum using a commercial 
ELISA kit following the standard protocol ( R & D  Systems). Activation of latent 
TGFpl to an immunoreactive form was achieved by acidification and neutralization of 
the samples. To 0.5 ml of serum, 0.5 ml 2.5 N acetic acid/10 M urea was added and 
mixed. After 10 minutes of incubation at room temperature, the acidified sample was 
neutralized with 0.5 ml of 2.7 N NaOH/l.O M HEPES free acid. This sandwich 
ELISA assay is similar to that described for IL -la except that this uses TGFpi soluble 
receptor Type II for coating the plates. A HRPO-conjugated polyclonal antibody to 
TGFpi was used as the second antibody and TMB was used as the chromogen in this 
assay. The sensitivity and the limit of the assay were 5 pg/ml and 2000 pg/ml,
respectively. Recombinant human TGFpi was used as the standard.
2.12 Receptor and receptor antagonist assays
The receptors are assayed by using commercial enzyme immuno assay (EIA) 
kits and the receptor antagonist assay developed in the author's laboratory. The 
concentrations were determined as described above.
2.12.1 Soluble IL-2 receptor
This assay was performed by using sIL-2r EIA kits (Immunotech Inc., 
Westbrook, ME, USA). This assay used mAbs directed against 2 different epitopes of 
the IL-2r. The samples or the standards were added to pre-coated wells with anti-sIL- 
2r mAb and a second antibody-conjugate (alkaline phosphatase-anti-sIL-2r antibody) 
was added to the wells. The plate was incubated for 2 hours at room temperature with 
constant shaking on the horizontal shaker (Virion) set at low speed. After 3 washings 
200 ul substrate, diethanolamine HC1 (1 M) was added to each well and incubated for 
30 minutes as before. After addition of stop reagent, the absorbance was read at 405 
nm. The sensitivity and limit of the assay were 12.5 pM and 400 pM. The values 
obtained by interpolation were converted to pg/ml (IpM = 42 pg/ml). Undiluted 
samples and recombinant human IL-2r as the standard were used in this assay.
2.12.2 Soluble IL-6 receptor
This was done by using sIL-6r EIA kits (Immunotech International) purchased 
through Immunotech, Inc. This is a ligand-immuno-enzymatic assay where microplates 
are pre-coated with an anti-IL-6  mAb. Undiluted samples and reconstituted standards 
were incubated with a second antibody (anti-sIL-6 r conjugated with alkaline 
phosphatase) and incubated at 8 °C for 16 hours with constant shaking with an orbital 
shaker (Bellco Biotechnology, Vineland, NJ, USA) as before. Washing, substrate 
reaction, and reading of absorbance were as described for sIL-2r. The sensitivity and 
limit of this assay were 12.5 ng/ml and 100 ng/ml, respectively. Recombinant human
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sIL-6 r was used as the standard.
2.12.3 Interleukin-1 receptor antagonist
This assay was performed using ELISA techniques developed in the author's 
laboratory (Lin et al., 1994). Antibodies and the standard were purchased from R & D  
Systems and all other reagents from KPL, Inc. (Gaithersburg, MD, USA) for this 
assay, unless indicated. The concentrated ELISAmate bovine serum albumin (BSA) 
was diluted 10 times with DDH2O and considered as Ix BSA solution. This solution
was then diluted again 2000 times in DPBS (Sigma Chemical Co.) yielding a BSA 
concentration of 5 ug/ml which was used for diluting standards and samples. The 
recombinant human IL-lra (214 ug/ml in Ix BSA, stock standard) was diluted 2140 
times in diluted BSA which gave 100 ng/ml IL-lra. Then a serial dilution was made 
giving 33.3, 11.1, 3.7, 1.2, 0.41, 0.137 and 0.046 ng/ml. The samples were diluted 
twice with diluted BSA and 100 ul of the diluted samples and the standards were added 
to each well of a flat-bottom, 96-well ELISA plate. The plate was covered and 
incubated overnight at 8°C.
At the end of the incubation, the plate was washed three times with 300 ul PBS 
(Sigma Chemical Co.) containing 0.05% Tween-20 (Sigma Chemical Co.) using a 
semi-automated ELISA plate washer (Bio-Tek, Model # EL403) followed by incubation 
at room temperature with 200 ul Ix ELIS Amate BSA solution. The plate was washed 
again three times with PBS as before, 100 ul anti-IL-lra antibody (1000 times diluted in 
Ix BSA) added to each well and the plate incubated for 1 hour as above. After 
washing four times, 100 ul of 100 times diluted (in Ix ELIS Amate BSA) peroxidase 
labeled anti-goat IL-lra antibody was added to each well and the plate incubated again 
for 1 hour at room temperature.
Following incubation, the plate was washed four times and 100 ul 2,2’Azino- 
di-(3-ethylbenzthiazolene) sulfate (ABTS) peroxidase substrate (1:1 dilution of ABTS 
peroxidase substrate and H2Q2) was added to each well. The plate was read at 405 nm
at 2 0  minutes.
2.12.4 Immunoreactive interleukin-1
This was calculated by using the formula DL-1 (IL-la  + IL-ip):IL-Ira x 103 
since it is believed that approximately 1000 units IL-lra is needed to counteract the 
effects of 1 unit of IL-1 in humans (Arend efal., 1990; McIntyre et a l, 1991; reviewed 
byDinarello, 1991).
2.13 Prostaglandin E%
PGE2 was measured using a commercial enzyme immunoassay (EIA) kit 
(TiterZyme PGE2 EIA kit, PerSeptive Diagnostics, Cambridge, MA, USA). This is a 
competitive EIA where wells were pre-coated with goat anti-rabbit antibody. The
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samples and standards were pipetted to the antibody pre-coated wells. Rabbit 
polyclonal anti-PGEa antibody was added to the wells leaving two wells empty. The
contents were mixed well, the plate covered and incubated at 8°C overnight. After the 
incubation, the phosphatase conjugated antibody was added to all wells except the 
blanks. The plate was covered and incubated again at 8 °C for 3 hours. The plate was 
washed and para-nitrophenyl phosphate, as substrate, was added to all wells. The plate 
was covered and incubated at 37°C for 1 hour. The reaction was stopped and the 
absorbance measured at 405 nm. The concentration was determined using the standard 
curve generated with PGE^. The sensitivity and limit of the assay were 1.5 pg/ml and
5000 pg/ml, respectively.
2.14 Cell surface receptor and antigen expression 
determination
2.14.1 Cell retrieval and resuspension
At the end of the incubation, the fluid was discarded, followed by a wash with 
200 ul DPBS. To each well, 200 ul 0.2% pre-warmed EDTA in DPBS was added and
the plate was incubated at 37°C for exactly 3 minutes. The plate was placed on ice 
immediately after the incubation and 100 ul DPBS was added to each well. The EDTA 
dissociates the cells and the cold treatment further facilitates the process, making it 
easier to retrieve them from the plate. Cells were collected by vigorous pipetting. Two 
hundred microliters ice-cold DPBS was added to each well and the remaining cells were 
collected as described above.
2.14.2 Cell staining and flow cytometry analysis
The cells were isolated, plated (two plates per experiment) and treated as 
described in Sections 2.2-2.4. After the cells were retrieved, they were mixed and the 
suspension was divided equally into five Falcon tubes. The cells were washed and
pelleted by centrifuging for 5 minutes at 210 g (8°C). The supernatant was discarded 
and 10 ul of the mAb was added to each tube. All mAbs were conjugated with either 
phycoerythrin (PE) or fluorescein isothiocyanate (HTC) and were purchased from 
Immunotech, Inc. The expression of the following cell surface antigens were studied: 
CD 11b, CD 14, CD 16, CD 18, CD25, CD71 and HLA-DR. All antibodies consist of 
different subclasses of murine IgG. The cells were incubated with 10 ul of each 
conjugated mAb as follows: IgGl FITCAgG2a PE, IgG2a FITC/IgGl PE; CD45 
FITC/CD14 PE; CD1 lb FITC/CD16 PE; HLA-DR FITC/CD18 PE; CD71 FITC/CD25 
PE. Then, the cells were incubated for 15 minutes at room temperature. At the end of 
the incubation, the tubes were centrifuged again and the supernatant discarded. To each
tube, 200 ul 0.1% paraformaldehyde was added and stored at 8°C for analysis, which 
was done within a few days of preparation.
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The cells were analyzed using a flow cytometer (FACScan, Becton Dickinson, 
Mountainview, CA, USA) calibrated each day by the flow cytometry technician using 
CaliBRTTE flow cytometer beads with the Autocomp program (Becton Dickinson) for 
optimum performance. The acquisition was performed using the Consort 30 program. 
The final acquisition parameters were set by observing the control cells based on
forward scatter (FSC) and side scatter (SSC) pattern at 90°. The FSC threshold was 
adjusted to exclude the debris, and FSC/SSC amplifications were manipulated so that 
the cells would fall in the middle of the screen. Once the parameters were set, all 
acquisitions were made using the same parameters. Two hundred to 1000 cells were 
acquired from each sample. The settings from day-to-day did not differ considerably.
A representative setting for the acquisition is given in Table 2.2.
The acquired data were transferred to an IBM PC and then analyzed using an 
analysis program (PcLysys, Becton Dickinson). The first gate was set on the basis of 
histogram plots of FSC between channel # 100 to 245 with the control cells, then 
CD 14-positive cells were observed using this gate. If the CD 14-positive cells appear to 
be in the range of 70 - 90 percent, the gate was accepted as the valid gate. The rest of 
the cells were analyzed using the same gate unless a major shift in cell size was 
observed due to the treatment. In these situations the gates were set on the peak 
populations. The data acquired were mean arbitrary fluorescent units (FU), as a 
measure of receptor density, and percentages of positive cells in linear scale.
2.15 Validation of assays
2.15.1 Protein assay
The results of the 0%- and H2O2 assays were expressed as nmole/mg protein 
and the protein contents was usually obtained from parallel plates. It was thought that 
the protein contents could be determined in the plate where the 0 2 * assay was
performed. To determine if the 0 2 * procedure had an effect on the protein
determination, protein contents were measured on separate plates which were treated
similarly with the exception that the 0 2 ‘ procedure was not performed on one. The
comparisons are shown in Table 2.3. Analysis of the protein data obtained by the two 
methods indicates no difference (p = 0.3). Data analysis on individual methods also 
showed no difference due to treatment (p = 0.4) in either method. The results indicate
that the O2 procedure did not have any adverse effects on the estimation of the protein
content of the cells in each well. This is supported by the fact that the mean cell
viability was found to be approximately 97% in the wells following the 0 2 * assay.
Therefore, the marginal means of the protein values obtained were used for calculations
of O2 and H2O2 production data.
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Table 2.2. Acquisition parameters for flow cytometry
FSC SSC FL1 FL2
Detector E00 313 557 568
Amplification 2 . 0 1 .0 Log Log
Data mode Lin Lin Log Log
Threshold 52 52 - -
Compensation - - FL1 toFL2 0.9 FL2 to FL1 22.5
Data acquisition parameter for the FACScan (Becton Dickinson, Mountainview, CA, 
USA) for cell surface receptor expression studies.
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Table 2.3. Comparison of protein determination by two
different procedures
Cell Concentrations*
0.75 x 106 1.25 x 106 1.87 x 106 2.5 x 106
Method I (protein ug/well) 1.03 0.93 0 .8 8 1 .1 2
±0.14 ±0.13 ± 0 .1 0 ±0.16
Method II (protein ug/well) 1 .0 2 0.89 0.78 0.89
±0.13 ± 0 .1 2 ± 0 .1 0 ±0.14
*Cell concentration indicates number of mononuclear cells/well which were plated and 
monocytes were allowed to adhere to the plate.
Method I indicates the determination of cell protein on the plate following the O2  assay
whereas Method II indicates protein determination on cell protein on parallel plate that 
received the same treatment.
Values presented are mean ± standard error of mean (SEM) of 6  experiments which 
represent the actual monocyte protein in ug/cell concentration. Two-way ANOVA 
indicates no significant difference between methods (p = 0.3) or cell concentrations 
(p = 0.4).
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2.15.2 H2 O2 assay
The bandwidth of a particular spectrum of light in a wavelength influences the 
absorption of light (Leslie, 1987). Therefore, it is important to determine the optimum 
wavelength for a particular bandwidth to read the absorbance. Furthermore, since the 
absorption of light by the oxidized and unoxidized forms of phenol red overlap (Pick 
and Keisari, 1980), these experiments were done to determine the appropriate 
wavelength to read the absorbance of phenol red in order to minimize the error 
associated with the unoxidized phenol red.
Known concentrations (2.5, 5.0, 10.0 and 25.0 nM) of H2O2  were added to
PR and the absorbance was read at 600, 610 and 620 nm following the method 
described in Section 2.7. The response curves are shown in Figure 2.1.
A highly significant difference in absorption in different wavelengths was 
found (pcO.001) indicating their profound effect on the measurement of H2O2 . Results
indicate that the 610 nm readings fall between the other two wavelengths used. The 
600 nm reading is likely to be influenced more by unoxidized phenol red and the 620 
nm would significantly decrease the absorption (Pick and Keisari, 1980). The 
absorbance was also observed to be significantly reduced at 620 nm. The present 
experiments agree with these findings. Similarly, Leslie, (1987) indicated that 
increasing the bandwidth decreases sensitivity and that the optimum wavelength to 
measure absorbance for H2O2 assay was 610 nm. Since in the present experiments a 
narrow bandwidth filter was used, the use of the 610 nm wavelength was thought to be 
appropriate. Therefore, the 610 nm wavelength was initially used to determine the 
H2O2 assays when standard curve for H2O2 was used. However, Pick, (1986)
showed that, using the appropriate extinction coefficient that considers both the 
absorption of oxidized and unoxidized phenol red, H2O2 release can be measured at
600 nm. In some experiments absorption was measured at 600 nm and H2O2  measured
using this method.
2.16 Statistics
Values <0.0 in untreated or unchallenged monocytes, obtained due to 
experimental variations, were considered to be zero for statistical analysis because 
production of the metabolites, mediators or phagocytosis-related functions in un­
challenged cells cannot be <0.0. Two-way analysis of variance (ANOVA) was done 
for comparing the protein data and the H2O2 assay validation data. Three-way ANOVA
was done for comparing the effects of cell concentrations, time (incubation), and doses 
on the PMA-stimulated production of O2 or H2O2 data. The same tests were performed
to examine the effects of cell concentrations, time, treatments, and doses of LPS or 
MPL on these parameters, cytokine release and phagocytosis-related activities by 
separating the data by time, cell concentration or by dose to test the appropriate 
response. Post hoc Fisher's PLSD (protected least significant difference) was 
performed to determine the individual group (treatment, time or dose) difference. Two-
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Figure 2.1. Absorption of light by phenol red at different 
wavelengths.
Changes in absorbance in different wavelengths by phenol red which was 
oxidized by H202. Two-way ANOVA shows a significant difference in 
absorption between wavelengths (pcO.OOl).
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Way ANOVA was also performed on all other analyses except to test a particular group 
of interest, in those cases non-parametric, Mann-Whitney or Kruskal-Wallis tests were 
performed. Bonferroni corrections for small sample size were made in some analyses. 
A value p<0.05 was considered as significant. Results are presented as mean ± 
standard error of mean (SEM).
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RESULTS
3.1 Effects of cell concentrations, incubation time and PMA 
doses on 0%" and H2O2 release
It has been reported that production by monocytes is a function of cell
number (Leslie and Allen, 1987) and H2O2 production is closely related to the Co­
production (Weiss, 1983; Segal, 1989). PMA has been used as a soluble stimulant for 
various functional assays at various doses ranging from 1 - 260 nM depending upon the 
cell concentrations and type of cells. In addition, the production has been measured at 
different time points (incubation time) ranging from 1 -120 minutes (Pick and Keisari, 
1980; Pabst et al., 1982; Leslie and Allen, 1987; Pogrebniak et a l, 1992; Pound, Lund 
and Jefferies, 1993). Therefore, it was imperative to determine a cell concentration, 
incubation time and dose of PMA which will yield optimum and/or reproducible results.
In order to determine the effects of these parameters on O2 and H2O2 production, cells
of different concentrations (2.5 x 106, 1.87 x 106, 1.25 x 106 and 0.75 x 106 mono­
nuclear cells/well) were used. The plate-adherent monocytes were cultured for 18 
hours in PR" RPMIc. At the end of the incubation, the cells were treated with 25, 50, 
75 and 100 nM PMA, and then assayed for O2 and H2O2 production at 30, 60,90,
120 and 150 minutes. In addition to determining the optimum cell concentration, PMA 
dose, and time of incubation required for O2 and H2O2 assays, these experiments were 
done also to validate these parameters for use in the subsequent experiments.
Results of the PMA-stimulated O2 - release are presented in Figure 3.1.1.
Significant effects of cell concentration on overall O2 release were found (p<0.05). 
Post hoc analyses revealed that the 0.75 x 106 cell concentration (low cell concentra­
tion) group produced the highest level of O2 - while the 2.5 x 106 cell concentration 
(very high cell concentration) group released the least amounts. Release by these 
groups was significantly different (p<0.005). Effects of cell concentration in 0 2 -
production were not found between 1.25 x 106 (medium cell concentration) and 1.87 x
106  (high cell concentration) groups. Analyses by individual treatment (dose) group
show significant effects of cell concentration only in the spontaneous release of O2
(p<0.005; Figure 3.1.1 A). The low cell concentration group was again found to 
release the highest levels and the very high cell concentration group produced the least
amounts of O2 . Similar results were found in the PMA-stimulated release of O2 at the
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Figure 3.1.1. PMA-stimulated release of Oz* by monocytes in
vitro. Effects of cell concentrations and time on Oz* release.
Mononuclear cells were plated at the concentrations/well indicated and the 
adherent monocytes were incubated for 18 hours (n = 6  - 7). The cells were 
either (A) not treated or treated with PMA at concentrations of (B) 25 nM, 
(C) 50 nM, (D) 75 nM, and (E) 100 nM. The release was measured at the 
time indicated and the legends are the same as Figure A. Data presented as 
means ± SEM. Three-way ANOVA was done to find out the significant 
overall effects and two-way ANOVA was done to determine the effects on 
individual doses. Overall effects: cell concentration, p<0.05; time, p<0.005; 
dose, p<0.002. Individual treatment (dose) effects: (A) time, pcO.OOl, cell 
con-centration, p<0.005; (B) time, p<0.001; (G) time, pcO.OOl; (D) time, 
pcO.OOl; (E) time, pc0.003.
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50 nM dose (p<0.05; Figure 3.1.1C). The medium cell concentration group at the 25 
nM PMA dose appears to release the overall highest level of O2 (group mean 1435 ±
181 nmole/mg protein) among the cell concentration groups studied up to 150 minutes 
(Figure 3.1. IB, second set of columns).
Highly significant effects of time on either spontaneous or PMA-stimulated 0 2 -
production by the monocytes were found (p<0.005). A time-dependent increased
production of O2 reaching maximum production at 150 minutes was found in all cell
concentration groups. Control cells produced small amounts of O2 (group means 82 -
273 nmole/mg protein) indicating the unstimulated state of the monocytes (Figure 
3.1.1 A) compared to the stimulated cells (group means 507 - 1808 nmole/mg protein;
Figures 3.1. IB - 3.1. IE). Spontaneous release of O2 at 30 minutes was significantly
different from 120 minutes (p<0.05) while PMA-stimulated release at 30 minutes by all 
cell concentration groups differed significantly from 90-minute release (p<0.05) by
showing enhanced O2* release. Significant differences were not found between 120-
and 150-minute release in the untreated monocytes or among 90-, 1 2 0 - and 150-minute
O2 release in the stimulated group. Again, the 25 nM dose at 150 minutes appears to
release the highest level of O2 (time point mean 1808 ±182 nmole/mg protein).
A highly significant dose difference in O2 release was seen at all cell
concentrations (p<0.002). Overall release with 25 nM PMA appeared to be higher than 
any other dose of PMA used. However, statistical difference was not found in 
individual cell concentrations or time points except in the medium cell concentration
group. Overall O2 release in this group with 25 nM PMA was significantly higher
than the 100 nM PMA-stimulated release (p<0.01; Figures 3.1.IB versus 3. LIE, 
second set of columns). Monocytes in the medium cell concentration group stimulated
with 25 nM PMA at 150 minutes were found to release the highest level of O2  (1976 ±
499 nmole/mg protein).
Since the results show that O2 production is cumulative and the magnitude of
its production varies with the dose of the stimulant, the data was analyzed to determine 
the optimum time to achieve reliable results. Analyses of the data reveal that the rate of 
production is very high at 30 minutes and decreases rapidly, reaching a stable level at 
90 minutes (data not shown). The rate of production was found to be constant between 
90 and 120 minutes. Differences in rate of spontaneous release of O2 ' were not found.
It was also found that the rate of O2 production was highest with 25 nM of PMA (time
point mean 22.3 ± 2.9 nmole/mg protein/minute) which was significantly different from 
the release at any other time points. Rate of release by the 100 nM dose did not differ 
from the release at any time points.
These data indicate that increased cell concentrations do not increase Co­
production linearly and that 0 % production increases over assay incubation time, but
the rate of release decreases with time. The 1.25 x 106 cell concentration appears to
yield the most O2 in response to PMA stimulation at the 25 nM dose.
The next set of the experiments was performed to determine the optimal cell 
concentration, PMA dose, and assay incubation time for the H2O2 assay. The cell
concentrations, doses and incubation time were the similar as described above for
PMA-stimulated O2 production (Section 3.1). Since the rate of O2 production
significantly decreased at 150 minutes, H2O2 assays were performed only at 30, 60,90
and 1 2 0  minutes.
The results of PMA-stimulated H2O2  production are presented in Figure 3.1.2. 
Unlike O2  production, significant effects of cell concentration on H2O2 production
studied up to 120 minutes were not found (Figures 3.1.2A - 3.1.2E). Analyses show 
that untreated cells produced minimum amounts of H2O2  at all cell concentrations
(group means 98 - 106 nmole/mg protein; Figure 3.1.2A), again confirming their 
unstimulated state compared to the stimulated cells which produced large amounts of 
this intermediate (group means 356 - 908 nmole/mg protein; Figures 3.1.2B - 3.1.2E). 
FQghly significant effects of time on H2O2  production by the monocytes were
found (p<0.002). However, unstimulated cells did not produce any substantial amount 
of H2O2 over time confirming their normal physiologic state (Figure 3.1.2A). A time-
dependent, PMA-stimulated increased production up to 90 minutes was seen in most 
cell concentrations at higher doses of PMA (Figures 3.1.2D and 3.1.2E). The overall 
release of H2O2 at 90 minutes was found to be higher (576 ±73 nmole/mg protein) and
was significantly different from the 30-minute release (p<0.05). A time dependent 
increase of H2O2 production by macrophages has been reported by many investigators 
(Pick and Keisari, 1980; Pick and Mizel, 1981). This result was expected since, in the 
present experiments, a similar system was used. Production was found to decrease at 
1 2 0  minutes indicating the limitation of the model in producing H2O2 .
Since inconsistencies in the effects of cell concentration and incubation time on 
H2O2 release were observed, the rate of H2O2 release was examined (data not shown).
A time-dependent decrease in rate of PMA-stimulated H2O2 release was found 
(p<0.003). No difference was found in the rate of spontaneous H2O2 release.
Analyses of the data revealed that the rate of production was highest at the 100 nM dose 
(dose mean 18.1 ± 2.0 nmole/mg protein/minute) at 30 minutes while the 25 nM dose 
produced the least amounts of H2O2 (dose mean 1 0 .6  ± 2 .1  nmole/mg protein/minute).
The overall release was stable between 60 and 90 minutes but significantly decreased at 
120 minutes. Although the rate of H2O2 production in all cell concentrations was found
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Figure 3.1.2. PMA-stimulated release of H2 O2 by monocytes 
in vitro. Effects of cell concentrations and time on H2 O2 
release.
Mononuclear cells were plated at the concentrations/well indicated and the 
adherent monocytes were incubated for 18 hours (n = 7). The cells were 
either (A) not treated or treated with PMA at concentrations of (B) 25 nM, 
(C) 50 nM, (D) 75 nM, and (E) 100 nM. H2O2 release was measured at the 
time indicated and the legends are the same as Figure A. Data presented as 
mean ± SEM. Three-way ANOVA was done to find out the significant 
overall effects and post hoc tests were done to determine the effects of 
individual variables. Overall effects: cell concentration, not significant; time, 
p<0.002; dose, p<0.05. Individual treatment (dose) effects: not significant.
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to follow a similar direction, it was found to be stable in the medium cell concentration 
group. These observations again confirm that the medium cell concentration (1.25 x
106) gives the greatest response to PMA when H2O2  production by monocytes is 
measured.
When the effect of PMA dose on the production of H2O2 was examined, a 
significant effect of dose was found (p<0.05). Data presented in Figures 3.1.2B - 
3.1.2E show that high doses of PMA (75 nM and 100 nM) stimulate the monocytes to 
produce significantly increased amounts of H2O2 compared to unstimulated monocytes
(p<0.05), with 100 nM producing the highest level. However, in the medium cell 
concentration group, H2O2 release by only 100 nM PMA reached statistical significance
when compared to control. In the 1.87 x 106 cell concentration group, low doses of 
PMA (25 and 50 nM) failed to produce substantial amounts of H2O2 where the highest 
production was seen at 60 minutes (Figures 3.1.2B and 3.1.2C). The highest 
production of H2O2 was obtained by 100 nM PMA in the 2.5 x 10^ cell concentration
group at 90 minutes (1097 ±578 nmole/mg protein).
Results from the experiments to determine a cell concentration appropriate for
the measurement of respiratory burst activity indicate that the 1.25 x 106. cell 
concentration yields the optimum response. This can be supported by the findings that 
a), this cell concentration released the highest level of O2 (total group mean) and H2O2
(individual dose and time mean); b). release of both O2 and H2O2  in this group
occasionally differed from the release by other cell concentrations; c). release by this 
cell concentration appeared to be more consistent between times and PMA doses than 
other groups; d). spontaneous release in this group appeared to be consistent over time. 
Although a relationship between cell concentrations and spontaneous release of O2 was
found, a significant difference in terms of PMA-stimulated O2 and H2O2 release was
not found at other cell concentrations (a significant overall difference is suggestive of 
differences between individual time and dose that was not consistent over experiments, 
possibly due to the reduced degree of freedom and increased variability). It may be 
possible that the number of cells used in these experiments exceeded the physiological 
limit to see a statistically significant difference. Leslie and Allen, (1987) described the 
production of O2  as a function of cell number. Warwick-Davies, Lowrie and Cole,
(1995a) reported that H2O2 release decreased at a higher concentration (2  x 105
monocyte-derived macrophages/well) compared to a lower cell concentration (1.5 x 105 
monocyte-derived macrophages/well). The release was decreased from 4.6 ± 1.1 
nmole/10  ^cells/hour to 1.6 ± 0.7 nmole/10^ cell/hour which is comparable to that of 
the present study. Leslie and Allen, (1987) found that human PBMCs at a density 
above 0.5 -1.0 x 106 showed reduced O2 production at 60 minutes. They also
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showed a progressive decline in production up to 120 minutes. This might explain the 
lack of difference in individual cell concentrations in O2 or H2O2 production since the
cell concentrations used in the present experiments were above these levels. Inciden­
tally, the protein assay did not show any difference in protein content between cell 
concentrations, which was unexpected. It further explains the lack of difference in the 
production of the metabolites or mediators between different cell concentrations. One 
possibility might be that overcrowding of cells in the higher cell concentrations limited 
their adhesion to the wells yielding a lower number of adherent cells which was similar 
to the number of cells adhered in the lower cell concentrations. The possibility of 
discrepancies in the protein assay or the loss of cells from the plate can be ruled out by 
the fact that the protein contents of the wells were found to be in the range of 0.78 ± 
0.10 ug/ml to 1.12 ± 0.16 ug/well (Table 2.3) which falls within the range reported by
Pabst et a l, (1982) of 12.0 - 18.0 ug/dish containing 1.0 - 2.0 x 10& human PBMs. 
Assuming that monocytes constitute 15% of the mononuclear cells in the present 
experiments, the number of monocytes per well would range from 0 .1 1  - 0.38 x 1 0^. 
The expected protein content per well, therefore, should be in the range of 1.35 - 3.38 
ug/well, which is close to the observed values found in the present experiments. 
However, the heterogenecity of this population at different cell concentrations may have 
ramifications which deserve an alternate explanation.
The results of these experiments to determine the effects of time on O2  and
H2O2  production indicate that the production of O2  is cumulative but the rate of
production decreased over time. It reached a stable rate of production between 90 and 
120 minutes and decreased thereafter. These findings agree with the results reported
earlier (Leslie and Allen, 1987). Since H2O2 is a result of O2 metabolism, a similar 
response for this metabolite was expected. It was found that H2O2 production reached 
stability at 60 minutes but it declined after 90 minutes. Therefore, measurement of 
these metabolites at 90 minutes was thought to yield reproducible and reliable results 
and used in further experiments.
PMA stimulation increased both Ox and H2O2 production. The PMA-
stimulated O2 production was found to be in the range of 623 - 1437 nmole/mg protein
in response to 25 nM -100 nM PMA with 1.25 x 10& - 2.5 x 10^ mononuclear 
cells/well 25 nM PMA being produced the highest level. Pabst et al., (1982) reported 
that 1 .0  - 2 .0  x 1 0& cells produced 1600 - 2 1 0 0  nmole 0 2 '/mg protein/hour in response
to 10 nM PMA 60 minutes after stimulation. In another study with murine 
macrophages Pogrebniak et al., (1992) reported a production of 3108 ± 111 nmole
0 2  /mg protein/20 minutes per 0.4 x 10^ cells in response to 260 nM PMA. Results of 
the present experiments agree with the findings in these reports. H2O2  production was
shown to be significant only in 75 and 100 nM PMA doses compared to control cells,
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while 100 nM PMA produced the highest amount, especially in the medium cell 
concentration group. Therefore, a PMA dose of 25 nM was used with lower cell 
concentrations and a 100 nM dose was used with medium cell concentrations in the 
subsequent experiments.
3.2 Effects of LPS and MPL on phagocytosis-related 
activities
Although the 1.25 x 10^ cell concentration group yields the optimal response in 
respiratory burst activity, this does not necessarily indicate a similar behavior in 
phagocytosis-related activities. Since cell concentrations, phagocytic celhRBC ratio 
(effectontarget ratio) and the assay incubation time were shown to affect the measure­
ment of the phagocytic functions (Gebran et a l, 1992), experiments were done with 
different cell concentrations, effectontarget ratios and time points. In this set of 
experiments, effects of LPS and MPL on phagocytosis-related activities such as 
1) extracellular lysis; 2) cellular adhesion; and 3) phagocytosis were examined.
Cells at different concentrations were plated, isolated, and treated as described 
for Ox production in Sections 2.2 - 2.4. Antibody-coated RBCs were added as 
described above (Sections 2.10.1 - 2.10.2). The approximate adherent celhRBC ratios 
were calculated as: 0.75 x 106 cell concentration, 1:25; 1.25 x 106 cell concentration,
1:14; 1.87 x 106 cell concentration, 1:10; and 2.5 x 106 cell concentration, 1:7. The 
assays were performed at 60 or 90 minutes as per method (Section 2.10). RBCs that 
are lysed extracellularly are measured and represent cellular cytoxicity by monocytes. 
The non-adhered RBCs were washed, the RBCs that adhered to the monocyte surface 
were lysed, and the supernatant was collected and assayed. This represented the 
number of RBCs adhered to monocytes that were not phagocytosed. Finally, the 
monocytes were lysed, and the phagocytosed RBCs were exposed and quantified as 
described above (Section 2.10.3).
In order to obtain optimum activities in the phagocytosis-related experiments, it 
was necessary to establish the specific effectontarget ratio since it may influence the 
outcome of these experiments (Gebran et a l, 1992). Results of the present experiments 
indicate that the mean total extracellular lysis and phagocytosis was highest in the low 
cell concentration group but maximum mean total extracellular adhesion was seen in the
1.25 x 1 0 6  cell group which had an effectontarget ratio of 1:14 (Table 3.1, page 98). 
The effectontarget ratio utilized in previous studies has ranged between 1:4 -1:300. 
Leon et a l, (1992) used a monocyte:bacteria ratio of 1:4 whereas Cooper, Mayer and 
Baggiolini, (1984) reported that significant phagocytosis did not occur at an 
effectontarget ratio less than 1:10. In that study, phagocytosis was increased as the 
ratio increased up to a ratio of approximately 1:300 when it approached to reach a 
plateau. Gebran et a l, (1992) demonstrated that an effectontarget ratio of 1:5 yielded 
the optimum phagocytosis. The level of phagocytosis obtained in the present 
experiments (Table 3.1) falls within the range of values reported by these authors.
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Therefore, the use of the 1.25 x 10^ cell concentration with the corresponding 
monocyte:RBC ratio is determined to be valid.
3.2.1 Effects of LPS and MPL on extracellular lysis
Although experiments were done both at 60 and 90 minutes incubation period, 
only the 60-minute data are presented here. (Analyses of the 60-minute and 90-minute 
data did not show any significant difference on cellular cytotoxicity.). Results of the 
effects of LPS and MPL pretreatment on Ab-dependent and Ab-independent cell- 
mediated cellular cytotoxicity are presented in Figure 3.2.1. Analyses of the data 
indicate overall significant effects of antibody (p<0 .0 0 2 ), treatment (p<0 .0 0 2 ), and 
dose (pcO.OOl) on cellular cytotoxicity as measured by RBC lysis. Antibody increased 
cytolytic activity in all cell concentrations (effectontarget ratio) both in the LPS- and 
MPL-pretreated groups, confirming the fact that Ab facilitates binding and engulfment 
of particulate antigens by MPs (Fearon and Wong, 1983). Although overall 
extracellular lysis was not influenced by cell concentration (p = 0.07), lysis in the very 
high cell concentration group was significantly different from the low cell concentration 
group (p<0.006).
Data was then analyzed to examine the effects of these parameters on cytolytic 
activity only in the Ab-treated group (ADCC). Significant cell concentration effects 
were seen in the Ab-dependent group (p<0.04), suggesting the specific requirement of 
effectontarget ratio for optimum cytolytic activity of monocytes. The mean total
cytolysis in the low cell concentration (0.75 x 106, i.e., high effectontarget ratio) group
was found to exhibit maximum cytolysis (33.3 ± 3.9 x 103 RBC) and the very high
(2.5 x 106) cell concentration (i.e., low effectontarget ratio) group showed the least
activity (20.7 ± 2.5 x 103 RBC; Table 3.1). The mean total cytolysis in low and very 
high cell concentration groups differed significantly (p<0.05) while other groups did 
not show any difference from each other. Cytolytic activity in the LPS-treated group 
was significantly (p<0.0002) lower than that of the MPL-treated group which was 
found to be dose-dependent (pcO.OOOl). However, increased Ab-dependent 
cytotoxicity at 0.01 ug/ml dose was not significantly different from the control. Further 
analysis of the data shows that mean cytolysis of the MPL-treated cells in the medium
cell concentration group exhibited the highest lysis of the RBCs (41.7 ± 6.5 x 103 
RBC) and LPS-treated monocytes in the very high cell concentration group caused the 
lowest lysis (16.7 ± 2.9 x 103 RBC).
Analysis of the Ab-independent cytolysis also shows a significant overall dose 
(p<0.0005) and treatment effects (p<0.007). MPL is shown to increase cytolysis in all 
cell concentrations whereas this activity was not seen in the LPS-treated group in any 
cell concentration. The mean total Ab-independent cytolytic activities in different cell
concentration groups were found in the range of 10.1 -17.9 x 103 RBC, which were 
not significantly different from each other (data not shown). Post hoc analysis revealed
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Figure 3.2.1. Antibody-dependent (Ab-Dep) and antibody-independent 
(Ab-Ind) extracellular lysis of sheep red blood cells (RBCs) by 
monocytes in vitro.
Mononuclear cells were plated at concentrations of (A) 0.75 x 10 ,^ (B) 1.25 x 10 ,^ 
(C) 1.87 x 10*\ and (D) 2.5 x 10  ^per well (n = 8 -10). Adherent monocytes were 
incubated for 18 hours with LPS or MPL at the concentrations indicated. Antibody- 
coated or uncoated RBCs were added to the cells and RBC lysis was measured after 
60 minutes. Data presented as mean ± SEM. Legends as Figure D.
ANOVA: Ab-dep, (A) LPS versus MPL p<0.03; (B) LPS versus MPL p<0.005, 
dose p<0.01. Ab-Ind, (B) dose x treatment interaction, p<0.03; (C) LPS versus 
MPL p<0.05. Ab-Dep versus Ab-Ind, LPS (A) and (B)p<0.01;(C) pcO.OOl; MPL 
(A) p<0.005, (B) p<0.0001, dose p<0.001, (C) p<0.005.
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MPL only at 100 ug/ml enhanced cytolysis in this group in all cell concentrations, 
indicating MPL-mediated enhancement of cytolytic activity in the absence of Ab. This 
activity was not seen to be significant in the lower doses (0 .0 1  - 1 0  ug/ml) or in low or 
very high cell concentration groups in these doses (Figures 3.2.1A - 3.2. ID).
Based on these data and the results from the previous experiments, the 1.25 x 
10^ cell concentration (effectontarget = 1:14) is determined to be the optimum 
concentration to be used in subsequent experiments. This cell concentration was also 
used to keep uniformity in cell concentration with other experiments for reliable 
comparisons.
Secondary analysis of the 1.25 x 106 cell concentration data indicates that Ab 
significantly increases cytolytic activity in both LPS- and MPL-pretreated groups 
(p<0.001), again confirming the requirement of Ab in this activity which is in 
agreement with a previous report (Gebran et ah, 1992). Since monocytes express 
receptors for the Fc portion of the IgG (Ab), this activity is believed to be mediated 
through the Fc receptors. While both LPS and MPL treatments significantly increase 
cytolytic activity in a dose-dependent manner (p<0.01), the MPL-treated group shows 
significantly increased activity compared to LPS (p<0.005; Figure 3.2. IB) suggesting 
that MPL stimulates the expression of the Fc receptors or it enhances some other form 
of mediator which enhances cytolysis. Since different types of Fc receptors are 
expressed on monocytes, it cannot be confirmed within the realm of the present 
experiments as to the involvement of the specific Fc receptor.
Data were then analyzed to examine the effects of treatment and dose in Ab- 
treated- and Ab-untreated groups independently. Significant treatment (p<0.03) and 
dose effects (p<0.05) were found in the Ab-treated group. Cytolysis between control 
and 10 or 100 ug/ml MPL was found to be significantly different (p<0.05) confirming 
that higher doses of MPL increase cytolysis.
Although overall difference was not found in the Ab-independent group 
between LPS and MPL, significant lysis was seen at 100 ug/ml of MPL (25.9 ± 6.3 x 
10^ RBC) compared to either control (7.5 ± 2.8 x 103 RBC) or LPS-treated monocytes
(8.2 ± 2.8 x 103) (p<0.05). There was no difference in RBC lysis between LPS- 
treated and control monocytes. Ab-independent increased cytolysis in the MPL-treated 
group suggests that MPL-stimulated monocytes to release cytotoxic substances that 
enhance their cytolytic activity. While there were differences in Ab-independent and 
Ab-dependent cytolytic activities in both treatment groups (LPS or MPL), no
differences were found in the untreated cells (Ab, 7.5 ± 2.8 x 103 RBC and Ab-
independent, 10.8 ± 3.8 x 103 RBC). It confirms that the monocytes are in their 
normal physiologic state and that the unstimulated monocytes do not initiate 
extracellular cytolysis.
ADCC is a two-step process; the binding and the attack. During this process 
the cytotoxic cell forms a stable conjugate with the target cell. The conjugate is formed 
through multiple receptor-ligand bonds between FcyR on the cytotoxic cell and IgG
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antibody bound to the target cell. Once the effector-target bonding is formed, the 
effector cell delivers a "lethal hit" to the target cell and destroys it. However, in certain 
instances, the target cell can be killed without the help of the Ab. A less popular view 
of soluble mediator-mediated cytolysis independent of binding also exists (Yamauchi et 
a l, 1989; Nissen-Meyer, Espevik and Austgulen, 1988, reported by Liesveld et al., 
1991). In the present experiments, both Ab-dependent and Ab-independent cytotoxic 
activity of monocytes stimulated with either LPS or MPL were studied. Sheep RBCs 
were used as target cells. It was found that the antibody enhanced the cytolytic activity 
of both LPS- and MPL-treated monocytes. Although the cytolytic activity was 
enhanced with both LPS and MPL treatments, that induced by MPL treatment was 
significantly higher than that induced by LPS. This was expected since previous 
reports have demonstrated that MPs can be involved in ADCC and particles coated with 
antibodies enhance phagocytosis by mononuclear phagocytes (Ralph et al., 1980;
Fearon and Wong, 1983; Cooper, Mayer and Baggiolini, 1984; Gebran et al., 1992; 
van Schie et al., 1992). In addition, MPs are able to lyse various cells either 
spontaneously or upon activation by bacterial products (Sone and Fidler, 1980), 
lymphokines (Shen et al., 1986; Connor, Shen and Fanger, 1990) and specific 
antibody (Kurisu et al., 1980; Connor, Shen and Fanger, 1990). The mechanism(s) of 
cell-mediated-cellular-cytotoxicity is not clearly understood. However, H2O2 , NO,
proteases and some proteins, such as lysozyme, arginase and lactoferrin, have been 
suggested to be involved in the lysis of susceptible cells (Espevik and Nissan-Meyer, 
1986; Mantovani, 1989; Segal, 1989; reviewed in Schwamberger, Flesch and Ferber, 
1991; Auger and Ross, 1992). H2O2  may work synergistically with other factors to 
lyse tumor cells (Adams et al., 1981). It is possible that extracellular lysis in 
monocytes is carried out by H2O2  independently or in association with other mediators
(possibly NO), as seen in the present experiments. A similar O2  release both in LPS-
and MPL-treated groups and increased H2O2  release in the MPL group suggest this
possibility (Section 3.5, Figure 1). Increased NO release with MPL was found in the 
present experiments (Section 3.6, Figures 1 - 5). On the other hand, Gidlund et a l, 
(1988) demonstrated that CD 14-negative human monocytes exhibited high cytolytic 
activity but no phagocytic activity. In the present experiments, the MPL-treated group 
expressed a lower level of CD 14 as compared to LPS (Figure 3.4.2A).
It is also possible that increased extracellular lysis was mediated by FcyRI or 
FcyRII since significant expression of FcyRIII was not seen in the present experiments 
and binding through FcyR may have been necessary for this activity. A previous report 
supports this speculation (van de Winkel et a l, 1989). These authors demonstrated that 
lysis of IgG-sensitized RBCs by human monocytes in vitro was mediated through 
FcyRI or FcyRII. Similarly, Klaassen et a l, (1990) demonstrated that the specific 
blocking of FcyRIII with an anti-FcyRIII mAb did not affect lysis towards sensitized 
RBCs. It has been demonstrated that only high affinity Fc receptors, FcyRI, are 
involved in the triggering of ADCC in macrophages (d’Uscio, Jungi and Blaser, 1991; 
van Schie et a l, 1992). Liesveld et a l, (1991) reported specific Ab-dependent killing
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of a colon cancer cell line was significantly higher than the non-specific killing of these 
cells. Significant inhibition of ADCC in the presence of antibody to FcyRIII was seen, 
however, failure of inhibiting non-specific ADCC in the presence of this antibody was 
seen, suggesting that other receptors are involved in ADCC in that system. 
Subsequently, inhibiting functional sites of CD l ib  and CD 18 with antibodies did not 
decrease ADCC, suggesting that these receptors are not involved in ADCC. The 
possibility of the involvement of soluble mediators independent of adhesion and Fc 
receptors has been postulated.
Hammerstrom (1981) reported that adherent human monocytes exhibited 
cytolytic activity only to transformed cells in vitro, but the mediator(s) responsible for 
this function could not be identified. It appears that the mediator referred to by these 
authors and the cytotoxic protein factor reported by Espevik and Nissan-Mayer, (1986) 
may have been the TNF. Later, use of TNF neutralizing anti-TNF antiserum or 
antibody did not decrease the ADCC of RBCs or the colon cancer cell line (van de 
Winkel, 1989; Liesveld et ai., 1991, respectively). It was postulated that tumoricidal 
activity of macrophages against the colon cancer cell line (Liesveld et a l, 1991) and a 
lymphoma cell line did not involved TNFa (Harwix et al., 1992). However, the latter 
authors have shown a synergistic activity of TNFa with other factors that have yet to be 
identified. In addition, it was reported that RNI was not involved since NO could not 
be detected in the culture supernatant. In the present experiments, TNFa was found to 
be minimally increased by MPL treatment, thus, negating the possibility of involvement 
of this cytokine in RBC lysis. Later, mouse peritoneal macrophages incubated with a 
synthetic NO donor exhibited increased tumor cell lysis; the specificity of the mecha­
nism was claimed since hemoglobin inhibited the cytolysis process (Li et al., 1995). 
Findings of the present experiments support the hypothesis that increased lysis by MPL 
may be associated with the enhanced production of H2O2 and NO by monocytes.
3.2.2 Effects of LPS and MPL on extracellular adhesion
Binding of cells to monocytes is a prerequisite for phagocytosis. However, 
monocytes may not phagocytose all the cells that bind to their surfaces that depends 
upon the activation state of the cells. Therefore, the effects of LPS and MPL on 
extracellular adhesion of RBCs on monocyte surface were examined and the results are 
presented in Figures 3.2.2A - 3.2.2D. Overall significant effects of cell concentration 
(p<0.05), treatment (p<0.005) and dose (p<0.01) on extracellular adhesion were 
found in the Ab-group. An overall effect of treatment was found only in the Ab- 
independent group (p<0.01). Furthermore, significant interaction between Ab-group 
and cell concentration was found (p<0.005) suggesting the requirements of Ab and 
specific effectontarget ratio. The mean total extracellular adhesion in the medium cell
concentration group was shown to be the highest (40.4 ± 3.3 x 103 RBC) which was 
significantly different from the very high cell concentration group (Table 3.1). 
Extracellular adhesion in the low cell concentration group was also different from the 
very high cell concentration group (p<0.05). These results confirm that medium cell
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Table 3.1. Effect of cell concentration on antibody- 
dependent phagocytosis-related activity1 by 
monocytes in vitro2
Mononuclear cell concentration
0.75 x 106 1.25 x 106 1.87 x 106 2.5 x 106
Extracellular lysis 
Extracellular adhesion 
Phagocytosis
33.3 ± 3.9a
37.6 ± 2.7a
15.7 ±  1.0a
28.9 ± 2.9 
40.4 ± 3 3a 
14.1 ±0 .9
26.8 ± 2 .8  
34.1 ± 2.7 
12.7 ± 0.7
20.7 ± 2.5b 
26.2 ± 1.9b
11.8 ± 0.7b
Values represent number of red blood cells (x 103) phagocytosed per well (Mean ± 
SEM of 8 -10  experiments).
^Methods as described in Sections 2.2 - 2.4 and 2.10.
a>b Different superscripts in a row indicate significant difference (p<0.05).
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concentration (1:14 effectontarget ratio) yields the best response under the conditions of 
the present experiments.
Secondary analysis of the 1.25 x 106 group data indicates an overall treatment- 
(p<0.001), dose- (p<0.05) and Ab- (pcO.OOl) dependent decrease of extracellular 
adhesion (Figure 3.2.2B). MPL pretreatment in the Ab-dependent group shows 
decreased adhesion with a very small amount (0 .0 1  ug/ml), and increasing doses do not
cause further decrease (range 29.6 -27.2 x 103 RBC). LPS treatment did not decrease 
the extracellular adhesion of RBC. This decrease by MPL was significantly different 
from the LPS-treated group (p<0.03). In the Ab-independent group, MPL pretreatment 
caused a dose-dependent decrease of the extracellular adhesion of RBCs to the
monocyte surface (25.5 - 17.8 x 103 RBC). Again, MPL-mediated decrease was 
significantly different from LPS-treated monocytes (p<0.005). No difference in LPS- 
treated cells were found. Taken together, the results of these experiments show that 
MPL decreases extracellular adhesion of RBCs to monocytes in the presence or absence 
of Ab, indicating either efficient lysis, enhanced phagocytosis or decreased expression 
of Fc receptors on the monocyte cell surface for binding.
Data on LPS- or MPL-stimulated, receptor-mediated binding of RBCs to 
human monocyte is not available. Cooper, Mayer and Baggiolini (1984) reported that 
LPS-treated murine macrophages increased both phagocytosis and Fc receptor activity. 
Based on the results of the present experiments, it was hypothesized that the decreased 
extracellular adhesion of RBCs in the MPL-treated group is due to efficient lysis. This 
is suggested by the observation that this group exhibited very high levels of 
extracellular lysis (Figure 3.2.1) and less phagocytosis (Figure 3.2.3) compared to the 
LPS-treated group. It may appear contradictory that MPL did not change FcyRIII 
(CD 16) expression which is known to interact in particulate adhesion. However, CD 16 
is not involved in phagocytosis but it is involved in binding of the immune complexes 
which does not act as a trigger for extracellular lysis (Klaassen et a l, 1990). It is 
possible that the increased FcyR expression enhanced extracellular adhesion in the LPS- 
treated group and thus, made more RBCs available for phagocytosis. An increased 
tendency of CD 16 expression in the LPS-treated group supports this speculation. 
Studies delineating the mechanism(s) of extracellular adhesion of RBCs in LPS- and 
MPL-treated monocytes were not found in the literature. This data may indicate 
different mechanisms of LPS- and MPL-stimulated phagocytosis in monocytes. The 
possibility of CD18-mediated activity cannot be ruled out, and will be discussed later 
with CD 18 expression.
3.2.3 Effects of LPS and MPL on phagocytosis
Phagocytosis is a innate function of MPs and it can be modulated by various 
stimuli. Monocytes were treated with LPS or MPL and phagocytosis of RBCs was 
measured. Results of these experiments are presented in Figures 3.2.3A - 3.2.3D. A 
highly significant effect of Ab on phagocytosis is seen (p<0.004). Data show that 
antibody caused increased phagocytosis in all cell concentrations and in both LPS- and
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Figure 3.2.2. Antibody-dependent (Ab-Dep) and antibody-independent 
(Ab-Ind) extracellular adhesion of sheep red blood cells (RBCs) to 
monocytes in vitro.
Mononuclear cells were plated at concentrations of (A) 0.75 x 10 ,^ (B) 1.25 x 10*\ 
(C) 1.87 x 106, and (D) 2.5 x 10  ^per well (n = 8 - 9). Adherent monocytes were 
incubated for 18 hours with LPS or MPL at the concentrations indicated. Antibody- 
coated or uncoated RBC were added to the cells and RBC adhesion to monocytes was 
measured after 60 minutes. Data presented as mean ± SEM. Legends as Figure C. 
ANOVA: Ab-Dep, (A) LPS versus MPL p<0.05; (B) LPS versus MPL p<0.03. 
Ab-Ind, (A) LPS versus MPL p<0.03; (D) LPS versus MPL p<0.05. Ab-Dep versus 
Ab-Ind, LPS (A) p<0.01; (B) p<0.05.
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MPL-pretreatment groups. Data again confirms the requirement for opsonization for 
optimal phagocytosis (Cooper, Mayer and Baggiolini, 1984; Gebran et al., 1992).
Because analyses of the data reveal that significant phagocytosis does not occur 
in the Ab-independent group, these analyses were performed without including this 
group in the model. Significant effects of cell concentration on phagocytosis were 
found (p<0.02). Total mean phagocytosis in the low cell concentration group was 
significantly different from the very high cell concentration group (p<0.05; Table 3.1). 
LPS pretreatment increased phagocytosis in all cell concentrations, where maximum 
phagocytosis was seen in the 1.25 x 106 cell concentration group (Figure 3.2.3B) 
which was significantly different from the MPL-treated group (p<0.02). Data show 
that phagocytosis at this cell concentration increased at lower doses of LPS (17.9 -19.7
x 103 RBC) compared to control (13.0 ± 1.9 x 103), whereas an increase was not seen
with the 100 ug/ml dose (12.1 ± 1.9 x 103 RBC). However, individual doses did not 
reach statistical significance, probably due to the large variations between samples.
Data also indicate that MPL did not cause any change in phagocytic activity from that of 
the control, indicating the normal resting state of the cultured monocytes. No 
differences were found in the Ab-independent phagocytosis in any cell concentrations 
suggesting that phagocytosis of RBCs by monocytes was mediated through only Fc 
receptors under the conditions of the present systems.
Phagocytosis was enhanced by LPS treatment in the present experiment. The 
lack of increase in phagocytosis at the 100 ug/ml dose of LPS is difficult to explain 
within the current experimental parameters. The data simply may be an artifact of the 
experiments or may be related to FcR expression. While CD 16 expression in the LPS- 
treated group did not seem to increase significantly, involvement of the other two Fc 
receptors, such as CD32 and CD64, which are involved in phagocytosis, is possible 
(Klaassen et al., 1990). Recent reports confirm that FcyRI and FcyRII are involved in 
the phagocytosis and killing of serum opsonized S. aureus by human monocytes in 
vitro while involvement of FcyRIII was not found (Zheng et ah, 1993,1995). High 
doses of LPS may have down regulated the expression of these receptors. Jungi et a l,
(1990) demonstrated that phagocytosis of Ab-coated RBCs was up-regulated by very 
small doses of LPS, but it was not correlated with up-regulation of FcyRI and FcyRII. 
No explanation was given for this discrepancy. However, it supports the concept that 
phagocytosis is a coordinated function of all three receptors but the exact mechanism(s) 
is yet to be determined.
LPS- and MPL-stimulated enhancement of phagocytosis has been reported by 
many investigators (Morland and Kaplan, 1977; Copper, Mayer and Baggiolini, 1984; 
Vecchiarelli et al., 1989). The latter authors reported increased killing of C. albicans by 
LPS-stimulated monocytes but no differences were found in phagocytosis of either 
fungi or bacteria. A dose-dependent increase in phagocytosis as measured by 
phagocytosis of IgG coated sheep erythrocytes was seen in bone marrow-derived 
mouse macrophages (Cooper, Mayer and Baggiolini, 1984). Leon et a l, (1992) 
reported that phagocytosis in LPS-stimulated monocytes increased as determined by
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Figure 3.2.3. Antibody-dependent (Ab-Dep) and antibody-independent 
(Ab-Ind) phagocytosis of sheep red blood cells (RBCs) by monocytes in 
vitro.
Mononuclear cells were plated at concentrations of (A) 0.75 x 10 ,^ (B) 1.25 x 10 ,^ (C)
1.87 x 10 ,^ and (D) 2.5 x 10  ^per well (n = 8 - 9). Adherent monocytes were incubated 
for 18 hours with LPS or MPL at the concentrations indicated. Antibody-coated or 
uncoated RBCs were added to the cells and RBC phagocytosis was measured after 60 
minutes. Data presented as mean ± SEM. Legends as Figure D. ANOVA: Ab-Dep,
(B) LPS versus MPL p<0.03, (C) p<0.05; Ab-Dep versus Ab-Ind, LPS and MPL at all 
concentrations p<0 .0 0 0 1 .
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phagocytosis of C. albicans. Similar results were found by Aepfelbacher et a l, (1992) 
in Mono Mac 6  cells where they used S. aureus as the target cells.
The findings of the present experiments partially agree with previous reports, 
indicating that both LPS and MPL stimulated phagocytosis of fluorescent beads by 
murine peritoneal macrophage, although MPL was less stimulatory than LPS (Ribi and 
Takayama, 1985). On the other hand, phagocytosis of C. albicans was increased in 
both the LPS and MPL groups compared to control cells whereas no difference was 
reported between the effects of LPS and MPL (Chen, Solem and Johnson, 1991). 
Similarly, Masihi et al., (1986) found that in murine peritoneal macrophages, the 
phagocytic activity was increased in both LPS- and MPL-treated groups although the 
MPL group showed lower activity than that of the LPS group. Chen, Solem and 
Johnson, (1991) found that mouse peritoneal macrophage killing of C. albicans was 
increased in the MPL-treated group while the LPS-pretreated group did not show any 
significant increase in activity.
Non-opsonic phagocytosis was not seen in the present experiments. This 
finding disagrees with an earlier study indicating the existence of non-opsonic 
phagocytosis (Gebran et al., 1992). This may be due to the use of cells of different 
maturity and origin or the sensitivity of the assay. However, these experiments confirm 
that human monocytes are capable of Ab-independent cytolysis and adhesion, possibly 
through the receptors other than FcyRIII receptors.
3.3 Effects of cell concentrations on cytokine release
Again, experiments were performed on all four cell concentrations to determine 
the optimal cell concentration for cytokine and related mediator release. The cytokine 
release was measured in all four different concentrations for IL-la, IL-6 , TNFa and 
GM-CSF. Cells were isolated and treated as described in Sections 2.2 - 2.4.
Overall cytokine release differed significantly at different cell concentrations 
(p<0.02; Figure 3.3A - 3.3E), however, the individual cell concentration group did not 
reach statistical significance. Again, the 1.25 x 106 cell concentration group showed 
the highest IL -la release (group means: LPS, 49.7 ± 10.9 pg/ml; MPL, 14.7 ± 4.3 
pg/ml). Similar results were found with other cytokines (data not shown). Since the
1.25 x 106 cell concentration represented the optimal responder in other assays, this cell 
concentration was used for measuring the cytokine and other mediator release in 
subsequent assays.
A significant effect of cell concentration was found on the release of IL-la 
which parallels the previous findings with Ox. Although the overall effect was
significant, responses to individual doses did not reach statistical significance. This 
may be due to the high individual variations and reduced degree of freedom. This 
observation confirms the earlier suggestion that the cell concentration used in these 
experiments may have exceeded the physiological limit to see subtle differences, or 
overcrowding of the cells limited monocyte adherence to the plate resulting a uniform 
monocyte concentration.
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Figure 3.3. LPS- and MPL-stimulated release of interleukin- 
la  (IL-la) by monocytes in vitro. Effects of cell concentration 
and dose on IL-la release.
Mononuclear cells were plated at the concentrations/well indicated 
(n = 5). The adherent monocytes were either (A) not treated or treated with 
LPS or MPL at concentrations of (B) 0.01 ug/ml, (C) 1 ug/ml, (D) 10 
ug/ml, and (E) 100 ug/ml and incubated for 18 hours. IL -la release was 
measured in the supernatant using an ELISA assay. Data represent mean ± 
SEM. ANOVA effects: overall cell concentration p<0.02; overall treatment 
p<0.004.
104
In
te
rle
uk
in
-1
 a 
(p
g/
m
l) 
In
te
rle
uk
in
-la
 
(p
g/
m
l) 
In
te
rle
uk
in
-la
 
(p
g/
m
l)
125
100-
75-
50-
25-
0 ,
100 -
75-
50-
25-
Control
T
m  us
1 1  MPL
0
100-
75-
50-
25-
I Ï
B 0  LPS
H  MPL
I 1
T I I T Ï
D 3  LPS
111 MPL
T■
1
LPS
MPL
0.75 1.25 1.87 2.5
Cell Concentration (x 106)
1
T T T T
T
0.75 1.25 1.87 2.5
Cell Concentration (x 106)
105
3.3.1 Effects of LPS and MPL treatment and dose on 
cytokine release
Cytokines are released by monocytes in response to various stimuli in vivo and 
in vitro. These experiments were performed to compare the effects of LPS and MPL 
treatment on the release of cytokines by monocytes in vitro.
Elevated levels of cytokines in sepsis have been demonstrated and increased 
levels of these mediators in response to LPS stimulation has been reviewed by many 
(Morrison and Ryan, 1987; Tracey and Lowry, 1990; Made and Simon, 1991; Ayala et 
al., 1992). In the present experiments, IL-la, IL-ip, IL-6 , IL-10, TNFa, GM-CSF 
and G-CSF were elevated in response to LPS treatment. MPL did not significantly 
stimulate IL-la, DL-lp, GM-CSF or G-CSF release whereas IL-10 release was 
increased, though to a lesser degree than seen with LPS. These findings agree with the 
concept that MPL is less stimulatory than LPS in equivalent doses (Takayama et a l, 
1984,1984a; Johnson er a/., 1987; Kiener efa/., 1988; Henricson er <z/., 1992). The 
effects of LPS and MPL on the release of individual cytokines and their relevance to 
their overall toxicity is discussed below.
3.3.1.1 IL -la and IL-lp release
Antigens stimulate MPs to produce and release IL-1, the early activation signal 
for T-cells to become antigen-specific T-cells, capable of expressing the IL-2 receptor. 
The subsequent release of IL-2 and other cytokines is vital to the immune response. In 
the present experiments, LPS treatment induced IL-la release that was significantly 
higher than the release by MPL-treated monocytes. MPL-treated cells did not produce a 
significant amount of IL-la whereas LPS released a large amount of this mediator 
(Figure 3.3.1.1 A) that was significantly different from MPL-treated monocytes 
(p<0.005). Similarly, MPL treatment did not stimulate the IL-ip release whereas LPS 
caused increased release at doses up to 10 ug/ml (Figure 3.3.1. IB). The release of IL- 
ip by LPS reached a peak at 1 ug/ml (310 ± 147 pg/ml), then it appeared to decline with 
no significant release at 100 ug/ml LPS compared to control cells. Low dose induction 
(0.01 -10  ug/ml) and inhibition of IL-lp release by 100 ug/ml LPS indicate the 
possibility of high dose inhibition or an auto-regulation of IL-lp release by monocytes. 
The low dose of MPL (0.01 ug/ml) released a small amount of IL-lp which is 
consistent with IL-1 a  release. Analysis of the data shows a significant treatment 
difference (p<0.04) while dose difference did not attain statistical significance. These 
findings indicate that MPL is less stimulatory compared to LPS in the induction of the 
immune response mediated through IL-la and IL-lp release.
Increased production of IL-1 in response to LPS has been reported in MPs 
(Rellstab and Schaffner, 1989; Bing et a l, 1992; Conti et a l, 1992; Couturier et a l, 
1992; Castro et a l, 1996). Since IL-1 is considered to be pro-inflammatory, a 
decreased level of this mediator in the MPL-treated group implicates the relatively non- . 
toxic property of MPL. However, a moderate increase of this cytokine has been
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Figure 3.3.11. Effects of LPS and MPL on interleukin-1 
release by monocytes in vitro.
Mononuclear cells at 1.25 x 10^ cells per well were plated and the adherent 
monocytes incubated with the indicated dose of LPS or MPL for 18 hours 
(n = 6 ). (A) interleukin-la and (B) interleukin Ip were measured in the 
supernatant using an ELISA assay. Two-way ANOVA: LPS versus MPL 
(A) p<0.005, (B) p<0.04.
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proposed to explain the immunomodulatory property of MPL (which is necessary for 
granulopoiesis) (Ribi et a l, 1986) probably through activation of GM-CSF and 
stimulation of T-cell activity. Also, MPL has been shown to enhance antibody 
production in mice by activating macrophages to produce IL-1 and to stimulate spleen 
cell proliferation (Johnson et a l, 1991). Alternatively, Johnson and Tomai, (1990) 
hypothesized that the ability of MPL to increase antibody formation may be mediated by 
IFNy secreted by T-cells which causes increased la antigen expression (in mice) on 
macrophages leading to IL-1 secretion, thereby initiating cellular events resulting in
antibody formation. The findings of the present experiments that both IL-la and IL-lp 
were elevated in the LPS-treated cells while MPL did not stimulate the release of either 
of these cytokines partially disagree with the findings of these above reports.
However, the finding that HLA-DR (mouse equivalent of la) expression is increased in 
MPL-treated cells agrees with the latter report. The MPL-mediated decreased release of 
IL-lp following gram-negative bacterial challenge has been shown in vivo in mice 
(Astiz et al., 1994). Similarly, in human volunteers injected with MPL, neither IL-la 
nor IL-lp could be detected in the serum (Astiz et a l, 1995). The difference between 
the present study and previous reports is that monocytes are used in the present study 
whereas macrophages were used in the previous studies.
3.3.1.2 IL-6 release
IL- 6  is a multifunctional cytokine and its functions include T-cell activation, 
B-cell differentiation, hematopoiesis and induction of acute phase proteins (Van Snick,
1990). IL- 6  can be released by many different types of cells and its role in infection is 
well documented (Fey and Gauldie, 1990; Van Snick, 1990; Fingerle et a l, 1993). 
However, data on MPL-stimulated IL-6  release in monocytes is not available. Results 
of the analysis of IL-6  release by LPS- and MPL-pretreated monocytes are presented in 
Figure 3.3.1.2. It shows a highly significant treatment difference (p<0.005); the MPL- 
treated group released significantly less IL-6  compared to the LPS-treated group 
indicating comparatively less stimulatory effects of MPL on monocytes to release IL-6 . 
Peak concentration of IL-6  (1442 ± 470 pg/ml) was achieved by LPS at 10 ug/ml dose, 
then its release seems to decrease. IL-6  release at 1 and 10 ug/ml of LPS was 
significantly different from the control (p<0.05). Data also show that MPL (low dose) 
treatment stimulates low levels of EL- 6  release compared to that of LPS-treated cells. 
However, MPL-stimulated release of IL-6  was not significantly different from that of 
the control (8 6  ± 46 pg/ml), confirming a non-toxic property of MPL. These data are 
consistent with the concept that LPS stimulates this multi-functional interleukin.
The increased release of IL-6  found in the present experiments agrees with 
previous reports demonstrating that LPS induces IL- 6  gene expression in MPs (Ritchie 
and Fuller, 1983; Bauer et a l, 1989) and EL-6  release by monocytes in vitro 
(Breuninger et a l, 1994; Otterlei et a l, 1995; Castro et a l, 1996). In vitro studies 
could not be found which demonstrated the effects of MPL on IL-6  release by human 
monocytes. However, human volunteers injected with MPL released moderate
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Figure 3.3.12. Effects of LPS and M PL on in terleukin - 6  
release by monocytes in vitro.
Mononuclear cells at 1.25 x 10^ cells per well were plated and adherent 
monocytes incubated with the indicated dose of LPS or MPL for 18 hours 
(n = 6 ). Supernatant interleukin- 6  was measured using an ELISA assay. 
Two-way ANOVA: LPS versus MPL p<0.005. Kruskal-Wallis tests: Dose 
effects, LPS p<0.02.
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amounts of EL- 6  (Astiz et a l, 1995). The low level of IL-6  released in the MPL-treated 
cells in the present experiments is in concert with its immunomodulatory yet less toxic 
effects on monocytes. Furthermore, the suppressive effect of higher doses of MPL 
may indicate that the suppressive effect of MPL is dose-dependent which agrees with 
the report that higher doses of MPL result in protection from lethal insults (Astiz et al., 
1993,1994).
3.3.1.3 IL-10 release
A significant dose- (p<0.005) and treatment- (p<0.001) dependent release of 
IL-10 by LPS- and MPL-treated monocytes was found (Figure 3.3.1.3). LPS at all 
doses stimulated IL-10 release, with the highest release being at the 100 ug/ml dose 
(748 ± 72 pg/ml). MPL-stimulated release of this cytokine was considerable only at 
100 ug/ml dose that was not different from that of the control. These data indicate that 
MPL, only at high doses, may stimulate monocytes to release IL-10, indicating its role 
in immune modulation. Again, an overall significant treatment difference confirms that 
MPL is less stimulatory than LPS at similar doses.
IL-10 is a inhibitory cytokine, released following a stimulus, that has been 
shown to auto-regulate its own production (reviewed by Docke et ah, 1994). The 
finding of the present experiments that LPS stimulates monocytes to release a large 
amounts of IL-10 agrees with previous reports (de Waal Malefyt et al., 1991; reviewed 
in Docke et al., 1994). Since MPL is less toxic than LPS, the decreased release of this 
cytokine by MPL was expected. MPL at small doses did not stimulate IL-10 release, 
but at 1 0 0  ug/ml, a considerable amount of this cytokine was released which was 
comparable to that released by LPS-stimulated monocytes, indicating a non-toxic yet 
immunomodulatory property of MPL. LPS-stimulated IL-10 release by monocytes has 
been documented, but this author reports here that MPL also stimulates monocytes to 
release this cytokine in vitro but at a lower level. This may explain a number of LPS- 
and MPL-mediated effects of monocytes such as ROIs and NO release, CD 16 
expression and phagocytosis.
The lack of NO release in the LPS-treated monocytes may be explained by the 
IL-10-mediated suppression of NO release. MPL is less toxic than LPS, thus, it is 
expected that MPL will stimulate cells to release this cytokine at a lower level or at a 
slower pace. If this argument is valid, then slower release (or low level) of EL-10 in the 
MPL-treated group did not have enough time to suppress the NO release. It has already 
been documented that accumulation of detectable amounts of NO release needs 6  to 12 
hours (Stuehr and Marietta, 1985, 1987) and IL-10 has been shown to inhibit NO 
release (Bogdan, Vodovotz and Nathan, 1991). Again, the enhanced phagocytosis in 
the LPS-treated group may be related to increased and enhanced release of IL-10 by the 
monocytes seen in the present study. This phenomenon has been reported previously 
(Spittler et al., 1995).
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Figure 3.3.13. Effects of LPS and MPL on interleukin-10 
release by monocytes in vitro.
Mononuclear cells at 1.25 x 10^ cells per well were plated and adherent 
monocytes incubated with the indicated dose of LPS or MPL for 18 hours 
(n = 8 ). Supernatant interleukin-10 was measured using an ELISA assay. 
Two-way ANOVA and Kruskal-Wallis tests: LPS versus MPL, pcO.OOl; 
dose effects, LPS p<0.005.
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3.3.1.4 TNFa release
Figure 3.3.1.4 indicates that TNFa release is stimulated by both LPS and 
MPL but the release of TNFa in the MPL-treated group is significantly lower than LPS- 
treated monocytes (p<0.002); the highest release (682 ± 248 pg/ml) was obtained at 10 
ug/ml LPS dose whereas this was 195 ±110 pg/ml for 10 ug/ml MPL. LPS-stimulated 
release of TNFa was significant at all doses except 0.01 ug/ml. However, the low 
level of TNFa release by high doses of MPL was not different from that of the control 
(54 ± 28 pg/ml). Results again confirm that MPL is a potent immunomodulatory agent 
and is yet less toxic than its parent molecule, LPS.
TNFa is a key mediator of endotoxic shock, therefore, an elevated level as 
seen in the present experiments was expected. TNFa was elevated in LPS-treated
groups and the MPL-stimulated response was significantly less than that of the LPS.
Increased release of TNFa in response to LPS by human monocytes has been reported 
(Rellstab and Schaffner, 1989; Lee et al., 1990; Bing et a l, 1992; Otterlei, et a l,
1995). Also, in vivo and in vitro studies that examined the phenomena of tolerance 
using either LPS or MPL indicated similar results to those found in the present 
experiments. Peritoneal macrophages from LPS- or MPL-pretreated mice and human 
PBMs showed decreased TNFa release in response to LPS challenge (Mathison et al., 
1990; Henricson et al., 1990,1992; Made and Simon, 1991; Mengozzi, 1991a; Astiz 
et ah, 1993; Leon et ah, 1992) indicating that both LPS and MPL have immuno­
modulatory effects. MPL-pretreated mice were shown to release less TNF compared to 
LPS or control groups in response to LPS challenge in vivo (Kiener et ah, 1988; 
Henricson, Benjamin and Vogel, 1990; Astiz et ah, 1993). Later, Astiz et ah, (1995) 
demonstrated that MPL injection in human volunteers caused less TNFa release 
compared to LPS, implying that MPL is less toxic than LPS in humans. Results of the 
present experiments agree with this.
3.3.1.5 GM-CSF release
Both GM-CSF and G-CSF have been shown to be involved in immune 
reactions and inflammation (Nicola and Vadas, 1984; Hogasen, Hestdal and 
Abrahamsen, 1993). Although LPS-stimulated release of these cytokines in human 
monocytes has been reported (Lee et ah, 1990; Hamilton et ah, 1992), MPL-stimulated 
production has not been documented. GM-CSF release by the LPS- and MPL- 
pretreated cells was studied and is presented in Figure 3.3.1.5. Data indicate that MPL 
does not stimulate monocytes to release significant amounts whereas LPS stimulation 
causes a dose-dependent (p = 0.05) increase in GM-CSF release which is significantly 
different from MPL (p<0.005). The release was 251 ± 114 pg/ml at 100 ug/ml dose of 
LPS. Very low levels of GM-CSF were detected in the control group. Results indicate 
that LPS stimulates the release of GM-CSF from monocytes in vitro, thus, confirming 
its stimulatory effects. This also suggests the involvement of GM-CSF in infection and 
sepsis. The differential effects of LPS and MPL are suggestive of MPL's non­
stimulatory property in releasing GM-CSF.
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Figure 3.3.14. Effects of LPS and M PL on tum or necrosis 
factor a  release by monocytes in vitro.
Mononuclear cells at 1.25 x 10  ^cells per well were plated and adherent 
monocytes were incubated with the indicated dose of LPS or MPL for 18 
hours (n = 6 ). Supernatant tumor necrosis factor a  was measured using an 
ELISA assay. Two-way ANOVA and Kruskal-Wallis tests: LPS versus 
MPL p<0.002; dose effects, LPS p<0.04.
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Figure 3.3.15. Effects of LPS and M PL on GM-CSF re lease  
by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were plated and adherent 
monocytes incubated with the indicated dose of LPS or MPL for 18 hours 
(n = 6 ). Supernatant GM-CSF was measured using an ELISA assay. 
Two-way ANOVA: LPS versus MPL p<0.005. Kruskal-Wallis test: dose 
effects, LPS p = 0.05.
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In the present experiments, GM-CSF was increased in a dose dependent 
manner in response to LPS stimulation, but it was not released in the MPL-treated 
group. The observation that GM-CSF was not detected in the control cells agrees with 
an earlier report (Hamilton et a l, 1992). These findings agree with the previous report 
indicating that LPS stimulates GM-CSF release by human monocytes in vitro within 24 
hours of incubation (Golde and Cline, 1975; Sullivan et ai., 1983; Lee et ai., 1990; 
Hamilton et al., 1992). However, Golde and Cline, (1975) indicated that GM-CSF 
was also released by unstimulated monocytes in culture within 5 hours. Similar results 
were reported by Bing et al., (1992). Since it is known that adherence of cells to plastic 
surfaces in itself is stimulatory, it is possible that attachment to the plastic beads 
provided enough stimulus to produce this cytokine in that study. In contrast, 
Henricson, Benjamin and Vogel (1990), while studying the effects of LPS and MPL 
pretreatment on cytokine release by mouse peritoneal macrophages, found that GM- 
CSF release was comparable in both groups while the MPL-treated group released 
lower amounts of TNF and IL-6 .
3.3.1.6 G-CSF release
Figure 3.3.1.6 indicates that low doses of LPS stimulate G-CSF while the 
MPL group does not release any significant amount of this mediator. MPL-pretreated 
cells released a similar amount of G-CSF to that of the control cells (56 ± 9 pg/ml, 
control versus 38 - 59 pg/ml for MPL). Overall LPS-stimulated release was signif­
icantly different from MPL-treated cells (p<0.005). The peak release of G-CSF (115 ± 
16 pg/ml) was obtained by 1 ug/ml LPS-pretreated cells which was significantly 
different from control cells (p<0.05). Higher doses of LPS (10 and 100 ug/ml) seem to 
lose the stimulatory effects on G-CSF release indicating a high dose inhibitory effect, 
probably conferring an auto-regulatory mechanism. These results again indicate that 
LPS is stimulatory whereas MPL is non-stimulatory.
G-CSF has also been associated with infections and sepsis (Shirafuji et al., 
1989; Watari et a l, 1989; Kawakami et a l, 1990,1992; Kawakami, 1994). Low 
doses of LPS were found to stimulate G-CSF production whereas high doses of LPS 
did not. MPL did not exhibit any stimulatory effects on G-CSF release. Hamilton et 
a l, (1992) reported that in vitro stimulation of monocytes with 0.01 ug/ml LPS 
produced G-CSF. Although these authors used comparable doses of LPS, they 
reported 10 times higher level of G-CSF release compared to the present study. This 
discrepancy may be related to the method of assay. In the present experiment, lower 
doses of LPS increased its production but at 10 ug/ml its release tended to decrease and 
at 100 ug/ml dose its production was similar to that of the control cells. However, they 
could not detect any G-CSF in control cells as opposed to the present study. The 
sensitivity of the assay was 7.5 ng/ml and the control and MPL-treated groups secreted 
in the range of 38 - 59 ng/ml, which was far below the detection level of that study (100 
ng/ml). It is possible that monocytes in culture, stimulated to release this mediator, 
become dysfunctional or differentiate to a different physiological stage or implement an
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Figure 3.3.I.6. Effects of LPS and M PL on G-CSF release by 
monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were plated and adherent 
monocytes incubated with the indicated dose of LPS or MPL for 18 hours 
(n = 5). Supernatant G-CSF was measured using an ELISA assay. 
Mann-Whitney test: LPS versus MPL p<0.005. ANOVA and post hoc 
tests: dose effects, control versus LPS 1 ug/ml p <0.05.
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auto-regulatory mechanism. This speculation can be supported by the observation that 
monocytes have been shown to produce a large amount of G-CSF up to 24 hours, then 
its production decreases and cannot be fully restored by further stimulation (Sullivan, 
Cans and McCarroll, 1983; Lee et a l, 1990).
3.3.2 Effects of LPS and MPL treatment on the release of 
soluble receptors and receptor antagonists
Soluble cytokine receptors and receptor antagonists are often considered as 
inhibitors of cytokines and believed to be involved in auto-regulatory mechanisms. It 
has been postulated that IL-lra, IL-2r and IL-6 r are involved in sepsis and septic shock 
(Holter, et al., 1987; Scheibenbogen et a i, 1992). Mononuclear cells at 1.25 x
lOfywell were plated, isolated and treated as in the previous experiments (Sections 2.2 - 
2.4) and the supernatant was assayed to determine the effects of LPS and MPL 
pretreatment on the release of sIL-2r, sIL-6 r and IL-lra.
3.3.2.1 sIL-2r release
Figure 3.3.2.1 represents the results of the effects of LPS and MPL 
pretreatment on IL-2r release. Analysis of the data revealed a significant dose effect 
(p<0.05). Interactions between dose and treatment effects (p<0.03) were also seen but 
individual treatment did not attain statistical significance except at the high dose of LPS 
(100 ug/ml). This high dose of LPS stimulated the release of increased amounts of IL- 
2r whereas the control and MPL-treated cell production of IL-2r did not change. The 
finding that LPS at the high dose releases IL-2r is in accord with the concept that EL-2r 
is involved in the regulation of the LPS-mediated immune response. It also indicates 
that MPL is not involved in the release of IL-2r, confirming the non-stimulatory 
property of MPL.
Soluble receptors are sometimes considered as inhibitors and thought to serve 
an auto-regulatory role. If this hypothesis is assumed to be correct, an increase in 
receptor or receptor antagonist production by monocytes stimulated with LPS might be 
expected. The high dose of LPS (100 ug/ml) resulted an increased IL-2r release while 
MPL and control cells did not produce significant amounts of this receptor. These 
findings are in accord with an earlier study which reported that IL-2r is secreted upon 
LPS stimulation within 24 - 48 hours (Holter et al., 1987; Valitutti et al., 1989; Kniep, 
Strelow and Lohmann-Matthes, 1992). By contrast, Scheinbenbogen et a l, (1992) 
could not detect any IL-2r in the supernatant of LPS-stimulated monocytes at 24 hours. 
The difference may be due to the methods use to culture the cells or the sensitivity of the 
assay. In the latter study, only 2% human AB serum was used as opposed to 10%
FCS used in the present experiments. The amount of serum present in the culture 
media has been shown to influence the release of a number of products and functional 
activity of MPs (Johnson, Adams and Hamilton, 1985; Liesveld et a l, 1991). Studies 
comparing the effects of LPS and MPL on sIL-2r release from human monocytes have 
not been published previously.
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Figure 3.3.2.I. Effects of LPS and MPL on soluble 
interleukin-2 receptor release by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were plated and adherent 
monocytes incubated with the indicated dose of LPS or MPL for 18 hours 
(n = 8 ). Soluble interleukin-2  receptor was measured in the supernatant 
using an ELISA assay. Kruskal-Wallis test: dose effects, LPS p<0.05. 
Post hoc ANOVA: control versus 100 ug/ml LPS p<0.03.
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3.3.2.2 sIL-6r release
A small amount of sIL- 6  receptors was released from both stimulated and 
unstimulated monocytes. IL-6 r release ranged between 13.9 -16.2 ng/ml in the treated 
or untreated cells, however, they did not differ significantly and no difference was 
found between treatment groups as well (Figure 3.3.2.2). In these experiments, the 
release of small amounts of these receptors is presumably due to the stage of 
differentiation of the monocytes in culture.
IL-6  mRNA has been demonstrated in unstimulated monocytes of healthy 
human volunteers and IL-6  receptor (IL-6 r) mRNA expression was down-regulated 
upon stimulation with LPS or IL-1 with a concomitant increase in IL- 6  mRNA 
expression (Bauer et al., 1989). It was suggested that down-regulation of the 
monocyte IL-6 r in response to increased IL-6  may confer a protective auto-regulatory 
mechanism of monocytes. If this hypothesis is valid, decreased or increased levels of 
sIL-6 r will be found in the serum or culture supernatant depending upon the extent and 
duration of the stimulus since the 80 kDa chain of the cell membrane is cleaved to yield 
the sIL-6 r (Hibi et al., 1990). In contrast to this postulation, Degiannis et al., (1992) 
using different pharmacological agents and stimuli found that IL-6 r generation is 
regulated differently from IL- 6  production. In the present experiment, small amounts 
of sIL-6 r were detected in the unstimulated cell which is consistent with an earlier report 
(Bauer et al., 1989) but no definite pattern of dose or difference between LPS and MPL 
were found. This finding indicates that significant release of this receptor may need 
stronger stimulation or may be related to the maturation stage of the monocytes.
3.3.2.3 IL-lra
Results of the IL-lra release by LPS- and MPL-stimulated monocytes are 
presented in Figure 3.3.2.3. Production of IL-lra in the MPL treated group tended to 
increase, but it was not statistically significant either from control or that induced by 
LPS. However, upward trends of IL-lra release in MPL-treated monocytes suggest 
that MPL is involved in the regulatory mechanism of immune response, at least in 
modulating IL-1 release or its function.
IL-lra administration was demonstrated to be protective from the lethal effects 
of LPS (Ohlsson etal., 1990; Alexander er a/., 1991; Wakabayashi etal., 1991). 
However, conflicting data on the release of IL-lra following LPS stimulation in 
monocytes in vitro exists in the literature. LPS-stimulated down-regulation of IL-lra 
production was reported by Kline, Monick and Hunninghake, (1992) whereas low 
dose up-regulation and high dose down-regulation have been reported by Arend et al.,
(1991). While monocyte-derived macrophages were shown to release IL-lra 
constitutively, LPS treatment did not enhance its release (Janson, Hance and Arend,
1991). The conflicting data may reflect a temporal phenomenon, the variation of the 
magnitude and duration of the stimulus or the magnitude of the mediator release. 
However, recently, MPL has been shown to increase the release of IL-lra in human 
volunteers (Astiz et al., 1995), which was significantly different from subjects who
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Figure 3.3.2.2. Effects of LPS and MPL on soluble 
interleukin-6 receptor release by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were plated and adherent 
monocytes incubated with the indicated dose of LPS or MPL for 18 hours 
(n = 5). Soluble interleukin-6  receptor was measured in the supernatant 
using an ELISA assay. No significant difference.
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Figure 3.3.2.3. Effects of LPS and MPL on interleukin-1 
receptor antagonist release by monocytes in vitro.
Mononuclear cells at 1.25 x 10  ^cells per well were plated and adherent 
monocytes incubated with the indicated dose of LPS or MPL for 18 
hours (n = 5). Interleukin-1 receptor antagonist was measured in the 
supernatant using an ELISA assay. No significant difference.
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received equivalent doses of LPS. However, the discordant release of IL-1 and IL- Ira 
may indicate the different patterns of regulation between these cytokines that has already 
been suggested (Arend et al., 1991). Although the mechanism of IL-lra release is not 
known, release of this antagonist without increasing the IL-1 or IL-1 mRNA production 
has been documented in human monocytes in response to p-glycans of yeast walls 
(Poutsiaka et a l, 1993).
Decreased IL-1 (both a  and p) and IL- 6  but equivalent amounts of IL-lra 
released by MPL-treated monocytes suggests either a temporal phenomenon or a lack of 
a co-stimulatory factor for release of this protein. Increased release of IL-lra has been 
found in experimental endotoxemia (Granowitz et al., 1991; Fischer et al., 1992), in 
patients with sepsis syndrome (Fisher et al., 1994) and in patients undergoing surgery 
(O'Nuallain et al., 1995), but was not found in isolated mononuclear cells by the latter 
authors. It was suggested that this protein is not released by these cells. The 
differences in release of IL-1, IL- 6  and IL-lra can be explained by the fact that these 
cytokines are regulated differently (Arend et a l, 1991; Poutsiaka et al., 1991). It is 
also possible that monocytes do not produce large amounts of this protein but mature 
macrophages do (Janson, Hence and Arend, 1991; Tilg et a l, 1994). EL-Ira has been 
shown to down-regulate IL-ip and TNFa release by mononuclear phagocytes (Marsh et 
ah, 1994) and it is primarily induced in monocytes by Fey receptor cross-linking 
(Arend, 1991; Dinarello, 1991,1991a; Marsh, Pope and Wewers, 1994). Thus, it 
appears that this non-toxic property of MPL may come from two different pathways: 
first, from decreased release of IL-1 and second, binding the small amounts of IL-1 
released by MPL stimulation to IL- Ira that is released concurrently.
3.3.2.4 Immunoreactive IL-1 release
Immunoreactive IL-1 is arguably the circulating form of this cytokine that is not 
bound to IL-lra which may represent the active EL-1 capable of stimulating the cells. 
Results of the analysis presented in Figure 3.3.2.4 indicate that LPS pretreatment 
causes a significant (p<0.01) increase in immunoreactive IL-1 (reaching 90.2 ± 45.9 at 
10 pg/ml dose). LPS at 100 ug/ml dose appears to have no effect on the level of 
immunoreactive IL-1 release. The level of immunoreactive EL-1 in the MPL-treated 
cells (5.7 -18.6 pg/ml) was not different from that of control cells (13.6 ± 5.0). These 
data further confirm that MPL is less stimulatory in inducing IL-1 release and that it 
plays a role in regulation of the release of IL-1 from human monocytes in vitro.
EL-la and EL-1(3 are released into the serum or in the culture media in response 
to a stimulus. The quantity measured by many ELISA assays measures the quantitative 
binding of the antigen to the antibody. The inactive forms of the antigen may still give a 
positive ELISA response (Whiteside, 1994). This may be responsible for, in most 
part, the lack of correlation between blood IL-1 level and clinical outcome both in 
human and animal studies (Lowry, 1993; Pinsky et al., 1993). The immunoreactive 
IL-1 is the net amount of EL-1 which is not bound to EL-Ira and can exert its effects on 
target cells. It was found that immunoreactive IL-1 was up-regulated by LPS treatment 
whereas no change was seen in MPL-treated cells, indicating that LPS exhibits
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Figure 3.3.2.4. Effects of LPS and MPL on immunoreactive 
interleukin-1 release by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were plated and the adherent 
monocytes were incubated with the indicated dose of LPS or MPL for 18 
hours (n = 6 ). Immunoreactive interleukin-1 accumulation in the 
supernatant was measured using an ELISA assay. Mann-Whitney tests: 
LPS versus MPL p<0.02. Post hoc ANOVA: control versus 10 ug/ml LPS 
p<0.03.
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stimulatory effects but MPL does not. This finding is consistent with the hypothesis 
that MPL is less toxic than LPS. To the knowledge of the author, this is the first report 
comparing the effects of LPS and MPL on immunoreactive IL-1 release from human 
monocytes. Measurement of this form of IL-1 will predict the net amount of released 
IL-1 which may exert its effects to activate other cells or affect the auto-regulatory 
mechanism.
3.4 Effects of LPS and MPL on cell surface receptor 
expression
Surface receptors are involved in activities, such as growth, activation, 
differentiation and effector function of monocytes. These receptors are either present 
constitutively or induced by different stimuli. These experiments were performed to 
profile and quantitate the cell surface receptor expression on monocytes following LPS
and MPL stimulation. Since it is established that the 1.25 x 106 cell concentration 
gives adequate and consistent results, these experiments were done with only this cell 
concentration following the treatment protocol described in Sections 2.1 - 2.4.
Consistent data on the expression of cell surface receptors are not available. 
Analysis of the data by mean fluorescence and percentages of positive cells contribute 
largely to this confusion. Here we report both the mean fluorescence (receptor density) 
and percentage of positive cells which may shed some light on the existing confusion in 
receptor expression.
3.4.1 C D llb  and CD18 expression
Figure 3.4.1.1 presents the results of C D llb  expression following LPS or 
MPL treatment. MPL tended to increase C D llb  receptor density whereas the effects of 
LPS on its expression remained unchanged. Although MPL-stimulated expression of 
these receptors is not significantly different from the control monocytes, overall expres­
sion of C D llb  was found to be significantly different from LPS-treated monocytes 
(p<0.02; Figure 3.4.1.1 A). The mean fluorescence in the stimulated cells ranged from 
1100 - 1137 FU while LPS-stimulated expression ranged between 657 - 895 FU. MPL 
significantly increased expression of C D llb  positive monocytes compared to control 
cells (p<0.04; Figure 3.4.1. IB). However, differences in the expression of positive 
cells between LPS- and MPL-treated groups did not reach statistical significance. The 
upward trends of increased fluorescence and CD1 lb-positive cells in the MPL-treated 
monocytes, and upward trends of CD1 lb-positive cells in LPS-treated cells indicate the 
possible role of LPS and MPL in modulating inflammatory response. It also suggests 
that MPL may enhance the CD1 lb-mediated immune response.
CD 18 receptor density was unchanged both in the LPS and MPL groups 
(Figure 3.4.1.2A). Figure 3.4.1.2B shows a significant difference between LPS- and 
MPL-treated groups (p<0.04). This differential expression of CD 18 may indicate the 
differential effects of LPS and MPL on monocyte CD 18 expression. However, the lack
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Figure 3 .4 .I.I. Effects of LPS and MPL on C D llb  
expression by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were adhered to culture 
plates and adherent monocytes were incubated with LPS or MPL at the 
indicated doses for 18 hours (n = 6 ). The cells were retrieved by 
EDTA-cold shock treatment and expression was measured by FACScan. 
Data were analyzed and expressed as mean ± SEM in (A) mean 
fluorescent unit or (B) percentage positive cells. ANOVA: (A) treatment 
effects, p<0.02; (B) dose effects, MPL p<0.04.
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Figure 3.4.I.2. Effects of LPS and MPL on CD18 
expression by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were adhered to culture 
plates and adherent monocytes were incubated with LPS or MPL at the 
indicated doses for 18 hours (n = 6 ). The cells were retrieved by 
EDTA-cold shock treatment and expression was measured by FACScan. 
Data were analyzed and expressed as mean ± SEM in (A) mean 
fluorescent unit or (B) percentage positive cells. Mann-Whitney tests: 
(A) no significant difference; (B) treatment effects, p<0.04.
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of significant difference in mean fluorescence and significant difference in the 
percentage of positive cells makes it difficult to interpret the results. The upward trend 
of CD 18 expression in the LPS-treated group, however, suggests its role in the LPS- 
mediated effects.
CD1 lb/CD 18 are adhesion receptors that promote interaction between 
leukocytes (Amaout et o/., 1985; Schwartz et a l, 1985), and with endothelial cells 
(Diener et a l, 1985; Amaout, Lanier and Faller, 1988; Luscinskas et a l, 1989; 
Meerschaert and Furie, 1995), specific opsonins deposited on invading bacteria and 
possibly rejected or hypoxic tissues. Thus, these receptors help migration of cells 
through vascular epethelium and elimination of opsonized particles. These hetero­
dimers are present on PMNs and monocytes and mediate many pro-inflammatory 
functions (Brown, Bohnsack and Gresham, 1988; Todd and Freyer, 1988; Amaout,
1990). LPS-stimulated monocytes were reported to up-regulate followed by shedding 
of the active form of CD 1 lb/CD 18 (Dana et al., 1991). An upward trend in receptor 
density (mean fluorescence) of C D llb  in the MPL-treated group and a downward trend 
in the LPS-treated monocytes in the present experiments can be explained by the 
mechanism of time- and dose-dependent expression of this receptor. It is possible that 
LPS has stimulated the monocytes to up-regulate these receptors earlier than MPL did 
and the unchanged expression of C D llb  in this experiment is the reflection of the loss 
of the membrane-bound receptors from monocytes. On the other hand, the low degree 
of stimulation by MPL is represented by the up-regulation of this receptor. These 
findings, thus, agree with the concept that MPL is less inflammatory when compared to 
LPS. The observation that mean fluorescence in the LPS-stimulated monocytes was 
unchanged agrees with an earlier report that receptor density in monocytes from sepsis 
and septic shock patients was found to be unchanged (Ertel et a l, 1993; Gawaz et a l, 
1995). When the receptor expression was measured as percentage of positive cells, 
LPS-treated monocytes tended to increase the expression of CD llb, that agrees with 
Breuninger et a l, (1994) but contradicts others (Fingerle et a l, 1993; Ertel et a l,
1993). The reason for these discrepancies between studies and expression of this 
receptor within a study are not clear. However, a common denominator that receptor 
density in LPS-stimulated monocytes remained unchanged suggests a time- and dose- 
dependent phenomenon or involvement of a "compensatory" mechanism in the 
expression of this receptor. It could be mediated through other cell surface receptors, 
cytokines or other stimulatory mechanism(s) that have yet to be determined.
A similar receptor density in LPS- and MPL-stimulated monocytes, but 
significantly increased percentages of CD 18-positive cells in LPS-treated cells 
compared to the MPL-treated group found in the present experiment is unusual.
Because association of the a and p subunits are required for their surface expression on 
the cell surface implying that the CD1 lb and CD 18 molecules co-express in a ratio of 
1:1 (from Shevach, 1994). Apparently, a decreased expression of CD 18 induced by 
MPL and concomitant increase in C D llb expression cannot be explained within the 
realm of these experiments. To rule out the possibility of artifacts or to elucidate the 
differential expression of these receptors may warrant further investigations. However,
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decreased expression of CD 18 in the MPL-treated cells parallels the finding that they 
showed decreased adhesion to RBCs. Studies by Brown, Bohnsack and Gresham,
(1988) demonstrated two distinct, functionally different molecules on human 
monocytes which bind IgG-coated erythrocytes resulting phagocytosis. One is 
involved in the C3bi-mediated rosetting that does not affect IgG-mediated phagocytosis. 
The other is recognized by the mAb against CD 1 lb/CD 18 (Ml/70) and, after ligation, 
inhibits IgG-mediated binding and phagocytosis. Since the rosette formation was not 
inhibited by anti-CDllb antibody (OKM1), it is possible that binding and phagocytosis 
of RBCs were mediated via CD 18. Later, it was shown to be involved in the non­
specific recognition of antigen (Golenbock et a l, 1990; Wright and Jong, 1986; Wright 
et al., 1989a). Based on these observations and the results of the present experiments, 
it would be reasonable to speculate that LPS increases CD18 expression whereas MPL 
decreases CD 18 expression. This speculation could further be supported by the 
observation that the LPS-treated monocytes showed higher levels of RBC adhesion 
than the MPL-treated cells. These findings implicate that both LPS and MPL modulate 
monocyte CD 1 lb/CD 18 expression that may influence the cell-cell interactions. 
However, this speculation contradicts the finding of an earlier study (Liesveld et al.,
1991). The difference between this study and the present experiments is that these 
authors used 5 -7  day old monocyte-derived macrophages and used a colon cancer cell 
line as a target whereas the present study used monocytes and RBCs as the target cells. 
This may represent maturation-dependent differences in the receptor expression and 
mediator release responsible for the ADCC.
3.4.2 CD14 expression
CD 14 is considered a phenotypic marker for MPs and recently has been 
described as a receptor for LPS in these cells (Wright et al., 1990; reviewed in Ulevitch 
and Tobias, 1994). However, conflicting reports on LPS-stimulated expression of 
CD 14 in monocytes in vitro exist in the literature. Analysis of the data by mean 
fluorescence, percentages of positive cells and use of different antibody may have been 
responsible for the discrepancy. The apparent dose-dependent suppression in mean 
fluorescence of CD 14 expression on monocytes by MPL in the present experiments is 
not statistically significant (Figure 3.4.2A). However, there was a significant 
treatment effect in the mean fluorescence of CD 14 expression between LPS and MPL 
(p<0.05). Similarly, a significant treatment effect was found between LPS- and MPL- 
treated groups in the percentages of CD 14-positive cells (p<0.01; Figure 3.4.2B) but in 
a reverse direction. The high dose of MPL (100 ug/ml) significantly increased the 
percentages of CD 14-positive cells compared to control monocytes (p<0.05). The 
decreased mean fluorescence, but increased percentages of positive cells, by MPL 
indicates a possibility of auto-regulation of CD14 expression in monocytes. Apparent 
down-regulation of this receptor by LPS implicates internalization or loss of CD14 
molecules from the cell surface or suppression of the auto-regulatory mechanism by 
LPS.
Decreased expression of CD 14 in isolated monocytes (Bazil and Strominger,
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Figure 3.4.2. Effects of LPS and MPL on CD14 expression by 
m onocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were adhered to culture 
plates and the adherent monocytes were incubated with LPS or MPL at 
indicated doses for 18 hours (n = 6 ). The cells were retrieved by 
EDTA-cold shock treatment and CD 14 expression was measured by 
FACScan. Data were analyzed and expressed as mean ± SEM in 
(A) mean fluorescent unit or (B) percentage positive cells. ANOVA and 
Mann-Whitney tests: (A) treatment effects, p<0.05; (B) treatment effects, 
p<0.01; dose effects, MPL p<0.05.
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1991; Grey et al., 1993; Breuninger et al., 1994) and increased expression in stimulated 
whole blood (Marchant et a l, 1992) and Mono Mac 6  cells (Aepelelbacher et a l, 1992) 
have been demonstrated. The results of the present experiments indicate that the CD 14 
receptor density was unchanged in LPS- and tended to decrease in MPL-treated cells.
On the other hand, percentages of positive monocytes were increased with MPL and 
tended to decrease with LPS. This reverse phenomenon in CD 14 expression supports 
the hypothesis that expression of this receptor, as seen in C D llb, undergoes a 
compensatory mechanism to defend the host. It is also possible that monocyte 
stimulation by LPS and its analogue is dose- and time-dependent and operates via 
different mechanism(s). This can be supported by the fact that small doses of LPS- 
stimulated CD14 expression (Appel e ta l, 1989) and CD 14 mediated, LPS-stimulated 
release of IL-1 a, IL-lp and TNFa could only be suppressed using specific mAb when 
the cells were stimulated with low concentrations of LPS, <1 ug/ml (Couturier et al, 
1992; Schumann et a l, 1990). It is known that lower doses of LPS require LBP to 
bind to the CD 14 while higher doses of LPS can stimulate monocytes directly (Wright 
et a l, 1990) and down-regulation of CD 14 expression in monocytes is due to the 
shedding of the receptors by proteolytic cleavage from the cell surface (Bazil and 
Strominger, 1991). This may relate to the observed lack of change in receptor density 
and the decreased tendency of CD 14 expression in the LPS-stimulated cells. Since LPS 
is a strong stimulus, CD 14 expression may have been up-regulated and the shedding of 
this receptor may have begun when the analysis was performed, as evidenced by the 
decreased tendency of CD14-posidve cells in this group. On the other hand, it can be 
speculated that increased expression of CD 14 by MPL is a slow process (as it is less 
stimulatory) and the expansion of the positive cells was opted to balance by decreasing 
the receptor density in individual cells to maintain homeostasis.
Time-dependent expression of CD 14 and sCD14 has been reported (Bazil and 
Strominger, 1991; Birkenmaier et a l, 1992; Grey et a l, 1993; Otterlei et a l, 1995). A 
majority of the authors reported that CD 14 expression in monocytes decreases within 4 
hours following LPS stimulation while one study found that CD 14 expression increases 
within 30 minutes to 3 hours (Birkenmaier et a l, 1992) in vitro. Bazil and Strominger, 
(1991) found that the decrease in CD 14 expression in vitro follows shedding of these 
receptors that starts at 2 hours and reaches a steady state at 6  hours. These findings 
indicate that CD 14 is up-regulated initially and the observed decrease in its expression 
results from increased shedding. Although in the present experiments sCD14 was not 
measured, findings with LPS-mediated CD 14 expression agree with previous studies, 
but data on MPL-mediated CD 14 expression in the literature is lacking. Aepfelbacher et
a l, (1992) reported that My4+ (CD 14) cells remain constant in LPS-treated cells but 
specific fluorescence intensity increased by 4 fold. Conversely, LPS treatment 
increased both the number of M02+ (CD 14+) cells and the fluorescence intensity. 
Similarly, Gessani et a l, (1993) reported that untreated human monocytes in vitro 
showed an increased CD 14 mean fluorescence while the number of CD 14 positive cells 
did not change, indicating that expression per cell increased.
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3.4.3 CD16 expression
Human monocytes possess Fc receptors on their surface that bind the Fc 
portion of the IgG molecule and subsequently may initiate adherence, phagocytosis and 
destruction of the IgG-coated cells. These IgG-dependent monocyte-mediated 
functions are very important in host defense against infections and tumors. Monocytes 
in these experiments appeared to express low levels of CD16-associated fluorescence. 
Data show that LPS can induce low levels of CD 16 expression on monocytes, 
however, it did not reach statistical significance (Figure 3.4.3). No change in the 
expression of this receptor by MPL was found. Similar results were found with the 
percentages of CD 16 positive cells. Since CD 16 is a member of the Fc receptor family 
and Fc receptors are known to be involved in phagocytosis, increased expression of 
this receptor would indicate the stimulatory state of the cells. These data suggest that 
LPS may play a role in stimulating monocytes to initiate CD16-mediated phagocytosis- 
related activity.
Data presented here show that LPS tended to enhance CD 16 receptor density at 
lower doses and at higher doses did not enhance its expression. The high individual 
variations may have been responsible for the lack of statistical significance. The finding 
that high doses of LPS did not enhance CD 16 expression may be related to the LPS- 
stimulated release of TNFa and IL-10. Dosé-dependent release of TNFa has been 
shown in the present experiments (Figure 3.3.1.4) and TNFa-mediated down 
regulation of CD 16 expression has been reported (reviewed by Segal, 1990). It was 
previously reported that CD 16 expression can be induced with appropriate stimulation 
(van de Wmkel and Capel, 1993). The number of CD 16-positive cells was shown to 
increase in sepsis (Fingerle et al., 1993). The lack of significant difference in either 
receptor density or percentage of CD 16-positive cells apparently contradicts the finding 
that the MPL-treated group enhanced extracellular lysis whereas the LPS group showed 
increased phagocytosis since these functions are mediated through Fc receptors. These 
findings indicate that some other receptors and/or mechanism(s) are involved in 
phagocytosis or that these two processes operate independently. It has been 
demonstrated that high affinity receptors (FcyRI) are primarily involved in the binding 
of the IgG complex to human monocytes (Carter, Leslie and Reves, 1982) and the 
antibody-sensitized extracellular lysis (Klaassen et a l, 1990; van Schie et a l, 1992). 
However, in another study it was shown to occur via FcyRII (Boot, Geerts and 
Aarden, 1989). It is possible that LPS up-regulated IL-10 release that induced the 
expression of high affinity receptor which in turn enhanced phagocytosis (Spittler et a l, 
1995) since aggregation of Fc receptors is required for binding and phagocytosis 
(Mellman, Plutner and Ukkonen, 1984). Further investigations are needed to prove 
this hypothesis. It is quite possible that LPS stimulates the expression of receptors 
other than Fc receptors (an upward trend of CD 18-positive cells was shown in the 
present experiments). This argument is supported by the finding that the high dose of 
LPS (100 ug/ml) did not increase phagocytosis compared to either MPL or control 
cells. Since 100 ug/ml LPS showed a tendency to decrease either CD 14 or CD 16 
expression, this explanation seems to be reasonable. However, the percentage of
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Figure 3.4.3. Effects of LPS and MPL on CD16 expression 
by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were adhered to culture 
plates and adherent monocytes were incubated with LPS or MPL at the 
indicated doses for 18 hours (n = 6 ). The cells were retrieved by 
EDTA-cold shock treatment and expression was measured by FACScan. 
Data were analyzed and expressed as mean ± SEM in (A) mean 
fluorescent unit or (B) percentage positive cells. ANOVA: no significant 
effects.
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positive cells did not change, suggesting that receptor density was increased by LPS in 
monocytes. Percentage of positive cells found in the present experiments agree with an 
earlier study (35.9 ± 4.4%; Jungi et a l, 1990). Studies describing the effects of MPL 
on CD 16 expression were not found in the literature. Although time-dependent 
expression of CD 16 has not been reported, it may follow a similar pattern of expression 
as CD 14, thus, representing a differential functional characteristic of LPS- and MPL- 
treated cells. Shedding of CD 16 by proteolysis in neutrophils has been reported 
(Huizinga et al., 1990). It is possible that the same mechanism exists in monocytes as 
well and thus, confers the differential effects on these cells.
3.4.4 CD25 expression
Figure 3.4.4A shows that very high doses of both LPS and MPL seem to 
stimulate CD25 expression which is not statistically significant (control, 830 ± 249 
versus LPS, 1108 ± 326 or MPL 1062 ±312 FU at 100 ug/ml dose). Data indicate that 
both LPS and MPL cause a similar level of CD25 expression in vitro. A  significant 
difference in the percentages of CD25-positive cells was found between LPS- and 
MPL-treated groups (p = 0.05; Figure 3.4.4B). LPS seems to increase the number of 
CD25-positive cells in a dose-dependent manner, but it did not reach statistical 
significance. There was no change in the MPL-treated group. These data suggest the 
involvement of CD25 in the inflammatory process and indicate that MPL is less 
stimulatory compared to LPS.
Mean fluorescence of CD25 expression was unchanged in either LPS- or MPL- 
treated monocytes but a very high dose of LPS (100 ug/ml) seemed to stimulate CD25 
expression when expressed as percentages of positive cells. This finding agrees with 
the previous reports that LPS stimulation up-regulates CD25 expression (Holter, et al., 
1987; Kniep, Strelow and Lohmann-Matthes, 1992; Scheibenbogen et al., 1992; Grey 
et al., 1993). This observation is also consistent with the finding that the high dose of 
LPS tended to increase sIL-2r release (p = 0.06). Although the reason for the 
difference between the mean fluorescence and percentage of positive cells is not clear, 
the lack of increase in sIL-2r release in the MPL-treated group and a similar level of 
CD25 receptor density (mean fluorescence) agrees with the suggestion that sIL-2r 
release is independent of CD25 expression (Scheinbenbogen et al., 1992). The lack of 
a significant difference in CD25 expression can also be related to the finding that IL-lra 
levels in either treatment were not different (though MPL tended to increase IL-lra 
release). It has been shown that increased IL-lra down-regulates CD25 expression in 
human monocytes as an auto-regulatory mechanism in inflammatory conditions (Conti 
et al., 1992). It may also be possible that it is a temporal phenomenon. Increased IL-1 
would lead to increased IL-lra which would stimulate CD25 expression followed by 
increased sIL-lr release. The increased IL-lr release may cause decreased CD25 
expression and thus, decrease the effect of IL-1. Lack of agreement between CD25 and 
the sIL-2r again justifies the suggestion that these two receptors are independently 
operated (Scheibenbogen et al., 1992). When the expression of this receptor was
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Figure 3.4.4. Effects of LPS and MPL on CD25 expression 
by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were adhered to culture 
plates and adherent monocytes were incubated with LPS or MPL at the 
indicated doses for 18 hours (n = 6 ). The cells were retrieved by 
EDTA-cold shock treatment and CD25 expression was measured by 
FACScan. Data were analyzed and expressed as mean ± SEM in (A) mean 
fluorescent unit or (B) percentage positive cells. ANOVA: (A) no 
significant effects; (B) treatment effects, p = 0.05
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analyzed as percentages of positive cells, LPS-stimulated expression was found to be 
significantly greater than the MPL group, confirming the less toxic property of MPL.
3.4.5 CD45 expression
Figure 3.4.5 presents the results of the effects of LPS and MPL pretreatment of 
CD45 expression in monocytes. While both LPS and MPL stimulate CD45 expression, 
the stimulation is significantly greater with MPL compared to LPS (p<0.05). Control 
cells were found to express very low levels of fluorescence (397 ±112 FU). These 
findings indicate that MPL can stimulate monocytes to express CD45, which is 
significantly different from LPS, suggesting the possible role of MPL in CD45 
mediated activity such as: signal transduction via tyrosine phosphatase and protein 
kinase and CD45-mediated cytokine release.
Both LPS and MPL enhanced CD45 density; MPL being more effective than 
LPS, indicating a selective stimulatory property of MPL. LPS-stimulated expression of 
CD45 has been reported earlier (Gruber et a l, 1992) but studies on the effects of MPL 
on CD45 expression have not been published. CD45 has been shown to have a role in 
signal transduction involving tyrosine phosphatase and protein kinase C (Tonks et al., 
1988; Spertini et al., 1994); Engagement of CD45 induces cytokine production by 
monocytes in vitro and CD1 la/CD18-dependent T-cell activation measured by cell 
clumping (Webb et al., 1990). CD45-mediated release of M-CSF in human monocytes 
has also been demonstrated (Gruber, Webb and Gerrard, 1992). Further investigations 
are needed to delineate the differential response of LPS and MPL to reveal their 
physiological significance in the present system.
3.4.6 CD71 expression
CD71 is considered as a cellular activation marker. Accordingly, an increased 
expression of this receptor would be expected in the LPS- or MPL -treated cells. In the 
present experiments, very low levels of CD71 expression in monocytes were seen. Its 
expression seems to increase with both LPS and MPL, while MPL being expressed 
less, but these differences did not attain statistical significance (Figure 3.4.6). LPS- 
stimulated expression ranged from 170 -191 FU and it was 132 - 178 FU for MPL, 
while control cells showed the lowest level of expression (126 ± 39 FU).
Although CD71 expression tended to be increased in both LPS- and MPL- 
treated monocytes, it did not reach statistical significance. Similar receptor density in 
the LPS and MPL groups and unchanged percentage positivity indicate that LPS and 
MPL stimulate this receptor similarly or these agents are unable to stimulate CD71 
expression. These findings are in accord with Hirata et a l, (1986) and Carozzi et a l,
(1989) who also could not stimulate human monocytes in vitro to express CD71. It 
was suggested that CD71 is expressed in the early stage of differentiation. Because in 
the present study monocytes were not expected to differentiate to macrophages, the lack 
of significant expression of CD71 was expected. This finding suggests that LPS and 
MPL do not stimulate monocyte differentiation within 18 hours, at least under the
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Figure 3.4.5. Effects of LPS and M PL on CD45 expression 
by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were adhered to culture 
plates and adherent monocytes were incubated with LPS or MPL at the 
indicated doses for 18 hours (n = 6 ). The cells were retrieved by 
EDTA-cold shock treatment and CD45 expression was measured by 
FACScan. Data were analyzed and expressed as mean ± SEM in
(A) mean fluorescent unit or (B) percentage positive cells. ANOVA and 
Mann-Whitney tests: (A) both dose and treatment effects, (p<0.04);
(B) no significant effects.
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Figure 3.4.6. Effects of LPS and M PL on CD71 expression 
by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were adhered to culture 
plates and adherent monocytes were incubated with LPS or MPL at the 
indicated doses for 18 hours (n = 6 ). The cells were retrieved by 
EDTA-cold shock treatment and CD71 expression was measured by 
FACScan. Data were analyzed and expressed as mean ± SEM in
(A) mean fluorescent unit or (B) percentage positive cells (mean ± SEM). 
No significant difference.
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conditions of the present experiments. Studies on the effects of LPS and MPL on 
CD71 expression on monocytes have not been published previously.
3.4.7 HLA-DR expression
Figure 3.4.7 shows that MPL at higher doses (10 and 100 ug/ml) increases 
HLA-DR expression in monocytes (both p<0.05). Augmented overall expression by 
MPL is statistically significant compared to that of LPS (p<0.02). The mean 
fluorescence in the control cells was found to be 1214 ± 128 FU, where the highest 
fluorescence was seen with 100 ug/ml of MPL (1967 ± 333 FU). The HLA-DR 
expression in the LPS-treated monocytes remained unchanged. The data clearly 
indicate the immunomodulatory ability of MPL through the expression of HLA-DR 
which is required for antigen presentation by the MPs and T-cell activation. 
Furthermore, a dose-dependent decrease in the percentages of HLA-DR-positive cells 
was found with both LPS and MPL (p<0.05). However, individual treatments did not 
reach significance. Differential expression of this antigen further confirms the 
differential response of monocytes to LPS and MPL. An increased mean fluorescence 
but a decreased tendency of percentage of HLA-DR-positive monocytes with MPL 
further indicates the existence of an auto-regulatory mechanism in the expression of this 
receptor in MPL-stimulated monocytes.
MHC class II molecules on monocytes are key molecules in antigen 
presentation. As normal peripheral monocytes represent a highly heterogeneous 
population, upon culture in vitro they lose their receptors (Gonwa and Stobo, 1984). 
These class II antigens play an important role in the specific immune response, 
especially in their interaction with various subsets of T-cells. LPS has been shown to 
depress antigen-induced T-cell proliferation in vitro, decrease HLA-DR expression and 
antigen presenting capacity (Yem and Parmely, 1981; Volk et a l, 1991). In the present 
experiments, HLA-DR expression (receptor density) was increased in MPL-stimulated 
cells in a dose-dependent manner, and expression was significantly higher in the MPL- 
treated group compared to LPS. These findings agree with a previous report that MPL 
caused increased expression of the la antigen (human equivalent of HLA-DR) on 
murine macrophages (Johnson and Tomai, 1990). On the other hand, HLA-DR 
expression was found to be decreased in septic patients and was reported to be 
associated with defective antigen presentation (Polk et a l, 1986; Appel et a l, 1989; 
Cheadle et a l, 1991; Volk et a l, 1991; Docke et a l, 1994; Gardiner et a l, 1994). 
Similarly, Lin et a l, (1993a, 1994) found decreased HLA-DR expression in patients 
with severe sepsis. The decreased percentages of positive cells in the LPS- and MPL- 
treated group agree with these reports. Although individual treatment did not reach 
statistical significance, the observation that MPL tended to decrease the percentages of 
positive cells but significantly enhanced HLA-DR expression reinforces the postulation 
that MPL is less stimulatory than LPS. It can be speculated that MPL stimulates a 
lower number of cells representing the initial low level stimulation while increasing the 
receptor density on stimulated cells. It is also possible that MPL inhibited the adhesion 
induced HLA-DR expression (Appel et a l, 1989), thus reflecting a decreased
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Figure 3.4.7. Effects of LPS and M PL on HLA-DR 
expression by monocytes in vitro.
Mononuclear cells at 1.25 x 106 cells per well were adhered to culture 
plates and adherent monocytes were incubated with LPS or MPL at the 
indicated doses for 18 hours (n = 6 ). The cells were retrieved by 
EDTA-cold shock treatment and HLA-DR expression was measured by 
FACScan. Data were analyzed and expressed as mean ± SEM in 
(A) mean fluorescent unit or (B) percentage positive cells. ANOVA and 
Mann-Whitney tests: (A) treatment effects, (p<0.02); (B) dose effects, 
(p<0.05).
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percentages of positive cells. The findings that short-time LPS stimulation increases 
monocyte HLA-DR expression (McLeish, Wellhausen and Dean, 1987; McLeish et al, 
1989; Schmittel, Scheibenbogen and Keilholz, 1995) and sepsis causes decreased 
expression (Polk, et a l, 1986; Cheadle et a l, 1991; Volk et a l, 1991; Docke et a l, 
1994; Gardiner et a l, 1994) implicates the presence of a stimulation dose-, time- or 
magnitude-dependent regulation (or a compensatory mechanism) of the HLA-DR 
expression in monocytes. Thus, the decrease in positive monocytes in the MPL-treated 
group suggests the existence of the compensatory mechanism in receptor expression in 
moderate stimulation (MPL has been shown to be less stimulatory than LPS) where the 
body can accommodate the total immune response by increasing the receptor density, 
thus sparing the energy expenditure, as opposed to LPS-treated cells that fail to offer 
the appropriate immune response.
Taken together, it appears that MPL is less capable of stimulating an 
inflammatory reaction and, in certain cases, more stimulatory in enhancing immune 
responses when compared to LPS. The protective role of MPL against LPS- (or 
bacteria) induced toxicity may be mediated through the inhibition of inflammatory 
cytokine release, by increasing the release of certain interleukin receptors or antagonists 
thus decreasing the availability of cytokine, by enhancing extracellular lysis, producing 
RNIs, and through modulation of the immune function through expression of the cell 
surface receptors. The exact mechanism(s) by which the MPL modulatory function 
operates warrants further studies.
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3.5 Effects of lipopolysaccharide and monophosphoryl lipid 
A on respiratory burst activity in human monocytes in vitro
This paper has been submitted to Journal of Leukocyte Biology for publication.
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Abstract: The ability of LPS to stimulate respiratory burst activity in 
human monocytes and the development of hyporesponsiveness to 
activating stimuli was compared with that of MPL. Significant amounts
of 02" (p<0.05) and H2 O2  (p<0.05) were produced in vitro as a result 
of both LPS and MPL stimulation. Pretreatment with either LPS or MPL 
attenuated the LPS-stimulated 02* release (p<0.05) whilst only MPL 
pretreatment inhibited the release of H2 O2 . Monocytes pretreated with 
MPL significantly attenuated PMA-stimulated release of both 02"
(pcO.Ol) and H2 O2  (p<0.05). The attenuation of PMA-stimulated 02" 
and H2 O2  release by MPL pretreatment was significantly greater than 
that shown by LPS {p = 0.05, pcO.Ol, respectively). Both LPS and 
MPL stimulated monocyte 02* release with or without serum in the 
medium, however, enhanced H2 O2  release was seen only in the presence 
of serum. Polymyxin B failed to inhibit MPL-stimulated 02* and LPS- 
stimulated H2 O2  release by monocytes. These data show that MPL 
stimulates the release of both 02" and H2 O2  and attenuates the PMA- 
stimulated release of these radicals. These data also suggest that 02" 
and H2 O2  release in vitro by adherent human monocytes are differently
regulated, possibly through differential stimulation of monocytes by 
LPS and MPL.
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INTRODUCTION
Endotoxin or lipopolysaccharide (LPS) is a complex glycolipid forming a part of the 
gram-negative bacterial cell wall. It is a potent inducer of pro-inflammatory mediators 
in monocytes including cytokines, eicosanoids and free radicals (1-3 ).
Monophosphoryl lipid A (MPL), a modified form of LPS, is less toxic than its parent 
molecule in humans and animals (4). In humans, MPL is less pyrogenic, stimulates 
only low levels of cytokine release and is associated with reduced overall toxicity 
compared to LPS (5-7). Both LPS and MPL activate respiratory burst activity in mouse
peritoneal macrophages measured by the increased release of superoxide (O2 ) and
hydrogen peroxide (H2O2) (8-10). Although increased release of O2 by LPS-
stimulated human monocytes has been documented (11), comparative studies on LPS-
and MPL-stimulated release of O2 and H2O2 using human monocytes are scarce.
Prior exposure to LPS induces hyporesponsiveness or tolerance to subsequent 
LPS stimulation in monocytes evidenced by decreased levels of cytokine release (12) 
and cytokine mRNA expression (13). Derivatives of LPS structurally similar to MPL 
also attenuated LPS-stimulated release of cytokines in mouse macrophages (14). While
cytokine- or LPS-mediated down-regulation of monocyte O2 and H2O2 release has
been reported (15-17), MPL-mediated down-regulation of respiratory burst activity has 
not been investigated. Therefore, the purposes of this study were 1) to compare the
effects of MPL and LPS on O2  and H2O2 release by human monocytes and 2) to
examine whether pretreatment of monocytes by these agents would render the 
monocytes hyporesponsive to activating stimuli.
MATERIALS AND METHODS 
Reagents
All reagents were purchased from Sigma Chemical Co. (St. Louis, MO) unless 
otherwise indicated. MPL (Ribi Chemicals, Hamilton, MT) and LPS from Salmonella
minnesota Re 595 were dissolved in Ca2+- and Mg2+-free Dulbecco’s phosphate 
buffered saline (DPBS). Phorbol 12-myristate 13-acetate (PMA) was dissolved in 95% 
ethyl alcohol. Since MPL is poorly soluble in water, 2 ul triethylamine (TEA) per mg 
of MPL or LPS were used before adding DPBS. These solutions were finally diluted 
with phenol red free complete RPMI-1640 (Gibco-BRL, Grand Island, NY) before 
use. The complete RPMI medium contained 300 mg/dl L-glutamine, 10 ml/dl heat- 
inactivated fetal calf serum (ECS) (Gibco BRL, Grand Island, NY), and 5 mg/dl
kanamycin. The toxins were sonicated at 37° C for 10 min before use in each
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experiment.
Superoxide dismutase (SOD), femcytochrome C (FC) and Polymyxin B (Poly 
B) were dissolved in non-pyrogenic H2O and kept at -70° C until use. Phenol red
solution contained: 816 mg sodium chloride, 99 mg DL (+) glucose, 20 mg phenol red, 
1000 units horseradish peroxidase, and 100 ml potassium phosphate buffer. Low 
endotoxin ( < 6  pg/ml) containing water, PCS, culture medium, and DPBS were used in 
all experiments.
Monocyte isolation and cell culture
Mononuclear cells were isolated from buffy coat containing 70 ml citrate phosphate 
dextrose adenine-1 per 450-500 ml whole blood (New York Blood Bank, NY). Cells 
were obtained within 6-7 hr of blood collection following a modified method of Boyum 
(18). Briefly, the blood was diluted 2.5 times with DPBS to which 400 ul 10% 
ethylene diamine tetraacetic acid (EDTA) was added. Twenty-four ml of the diluted 
blood was layered over 12 ml of NycoPrep 1.077 (Gibco BRL, Grand Island, NY) in
50 ml Falcon tubes and centrifuged for 20 min (700 g at 21Ô C). The mononuclear cells 
were harvested and washed once with DPBS (700 g, 8  min). The supernatant was 
discarded, the pellet resuspended in 30 ml DPBS and centrifuged again (160 g, 6  min) 
to remove the platelets. After the final wash, the pellet was resuspended in 25 ml 
complete RPMI. Cell concentration and viability were determined by trypan blue 
exclusion. The viability of the isolated cells was >98%. A differential count was done 
using a coulter counter (Microdiff, Model MD16, Coulter Corp., Miami, FL). The 
isolated cells contained an average of 18.4 ± 2.0% monocytes, 5.7 ± 0.5% 
granulocytes, 74.4 ± 2.0 lymphocytes and 1.6 ± 0.2% other cells. The cell 
concentrations were adjusted to 1 .0  x 1 0 6 monocytes/ml.
Adherent monocytes were obtained by adhesion. Aliquots of the cell 
suspension (220 ul) were added to each well of 96-well, flat-bottomed tissue culture 
plates (Primaria, Baxter Scientific Products, Edison, NJ) which were subsequently
incubated at 37°C in 5% CO2 for 2  hr. Following incubation, the plates were washed
twice; first with prewarmed DPBS with 5% FCS followed by DPBS at room 
temperature. The identity of the adherent cells on replicate plates was confirmed using 
flow cytometry (after 2 hr or 18 hr incubation). Cells were recovered using EDTA
(0.2%) and cold shock (-70®C, 30 sec). Flow cytometric analysis of representative 
samples showed >85% of the cells were CD 14-positive; trypan blue exclusion showed 
>95% viability after 18 hr incubation. The final number of monocytes in each well was 
approximately 2 .0  x 1 05.
Adherent monocytes were incubated (37°C, 5% CO2) in complete RPMI 
medium with different doses of LPS or MPL for 18 hr. At the end of the incubation, 
the supernatants were discarded and the plates were washed once with DPBS. The O2
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and H2O2 release was measured without or with further stimulating the monocytes with
LPS (100 ug/ml) or PMA (100 nM) to examine the development of hyporesponsiveness 
to these challenges.
In addition, monocytes were collected from critically ill, non-septic patients 
using Percoll (Pharmacia, Piscataway, NJ) as described earlier (19). Briefly, 18 ml of 
venous blood with 2 cc sodium citrate (5%) was centrifuged at 300 g for 20 min. The 
platelet-rich plasma was collected and centrifuged at 2500 g for 10 min to obtain 
platelet-poor plasma (PPP). The pellet containing blood cells was resuspended with 40 
ml of 0.75% Dextran (500 kD) in 0.9% saline and allowed to stand for 30 min at room 
temperature. The leukocyte-rich supernatant was collected, centrifuged at 280 g for 6  
min, and the pellet resuspended in 3 ml PPP. The suspension was under-layered with 
42% and 52% Percoll in PPP. The gradient was centrifuged at 280 g for 10 min and 
the mononuclear cells at the 42% interface were collected, washed first with Krebs- 
Ringer phosphate buffer (with 0.2% dextrose and 10% FCS) and then with DPBS as 
before. The cells were resuspended in complete RPMI, counted, the concentration 
adjusted and the monocytes obtained as described before. The viability of the cells was 
found to be >95% and contained 56 ± 5% lymphocytes, 37 ± 2% monocytes, 5.6 ± 
0.9% neutrophils and <1.0 other cells as determined by Wright-Giemsa staining. The 
purity of the monocytes after adherence was determined to be greater than 9 5 % using
the same technique. The release of O2 and H2O2 by these cells was determined in the
presence or absence of serum (FCS) and Poly B.
0 %' m easurem ent
Superoxide production was measured using a modification of the SOD sensitive 
reduction of FC described previously (20). Femcytochrome C (180 ul) and DPBS, 
LPS or PMA (20 ul) were added to wells containing cells and the absorbances at 550 
nm were measured after 90 min using a Bio-Tek ELISA plate reader (Model EL 311). 
Production was expressed as nmole/2xl05 monocytes.
H 2 O 2 m easurements
Hydrogen peroxide was measured using a slight modification of the method described 
earlier (20). Phenol red solution (180 ul) was added to each well and another column 
of wells without any cells. Twenty microliters of IN NaOH was added to one column 
of wells that served as the cell blank. Control solution (DPBS), LPS or PMA (20 ul)
was added to the appropriate wells and the H2O2 release measured as before. 
Production was expressed as nmole/2xl05 monocytes.
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Data analyses and Statistics
Net production of 0% or H2O2 by pretreated-challenged monocytes was determined by
subtracting the pretreatment values from the corresponding pretreated-challenged values 
in the same plate. Data were analyzed using the StatView statistical program on a 
Macintosh computer (Abacus Concepts, Inc., Berkeley, CA). Non-parametric Mann- 
Whitney U and Kmskal-Wallis tests were performed to determine the overall treatment 
and dose differences, respectively. A value of p<0.05 was considered significant. 
One-way ANOVA was done in individual treatment groups where Fisher post hoc tests 
were done to determine the differences between individual doses. Results are presented 
as mean ± the standard error of mean (SEM).
RESULTS
Effects of LPS and MPL on 0%' and H2O2 release by monocytes
All doses of both LPS and MPL stimulated the release of O2  (LPS,/?<0.03 and MPL,
p<0.02; Fig. 1 A). Release by LPS- and MPL-treated monocytes did not significantly 
differ from each other. Similarly, both LPS and MPL pretreatment resulted in increased 
H2O2 release (LPS,p<0.01 and MPL, p<0.005; Fig. IB), but MPL was found to
stimulate a significantly higher level of H2O2 release compared to LPS (p<0.03).
These findings indicate that despite its reduced toxicity (4-5), the potency of MPL to 
induce the respiratory burst response in human monocytes in vitro is equal to or more 
than that of LPS. Fig. 2 shows that the monocytes continued to produce significant 
amounts of these radicals 18 hr after the stimulants were removed but the differences 
between LPS- and MPL-stimulated O2 and H2O2 release were diminished.
Effects of LPS and MPL pretreatment on O2 ' and H2 O2 release by LPS- 
challenged monocytes.
Hyporesponsiveness is related to agonist activity of the inducer and is dose dependent 
(13,21). Pretreatment of these monocytes in vitro with either LPS or MPL, at all
doses, significantly inhibited the release of O2 upon subsequent challenge with LPS
(LPS, p<0.05 and MPL, p<0.04; Fig. 3A). There was no difference between the 
effects of LPS and MPL. LPS-challenged H2O2 release in these experiments showed a
significant inhibition in the MPL pretreatment group (p<0.05), but the LPS-mediated 
attenuation failed to reach statistical significance (Fig. 3B).
148
1.5
S
|  1-25- 
1
in 1 -O.
i-H
N
u 0.75 -! LPS
0 .5 -
MPLIoo
0 0.01 101 100
I 1,5
Dose (ug/ml)
Fig. 1. Effects of lipopolysaccharide (LPS) and monophosphoryl 
lipid A (MPL) on superoxide and hydrogen peroxide production by 
monocytes in vitro. Adherent monocytes were incubated for 18 hr 
with the indicated amounts of LPS or MPL (n = 7) and (A) 
superoxide and (B) hydrogen peroxide release were measured. (A) 
Dose effects: LPS p<0.03, MPL /?<0.02; (B) Dose effects: LPS 
p<0.01, MPL p<0.005. Treatment effect: p<0.03.
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Fig. 2. Effects of lipopolysaccharide (LPS) and monophosphoryl lipid A 
(MPL) on superoxide and hydrogen peroxide production by monocytes in 
vitro. Adherent monocytes were incubated for 18 hr with the indicated 
amounts of LPS or MPL (n = 7) then the cells were washed and incubated 
for another 18 hr in culture medium and (A) superoxide and (B) hydrogen 
peroxide release were measured. (A) Dose effects: both LPS and MPL 
p<0.04; (B) Dose effects: both LPS and MPL p<0.05.
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Effects of LPS and MPL pretreatment on the release of Oz* and H2O2 by 
PMA-challenged monocytes.
In the previous experiments a difference was demonstrated between the attenuation of 
LPS-stimulated O2 and H2O2 release. To determine whether this phenomenon was
stimulus-specific, we measured the release of these metabolites following PMA 
stimulation. Fig. 4A demonstrates that MPL pretreatment at all doses attenuates PMA- 
stimulated O2 release (p<0.01). Although overall LPS pretreatment did not reach 
statistical significance, LPS at 0.01 and 1.0 ug/ml significantly attenuated PMA- 
stimulated 0 2 * release (p<0.05). Similarly, PMA-stimulated H2O2 release was
attenuated in the MPL pretreated monocytes (p<0.04); the result being significantly 
different from those in the LPS pretreated group (p<0.01; Fig. 4B). The ability of 
MPL to attenuate PMA-stimulated release of these radicals and inability of LPS to 
demonstrate this behavior suggests a differential modulation of oxygen metabolism by 
LPS and MPL.
Effects of serum factors and Poly B on LPS and MPL stimulated O2 and 
H2O2 release
One pathway for LPS activation of monocytes involves the formation of a complex with 
LPS-binding protein which then interacts with CD 14 (22). Since LPS and MPL appear 
to show differential modulation of monocyte respiratory burst, we examined whether 
these variations were due to the differences in stimulatory mechanism(s). Addition of
serum to the medium significantly increased the release of O2 (pcO.OOl, Fig. 5A). 
Consistent with the previous experiments, both LPS and MPL stimulated monocyte 0 2 - 
release in a similar fashion. In addition, LPS and MPL were found to enhance 0 2 - 
release in the absence or presence of serum. Poly B significantly inhibited LPS- 
stimulated 0 2 - release (pcO.OOl), but failed to inhibit MPL-stimulated release by the
monocytes. Unlike O2 release, LPS and MPL were found to stimulate monocyte 
H2O2 release only in the presence of serum (p<0.05; Fig. 5B), suggesting the 
requirement of serum factor for LPS- or MPL-stimulated H2O2 release. Poly B did not 
inhibit LPS-stimulated H2O2 release but significantly inhibited MPL-stimulated release 
of H2O2 by monocytes (p<0.01). These data indicate a differential requirement of 
serum factor for LPS- and MPL-mediated reactive oxygen intermediate (ROIs) release, 
thus suggesting a different stimulatory pathway of monocyte activation.
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Fig. 3. Effects of lipopolysaccharide (LPS) and monophosphoryl 
lipid A (MPL) pre-treatment on LPS-stimulated release of 
superoxide and hydrogen peroxide by monocytes in vitro. Adherent 
monocytes were incubated with the indicated amounts of LPS or 
MPL (n = 7) for 18 hr and then challenged with 100 ug/ml of LPS 
and (A) superoxide and (B) hydrogen peroxide release were 
measured. (A) Dose effects: both LPS and MPL, p<0.05.
(B) Dose effects: MPL, p<0.05.
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Fig. 4. Effects of lipopolysaccharide (LPS) and monophosphoryl 
lipid A (MPL) on phorbol myristate acetate (PMA)-stimulated release 
of superoxide and hydrogen peroxide by monocytes in vitro. 
Adherent monocytes were incubated with the indicated amounts of 
LPS or MPL (n = 7) for 18 hr then stimulated with 100 nM PMA 
and (A) superoxide and (B) hydrogen peroxide release were 
measured. (A) Dose effect: MPL,p<0.01; treatment effect: 
p=0.05; (B) Dose effect: MPL, /?<0.04; treatment effect: /?<0.01.
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Monocyte and macrophage activation by LPS, cytokines, and activators of membrane 
bound lipids induce ROIs release in vitro and in vivo. The release of ROIs, generally 
known as oxidative or respiratory burst, includes O2 , H2O2 , hydroxy radical ( OH),
hydroxyl ion (OH-) and singlet oxygen (IO2). The respiratory burst in phagocytes 
reflects the activation of a membrane-bound enzyme system that transfers electrons 
from cytosolic NADPH to extracellular oxygen, producing O2 through the activation of
protein kinases. The O2 is dismuted to H2O2 by SOD (23).
Lipopolysaccharide stimulation of monocyte O2 and H2O2 release has been
previously documented (1,24-26). Similarly, peritoneal macrophages from mice
exposed to LPS or MPL were shown to release O2 and H2O2  in vitro (8-10). These
authors demonstrated ROIs release both in human and animal cells using some form of 
co-stimulation or IFNy-primed cells. Here we have demonstrated that both LPS and
MPL can stimulate human monocytes to release O2 and H2O2 in vitro, in the absence
of exogenous co-stimulation. Our findings are in agreement with a recent study (11)
but contrast with an earlier report (27) that demonstrated decreased O2 release by
human monocytes treated with very small amounts of LPS compared to untreated cells. 
MPL-dependent enhanced H2O2 release has been documented in mouse peritoneal
macrophages (9).
MPL has been demonstrated to be less toxic than LPS in equivalent doses as 
measured by the Chick Embryo Lethal Dose test, pyrogenicity tests, the dermal 
Shwartzman reaction, cytokine release in vivo and in vitro, and in clinical trials (4-7).
We observed that LPS and MPL stimulated monocytes released similar amounts of O2*.
The lack of observed differences between LPS- and MPL-mediated O2 release may be
related to the degree of dose response. The lowest dose used in our study may have 
exceeded the optimum dose required for stimulating the monocytes to release these 
metabolites, thus masking the differential stimulatory ability of LPS and MPL. This is
evidenced by the fact that O2 release by either LPS- or MPL-treated monocytes was not
different between treatment doses (0.01 -100 ug/ml; Fig. 1). Previous studies
demonstrating monocyte O2 ' and H2O2 release used much smaller doses of LPS or
MPL than we used in the present study (11,25-28). With low doses of LPS and MPL 
Henricson et al., (21) were able to demonstrate the differential expression of 
inflammatory genes in murine macrophages, but no differences were found with higher 
doses (between 0 .0 0 1  - 1 .0  ug/ml) comparable to that used in the present study. 
However, we found significant differences between LPS- and MPL-stimulated H2O2
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release suggesting a differential modulation of H2O2 release by LPS and MPL. It may
be possible that a higher degree of stimulation was needed to elicit appreciable amounts 
of H2O2  release in our model. This can be supported by the fact that 25 nM PMA
stimulated optimum O2 release whereas 100 nM PMA was required to obtain a
comparable level of H2O2 in the monocytes (data not shown). Alternatively, high
doses of LPS may have inhibited or inactivated SOD which catalyzes the conversion of
O2  to H2O2 , thus limiting the formation of H2O2  by LPS-treated monocytes, whilst in
MPL-treated cells it remained active without altering the release of H2O2 . It is
noteworthy that H2O2  release, on a molar basis, in MPL-treated monocytes was not
increased, rather O2 release in LPS-pretreated cells was relatively decreased.
Decreased levels of SOD in rat liver during endotoxemia (29) and oxidation of flavin 
adenine dinucleotide, a component of NADPH oxidase, by LPS (30-31) have been 
reported. Observations of increased levels of SOD caused by low doses of TNF (32) 
and decreased levels of this enzyme in endotoxemia, indicate a dose- and time- 
dependent modulation of SOD. When the LPS- and MPL-pretreated cells were washed
and left in culture medium for another 18 hr, they continued to produce O2 and H2O2 ,
but produced similar amounts of these metabolites (Fig. 2). These observations further 
support our postulation that LPS inhibits SOD activity in monocytes in a dose- and 
time-dependent manner.
We demonstrated LPS- and MPL-induced hyporesponsiveness by LPS- 
challenged monocytes in terms of subsequent O2 release and MPL-mediated H2O2
(Fig. 3). These observations also suggest that O2  and H2O2 metabolism in LPS- 
challenged monocytes are regulated differently. Indeed, this is further supported by the 
observations that O2 accumulated up to 150 min whilst H2O2 production did not 
accumulate after 90 min in different concentrations of monocytes stimulated with a wide 
range of PMA concentrations (data not shown). Although differential regulation of O2 
and H2O2 by human monocytes has not been reported, differential release of ROIs in 
murine peritoneal macrophages has been observed (8 , 33). The latter authors 
postulated that enhanced H2O2 release without concomitant O2 production by 
lymphokine-activated macrophages was modulated through up-regulation of Mn-SOD 
and the increased H2O2 release was secondary to enhanced O2 production at a cellular 
location accessible to SOD. This may explain the observation that LPS increased H2O2 
release without a corresponding nitroblue tétrazolium reduction (measures intracellular 
O2 ) in murine peritoneal macrophages (8 ). However, this possibility was thought to 
be remote (reviewed in 34) and our data favors the possibility of differential modulation 
of O2 and H2O2 . Discordant release of ROIs release by mononuclear cells in response
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to a variety of stimulants has also been observed, implicating independent regulation 
(35). Similarly, selective inhibition of monocyte H2O2 release by transforming growth
factor-p (TGF-p) supports the idea of a differential modulation of O2 and H2O2 release
(15). The difference in magnitude of hyporesponsiveness between LPS- and MPL- 
pretreated groups further supports the hypothesis that LPS and MPL modulate 
monocyte respiratory burst differently.
Our findings that PMA-stimulated release of O2  and H2O2 was attenuated in
MPL-pretreated cells and did not change in LPS groups (Fig. 4) are in contrast to an
earlier study (28). These authors reported that O2 and H2O2 release in LPS-pretreated
cells was decreased after PMA challenge whilst no change was found in the MPL 
group. The reason for the different observations may be related to different 
experimental conditions including the use of 25% pooled human serum, different 
adhesion surface (36-37) and a very high dose of PMA that may have influenced their 
results by down-regulating protein kinase C (PKC) or phospholipase C (PLC) with a 
resulting decrease in ROIs (38-39).
MPL induced significant hyporesponsiveness to both LPS- and PMA-stimulated 
O2 release, and PMA-stimulated H2O2 release. By comparison, LPS-mediated
hyporesponsiveness was observed only in LPS-stimulated O2 release and PMA- 
stimulated H2O2 release. These observations are also consistent with differential LPS- 
and MPL-modulated monocyte ROIs release. Although LPS tolerance has been 
described as a post-receptor phenomenon (40), the exact mechanism(s) of LPS- or 
MPL-mediated ROIs release and development of hyporesponsiveness is not known. 
Since our current understanding of the stimulatory mechanism(s) which lead to the 
induction of hyporesponsiveness is limited, we undertook this study to determine 
whether LPS and MPL stimulate monocytes differently.
Polymyxin B avidly binds to anionic portion of lipid A, presumably accounting 
for its ability to neutralize the effects of LPS, as well as inhibit PKC (reviewed in 1).
The observation that while LPS and MPL stimulated both O2 and H2O2 release, Poly B
inhibited only LPS-stimulated O2 and MPL-stimulated H2O2 release suggests different
stimulating mechanisms for LPS and MPL. Differences in LPS- and MPL-mediated 
ROIs release in mouse peritoneal macrophages have been demonstrated (8 ) that may be 
mediated through interference of the activation signal by the oligosaccharide component 
of LPS that MPL lacks (41). It may have been mediated through differential binding of 
LPS and MPL to serum factors or to the monocyte receptors. Differential TNF 
production by different LPS and MPL in monocytes has been attributed to the lengths 
of the side chains of these molecules (42). Whilst in the presence of recombinant CD 14 
MPL increased TNF production; however, no significant effects of MPL-mediated TNF 
production were detected in the presence of anti-CD 14 antibody. Thus, it was 
suggested that MPL may use other mechanism(s) in addition to CD 14 for monocyte
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stimulation (42). The observation that both LPS and MPL stimulated monocyte release 
of O2 in the absence of serum suggests that additional receptors, other than CD 14, are
involved in the LPS- and MPL-mediated activation of monocytes for Ox release.
Involvement of the members of the integrin family has been reported previously (43, 
44). Associations between increased expression of CD 11 (a, b, c)/CD18 and H2O2
(43), and CD l ie  and O2 (44) have been demonstrated in human monocytes in vitro.
Alternatively, LPS and MPL stimulate monocytes to release different 
concentrations of cytokines (44) and thus, in culture, prime or deactivate the cells 
differently (25, 26, 43,45, 46). Thus, it is not surprising that these cells responded to 
a challenge differently. Differences in the hyporesponsiveness induced by different 
lipid A structures in murine peritoneal macrophages have been documented (14). 
Furthermore, unpublished data from our laboratory and others (43, 47) showed that in 
vivo priming of monocytes with different cytokines and sepsis produce different
amounts of O2 and H2O2 release in vitro. A  similar pattern of in vitro priming effects
on ROIs release has also been demonstrated (15,45).
Finally, differential stimulation of the early-inflammatory-gene expression by 
LPS and MPL has been demonstrated in murine macrophages (21). The absence of the 
hydrophilic phosphoryl group was thought to disrupt the conformation of the lipid A 
moiety (3). This conformational change may causé MPL to bind to putative LPS 
receptors with lower affinity or may facilitate its interaction with alternative signaling 
pathways resulting in differential kinetics of gene expression and stability of the gene 
products. MPL-stimulated inflammatory gene induction was slower and remained 
elevated longer than the LPS in mice macrophages (21), possibly accounting for the 
differential monocyte functions.
In summary, we have demonstrated that both LPS and MPL stimulate monocyte 
O2  and H2O2 release, but the magnitudes and induction of hyporesponsiveness to
specific stimuli differ significantly. In addition, we have shown that the susceptibility 
of these two radicals to tolerance induction is different, indicating that their generation 
may be differentially regulated, at least in LPS-challenged monocytes. Our findings 
suggest that the stimulatory mechanism(s) by which monocytes induce the O2 and 
H2O2 release differs between LPS and MPL. Further experiments are required to 
address this possibility.
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This paper has been submitted to Clinical Immunology and Immunopathology 
for publication.
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ABSTRACT
The effects of acute and prior exposure to lipopolysaccharide (LPS) and staphylococcal 
enterotoxin B (SEE) on O2 release by blood monocytes were examined in normals and 
in patients with severe sepsis and septic shock. LPS and SEE initially stimulated the 
release of O2 by monocytes isolated from buffy coats of blood donors (p<0.05) and
induced hyporesponsiveness to LPS on re-challenge (p<0.05). PMA-stimulated 0 2 -
release was significantly attenuated by LPS (p<0.05) and SEE (p<0.02). In freshly 
isolated monocytes from normal individuals, LPS and SEE pretreatment induced 
significant hyporesponsiveness to subsequent challenge with both stimuli (p<0.05). 
Monocytes isolated from patients with severe sepsis and septic shock demonstrated
high spontaneous O2 release. Stimulation of these cells with LPS and SEE resulted in 
less O2 production when compared to controls (p<0.05). In patients recovering from
their initial infection, O2 release in response to the same stimuli was significantly
increased when compared to release during the acute stage (p<0.05). These data 
demonstrate that both LPS and SEE induce hyporesponsiveness to LPS-, SEE- and
PMA-stimulated O2 release. A similar pattern of hyporesponsiveness is observed
during clinical sepsis which may represent a mechanism for modulating the 
inflammatory response during severe infections.
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INTRODUCTION
Activation of monocytes and macrophages by lipopolysaccharide (LPS) and 
other stimuli results in the release of reactive oxygen intermediates (ROIs) through a 
process known as the oxidative burst (1-3). The generation of ROIs plays an 
important role in host defense and regulates immune function by modulating monocyte 
and macrophage activity (1-5). ROIs also contribute to the inflammatory response and 
may produce tissue damage by inducing oxidant injury (6 -8 ).
Monocytes isolated from patients with septic shock demonstrate an attenuated 
release of cytokines in response to LPS that normalizes as the patients recover from 
their infection (9-11). This hyporesponsiveness to endotoxin is postulated to represent 
a form of early endotoxin tolerance. Prior exposure of monocytes to LPS induces a 
relative resistance on subsequent stimulation manifested by decreased cytokine release 
(12,13). Classically, the hyporesponsiveness involved in tolerant cells is specific for 
endotoxin and does not include resistance to gram-positive bacterial toxins (14,15). 
However, recent observations suggest that the monocyte hyporesponsiveness 
associated with both endotoxin tolerance and sepsis extends to other stimuli including 
gram-positive bacterial toxins (16,17).
The purposes of this study were: 1) to compare the effect of LPS and 
staphylococcal enterotoxin B (SEB) on monocyte superoxide (O2O production; 2) to
examine the development of tolerance or hyporesponsiveness with each of these stimuli 
to subsequent re-challenge; and 3) to examine whether severe sepsis and septic shock 
induced similar changes in monocyte O2 release in response to stimulation with both 
LPS and SEB.
MATERIALS AND METHODS
Patients and volunteers selection
The study was conducted with approval from the Institutional Research Board 
of Saint Vincents Hospital and Medical Center of New York. Monocytes were isolated 
from buffy coats from the New York Blood Bank and from healthy volunteers and 
infected patients. Informed consent was obtained from the subjects or their surrogates. 
Patients with severe sepsis (sepsis) and septic shock were prospectively entered into 
the study. A total of 17 subjects were enrolled in the study of whom 6  represented 
normal controls, 6  patients with severe sepsis and 6  patients with septic shock.
Severe sepsis was defined by the presence of an identifiable site of infection, 
evidence of an inflammatory response and systemic hypoperfusion. Septic shock was 
defined by sepsis-induced hypotension persisting despite adequate fluid resuscitation 
and requiring vasoactive therapy (18). All patients were entered within 24 hr of 
meeting study criteria. Of the patients with severe sepsis, 1 had gram-negative
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infections, 2 had gram-positive infections and 2 had mixed infections. Of the patients 
with septic shock, 1 had gram-negative infections, 4 had gram-positive infections and 1 
had mixed infections. Mortality was 60% in the patients with severe sepsis and 67% in 
the patients with septic shock. Blood samples were taken on admission and between 
5-7 and 14-16 days. The lowest Acute Physiology and Chronic Health Evaluation II 
(APACHE H) score was considered as the recovery sample. The minimum score 
decrease of 5 was arbitrarily accepted as a sign of recovery. Normal volunteers or 
patients on steroids, immunosuppressive agents, or non-steroidal inflammatory agents 
were excluded.
Reagents and solutions
All reagents were purchased from Sigma Chemical (St. Louis, MO) unless 
otherwise indicated. LPS from Salmonella minnesota Re 595, and SEB from
Staphylococcus aureus were dissolved in Ca2+- and Mg2+-free Dulbecco’s phosphate
buffered saline (DPBS). Phorbol 12-myristate 13-acetate (PMA) was dissolved in 95% 
ethyl alcohol. These solutions were then diluted with phenol red-free complete RPMI- 
1640 (Gibco-BRL, Grand Island, NY) before use. The complete RPMI medium 
contained L-glutamine, 300 mg/dl; heat-inactivated fetal calf serum, 10 ml/dl (Gibco
BRL, Grand Island, NY); and kanamycin 5 mg/dl. The toxins were sonicated at 37^C 
for 15 minutes before use in each experiment. Superoxide dismutase (SOD) and 
ferricytochrome C (EC) were dissolved in non-pyrogenic H2O and were kept at -70°C
until use. Low endotoxin (< 6  pg/ml) water, fetal calf serum, culture medium and 
DPBS were used in all experiments.
Monocyte isolation and cell culture
Mononuclear cells were isolated either from buffy coats containing 70 ml citrate 
phosphate dextrose adenine-1 (CPDA-1) per 450-500 ml whole blood or 30 ml freshly 
drawn venous blood in vacutainer tubes (Becton Dickinson, Rutherford, NJ) containing
1.5 ml adenine-citrate-dextrose (ACD) solution. The cells from the buffy coats were 
obtained within 6-7 hr of blood collection. The cells from the normal volunteers and 
patients were processed within 30 min of collection. Monocytes were isolated from the 
blood following a modified method described previously (19). Cell concentration and 
viability were determined by trypan blue dye exclusion. The viability of the isolated 
cells was >98%.
Monocytes were obtained by culture plate adhesion. The identity of the cells 
adhered to parallel plates (after 2 - or 18-hr incubation) was confirmed using flow 
cytometry. Cells were retrieved using EDTA and cold shock. Flow cytometry analysis 
showed >85% CD 14 positive cells, and the trypan blue exclusion showed >95%
viability. The final number of monocytes in each well was 2.0 x 105 and 0.8 x 105 in 
the buffy coat and patient experiments, respectively. The adherent monocytes were 
incubated with diluent, LPS, SEB or PMA for 18 hr and the O2 release by the cells
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was measured. In one set of experiments, the monocytes were re-challenged with 
LPS, SEB or PMA to examine the development of hyporesponsiveness to these stimuli.
Ox measurement
SOD inhibitable reduction of FC was measured for 0 2 * release (20). At the
end of the incubation period, the supernatants were discarded and the plates were 
washed once with DPBS. Then 180 ul FC and 20 ul of appropriate treatments were
added and the change of absorbance for 0% release was measured at 90 minutes. The
absorbances were measured at 550 run using a Bio-Tek ELISA plate reader (Model EL 
311). Production is expressed as nmole per well or percentage change from the 
baseline. Monocytes freshly prepared from peripheral blood produced more O2 than 
the monocytes isolated from the buffy coat.
Data analyses and Statistics
Net O2 production in a treatment group was determined by subtracting the
pretreatment values from the corresponding challenged values in the same plate. Data 
were analyzed using the StatView statistical program (Abacus Concepts, Inc.,
Berkeley, CA) using a Macintosh computer. Two-way ANOVA with Bonferroni 
correction for small sample size was used to compare overall group and treatment 
effects. Fisher’s post hoc tests were done to determine the differences between 
individual treatments and doses. Due to small sample size and high individual 
variations in the clinical samples, data were expressed as percentage change from the 
baseline. Non-parametric Mann-Whitney or Kruskal-Wallis tests were performed on 
these data. A value p<0.05 was considered significant. Results are presented as mean 
and ± standard error of mean (SEM).
RESULTS
Monocytes obtained from buffy coats of normal blood donors and stimulated 
with LPS and SEB released significant levels of O2 at all doses (Fig. 1) (p<0.05).
SEB stimulation resulted in significantly greater release of O2 than the LPS over the 
dose range studied (p<0.01). Both LPS and SEB pretreatment attenuated subsequent 
LPS-challenged O2 release (p<0.01) (Fig. 2). Although both LPS and SEB pre­
treatment appeared to inhibit SEB-stimulated O2  release, they failed to reach statistical 
significance (Fig. 3). Pretreatment with SEB also inhibited PMA-stimulated release of 
O2 by the monocytes at all doses tested (p<0.02) while inhibition by LPS was seen at a 
single dose (0.01 ug/ml; p<0.05) (Fig. 4). Data obtained using monocytes
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Fig. 1. Effects of LPS and SEB on superoxide release by 
monocytes in vitro. Buffy coat monocytes from normal volunteers 
were incubated with the indicated amounts of stimulants for 18 hr. 
Superoxide release was determined at 90 min (n = 7). Data are 
presented as mean ± SEM. Two-way ANOVA with Bonferroni 
correction: treatment, p<0.01; dose, pcO.OOl. Post hoc Fisher's 
PLSD: LPS or SEB, p<0.05.
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Fig. 2. Effects of LPS and SEB pretreatment on LPS-challenged 
superoxide release by monocytes in vitro. Buffy coat monocytes 
from normal volunteers were incubated with the indicated amounts 
of stimulants for 18 hr. Superoxide release was determined at 90 
min after 100 ug/ml LPS challenge (n = 6 ). Data are presented as 
mean ± SEM. Two-way ANOVA with Bonferroni correction: 
dose, pcO.OOl. Post hoc Fisher's PLSD: LPS or SEB pcO.Ol.
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Fig. 3. Effects of LPS and SEB pretreatment on SEB-challenged 
superoxide release by monocytes in vitro. Buffy coat monocytes 
from normal volunteers were incubated with the indicated amounts 
of stimulants for 18 hr. Superoxide release was determined at 90 
min after 100 ug/ml SEB challenge (n = 5). Data are presented as 
mean ± SEM.
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Fig. 4. Effects of LPS and SEB pretreatment on PMA-challenged 
superoxide release by monocytes in vitro. Buffy coat monocytes 
from normal volunteers were incubated with the indicated amounts 
of stimulants for 18 hr. Superoxide release was determined at 90 
min after 100 nM PMA challenge (n = 6 ). Data are presented as 
mean ± SEM. Two-way ANOVA with Bonferroni correction: 
dose, p<0.005; Post hoc Fisher's PLSD: LPS 0.01 ug/ml, /?<0.05; 
SEB, p<0.02.
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isolated from fresh blood from normal volunteers, first incubated with LPS or SEB for 
18 hr then challenged with LPS, SEB or PMA, are presented in Fig. 5. LPS
pretreatment significantly attenuated the Ox release both to LPS and SEB challenge
(p<0.05) but not to PMA. SEB pretreatment also attenuated O2  release to LPS and
SEB (p<0.01) but not PMA.
Monocytes isolated from patients with sepsis and septic shock exhibited 
significantly greater spontaneous Ox release when compared to controls (p<0.05; Fig.
6 ). Stimulation with LPS and SEB significantly increased O2 release in control 
monocytes (p<0.05). By contrast, in the infected patients, increments in O2 . release
were significantly less than controls following stimulation with LPS and SEB (Fig. 7). 
Of 11 patients with sepsis and septic shock, 4 patients survived. Data from these 
patients at entry and during recovery were collected and analyzed. The mean APACHE 
scores at entry and during recovery, respectively, were 28+2 and 20+3. Recovery was 
associated with significantly increased monocyte O2 release in response to LPS, SEB
and PMA (Fig. 8 ). 0 2 * release from control cells was similar to that released by the 
monocytes from the recovering patients in response to these stimuli.
DISCUSSION
The respiratory burst is induced in phagocytes by various stimuli and results 
from the activation of a membrane-bound enzyme system that transfers electrons from
cytosolic NADPH to extracellular oxygen producing ROIs (1,21). ROIs are involved 
in the phagocytosis and killings of pathogens (4), tissue injury and organ failure (22) 
and decreased host response against infections (23). In our study, LPS was observed to
stimulate Ox release from monocytes. Previous studies have yielded conflicting results
concerning the role of LPS in stimulating monocyte O2 release (24-26). These
differences may reflect different incubation periods, the influence of priming with 
IFN-y, the use of different serum concentrations and the use of smaller doses of LPS. 
Other methodological variations which could produce inconsistent results include LPS 
contamination and the variable influence of plastic adherence of cells in enhancing or 
suppressing ROIs production (25, 27, 28).
SEB belongs to a group of proteins that exhibit superantigen activity (29). 
Although their activity is in part mediated through T-cells, superantigens can directly 
activate monocytes by binding to HLA-DR class II molecules (30-31). To our
knowledge, SEB-stimulated release of O2 by human monocytes has not been pre­
viously described. Here we report that SEB, similar to other gram-positive toxins and 
LPS, stimulates monocytes to release O2 (32). SEB induction of protein tyrosine
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Fig. 5. LPS- and SEB-induced hyporesponsiveness of monocytes 
to activating stimuli in vitro. Peripheral blood monocytes from 
normal volunteers were incubated without (control) or with 1 ug/ml 
LPS or SEB for 18 hr. Superoxide release was determined at 90 
min after 100 ug/ml LPS or SEB, or 100 nM PMA challenge (Ch)
(n = 6 ). Data are presented as mean ± SEM. Kruskal-Wallis tests, 
ANOVA and Fisher's PLSD: *p<0.05. LPS, control vs LPS or 
SEB Ch; SEB, control vs LPS or SEB Ch.
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Fig. 6 . Superoxide release by monocytes from normal control 
subjects (n = 6 ) and patients with sepsis (n = 5) or and septic shock 
(n = 6 ) in vitro. Monocytes were incubated in RPMI for 18 hr. 
Spontaneous superoxide release was determined at 90 min with 
ferricytochrome C. Data are presented as mean + SEM. ^Two-way 
ANOVA with Bonferroni correction: control versus sepsis or septic 
shock, p<0.05.
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Fig. 7. Effects of LPS, SEB, or PMA on superoxide release by 
monocytes from normal control subjects (n = 6 ) and patients with 
sepsis (n = 5) or septic shock in vitro. Monocytes were incubated in 
RPMI for 18 hr. Superoxide release was measured at 90 min after 
stimulating with 1 ug/ml LPS or SEB or 25 nM PMA. Data are 
presented as mean ± SEM. *Two-way ANOVA with Bonferroni 
correction: group, p<0.02; Post hoc Fisher's PLSD: control versus 
sepsis or septic shock, p<0.05 for both LPS and SEB.
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Fig. 8 . Effects of LPS, SEB or PMA on superoxide release by 
monocytes from sepsis and septic shock patients (n = 4) during 
acute and recovery stages in vitro. Monocytes were incubated in 
RPMI for 18 hr. Superoxide release was measured at 90 min after 
stimulating with 1 ug/ml LPS or SEB or 25 nM PMA. Data are 
presented as mean ± SEM. *Mann-Whitney test: entry versus 
recovery, LPS, p<0.02; SEB, p<0.02: PMA, p<0.04.
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kinase (PTK) and protein kinase C (PKC) activity in monocytes (33-35) may play a 
role in the release of 0% by SEB-stimulated monocytes.
Prior exposure to LPS results in hyporesponsiveness to subsequent stimulation 
with the same agent (14). This phenomenon is termed endotoxin tolerance and is most 
commonly assessed as attenuated cytokine release on subsequent stimulation (9 -1 1 ). 
Classically, the hyporesponsiveness associated with endotoxin is described as being 
limited to further exposure to endotoxin and does not involve gram-positive toxins or 
other stimuli (14-15). Our data demonstrate that endotoxin tolerance also results in the
down-regulation of monocyte 0% release. Moreover, this hyporesponsiveness to
subsequent challenge includes other stimuli such as SEB. These observations are 
consistent with recent reports indicating that LPS-tolerant mononuclear cells from 
normal volunteers demonstrated an attenuated cytokine response when incubated with 
TSST (36). Similarly, pretreatment in vivo with derivatives of lipid A significantly 
diminishes the cytokine release in gram-positive sepsis and gram-positive bacterial 
toxins (16). We have demonstrated that the converse is also true; exposure to SEB - 
induced subsequent hyporesponsiveness to LPS challenge. Similarly, studies in
isolated murine macrophages have demonstrated the attenuation of LPS-stimulated O2
release following pretreatment with gram-positive lipoteichoic acids (3 7 ).
In contrast to LPS- and SEB-mediated activation which are receptor-dependent, 
PMA directly activates monocyte protein kinase C (38). Previous studies have yielded 
conflicting observations demonstrating both attenuated and unimpaired responses to 
PMA in cells which were endotoxin tolerant (37,39,40). In our study, the effect of
SEB and LPS pretreatment on monocyte Ox release upon subsequent challenge with
PMA differed in magnitude but not direction. SEB appeared to induce greater 
hyporesponsiveness to PMA while the LPS attenuation did not achieve statistical 
significance. Whether these observations represent true differences is unclear.
Sepsis and septic shock have been reported to induce monocyte 
hyporesponsiveness similar to that seen in endotoxin-tolerant cells. Our data extends 
previous observations which showed an attenuated cytokine release by monocytes from 
patients with septic shock (9,10). A generalized hyporesponsiveness was present in
septic monocytes as evidenced by an impaired release of O x  in response to LPS, SEB
and PMA stimulation. This pattern was similar to that observed in monocytes from 
control subjects on repeated challenge with SEB and LPS suggesting that the 
hyporesponsiveness observed in sepsis patients and LPS tolerance are manifestations of 
the same process. In patients who recovered from their initial infection, monocyte 
responsiveness to these stimuli appeared to normalize and approach that of the normal 
healthy control. The generalized nature of this hyporesponsiveness, which appears to 
involve several aspects of monocyte activity and a broad range of stimuli, may represent 
an important mechanism for modulating the inflammatory response during severe 
infection. Several substances are released during initial monocyte activation that down-
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regulate monocyte activity and attenuate monocyte responses to a broad range of 
stimuli. These potential mediators include interleukin-10, prostaglandin E% and
transforming growth factor-p all of which are released during sepsis and inhibit the
release of ROIs from stimulated monocytes (17,41,42). Moreover, these same
mediators appear to play an important role in the development of endotoxin tolerance
( 11).
In summary, LPS and SEB both stimulate the release of 02 from normal 
monocytes and appear to induce subsequent hyporesponsiveness to monocyte 
stimulation to themselves and each other. A similar pattern of monocyte hypo­
responsiveness to SEB, LPS and PMA is evidenced in the monocytes of patients with 
severe sepsis and septic shock which reverses with recovery from the initial infection. 
The induction of monocyte tolerance or hyporesponsiveness may represent a 
mechanism for modulating the inflammatory response during sepsis.
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3.7 Monophosphoryl lipid A stimulated up-regulation of 
nitric oxide synthase and nitric oxide release by human 
monocytes in vitro
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BH4  = tetrahydrobioptenn
DPBS = Dulbecco’s phosphate buffered saline
ETOH = ethyl alcohol
FAD = flavin adenine dinucleotide
FTTC = fluorescein isothiocyanite
FMN = flavin mononucleotide
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NADP = Nicotinamide adenine dinucleotide phosphate
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Abstract
Monophosphoryl lipid A (MPL) is a derivative of lipopolysaccharide (LPS) 
with reduced toxicity which has been shown to modulate various immune functions in 
monocytes. We examined whether human monocytes can be stimulated to produce 
nitric oxide (NO) and its inducible catalytic enzyme nitric oxide synthase (iNOS). 
Monocytes were stimulated with LPS or MPL and both iNOS and NO (as nitrite) 
production were measured. MPL at high doses (100 and 250 ug/ml) stimulated 
monocytes to release NO. NO release at 100 ug/ml MPL was significantly greater than 
both the control and LPS-treated monocytes (p<0.05). NO release by control cells and 
the LPS-treated cells was not significantly different. Both arginase and N-monomethyl 
arginine (NMLA) inhibited the MPL-stimulated release of NO (p<0.01). MPL 
significantly increased iNOS expression as measured by both fluorescent microscopy 
and flow cytometry (p<0.05). Similarly, both soluble iNOS (siNOS) and particulate 
iNOS (piNOS) activity were significantly up-regulated by MPL (p<0.05). Significant 
correlations were found between piNOS expression and siNOS release (r = .72, 
pcO.OOOl), and between 12-hr NO release and siNOS production (r = .44, p<0.005). 
These experiments confirm that human monocytes can be stimulated with MPL to 
produce NO in vitro and suggest that up-regulation of piNOS does not preclude NO 
release.
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1. Introduction
Monophosphoryl lipid A (MPL), a modified form of lipopolysaccharide (LPS), 
is less toxic than its parent molecule in humans and animals (Takayama et al., 1984).
In humans, MPL is less pyrogenic, demonstrates attenuated cytokine release and is 
generally less toxic than LPS (Rudbach et al., 1994; Astiz et al., 1995; Ulrich and 
Myers, 1995). LPS stimulation of nitric oxide (NO) release by animal cells and 
macrophages is well documented, but evidence of NO release by human monocytes is 
equivocal (Dennis, 1994; Dugas et al., 1995). A number of reports suggest that human 
monocytes can be stimulated to release a modest amount of NO (Hunt and Goldin,
1992; Kolb et al., 1994; Leibovich et al., 1994; Mautino et al., 1994; Pietraforte et al., 
1994) while others reported that these cells produce very little, if any, NO (Schneemann 
et al., 1993; Reiling et al., 1994; Weinberg et al., 1995; Konur et al., 1996). The 
majority of the above studies measured the NO release between 3-12 days of culture 
when the monocytes may have differentiated into macrophages (except Hunt and 
Goldin, 1992; Leibovich et al., 1994; Konur et al., 1996). Although, human 
monocytes co-cultured with transformed cells (DeTa cells) were shown to release 
significant amounts of NO (Zembala et al., 1994; Siedlar et al., 1995) these cell co­
cultured with RT4 carcinoma cells did not produce any NO (Konur et al., 1996).
A paradox also exists between inducible nitric oxide synthase (iNOS), a 
catalytic enzyme for NO synthesis, and NO release by these cells. Freshly prepared 
monocytes express constitutive nitric oxide synthase (cNOS) mRNA and can be
stimulated to express iNOS mRNA without subsequent release of NO2 '  (Reiling et al.,
1994). Recently, Weinberg et al., (1995) reported that despite the presence of iNOS 
and iNOS mRNA, human monocyte-derived macrophages released only small amounts 
of NO in response to LPS and interferon-y (IFN-y). In this study we examined the 
effects of LPS and MPL stimulation on NO release and the expression of iNOS by 
human monocytes in vitro.
2. Materials and methods
2 .1 Reagents and antibodies
All reagents were purchased from Sigma Chemical Co. (St. Louis, MO) unless 
otherwise indicated. MPL (Ribi Chemicals, Hamilton, MT) and LPS from Salmonella
minnesota Re 595 were dissolved in Ca2+- and Mg2+- free Dulbecco’s phosphate 
buffered saline (DPBS). Since MPL is poorly soluble in water, 2 ul triethylamine 
(TEA) per mg of MPL or LPS was used before adding DPBS. A soluble form of MPL 
(dissolved in ethyl alcohol) was also obtained (Ribi Chemicals). These toxins were 
sonicated at 37°C for 10 min before use in each experiment. Complete RPMI-1640 
medium (Gibco-BRL, Grand Island, NY) contained L-glutamine, 300 mg/dl; fetal calf 
serum (FCS, heat-inactivated), 10 ml/dl (Gibco BRL); and kanamycin 5 mg/dl. Griess
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reagent contained (per 100 ml): sulphanilamide, 1 gm; N-(napthyl) ethylene diamino 
dihydrochloride, 100 mg; phosphoric acid (H3PO4), 2.5 gms; distilled deionized water 
(DDH2O) to volume. Low endotoxin (< 6  pg/ml) water, FCS, culture medium and 
DPBS were used in all experiments. Fresh iNOS isolation buffer (10 mM K2HPO4 ,
pH 7.5) was prepared containing L-arginine, 0.5 mM; glycerol, 100 ul/ml; 
phenylmethylsulfonyl fluoride, 20 ug/ml; leupepdn, 1 ug/ml; pepstadn A, 5 ug/ml; 
aprotinin 5 ug/ml. Fluorescein isothiocyanite (FITC)-conjugated mouse anti­
macrophage iNOS monoclonal antibody (mAb) was purchased from Transduction 
Laboratories (Lexington, KY). Phycoerythiin (PE)-conjugated CD14 mAb and 
matching isotype IgGs were used as controls.
2.2 Monocyte isolation and culture
Mononuclear cells were isolated from buffy coats containing 70 ml citrate 
phosphate dextrose adenine-1 (CPDA-1) per 450-500 ml whole blood (New York 
Blood Bank, NY). Cells were obtained following a modified method of Boyum et al., 
(1983) within 6-7 hr of blood collection. Briefly, the blood was diluted 2.5 times with 
DPBS to which 400 ul 10% EDTA was added. Twenty-four ml of the diluted blood 
was layered over 12 ml of NycoPrep 1.077 (Gibco BRL) in 50 ml Falcon tubes and 
Centrifuged at 700 g and 21® C for 20 min. The mononuclear cells were harvested and 
washed once with DPBS (700 g, 8 min). The supernatant was discarded, the pellet 
resuspended in 30 ml DPBS and centrifuged again (160 g for 6  min) to remove the 
platelets. After the final wash, the pellet was resuspended in 25 ml complete RPMI. 
Cell concentration and viability were determined by trypan blue exclusion. The viability 
of the isolated cells was >98%. A differential count was done using either a Coulter 
counter (Microdiff, Model MD16, Coulter Corp., Miami, FL) or a CDC Hematology 
Systems (CDC Technologies, Oxford, CT).
Monocytes were obtained by incubating the mononuclear cells in 96-well tissue 
culture plates (Primaria, Baxter Scientific Products, Edison, NJ) for 2 hr at 37° C in 
5% CO2 . The plates were washed twice, first with prewarmed DPBS containing 5%
FCS followed by DPBS at room temperature. The identity of the adherent cells on 
replicate plates (after 18-hr incubation) was confirmed using either flow cytometry or 
microscopy. Cells were recovered using EDTA (0.2%) and cold shock (-70° C, 30 
sec) and stained with anti-CD 14 mAb (Immunotech, Westbrook, ME) or Wright- 
Geimsa stain (Baxter Scientific Products, Edison, NJ). Analyses with flow cytometry 
of representative samples showed >85% CD 14 positive cells and microscopy indicated 
the presence of >90% monocytes. Neutrophil contamination was approximately 2%. 
The trypan blue exclusion test showed >95% viability after 18 hr of culture.
The adherent monocytes were incubated (37° C, 5% CO2) in RPMI medium
with or without LPS or MPL for 18 hr. LPS or MPL doses between 0.01 and 100 
ug/ml were used in the first set of experiments. MPL doses up to 250 ug/ml were used 
to determine the effects of cell concentration on NO release in another set of
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experiments. In addition, monocytes were incubated for 18 hr with LPS and MPL (100 
ug/ml) with or without arginase (20 units/ml) and N-monomethyl L-arginine (NMLA, 
200 uM). Finally, monocytes were incubated for 12 hr for iNOS measurements either 
by enzymatic method, microscopy or by flow cytometry.
2 .3 NO measurements
At the end of the incubation period, supernatants were collected and their NO2",
a stable end product of NO metabolism, content was measured using previously 
described methods (Ding et al., 1988). Briefly, 100 ul of the sample was placed in a 
96-well ELISA plate and 100 ul of Griess reagent added. The plate was incubated for 
10 min at room temperature and the absorbance was read at 550 nm using a Bio-Tek 
ELISA plate reader (Model EL 311). The concentrations were calculated by 
interpolation from a standard curve made with sodium nitrite and was expressed as 
nmole (uM) per number of cells.
2.4 iNOS isolation and measurements
2.4.1 Enzymatic method:
iNOS was isolated and quantitated by modifications of the previously described 
methods (Forstermann et al., 1994; Hevel and Marietta, 1994). Briefly, 2.0 x 107 
mononuclear cells in 2  ml medium were added to tissue culture plates (65 x 15 mm; 
Primaria, Baxter Scientific, Edison, NJ) and the adherent cells were obtained as
described for NO2" assay. To these cells 100 ug/ml of LPS or MPL in RPMI was
added, and incubated for 12 hr as before. Following incubation, the monocytes were 
washed once with 2 ml DPBS then 1 ml of ice cold iNOS isolation buffer was added to 
each plate. The cells were homogenized for 30 seconds with a probe sonicator 
(Sonicator XL, Heat Systems, Farmingdale, NY) and subjected to three cycles of rapid 
freeze-thawing. The cell homogenates were centrifuged at 100,000 g (34,000 rpm) at
4° C for 60 min in an ultracentrifuge (Model L7, Beckman Instruments, Palo Alto,
CA).
One hundred microliter aliquots of the supernatant were placed in 1.5 ml 
Eppendorf tubes, (the remaining supernatant being discarded). The pellets were 
resuspended in 100 ul of the iNOS isolation buffer and quantitatively transferred to 
another set of Eppendorf tubes. Then the following reagents (10 ul each; expressed in 
final concentration) were added to the supernatants and pellets: p-NADPH, 1 mM; 
NADP, 0.25 mM; NaCl, 15 mM; tetrahydrobiopterin (BH4 ), 4 uM (ICN, Costa Mesa,
CA). The solutions were mixed and incubated for 30 min at room temperature. The
conversion of NO3" to NO2" was initiated by adding 20 ul of 600 m il nitrate reductase
and was terminated after a 30-min incubation at room temperature by adding 200 mU L- 
glutamate dehydrogenase, 100 mM NH4 CI and 4 mM freshly prepared oc-ketoglutarate
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(ICN, Costa Mesa, CA) (10 ul, final concentration). The mixture was incubated at 
room temperature for 10 min to eliminate any excess NADPH. Following the
incubation, NO2 '  was measured in the reaction mixture in duplicate as described
previously. Results were expressed as iNOS arbitrary units/1.0 x 106 monocytes. The 
calculation was. based on the assumption that one unit of iNOS converts one nmole of 
L-arginine to citrulline and NO per min.
2.4.2 Immunofluorescent microscopy jnethod
Cells were isolated and the cell concentrations were adjusted to 1.0 x 107 
cells/ml as before. Cells were adhered to cover slips (diameter, 18 mm) in 12-well 
tissue culture plates (diameter 22 mm) (Baxter Scientific) allowing monocytes to adhere 
both to cover slips and culture plates. The cover slips were prepared for tissue culture 
by immersing them in 95% ethyl alcohol for 2 days, washing five time with DPBS and 
then steam sterilizing. The cover slips were rinsed again with DPBS before using. One 
milliliter of the cell suspension was added to each well in which cover slips were placed 
and the adherent monocytes were obtained as described above. The monocytes were 
treated with MPL or LPS (100 ug/ml) and incubated for 12 hr as indicated earlier. 
Following the incubation period, the monocytes were washed once with DPBS and 
labeled with mouse anti-iNOS mAb-FITC using the suppliers protocol (Protocol # 9; 
Transduction Laboratories, Lexington, KY). In short, the monocytes were fixed by
adding 500 ul of methanohacetone (1:1) to each well and kept at -20° C for 10 min.
The fixing solution was discarded and the plate was air dried. Five hundred microliters 
of bovine serum albumin (BSA, 0.2% in DPBS) was added to each well containing the 
cover slips and incubated for 10 min at room temperature. After discarding the BSA, 
350 ul of anti-iNOS-FITC mAb (2.0 ug/ml, diluted in 0.2% BSA) was added to the
wells and incubated again for 45 min at 37° C. A matching isotype control was used in 
each experiment. The cells were washed for 5 minutes with DPBS, three times. 
CD14-PE mAb was added to monocytes along with iNOS-FTTC in some experiments. 
The cover slips were then removed from the wells (the monocytes in the wells were 
saved for flow cytometry) and placed on microscopic slides with 10  ul of mounting
media containing 0.1% p-phenylenediamine and 50% glycerol in DPBS. The
monocytes were observed under visible and fluorescent light at 400x magnification. An 
average of 150 cells were counted and results were reported as percentage ± SEM of 
positive cells.
2.43 Flow cytometry method
After recovering the cover slips the remaining cells in the wells were prepared 
for immunofluorescent staining; the DPBS was discarded and 0.5 ml of 
paraformaldehyde (0.5% in DPBS) was added to each well. The monocytes that 
remained in the wells were removed by scraping with cell scrapers (Baxter Scientific, 
Edison, NJ) and transferred to flow cytometry tubes. The data were acquired by a
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FACScan Research program and analyzed by using PcLysys software (Becton 
Dickinson, Mountainview, CA) following methods described previously (Loken et al., 
1990; Lin et al., 1993).
2 5  Data analyses and Statistics
Data were analyzed with the StatView statistical program using a Macintosh 
computer (Abacus Concepts, Inc., Berkeley, CA). A Two-way ANOVA was done to 
compare the over-all group and treatment effects. Fisher’s post hoc tests were done to 
determine the differences between individual treatments and doses. For experiments 
with small sample sizes, non-parametric Mann-Whitney or Kruskal-Wallis tests were 
performed. Regression analysis was performed to determine the relationship between 
iNOS and NO production. A value /?<0.05 was considered significant. Results are 
presented as mean ± standard error of mean (SEM).
3. Results
3.1 Effects o f LPS and MPL on NO release by monocytes
MPL at 100 ug/ml stimulated monocytes to release greater amounts of NO2"
(8.0 ± 0.3 uM) than either control (4.0 ± 0.4 uM) or LPS-stimulated cells (p<0.05). 
LPS did not stimulate monocytes to release NO (Fig. 1 A). Since NO3- and phenol red
may interfere with NO2" determination (Hevel and Marietta, 1994), we conducted the
same experiments in NO3" and phenol red-free medium. Both sets of experiments
showed similar results except that the overall production was slightly lower in the latter 
experiments, conceivably, due to the decreased background noise or lower number of 
cells (Fig. IB).
3.2 Effects o f cell concentrations on MPL stimulated NO release by monocytes
MPL-stimulated NO release was confirmed in a separate set of experiments with 
different doses of MPL and different cell concentrations. MPL-stimulated monocytes 
showed a significant dose- (pcO.OOl) and cell concentration- (p<0.001) dependent NO 
release (Fig. 2). Nitric oxide released by monocytes stimulated with 100 and 250 ug/ml 
MPL were significantly greater than unstimulated cells (p<0.005 and pcO.OOOl, 
respectively).
3.3 Inhibition of MPL stimulated NO release by NMLA and arginase in monocytes
Both NMLA and arginase inhibited MPL-TEA-stimulated release of NO 
(p<0.01 a n d <0.005, respectively) (Fig. 3A). TEA alone did not stimulate monocytes
to release significant amounts of NO (1.5 ± 0.6 uM/2.0 x 105 monocytes). In addition, 
the soluble form of MPL (MPL-ETOH) failed to stimulate the release of significant 
amounts of nitrite (Fig. 3B), demonstrating that the MPL-TEA combination was 
necessary to stimulate monocytes to release NO.
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Fig. 1. Effects of lipopolysaccharide (LPS) and monophosphoryl 
lipid A (MPL) on nitric oxide release by human monocytes in vitro. 
Culture plate-adherent monocytes in medium with (A) or without 
(B) nitrate and phenol red were incubated for 18 hr with the 
indicated amounts of LPS or MPL and nitrite (N02") content was 
measured in the supernatant (A, n = 6 ; B, n = 8 ). Data presented as 
means ± SEM. ^Control or LPS vs MPL (100 ug/ml), pcO.OOl.
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Fig. 2. Effects of cell concentrations on monophosphoryl lipid A 
(MPL)-stimulated nitric oxide release by human monocytes in vitro. 
Culture plate-adherent monocytes in RPMI medium without nitrate 
and phenol red were incubated for 18 hr with the indicated amounts 
of MPL, and nitrite content was measured in the supernatant (n = 8 ). 
Cell concentrations indicate number of monocytes/well. Data are 
presented as means ± SEM. Cell concentration effects, p<0.001; 
dose effects, control vs MPL (100 or 250 ug/ml), p<0.005.
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Fig. 3. Effects of n-monomethyl arginine (NMLA) and arginase on 
monophosphoryl lipid A (MPL)-stimulated nitric oxide release by 
human monocytes in vitro. Culture plate-adherent monocytes in 
nitrate and phenol red-free medium were incubated for 18 hr with 
(n = 5) or without (n = 7) NMLA and arginase. Nitrite content was 
measured in the supernatant and data are presented as means ± SEM. 
(A) MPL dissolved in triethylamine (TEA). (B) MPL dissolved in 
ethyl alcohol (ETOH). *MPL-TEA vs control or TEA, p<0.005;
** Control vs NMLA or arginase, p<0.01.
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3.4 Up-regulation o f iNOS by MPL in monocytes
Results obtained by fluorescent microscopy indicate that the percentage of 
iNOS-positive cells was increased significantly (p<0.05), both in MPL-TEA and MPL- 
ETOH-treated groups compared to control, TEA and LPS groups (Fig. 4A). The 
percentage of iNOS positive cells in ETOH treated cells did not significantly differ from 
the MPL groups. However, iNOS expression in these cells, when measured by flow 
cytometry as mean fluorescence (FLU), was found to be significantly up-regulated 
(p<0.05) only in the MPL-TEA-treated monocytes (Fig. 4B). These findings indicate a 
phenotypical and possibly functional polarization of monocytes following selective 
stimulation of NO pathways.
3 5  Up-regulation o f different forms o f iNOS by MPL and their functional correlation 
with NO release by monocytes
Expression of piNOS by MPL-TEA-treated monocytes (10.0+2.0 arbitrary 
units) was found to be significantly greater than the control (1 .6  ± 0.05 arbitrary units) 
or TEA- (3.9 ±2.1 arbitrary units) treated cells (p<0.05). Both LPS-TEA and MPL- 
ETOH groups expressed higher levels of piNOS than the control monocytes but they 
did not reach statistical significance (Fig. 5A). Although no significant overall group 
differences were found in siNOS release by monocytes, post hoc analysis of the data 
presented in Fig. 5B showed a significant difference between MPL-TEA and control 
monocytes (p<0.05). LPS -TEA-treated monocytes released a similar level of siNOS 
(9.6 ± 2.8 arbitrary units) as MPL-TEA (9.5 ± 2.2 arbitrary units) but LPS-TEA failed 
to reach statistical significance when compared to control.
NO release measured at 12 hr was elevated in the MPL-treated group (11.0 ±
3.9 uM/1.0 x 106 monocytes), however, it was not significantly different from either
control (4.1 ± 0.8 uM/1.0 x 106 monocytes) or LPS-treated cells (7.5 ± 2.2 uM/1.0 x
106 monocytes). Nevertheless, a significant correlation between siNOS and piNOS 
was found (r = .72, pcO.0001). A lack of correlation between 12-hr NO release and 
piNOS (data not shown), but a positive correlation with siNOS (r = .44, p<0.001), 
suggest that the piNOS may not be sufficiently active and iNOS must be released in a 
soluble form i.e., siNOS to efficiently activate the NO pathway.
4. Discussion
Nitric oxide acts as an important regulator of various functions including 
smooth muscle relaxation, neurotransmission and cell-mediated cytotoxicity. It is 
produced from an NADPH-dependent oxidation of L-arginine by NOS acting as the 
catalytic enzyme in which L-citrulline and NO are formed in equimolar amounts. In 
principle, the activity of NOS can be measured as the formation of NO (Billiar, 1995).
Since NOa" and NO3* are the stable end-products of NO metabolism, we measured 
NO2" to quantitate NO release. Here we report that human monocytes can be stimulated
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Fig. 4. Effects of lipopolysaccharide (LPS) and monophosphoryl lipid A 
(MPL) on inducible nitric oxide synthase (iNOS) expression by human 
monocytes in vitro. Adherent monocytes were incubated for 1 2  hr with the 
indicated agents and (A) percentages and (B) mean fluorescence of the 
iNOS positive cells were measured (n = 5). Data are presented as means ± 
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with MPL in vitro to express iNOS activity and release NO. We also found that lower 
cells concentrations showed higher levels of NO release (Fig. 2). The relatively greater 
amounts of NO release by small numbers of cells may indicate auto-regulation of NO 
release. This possibility is supported by earlier suggestions that NO itself may inhibit 
its own production (Mautino et al., 1994; Griffith and Stuehr, 1995; Griscavage et al., 
1995; Sheffler et al., 1995) possibly through binding to NOS (Wang et al., 1994; 
Griscavage et al., 1995). On the other hand, depletion of L-arginine by greater 
numbers of cells may decrease the NO release by limiting substrate availability 
(Vodovotz et al., 1994; Mautino et al., 1994).
The mechanism(s) by which MPL stimulates monocytes to release NO is not 
known. Artifacts in NO2" measurements may have resulted from TEA or MPL forming
an azo compound with Griess reagents. Lack of significant release of NO in response 
to TEA or MPL mitigates against this consideration (Fig. 3A). The data presented in 
these experiments suggest that MPL-stimulated NO release may be mediated through an 
endocytic mechanism. This hypothesis is supported by the observation that MPL forms 
micelles (or liposomes) with TEA, suspended in the liquid vehicle (Ulrich et al., 1988; 
Ulrich and Myers, 1995). Increased adjuvancy of liposomal MPL (Ulrich and Myers,
1995) and specific cytotoxic activity of mouse splenocytes by liposomes-entrapped- 
MPL (Zhou and Huang, 1993) has been documented. While LPS may also form 
micelles with TEA, it is possible that the micelles containing MPL are endocytosed by 
monocytes and this endocytic stimulation initiates the MPL-mediated NO release which 
is different from LPS. The observation that the soluble form of MPL-ETOH that does 
not form micelles did not stimulate NO release (Fig. 3B) supports this hypothesis.
MPL-stimulated release of NO in mouse peritoneal macrophages has been 
documented (Gustafson and Rhodes, 1992). It is possible that the NO release by 
monocytes is mediated through the up-regulation of HLA-DR. Siedlar et al., (1995) 
demonstrated that monocytes co-cultured with DeTa cells with anti-HLA-DR antibody 
significantly decreased DeTa cell-stimulated NO release by monocytes in vitro 
suggesting that HLA-DR molecules are engaged in the regulation of NO production.
Our previous findings that MPL up-regulates the HLA-DR expression in a dose- 
dependent manner as compared to LPS agree with this report (Saha et al., 1995).
Both indirect and direct evidence of LPS-stimulated NO release in human 
monocytes have been reported (Hunt and Goldin, 1992; Leibovich et al., 1994; Zinetti 
et al., 1995), however, these authors used different sources of LPS than that used in 
the present study. Recently, Rittig et al., (1995) reported that human monocytes 
incubated for at least 36 hr with LPS or Borrelia bugdorferi increased NO production 
by 4-fold. By contrast, others have not been able to detect significant NO release in 
LPS-stimulated monocytes (James et al., 1990; Schneemann et al., 1993; De Maria et 
al., 1994; Zembala et al., 1994; Weinberg et al., 1995). Schneemann et al. (1993) used 
48-hr culture supernatants of monocytes stimulated with LPS and IFN-y whereas 
Weinberg et al. (1995) used 13 different stimulants including LPS, cytokines, phorbol 
esters and concanavalin A for 3-4 days both with or without BH4 . Although Zembala
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et al. (1994) could not detect NO2" release in 36-hr supernatant in response to LPS,
TNF and IFN-y, NO2" was released when the monocytes were co-cultured with human
colorectal carcinoma cell line, DeTa cells. Similar to these last studies, we were not 
able to demonstrate any significant release of NO following LPS stimulation.
NO synthesis is mediated through up-regulation of NOS. In this pathway L- 
arginine, molecular O2 and NADPH are co-substrates; flavin mononucleotide (FMN), 
flavin adenine dinucleotide (FAD), heme and BH4 are cofactors; and NO and citrulline 
are co-products. This reaction is catalyzed by NOS (Nathan, 1992). Three forms of 
NOS have been identified and isolated; constitutive NOS (cNOS) from epithelium, 
cNOS from central nervous system and iNOS from monocytes/macrophages. These 
represented the products of three separate genes on distinct chromosomes. LPS and 
cytokines induce iNOS and iNOS mRNA in monocytes (Reiling et al., 1994; Dugas et 
al., 1995; Griffith and Stuehr, 1995; Weinberg et al., 1995). iNOS mRNA was 
detected by reverse transcriptase-polymerase chain reaction (RT-PCR) (Reiling et al., 
1994; Weinberg et al., 1995) but Weinberg et al., (1995) could not detect it by northern 
analysis or RNAse protection assay. In our study, we did not find significant up- 
regulation of iNOS by LPS as measured by fluorescent microscopy or flow cytometry. 
On the other hand, both MPL-ETOH and MPL-TEA increased the number of iNOS 
positive cells, demonstrating MPL’s ability to stimulate monocyte NO pathway. The 
inability of the monocytes to release significant amounts of NO despite the presence of 
increased amounts of iNOS led us to examine the phenotypical and functional 
correlations of iNOS expression and NO release in these cells.
MPL-TEA-stimulated cells were found to produce increased amounts of iNOS 
(both piNOS and siNOS) confirming that MPL-TEA up-regulates monocyte iNOS 
expression. TEA-induced piNOS was not significantly different from control but 
differed from MPL-TEA suggesting that the MPL-TEA combination is required for 
significant NO release. This observation was further supported by the findings that 
iNOS expression in these cells, as measured by flow cytometry, significantly increased 
only in the MPL-TEA group (Fig. 4B).
MPL-ETOH-induced iNOS expression was also found both by increased 
percentages of iNOS positive cells (fluorescent microscopy) and increased conversion
of NO3" to NO2" in the presence of exogenous substrates and cofactors (enzymatic
method), whereas LPS-induced iNOS expression was found only by the enzymatic 
method. However, increased mean fluorescence in the MPL-TEA group by these 
methods as well as by flow cytometry indicates a phenotypic polarization of the 
monocytes following MPL-TEA stimulation. This can be supported by the fact that 
some MPL-TEA treated cells exhibited a dual population when analyzed for iNOS 
expression (data not shown). Increased percentages of positive cells but lower mean 
fluorescence in the MPL-ETOH group further substantiates this postulation. It is 
possible that a significant number of stimulated monocytes express very low levels of 
this enzyme but only the selective high expressors produce NO.
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As evidenced in our study, up-regulàtion of iNOS itself does not necessarily 
result in increased NO release. LPS stimulated up-regulation of iNOS without a 
corresponding increase in NO release has been previously documented in human 
monocytes (Reiling et ah, 1994; Weinberg et al., 1995; for review see Denis, 1994). 
Several possible mechanisms have been suggested; presence of inhibitors, appearance 
of non-functional enzymes and lack of cofactors. Since the presence of inhibitors could 
not be detected, appearance of a non-functional enzyme or a lack of a cofactor was 
suggested to explain this phenomenon (Weinberg et al., 1995). The apparent oxidation 
of cofactors such as FAD, FMN, NADPH, BH4 and glutathione was previously
indicated by others (Rogers and Ignarro, 1992; Assreuy et al., 1993). It is possible that 
ETOH or LPS makes one or more of the necessary cofactor(s) unavailable to elicit the 
NO pathway. In mouse macrophages NOS is inactivated by prolonged incubation with 
LPS and IFN-y (Vodovotz et al., 1994). The presence of endogenous inhibitors of 
iNOS or translocation of the enzyme leading to inactivation rather than blocking of the 
necessary cofactors was suggested.
NOS may exist as a soluble enzyme (specially iNOS) or in a sedimentable or 
particulate form (Nathan, 1992; Griffith and Stuehr, 1995). We found iNOS activity in 
both forms; however, our preparations were from crude homogenates of human 
monocytes whereas others purified the enzyme either from macrophages or from other 
species (Denis, 1991; Nathan, 1992). To examine the physiological relationship 
between piNOS and siNOS, we measured NO release by monocytes at 12 hr. Despite 
significant expression of iNOS in MPL-TEA-treated cells at 12 hr, we could not detect 
significant amounts of NO in the supernatant. This finding is consistent with the earlier 
reports that up-regulation of NOS is an earlier event and a longer time is required for 
appreciable accumulation of NO in the supernatant (Martin and Edward, 1993; Mautino 
et al., 1994; Reiling et al., 1994; Rittig et al., 1995). The lack of correlation between 
piNOS and NO release and its strong positive correlation with siNOS suggests that 
piNOS in human monocytes may be inactive or insufficiently active to produce large 
amounts of NO. It is also possible that piNOS must be converted to an active form or 
be released as a soluble form to activate the NO metabolism pathway.
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ABSTRACT
Exposure to endotoxin produces a state of macrophage hyporesponsiveness on 
subsequent stimulation. Monocytes from patients with septic shock demonstrate a 
similar hyporesponsiveness to endotoxin. The purpose of this study was to examine 
whether this state of hyporesponsiveness extends to other inflammatory stimuli, and the 
relationship of this stage to cell surface receptor expression and the release of anti­
inflammatory cytokines. Twelve normal subjects, 10 patients with severe sepsis, and 9 
patients with septic shock were included in the study. Monocytes from each subject 
were isolated and stimulated with lipopolysaccharide (LPS), staphylococcal enterotoxin 
B (SEE) and phorbol myristate acetate (PMA). Tumor necrosis factor-a (TNF-a) and 
interleukin-1(3 (IL-1(3) were measured in the supernatants by enzyme-linked 
immunosorbant assay (ELISA). Serum levels of transforming growth factor-pl (TGF- 
(31), prostaglandin E^ (PGE2), and interleukin-10 (IL-10) were also measured by
ELISA. Expression of monocyte CD 14 and HLA-DR in whole blood were measured 
by flow cytometry. Patients with septic shock demonstrated significantly decreased 
TNF-a and IL-1J3 release as compared with normal subjects in response to LPS. In 
response to SEE, patients with severe sepsis and patients with septic shock 
demonstrated significantly decreased release of TNF-a and IL-1(3. Significant 
decreases in TNF-a release were found in the patients with septic shock after PMA 
stimulation. There were no significant differences in the monocyte response to the 
different stimuli between patients with gram-positive sepsis and gram-negative sepsis. 
HLA-DR expression was significantly decreased in patients with septic shock (58 ± 9 
fluorescence unit; FU), as compared with normal subjects (102 ± 14 FU) (p< 0.05). 
No differences in CD 14 expression were observed. IL-10 levels were significantly 
increased in patients with severe sepsis (16 ± 4  pg/ml) and in patients with septic shock 
(42 ± 15 pg/ml) and were detectable in 1 normal subject. TGF-(31 levels were 
decreased in patients with septic shock (25 ± 6  pg/ml) as compared to those in normal 
subjects (37 ± 2 pg/ml) (p<0.05). PGE2 levels were significantly increased in patients 
with severe sepsis and patients with septic shock. These data are consistent with a 
more generalized monocyte hyporesponsiveness to bacterial toxins that may be related 
to altered cell surface receptor expression and the release of anti-inflammatory 
cytokines.
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INTRODUCTION
Exposure to endotoxin produces a state of hyporesponsiveness on subsequent 
exposure. In vitro studies in isolated monocytes and in vivo studies in normal subjects 
demonstrate an attenuated cytokine response on successive exposures (1-3). This state 
has been termed endotoxin tolerance and is classically described as being specific for 
endotoxin (1,2). Monocytes isolated from patients with gram-negative sepsis respond 
to endotoxin with a similar attenuated release of cytokines that is postulated to represent 
a form of early endotoxin tolerance (4-6).
Interleukin-10 (IL-10), transforming growth factor-pl (TGF-pl) and prosta­
glandin E2 (PGE2) appear to play a role in endotoxin tolerance (6 -8 ). These substances
are released in a variety of infections, including gram-positive and gram-negative 
sepsis, and play an important role in modulating the inflammatory response to infection 
(9-11). Each of these mediators has the capacity to down-regulate macrophage function 
and attenuate macrophage responsiveness to a broad range of stimuli (7 ,8 ).
The purpose of this study was to examine whether in patients with severe sepsis 
and septic shock attenuated monocyte responsiveness, in patients, was associated with 
the release of anti-inflammatory substances and involved other stimuli of monocyte 
cytokine release in addition to endotoxin. The influence of the underlying organism on 
the induction of monocyte hyporesponsiveness and the role of altered surface receptor 
expression was also examined.
METHODS
The study was approved by the Institutional Research Board (IRB) of Saint 
Vincents Hospital and Medical Center of New York and was carried out according to its 
protocol. Informed consent was obtained from all participating subjects or their 
surrogates. The study consisted of three groups of subjects. The first group included 
1 2  normal control subjects, the second group included 1 0  patients with severe sepsis, 
and the third group included 9 patients with septic shock. Severe sepsis was defined by 
an identifiable site of infection and evidence of a systemic inflammatory response as
manifested by three of the following parameters: (1) temperature > 38° C or < 30° C; 
(2) heart rate > 90 beats/min; (3) respiratory rate > 20 breaths/min; and (4) a white cell 
count > 12,000/mm3 or < 4,000/mm3. Evidence of systemic hypoperfusion consisted 
of an elevated arterial lactate level, oliguria or altered mental status. Septic shock was 
defined as a sepsis-induced systolic blood pressure < 90 mm Hg persisting despite fluid 
resuscitation requiring vasopressor therapy (12). All patients were entered into the 
study within 24 hours of meeting these criteria. Patients or subjects taking steroids, 
immunosuppressive agents, or nonsteroidal anti-inflammatory agents were excluded.
All reagents were purchased from Sigma Chemical Co., St. Louis, MO, unless
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otherwise indicated. Lipopolysaccharide (LPS) from Salmonella minnesota Re 595 
and staphylococcal enterotoxin B (SEB) were dissolved in phosphate buffered saline
(PBS). Stock solutions of LPS and SEB were kept at 8 ° C. Phorbol 12-myristate 13- 
acetate (PMA) was dissolved in ethyl alcohol (95%) in a stock solution of 1 mmole/L 
and kept at -70° C .
Mononuclear cells were isolated from 30 ml of freshly drawn venous blood in 
Vacutainer tubes (Scientific Products, Edison, NJ) containing 1.5 ml adenine-citrate- 
dextrose solution. Monocytes were isolated from the blood following a modified
method of Boyum (13). The blood was diluted with Ca2+- and Mg2+-free Dulbecco’s
phosphate-buffered saline (DPBS) (Gibco- BRL, Grand Island, NY). A 24 ml sample 
of the diluted blood was layered over 12 ml of NycoPrep (Gibco-BRL) and centrifuged
at 700 g and 21° C for 20 minutes. The white buffy layer (mononuclear cells) between 
the NycoPrep and the fluid layer was obtained, and the cells were washed once with 
DPBS by centrifuging the tube for 8  minutes at 700 g at 21° C. The supernatant was 
discarded, and the pellet was resuspended in 30 ml DPBS and centrifuged again at 160 
g. After the final wash, the supernatant was discarded and the pellet resuspended in 
RPMI medium containing 30 mg/ml L-glutamine; 10 ml/dl fetal calf serum, (Gibco- 
BRL); and 5 mg/dl kanamycin. Cell concentration and viability was determined by 
trypan blue dye exclusion method. A differential count was done using an automated 
cell counter (Microdiff, model MD16, Coulter Corp., Miami, FL) and the cell
concentration was adjusted to 4 x 105 monocytes/ml.
Culture-plate-adherent monocytes were obtained by following standard 
methods. A 200 ul sample ml of cell suspension was plated in Falcon 96-well, flat-
bottomed tissue culture plates (Scientific Products). The plates were incubated at 37° C 
with 5% CO2 for 2 hours. At the end of the incubation period the plates were washed
two times. The adherent monocytes (8  x IfrVwell) were incubated for 18 hours in 
either DPBS, 1 ug/ml LPS, 25 nmol/L PMA, or 1 ug/ml SEB. The supernatant was 
recovered and stored at -70° C for cytokine analysis. PMA and LPS were included the 
entire 12 subjects, 10 patients with severe sepsis and 9 patients with septic shock. SEB 
was added later in the experiment and included 8 normal subjects, 6  patients with severe 
sepsis and 5 patients with septic shock.
In a separate set of experiments, we confirmed the identity of the remaining cells 
adhered to the plate by using flow cytometry. Cells were retrieved by using ethylene 
diamine tetraacetic acid (EDTA) and cold shock. Flow cytometry analysis consistently 
showed > 90% purity, and trypan blue exclusion tests showed an average > 98% 
viability. The identity of the remaining 10% of cells was not determined. However, 
because 70% to 90% of monocytes express CD 14, it is most likely that those represent 
CD 14 negative monocytes (14).
All cytokines were assayed by using commercial ELISA kits. All samples were 
diluted by using the appropriate diluent, and the concentrations were calculated from
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standard absorbances by best fitting binomial regression curves with the StatView 
statistical and graphics program (Abacus Concepts, Inc., Berkeley, CA) on a Macintosh 
computer. Interleukin-Ip (IL-ip) was assayed with the IL-ip ELISA kit (Quantikine 
human IL-ip, R & D systems, Minneapolis, MN). The sensitivity and limit of this 
assay were 0.3 pg/ml and 250 pg/ml, respectively. Serum IL-10 was assayed with a 
specific IL-10 antibody-precoated solid-phase sandwich ELISA (Cytoscreen IL-10 kit, 
BioSource, Camarillo, CA). The sensitivity and limit of the assay were 5.0 pg/ml and 
500 pg/ml, respectively. Tumor necrosis factor a  (TNF-a) was assayed by using 
human TNF-a ELISA kits (Cytoscreen hTNFa, BioSource). The sensitivity and limit 
of the assay were 1.0 pg/ml and 1000 pg/ml, respectively. Total activated TGF-pl was 
assayed after acidification of the serum with a commercial ELISA kit following the 
standard protocol (R & D Systems) (15). In the absence of acidification, TGF-pl levels 
were undetectable. The sensitivity and the limit of the assay were 5 pg/ml and 2000 
pg/ml, respectively. PGE2 was measured with a commercial EIA kit (TiterZyme PGE2
EIA kit, PerSeptive Diagnostics, Cambridge, MA). The sensitivity and limit of the 
assay were 1.5 pg/ml and 5000 pg/ml, respectively.
Cell surface receptor expression was assessed by flow cytometry with fluo- 
rescinated monoclonal antibody. All monoclonal antibodies were conjugated with either 
phycoerythrin or fluorescein isothiocyanate and were purchased from Immunotech 
International, Westbrook, ME. The cells were analyzed by using a flow cytometer 
(FACScan; Becton Dickinson, Mountainview, CA). The acquisition was performed 
using the Consort 30 program (Becton Dickinson). Five thousand cells were acquired 
from each sample and analyzed (PCLYSIS, Becton Dickinson). The first gate was set 
on monocytes in dot plots by using FSC and SSC characteristics. The CD 14-positive 
cells were identified by observing the FL2-labeled cells. The second gate was set to
include >99% CD 14 positive cells. The mean fluorescence of the cells expressing 
HLA-DR was then obtained as arbitrary fluorescence units (FU) in linear scale (16,17).
Two-way analysis of variance (ANOVA) was done to compare the overall 
group and treatment effects. Because of the non-uniform distribution of the data, non- 
parametric tests were performed. Kruskal-Wallis test was used for overall group and 
treatment effects, and Mann-Whitney U test was used for paired analysis. The data 
were also analyzed by ANOVA after log transformation. Undetectable samples were 
assigned the lowest sensitivity value of the specific assay. Linear regression analysis 
was used to examine relationships between variables. A value of p<0.05 was con­
sidered significant. Results are presented as mean ± standard error of mean (SEM).
RESULTS
The mortality was 50% in the patients with severe sepsis and 77% in the group 
of patients with septic shock whereas APACHE II scores were 26 ± 3  and 32 + 3, 
respectively. Of the infected patients 7 had gram-negative infections, 7 had gram- 
positive infections, 4 had mixed infections and 1 had a presumed viral infection.
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Unstimulated monocytes from patients with severe sepsis and septic shock 
displayed significantly lower levels of cytokine release than did normal subjects (Table I 
and II). The release of TNF-a and IL-lp in response to LPS was significantly 
decreased in the septic shock patients as compared with that in normal subjects (Tables I 
and H). Both in patients with severe sepsis and in patients with septic shock, decreased 
release of TNF-a and IL-lp in response to SEB was observed (Tables I and II). After 
stimulation with PMA, significant decreases were observed solely in TNF-a release in 
patients with septic shock (Table I).
Monocyte HLA-DR expression was decreased both in patients with severe 
sepsis (76 ± 12 FU, p< 0.06) and in patients with septic shock (58 ± 9 FU, p< 0.05) 
as compared with that in normal subjects (102 ± 14 FU). There were no significant 
differences in monocyte CD 14 expression in patients with severe sepsis (143 ± 27 FU) 
and septic shock (140 ± 26 FU), as compared with normal subjects (158 ± 25 FU).
IL-10 was detectable in a single normal subject. Six of 10 patients with severe 
sepsis had detectable levels of 16 ± 4  pg/ml (p< 0.01) (Table III). Seven of 9 patients 
with septic shock had detectable levels of 42 ± 15 pg ml (p<0.01). PGE2 levels were
significantly increased in both groups of infected patients (Table III). Levels of TGF- 
pi were significantly decreased in the patients with septic shock (25 ± 6  pg/ml; p<0.05) 
as compared with levels in normal subjects (37 ± 2 pg/ml) (Table HI).
HLA-DR expression was not significantly correlated with individual measure­
ments of IL-10, TGF-pl, and PGE2 . Similarly, the release of individual cytokines after
incubation with SEB, LPS, and PMA was not directly correlated with serum IL-10, 
TGF-pl, and PGE2 levels.
To examine the influence of the infecting organisms on the monocyte response 
to different stimuli, subsets of patients with severe sepsis and septic shock were 
analyzed as a single group with regard to gram-positive or gram-negative infection. 
Monocytes from patients with gram-positive sepsis and those with gram-negative sepsis 
demonstrated a similar response to stimulation, although there was a tendency to lower 
values in monocytes from patients with gram-positive sepsis (Table IV).
D ISCU SSIO N
Our data are consistent with earlier reports that demonstrate monocyte 
hyporesponsiveness and decreased cytokine release in response to LPS in patients with 
sepsis (4-6). The decrease in monocyte response appears to correlate with the severity 
of sepsis and is most pronounced in patients with septic shock. In patients surviving 
sepsis, a normal monocyte response to LPS is observed on recovery (4). Previous 
studies have suggested that monocyte hyporesponsiveness during sepsis may represent 
a manifestation of endotoxin tolerance (6 ). The primary mechanism underlying the 
decreased responsiveness in both septic and endotoxin-tolerant cells appears to involve 
decreased transcriptional activity as evidenced by decreased cytokine mRNA production
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Table I. TNFa release in vitro
Normal Severe Sepsis Septic Shock
Treatment
Control 56 ±30 1 0 ± 3 f 8 ± 2 f,
LPS 839 ±119 583 ±186 295 ± 90 f *
SEB# 309 ±110 34 ± 12 f  ,* 1 2  ± 6  t ,  *
PMA 370 ±94 371 ±157 262 ± 1 2  t
TNFa release (pg/ml) in monocytes from 12 normal subjects, 10 patients with severe 
sepsis and 9 patients with septic shock. Cells were incubated without (control) or with 
LPS (1 ug/ml), SEB (1 ug/ml) and PMA (25 nmol/L). # SEB includes 8 normal 
subjects, 6  patients with severe sepsis and 5 patients with septic shock. Results 
indicate mean ± SEM. *p<0.05 versus normal subjects; t  p<0.05 versus normal 
subjects after log transformation.
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Table IL IL-Ip release in vitro
Normal Severe Sepsis Septic Shock
Treatment
Control 31 ±13 16± 6 5 ± 3 t
LPS 662 ± 97 481 ± 183 335± 134t
SEE # 306 ±158 17 ± 6  f , * 7 ± 4 f *
PMA 270± 162 133 ±51 158 ± 102
IL-lp release (pg/ml) in monocytes from 12 normal subjects, 10 patients with severe 
sepsis and 9 patients with septic shock. Cells were incubated without (control) or with 
LPS (1 ug/ml), SEE (1 ug/ml) and PMA (25 nmol/L). # SEE includes 8  normal 
subjects, 6  patients with severe sepsis and 5 patients with septic shock. Results 
indicate mean ± SEM. *p<0.05 versus normal subjects; t  p<0.05 versus normal 
subjects after log transformation.
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Table III. Serum levels of interleukin-10 (1L-10), prostaglandin E2 (PGE2) and 
transforming growth factor (3 (TGF-pl)
IL-10 p g e 2 TGF-pl
(pg/ml) (pg/ml) (pg/ml)
Normal UD (#) 119 ±39 37 ± 2
Severe Sepsis 16 ± 4*t 1443 ± 807*f 30 ± 5
Septic Shock 42 ±15*f 410 ± 89f 25 ± 6 *t
Serum levels of IL-10, PGE2 and TGFpl in 12 normal subjects, 10 patients with severe
sepsis and 9 patients with septic shock.
Values are expressed as mean ± SEM.
(#) Undetectable, one normal subject had a low detectable level (see text).
*p<0.05 versus normal subjects, 
t  p<0.05 after log transformation.
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Table IV. Response of isolated monocytes in vitro from patients with gram-positive 
sepsis and gram-negative sepsis to different stimuli
TNFoc (pg/ml) IL-lp (pg/ml)
Gram (+) Gram (-) Gram (+) Gram (-)
LPS 302 + 207 478 ±175 300 ±243 481 ± 147
SEE 11 ± 5  43 ±19  9 ± 4  23 ±13
PMA 75 ± 3  391 ±182 91 ±47 218 ±134
Monocytes were isolated from 7 patients with gram-positive sepsis and 7 patients with 
gram-negative sepsis and then the cells were incubated for 18 hr with 1 ug/ml LPS,
1 ug/ml SEE or 25 nmol/L PMA.
Values are expressed as mean ± SEM.
No significant difference was found.
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(2,5,11,18). Post-translational changes may play a role, although these alterations have 
been described less frequently (19).
Endotoxin tolerance is classically described as resistance to LPS resulting from 
a recent prior exposure to LPS and does not include resistance to gram-positive 
organisms or gram-positive toxins (1,2). Indeed, Munoz et al. (4) found that 
monocytes from patients with gram-negative sepsis demonstrated a significantly 
attenuated response to LPS as compared with monocytes from patients with gram- 
positive sepsis. In our study, patients with gram-positive sepsis and patients with 
gram-negative sepsis both seemed to develop similar degrees of hyporesponsiveness to 
LPS and SEE stimulation. These observations are consistent with recent reports 
suggesting that exposure to LPS or gram-positive toxins results in a more generalized 
hyporesponsiveness to bacterial toxins. Astiz et al. (20) observed that exposure to an 
analog of lipid A resulted in resistance to gram-positive toxins, and Granowitz et al. (3) 
found that the monocytes in patients rendered tolerant to endotoxin demonstrated 
attenuated cytokine release in response to the superantigen toxic shock toxin. McCall et 
al. (18) reported that neutrophils from patients with a diverse group of infections were 
resistant to LPS stimulation, whereas Card et al. (21) observed that lipoteichoic acids 
from gram-positive bacteria desensitized monocytes to LPS stimulation.
The hyporesponsiveness to LPS and SEE both in patients with gram-negative 
sepsis and in patients with gram-positive sepsis probably reflects the release of similar 
monocyte inhibitory substances during their infection. This would be consistent with 
the comparable pattern of pro-inflammatory cytokine release seen in both groups of 
patients (22,23). IL-10, PGE2 , and TGF-pl are released by a variety of infecting
organisms and regulate the monocyte response to various stimuli (8,24,25). Decreases 
in HLA-DR expression that were present both in patients with severe sepsis and in 
patients with septic shock may have also contributed to the decreased response to SEE. 
The activation of isolated monocytes by SEE requires binding to the HLA-DR receptor 
and can be inhibited by antibodies to HLA-DR (26,27).
In contrast to results with SEE and LPS, cytokine release in response to PMA 
was less affected. In vitro studies suggest that cells that are hyporesponsive to LPS and 
gram-positive toxins may retain their responsiveness to PMA. Matic et al. (28) 
observed that PMA maintained the ability to trigger TNF-oc release in LPS tolerant 
macrophages. Similarly, Card et al. (21) reported that murine macrophages that were 
resistant to LPS and lipoteichoic acid stimulation responded to PMA. The differences 
in the response to PMA may be related to the fact that PMA directly activates monocyte 
protein kinase C, in contrast to the receptor dependent mechanisms that are required for 
monocyte activation by LPS and SEE (29).
The expression of class II major histocompatibility antigens is required for 
monocytes to act as accessory cells and present antigen to lymphocytes (30). HLA-DR 
expression was significantly decreased both in patients with severe sepsis and in those 
with septic shock. IL-10 and PGE2, which were both elevated in patients with severe
sepsis and patients with septic shock, may have contributed to the decreased HLA-DR 
expression (31,32). Experimental studies suggest that decreases in HLA-DR
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expression during sepsis may also result in impaired antigen presentation and 
immunocompetance (33). In patients with multiple trauma, decreases in HLA-DR have 
been associated with a greater risk for developing sepsis and a higher mortality rate 
(34,35)/
Significant decreases in monocyte CD 14 expression were not observed in this 
study. Decreases in monocyte CD 14 expression have been observed in other studies 
during sepsis, and these decreases could possibly be related to shedding of this receptor 
(36,37). Although CD 14 is involved in LPS activation by serving as a receptor for the 
LPS-LPS binding protein complex, altered receptor expression has not been linked with 
monocyte hyporesponsiveness in endotoxin tolerant subjects (9). Similarly, McCall et 
al. (18) found that CD 14 expression was not altered in neutrophils from patients with 
sepsis that were tolerant to endotoxin stimulation.
During monocyte activation, substances which subsequently inhibit monocyte 
activity are released at the same time that proinflammatory mediators are being 
generated. These substances serve to modulate monocyte activity and the inflammatory 
response. IL-10, PGE2 and TGF-pl decrease monocyte activation by a wide range of
stimuli and also decrease monocyte HLA-DR expression (7,8,32,38,39). IL-10 levels 
vary widely in sepsis and are most frequently measurable in patients with septic shock, 
as demonstrated in this study (9,10). PGE2 levels increase in experimental sepsis and 
are presumed to contribute to immunologic abnormalities during bums and traumatic 
injury (11,40). Incidentally, the highest PGE2  levels we observed were in patients
with severe sepsis and traumatic injury. Either in combination or alone, IL-10, PGE2
and TGF-pl attenuate cytokine release after LPS stimulation resulting in a pattern of 
hyporesponsiveness similar to endotoxin tolerance (6,7,32,39). The failure to find 
significant correlations between serum levels of these cytokines and either HLA-DR 
expression or in vitro cytokine release probably reflects the complex interplay between 
these and other anti-inflammatory substances.
TGF-pl levels appeared to decrease in proportion to the degree of the septic 
state. This decrease was not expected because monocyte activation is associated with 
increased release of TGF-pl (41). This pattern contrasts with those of other cytokines 
that are usually elevated in septic shock (22,23). TGF-pl exists in active and latent 
forms; the latter is the primary form present in cells. Acidification converts latent TGF- 
pi to its active form, thereby facilitating measurement of TGF-pl (15). In our study, 
TGF-pl levels were undetectable in plasma that was not acidified, whereas total levels 
were decreased. Weinsch et al. (25) reported similar observations when using the same 
assay in patients with malaria, in whom they found that total TGF-pl levels were 
significantly decreased during acute illness and normalized with recovery. lunger et al. 
(42), using a different ELISA, reported that during experimental sepsis, active TGF-pl 
levels increased while total TGF-pl decreased, suggesting increased conversion of 
latent TGF-pl. Whether the decrease we observed in TGF-pl reflects decreased 
production, increased consumption, or tissue accumulation cannot be determined from 
this study.
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The combination of increased release of anti-inflammatory mediators, decreased 
surface receptor expression, and altered monocyte responsiveness suggests that 
monocyte function is being altered in a manner to attenuate the severity of the 
inflammatory syndrome during severe sepsis arid septic shock. Although these changes 
may initially be of benefit in moderating the degree of inflammation, persistence of 
decreased HLA-DR expression and monocyte responsiveness to LPS has been 
associated with an increased mortality rate (4,34). It is not clear whether these 
observations reflect the underlying severity of the initial septic state and its sequelae, or 
complications related to an altered immune response associated with these changes in 
monocyte function.
In conclusion, sepsis is associated with monocyte hyporesponsiveness to LPS 
and gram-positive toxins. This hyporesponsiveness appears to be proportional to the 
severity of sepsis and may be related, in the case of the superantigens, to the decreased 
expression of surface receptors. The release of anti-inflammatory cytokines during 
septic shock probably contributes to these alterations in monocyte function.
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DISCUSSION
The present studies examined two general issues: a), comparison of the effects 
of LPS and MPL on a number of monocyte activities and b). development of tolerance 
to certain activities in monocytes by LPS and MPL in vitro or in sepsis and septic shock 
in vivo. It has been a general consensus that MPL is less toxic compared to LPS, both 
in vitro or in vivo (Takayama et al., 1984; Rudbach et al., 1994; Takayama et a l, 1994; 
Astiz et al., 1995; Ulrich and Myers, 1995). However, the degree of MPL toxicity 
varies widely, depending upon its extraction method, relative structure of the molecule, 
vehicle in v/hich the substance is suspended or dissolved, mode and method of 
administration, the models used and the type of LPS it has been compared with (Ribi et 
al, 1982; Qureshi, Takayama and Ribi, 1982; Takayama et al., 1984,1984a; Brade et 
al., 1987; Rudbach et al., 1994; Jahr et al., 1995; Ulrich and Myers, 1995; Astiz et al.,
1995). Most of the animal studies reported to date concentrated on mortality, 
cardiopulmonary parameters, cytokine release in vivo and in vitro (Rackow et al.,
1989; Carpati et al., 1992; Fahmi and Chaby, 1993; Astiz et al., 1989,1991,1993, 
1994; Gustafson and Rhodes, 1992, 1994; Chen, Solem and Johnson, 1991;
Henricson et al., 1992; Gustafson, Rhodes and Hegel, 1995). A few authors examined 
the effects of MPL on phagocytosis, and ROIs and NO release in animal cells in vitro 
(Henricson et al., 1993; Ribi and Takayama, 1985). Human studies are mainly 
restricted to relative pyrogenicity, cardiopulmonary parameters and cytokine release in 
vivo (Vosika, Barr and Gilbertson, 1984; Johnston and Greisman, 1985; Astiz et al., 
1995; Rudbach et al., 1995), and cytokine release and bactericidal activity in vitro 
(Rudbach et al., 1995; Carozzi et a/., 1989). Although a considerable amount of work 
with different forms of detoxified LPS or related structures has been reported in vitro 
with animals and human cells, a comprehensive, comparative study of LPS and MPL 
has not been published. Since LPS is the major contributor of sepsis and septic shock, 
the present study examined the effects of LPS and MPL on a number of areas involved 
in acute inflammation pertaining to these ailments. In addition, the detoxified nature of 
MPL has been shown to be beneficial in protecting animals and humans from the lethal 
effects of LPS, sepsis and septic shock (Astiz et al., 1993; Henricson, Benjamin and 
Vogel, 1990; Rackow et a l, 1989; Astiz et al., 1989; Astiz et a l, 1994; Rudbach et a l, 
1993,1994; Astiz et a l, 1995) mediated through a mechanism generally known as 
tolerance or hyporesponsiveness (Greismati and Homick, 1973; Sullivan et a l, 1983; 
Rietschel et a l, 1982; Johnston and Greisman, 1985; Viera et a l, 1989). These studies 
also compared the development of hyporesponsiveness induced by LPS and MPL to 
certain stimuli including LPS. It has been widely accepted that the development of 
tolerance to LPS is specific and may be measured by decreased cytokine release 
(Rietschel et a l, 1982; Johnston and Greisman, 1985; Virca et a l, 1989; Takasuka, 
Tokunaga and Akagawa, 1991; Astiz et a l, 1995). Although a few reports indicated
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non-specificity of the tolerance phenomenon (Gonnella et ah, 1994; reviewed in 
Cavaillon, 1995), the cross-tolerization between toxins of gram-positive and gram- 
negative bacteria has not been demonstrated. Since sepsis or septic shock can be 
mediated through both of these toxins (Stevens, Biyant and Hackett, 1992; Rackow 
and Astiz, 1993; Solomkin and Fink, 1994), the current studies were expanded to 
examine the non-specificity of the tolerance phenomenon and to determine whether 
other mechanism(s) besides cytokines are affected by this process. In addition, 
development of in vivo tolerance in sepsis and septic shock and the behavior of 
monocytes in vitro was examined.
Although MPL has been demonstrated to be less toxic by many parameters,
O x  and H2O2 release by MPL in the present experiments is found to be similar or
greater (respectively) than that released by LPS-stimulated monocytes. However, MPL 
was found to render the cells significantly hyporesponsive to activating stimuli 
compared to LPS. The LPS doses used may have stimulated the cell to release 
maximum amounts of these mediators under the present experimental conditions. This 
is evident by the lack of dose response of its release (Section 3.5, Figure 1). This can 
be supported by previous reports that used much smaller doses (see Section 3.5, 
Discussion). This explanation is applicable to H2O2 as well. However, in the case of
MPL, the increased H2O2 release requires an alternate explanation. It is possible that a 
higher degree of stimulation (i.e., a higher dose) was needed to elicit appreciable 
amounts of H2O2  release in the present experiments (Section 3.1). Alternatively, high
doses of LPS may have inhibited or inactivated SOD that catalyzes the conversion of 
O2 to H2O2 , thus, limiting the formation of H2O2 by LPS-treated monocytes, while in 
MPL-treated cells it remained active without altering the release of H2O2 . It is 
noteworthy that H2O2 release, in comparison to O2 release on a molar basis, in MPL-
treated monocytes was not increased; rather O2 release in LPS-pretreated cells was
relatively decreased. (For details please see Section 3.5, Discussion.). So it becomes
apparent that both LPS and MPL stimulate monocytes at very low doses to release O2
but the concurrent release of some mediators or destruction of some enzymes may 
inhibit or limit the enhanced release of H2O2 by the LPS-treated cells. This is
supported farther by the fact that removal of these stimuli (cell were washed and 
incubated with RPMIc for another 18 hours) caused both LPS- and MPL-treated
monocytes to release similar amounts of either O2 or H2O2 (Section 3.5, Figure 2).
This MPL-mediated enhanced ROIs release in association with NO may explain the 
enhanced non-specific resistance to bacteria- or LPS-challenge observed in mice (Chase 
et a l, 1986; Ulrich, Masihi and Lange, 1988; Henricson et ah, 1990; Rudbach et ah, 
1993; reviewed in Ulrich and Myers, 1995) and the improved bactericidal activities of 
human peritoneal macrophages treated with MPL.m vitro (Carozzi et ah, 1989).
Both LPS and MPL show similar levels of agonist activity in O2 production
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but H2O2 release was higher with MPL. Since tolerance is associated with agonist 
activity, the lack of hyporesponsiveness observed in terms of subsequent H2O2 but not
O2  release in LPS-pretreated, LPS- or PMA-challenged cells suggests that O2  and
H2O2 metabolism in LPS-or PMA-challenged monocytes may be regulated differently
(please see Section 3.5, Discussion). In addition, differences between O2  and H2O2
release in LPS- or MPL-pretreated, PMA-stimulated cells support the concept that LPS 
and MPL modulate respiratory burst activity differently. The mechanism(s) of LPS- or 
MPL-sdmulated ROIs release and development of hyporesponsiveness is not known. 
However, these findings suggest that these differences are related to variations in the 
stimulatory mechanism(s) which lead to the induction of hyporesponsiveness. These 
variations may be modulated (not necessary in this order) by a), differences in cytokine 
release leading to differences in cell priming; b). differential stimulation of the cell 
surface receptors; c). differences in regulatory protein kinetics and gene expression 
regulating monocyte functions.
In addition to the discussion in Section 3.5 on cytokine-mediated ROIs release, 
an additional mechanism is implicated by the present data. LPS-stimulated monocytes 
have produced a significantly higher level of IL-10 (Figure 3.3.1.3). Increased IL-10
release may have decreased the release of O2  and H2O2 in LPS-pretreated monocytes, 
masking differences in O2 release seen by LPS and MPL. Suppression of ROIs by
high levels of IL-10 and stimulation of ROIs by low levels of this cytokine have already 
been reported (Bogdan, Vodovotz and Nathan, 1991; reviewed in Bogdan and Nathan, 
1993; Niiro et ah, 1992). It appears that the lower level of IL-10 released by MPL 
stimulation had minimal effects on MPL-induced ROIs release in the present system. If 
this hypothesis is correct, then MPL-induced hyporesponsiveness to LPS- and PMA- 
challenge seems to be logical. It appears that IL-10 has deactivated the LPS-treated 
cells to release these intermediates suggesting inactivation or loss of internal regulatory 
mechanism(s) which maintain the functional integrity of certain cellular pathways. By 
contrast, MPL-treated cells remained potent, thus regulating their own environment by 
down-regulating the ROIs release in response to further stimulation. Since SEB has
been shown to give a higher level of O2 release as well as a higher degree of
hyporesponsiveness to both LPS and PMA-challenge (Section 3.6, Figures 1 - 4), 
SEB-stimulated cells must not have produced a higher level of IL-10. The IL-10 levels 
in these experiments were not measured. However, subset analysis of the serum IL-10 
of sepsis and septic shock patients in the present experiments showed that patients with 
gram-positive and gram-negative bacterial infection had similar levels of IL-10 (27 ± 7 
pg/ml and 18 ± 9 pg/ml, respectively). It is also possible that ROIs release was 
modulated by TGFp since a similar pattern was found with this cytokine in the same 
patient group (26 ± 2 versus 24 ± 4  pg/ml). TGFp has been shown to selectively 
inhibit H2O2 release (Warwick-Davies, Lowrie and Cole, 1995) that may explain the
differential release of LPS- and MPL-stimulated H2O2  release in the present
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experiments. Studies of ROIs release in monocytes from critically ill patients with or 
without serum supports this concept of mediator-related suppression of ROIs release.
It is noteworthy that LPS tended to release more O2 and less H2O2 than MPL although
the results did not reach statistical significance (Section 3.5, Figure 5). These 
experiments were done only after 90 minutes of incubation where IL-10 and TGFp 
release may not have reached significant amounts to inhibit the ROIs release. It has 
been shown to take 5 - 7  hours for its release (de Waal Malefyt et a l, 1991; reviewed in 
Docke et al., 1994). A similar amount of time has been shown to require to cause 
approximately 15% inhibition of O2  release by monocytes in vitro (Niiro et a i, 1992).
Although data on critically ill patients are not available, cytokine levels in these patients 
in the absence of infection as in the present study did not release significant amounts of 
cytokines (Linda Kirchsenbaum, unpublished data).
Differential stimulatory mechanisms may have resulted in the observed 
differences in receptor expression, cytokine release and subsequent differential 
modulation of monocyte functions. Increased expression of GDI lb/CD 18 and CD45 
have been associated with increased release of H2O2 (Williams et a l, 1995; Liles et al,
1995, respectively). In the present experiments, increased expression of GDI lb  has 
been found in the MPL-treated cells whereas no change was found in the CD 18 
expression (there was a treatment effect between LPS and MPL but expression by 
individual agents was not different from the control). Engagement of CD45 has been 
shown to increase luminol-induced chemiluminescence (H2O2 release) by human
monocytes in vitro (Liles et a l, 1995). This correlation between GDI lb  and CD45 
with increased H2O2  release agrees with these reports and explains the MPL-mediated
up-regulation of ROIs release. Although the mechanisms for LPS- or MPL-induced 
release of ROIs cannot be determined from this study, it becomes apparent that LPS 
and MPL stimulate monocytes differentially either via different receptors or by 
stimulating different numbers of some common receptors. Concurrently, differential 
release of cytokines, specially IL-10, and other mediators like PGE2  act differentially
on the cells through a paracrine mechanism, subsequently down-regulating the release 
of the ROIs.
Differential regulation of LPS and MPL may be mediated also through the 
modulation of CD45 expression leading to the differential release of ROIs. This release 
is augmented by cytokines, especially, TNFa and GM-CSF via a common pathway 
(Liles et a ll 1995). If this postulation is correct, then MPL would produce more H2O2
and LPS would produce more O2 . Note that the MPL-treated group up-regulated both
CD l ib  and CD45 and MPL did not induce TNFa or GM-CSF release whereas LPS
up-regulated CD 18 expression and release of these cytokines. Thus, the findings of the
present experiments support this previous report and fits with the proposed model of
differential ROIs release by LPS and MPL (Liles e ta l,  1995).
The development of tolerance seems to follow a different pathway which has
already been discussed in Section 3.5 (under Discussion) that is restricted to the cellular
224
level. Recently, Abraham (1996) reviewed the molecular mechanism involved in 
inflammatory conditions and critical illness. It was shown that ROIs released by LPS- 
stimulated cells or during sepsis and septic shock may be regulated via an inducible 
transcription factor, NF-kB. Under resting conditions, inactive NF-kB is found in the 
cytoplasm as a complex with an inhibitory unit, IkB oc, IxBp or IxBy. With appropriate 
stimuli, the inhibitory unit is rapidly phosphorylated and proteolyzed causing it to 
dissociate from the NF-kB which migrates to the nucleus. Once there, it binds to DNA 
leading to the transcription of the respective genes. NF-kB has been associated with 
IL-lp, IL-6 , TNFa, ROIs, and NO release (Xie, Kashiwabara and Nathan, 1994; 
reviewed in Burdon, 1995; Abraham, 1996). The limitation of continued up-regulation 
of gene transcription appears to occur through the increased production of IxBa. ROIs 
have been described as potent activators of NF-kB and the activation appears to be 
mediated through the dissociation of LcBa from NF-kB in the cytoplasm in different 
cells. In monocytes and macrophages, NF-kB is phosphorylated upon LPS stimulation 
possibly through the activation of PKC (Ghosh and Baltimore, 1990; Cordle et a l, 
1993). Therefore, it is tempting to speculate that high doses of LPS dissociate the NF- 
kB-IkB to an extent that the IkB become phosphorylated or destroyed whereas in the 
case of MPL, the IkB remains unphosphorylated or maintains a delicate balance with 
the N F-kB. Thus, upon a second stimulation MPL can suppress the NF-KB-mediated 
up-regulation of monocyte function. A transient rise in IkB -a in endotoxin-challenged 
THP-1 cells indicated that the LcB-a may be labile and tolerance is mediated through the
enhanced synthesis of the inhibitor, IxB-a, in these cells (LaRue and McCall, 1994).
These authors suggested that the balance between the repressor and inducer may be lost 
by inhibition of the repressor or limiting the regulatory protein i.e., kinases or 
phosphatases. Since PMA decreases PKC activity in long-term incubations 
(Rodriguez-Pena and Rozengurt, 1984, reported by Vincenti, Burrell and Taffet,
1992), it is possible that inducer activity was down-regulated in both treatment groups 
while MPL-treated monocytes preserved the repressor activity. It can be supported by 
the observation that total ROIs release was much lower when the cells were incubated 
for an additional 18 hours and PMA-stimulated release of these metabolites was 
inhibited in the MPL group (data not shown).
In the present experiments, NO release and iNOS expression have been found
to be up-regulated with MPL. Although iNOS seemed to be increased by LPS in one of
the three methods used (enzymatic method), it did not reach statistical significance. The
possible mechanism(s) and rationale for MPL-mediated NO release has been addressed
(Section 3.7, under Discussion). This discussion will be limited to the relationships of
NO and iNOS release with other mediators and receptor expressions, and their possible
relationship to sepsis and septic shock. MPL is less toxic than LPS, but data from the
present experiment seems paradoxical and therefore needs clarification. NO is released
by cells as a tool to defend themselves in response to a stimulus. It was suggested that
monocytes lack the necessary armature to release large amounts of NO (that has been a
debate for many years) (Dennis, 1994; Dugas et a l, 1995; Konur et a l, 1996) or that
LPS destroys some of the necessary cofactors necessary for NO synthesis (Rogers and
225
Ignarro, 1992; Assreuy et a l, 1993; Weinberg et a l, 1995). None of these questions 
can be answered within the realm of the present experiments, however, these were 
discussed earlier (Section 3.7, under Discussion). Nevertheless, the present data show 
that the monocytes are capable of synthesizing NO but some other mechanism(s) 
regulated (inhibited) the NO release from LPS-stimulated cells. MPL-stimulated release 
of NO supports this concept. Inhibition of NO release by LPS-stimulated monocytes 
may be related to increased IL-10 or PGE2 release (reviewed in Bogdan and Nathan,
1993). IL-10 was significantly up-regulated in LPS-treated cells in the present 
experiments. One could argue that 100 ug/ml MPL also released considerable amount 
of IL-10 yet produced significant amounts of NO. It is noteworthy that IL-10 released 
by this dose of MPL was not statistically different from the control cells (Figure 
3.3.1.3). Furthermore, the literature indicates that a large amount of IL-10 is needed to 
inhibit NO release (reviewed in Bogdan and Nathan, 1993). In murine macrophages, 
low concentrations of IL-10 stimulated H2O2 and NO release whereas high
concentrations of this cytokine down-regulated their release possibly by deactivating the 
cells. It is possible that IL-10-releasing MPL-treated monocytes are still capable of 
regulating their own environment through collaboration with other contributing factors 
(possibly HLA-DR, FOyR, CD45) that enhanced the generation of cytotoxic mediators 
including NO. Although PGE2  was not measured in the present experiments, it is
possible that LPS stimulated the monocytes to release higher amounts of this mediator. 
This can be supported by the observation that septic and septic shock patients were 
found to release increased amounts of this mediator in vivo in the present experiments.
The mechanism by which MPL affects phagocytosis is not known. The present 
data show that MPL increased both ADCC and Ab-indepéndent extracellular lysis that is 
higher than that seen by LPS. This increase may be related to the increased H2O2  and
NO release by MPL-stimulated monocytes. Although general consensus regarding 
H2O2- and NO-mediated cytolysis does not exist (Espevik and Nissan-Meyer, 1986;
Todd et al., 1984; van de Winkel et al., 1989; Schwamberger Flesch and Berber, 1991; 
Augur and Ross, 1992; Li et al., 1995), a parallel between H2O2  and NO release and
cytolysis suggests this possibility. The synergistic effects of H2O2 and NO can be
further justified by the failure of LPS-stimulated cells to show ADCC despite significant 
release of H2O2 . This concept agrees with previous reports (Adams et al., 1981;
Espevik and Nissan-Mayer, 1986; Liesveld et al., 1991). One could argue that these 
observations indicate that MPL showed greater stimulation of monocytes than LPS. In 
the absence of any alternative explanation, and based on the present data, it can be 
speculated that LPS exerted an inhibitory effect on the immune system whereas MPL 
showed a stimulatory response' A negative correlation between NO production and IL- 
10 release (p<0.01) suggests the inhibitory effects of LPS on NO release that agrees 
with earlier reports (reviewed in Bogdan and Nathan, 1993). The low-dose stimulation 
and high-dose inhibition of cellular functions is an indication of toxic response when 
cells approach death as a consequence of toxic effect mediated by high dose. The
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absence of LPS-mediated cytolytic activity in LPS-treated monocytes may represent a 
paralysis of a selective monocyte immune function by LPS, thus, it can be inferred that 
LPS is toxic while MPL is less toxic than LPS.
Decreased extracellular adhesion was seen in the MPL-treated cells whereas no 
change was seen with the LPS group. The data indicated that this decreased adhesion 
may be the result of efficient and increased lysis of RBCs by the monocytes (discussed 
in Section 3.2.2). The lack of consistent differences in the expression of adhesion- 
related receptors in either the LPS or MPL group negates the possibility of differential 
adhesion of RBCs to the monocytes. The observed slight increase in expression of 
CD 16 in the LPS-treated group, although statistically non-significant, may lend weight 
to the observation that CD 16 mediated cellular adhesion whilst not triggering cytolysis 
(Klaassen et al., 1990). Activated monocytes showing increased ADCC resulting from 
increased binding of antibody-coated RBCs in v/Zro agrees with the work of Todd et 
al., (1984). The increased C D llb  expression by the MPL-treated group and increased 
CD 18 in the LPS group may indicate the possibility of increased adhesion as suggested 
earlier (Wright et al., 1989; 1989a; Golenbock et al., 1990). However, a later report 
refuted the claim that these receptors are involved in cell binding, since inhibition of the 
functional sites of C D llb  or CD 18 did not show any decrease in ADCC (Liesveld et 
al., 1991). It is possible that extracellular lysis may also be mediated without binding 
i.e, mediated by soluble mediators (Yamauchi et al, 1989; Nissen-Meyer, Espevik and 
Austgulen, 1988; reported by Liesveld et al., 1991). Nevertheless, data from the 
present experiment suggests that increased CD1 lb in the MPL group caused increased 
adhesion, thus initiating increased ROIs release which caused increased lysis of the 
RBCs resulting in decreased net adhesion. This phenomenon of CD11-mediated 
respiratory burst has been reported (Trezzini et al., 1991). Although IL-10 has been 
shown to suppress many immune functions, it did not show any effect on 
CDllb/CD18 expression on human monocytes (de Wahl Malyafyt, 1991a; Spinier et 
al., 1995). The decreased cellular adhesion in the MPL group indicated that a decreased 
number of cells was available for phagocytosis by the MPL-treated monocytes. By 
contrast, increased binding of RBCs in the LPS-treated group indicated the availability 
of an increased number of RBCs for phagocytosis by the LPS-treated monocytes.
Indeed, LPS-stimulated monocytes exhibited increased phagocytosis while 
MPL did not, supporting the hypothesis that MPL is less stimulatory than LPS.
Based on the present data it can be postulated that LPS stimulates monocytes to release 
H2O2 and IL-10, and increased IL-10 subsequently limits or inhibits further release of 
H2O2 . At the same time, LPS stimulates expression of CD 16 (and possibly CD32 and
CD64) and CD 18, thus, increasing RBC binding to the monocytes and making more 
RBCs available for phagocytosis. On the other hand, MPL also stimulates H2O2  and 
NO release from monocytes, but low levels of IL-10 do not limit the release of H2O2  as 
evidenced by its significantly higher release than LPS. Thus, the H2O2  and NO
synergistically cause lysis of RBCs, subsequently decreasing the available RBCs for 
phagocytosis. Although increasing the number of RBCs increased extracellular lysis,
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the MPL treatment did not enhance monocyte-phagocytosis of RBCs. In addition, 
since CD45 has been associated with inhibition of the CD32- and CD64-mediated 
intracellular signaling pathway (tyrosine phosphorylation leading to calcium 
mobilization) in the THP-1 monocytic cell line (Rankin et a l, 1993), it is possible that 
CD45 down-regulated CD32- and CD64-mediated functions in MPL-treated 
monocytes. Present data show that CD45 is up-regulated in MPL-treated cells and 
LPS-treated monocytes did not show any change in CD45 expression. This may 
explain the LPS-stimulated phagocytosis that may have been facilitated by increased 
binding and up-regulation of CD32- and CD64-mediated functions. CD 16 tended to be 
increased and CD 18 was significantly greater with LPS-treated monocytes which may 
represent increased binding. Although CD16 mediates ligand attachment and 
phagocytosis, it does not initiate phagocytosis (Clarkson and Ory, 1988) suggesting 
that additional mechanisms are involved in triggering this process. Later, phagocytosis 
of IgG-coated sheep RBCs by human monocytes in vitro, even in the presence of 
blocking antibody to FcyRI and FcyRII (Casado et a l, 1994) implicates the binding of 
the particulate materials through CD 16 and triggering of the phagocytosis by additional 
mechanism(s). Recently Worth et al., (1996) showed that fibroblasts transfected with 
CD 1 lb/CD 18 and CD32 enhanced binding and phagocytosis whereas cytoplasmic tail 
deficient mutant CD32 (FcyRUa) transfected cells were unable to phagocytose IgG- 
coated sheep RBCs. Because binding was unaffected with cells, expressing mutant 
CD32 and phagocytosis was enhanced in the presence of CD 1 lb/CD 18 molecule, it 
was suggested that these molecules can transduce a phagocytic signal generated by 
CD32. IL-lp, IL-10, TNFa, GM-CSF, or G-CSF were increased in LPS-treated 
groups. All of these cytokines have been demonstrated to be associated with increased 
phagocytosis (Capsoni et a l, 1995; Ren and Savill, 1995; Spittler et a l, 1995; 
Kitagawa et al., 1996). Therefore, it is possible that increased phagocytosis in LPS- 
stimulated monocytes may be mediated through these cytokines. IL-10 has been 
shown to up-regulate CD64 expression on monocytes (te Velde et a l, 1992; Bogdan 
and Nathan, 1993; Spittler et al., 1995) while no changes were found in the expression 
of FcyRII and FcyRIII (te Velde et al., 1992; Spittler et al., 1995), thus the increased 
IL-10 release in the LPS-treated monocytes indicate the possibility that phagocytosis 
was mediated by FcyRI. Nevertheless, studies in COS-1 cells transfected with FcyRI 
and FcyRII have shown that FcyRII mediated both binding and phagocytosis of IgG- 
sensitized RBCs whereas FcyRI receptor mediated only the binding (Indik et al.,
1991). Because increased CD 16 expression in LPS-treated cells was not statistically 
significant, increased phagocytosis in these cells cannot be attributed to CD 16. 
However, it seems reasonable to speculate that phagocytosis in the present experiments 
was mediated through a collaborative effort of all three phagocytosis receptors with 
possible association with CD 18 molecules. The study to determine the involvement of 
the specific monocyte receptors in phagocytosis is being planned.
Data on cytokine release has shown a consistent pattern that MPL did not 
stimulate monocytes to release significant amounts of IL-la, IL-lp, IL-6 , TNFa, sDL- 
2r and GM-CSF, G-CSF compared to LPS. Since MPL is less stimulatory than LPS,
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it was expected that MPL would stimulate monocytes to release lesser amounts of 
cytokines compared to LPS-stimulated cells. Data from the present experiments agree 
with the general consensus. Although MPL released a considerable amount of IL-10 at 
1 0 0  ug/ml, it was not significantly different from control cells and the overall release 
was significantly lower than the LPS group. In addition, sIL-2r and immunoreactive 
IL-1 was significantly higher in the LPS group. These data clearly indicate that MPL is 
less efficient in stimulating cytokine release compared to LPS. No significant change 
was found with sIL-6 r and IL-Ira. Increased immunoreactive IL-1 in the LPS-treated 
monocytes indicated its stimulatory nature. The high dose suppression can be 
explained by the release of IL-10. ILrlO has been shown to inhibit IL -1 release by 
murine macrophages (reviewed in Bogdan and Nathan, 1993) and to inhibit LPS- 
stimulated release of both IL -lp  and TNFa in vitro in human whole blood preparation 
(Chemoff et al., 1995). It is possible that immunoreactive IL-1 was down-regulated by 
high levels of IL-10 that may represent an auto-regulatory mechanism to protect the 
host. In addition, MPL-stimulated release of IL-10 suggests the non-toxic, yet 
immunomodulatory property of MPL. Here this author reports for the first time that 
MPL- stimulated release of IL-10 may modulate monocyte immune functions such as 
extracellular lysis, extracellular adhesion and phagocytosis. Since IL-10 may be 
inhibitory to many monocyte functions, it may appear that IL-10 inhibited LPS- 
mediated RBC lysis by inhibiting H2O2 and NO. On the other hand, IL-10 may have
increased phagocytosis by increasing binding through CD 16 expression in association 
with CD 18 LPS mediated the up-regulation of phagocytosis, possibly as a result of 
increased monocyte expression of FcyRII receptors in association with increased 
release of IL-lp, TNFa, GM-CSF, G-CSF and other mediators. Thus, it appears that 
phagocytosis-related activity is a complex interplay of multiple systems that has been 
carefully orchestrated. Additional work has already been planned to understand the 
mechanisms involved in LPS-mediated phagocytosis in human monocytes.
As with previously published data (discussed in Section 1.14), consistent data 
showing LPS-stimulated receptor expression in monocytes was not found in the present 
experiments. Multiple factors have been thought to be responsible for these variations 
such as the use of different cell lines, dose of stimulant, duration of exposure, 
maturation stage of the cells, co-stimulatory agents, the use of different antibody and 
techniques. In the present study, four different responses have been found: a). LPS 
up-regulated certain receptor expression compared to MPL (CD 18 and CD25); b). MPL 
up-regulated some receptor expression compared to either control or LPS (CD1 lb and 
CD45); and c). MPL up-regulated or down-regulated depending upon the techniques 
used (CD 14 and HLA-DR); d). neither LPS nor MPL showed any significant change in 
the receptor expression (CD 16 and CD71). The importance and physiological relevance 
of these receptors have been described throughout the text.
CD 18 may bind with CD54 and is involved in the non-specific recognition of 
antigens (Golenbock et a l, 1990; Wright et a i, 1989), oxidative burst response 
(Trezzini et a l, 1991) and TNFa release from monocytes {Wright et a l, 1990; 
Couturier et a l, 1992). CD25 molecules are involved in T-cell growth by providing a
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co-stimulatory effect and were found to be expressed on LPS-stimulated monocytes 
(Hoiter et c i ,  1987; Wahl et al., 1987; Kniep, Strelow and Lohmann-Mathes, 1992; 
Scheibenbogen et al., 1992; Grey et a i, 1993). Although its physiological role is not 
clearly understood, LPS-stimulated monocytes have been shown to express CD25 that
was associated with IL-2-mediated enhanced 0% release in vitro (Wahl et al., 1987).
Present findings that LPS stimulated monocyte expression of this receptor agree with 
these reports. MPL-stimulated cells did not show any increased expression suggesting 
that MPL is less stimulatory than LPS. The role of CD45 in monocytes is not clear; 
however, in other leukocytes it has been linked to the activation of tyrosine 
phosphatase. The increased expression of these receptors on MPL-stimulated cells may 
explain the MPL-stimulated up-regulation of ROIs release. CD45 has been shown to be 
involved in the up-regulation of luminol-induced chemiluminescence (H2O2  release) in
human monocytes in vitro already explained above (Liles et a l, 1995). CD45-mediated 
down-regulation of CD32 and CD64 expression has also been described (Rankin et a l,
1993). Lack of a significant difference between LPS and MPL in CD 16 expression 
may have resulted from proteolytic cleavage and subsequent shedding of CD 16 
receptors from the LPS-stimulated monocytes (Capsoni et a l, 1994). The lack of 
change in the expression of CD71 is not surprising, indicating similarity between MPL 
and LPS stimulatory pathways regarding maturation response in vitro.
Septic shock has been described as an immune disorder when the balance 
between the reactive mechanisms and the protective mechanisms has been lost 
(reviewed in Natanson et a l, 1994; Bone, 1996). In addition to the release of pro- 
inflammatory cytokines, the release of anti-inflammatory cytokines and other mediators 
in sepsis and septic shock has been presented. This includes up-regulation of IL-4, IL- 
10, TGFp, PGE2 , sTNFr, IL-lra and the list is growing. Consequently, the pro-
inflammatory cytokines, mediators and receptors involved in inflammation will be 
down-regulated to ameliorate the inflammatory response to protect the host from 
additional stimuli (continuous stimulation from the existing mediators or new stimuli 
from the immediate environment). If this hypothesis is correct, it would be reasonable 
to postulate that, upon receiving a stimulus, the body's innate mechanism will try to 
eliminate it, i.e, the monocytes will up-regulate their defensive armature. This includes 
up-regulation of pro-inflammatory cytokines, adhesion molecules, ROIs, RNIs and 
phagocytosis-related activities. Concurrently, the anti-inflammatory cytokines can also 
be up-regulated as has recently been documented (Natanson et a l, 1994; reviewed in 
Bone, 1996). In addition, down-regulation of pro-inflammatory cytokines or their 
mRNA following a second stimulus in vivo or in vitro has been reported by many 
(Greisman, 1983; Johnston and Greisman, 1985; Zuckerman et ai., 1989; Virca et a l, 
1989; Haas et a l, 1990; Mathison et a l, 1990; Takasuka, Takunaga and Akagawa, 
1991; Fahmi and Chaby, 1993; Granowitz et a l, 1993) and is confirmed in the present 
experiments. These findings suggest a protective mechanism in response to 
overwhelming stimulation to protect the host (tolerance or hyporesponsiveness).
Thus, it is reasonable to speculate that in an overwhelming stimulation or in sustained
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stimulation (presence of infections or toxins), the monocytes will go through a 
transition period to cope with the situation that must be mediated through an initial up- 
regulation followed by a down-regulation of the associated mediators, cytokines or 
receptors. In the present experiments, significant differences between LPS and MPL- 
mediated CD 14 and HLA-DR expressions were seen but the mean fluorescence and 
percentages of positive cells were found to be in the reverse direction. Increased or 
decreased expression of these receptors have been reported with no general consensus 
(discussed above). This may represent the spatial (dose-dependent) regulation of these 
mediators, leaving room for speculation of a compensatory mechanism that may be 
referred to is auto-regulation. The present data suggest that stimulus-induced 
expression of these receptors is auto-regulated through a complex compensatory 
mechanism involving a receptor-cytoldne-mediator mechanism. This can be supported 
by the fact that low-dose or short-time stimulation increased CD 14 expression (Appel et 
a i, 1989; Couturier et al., 1992; Schumann et al,, 1990), CD 1 lb/CD 18 (McLeish, 
Wellhausen and Dean, 1987; McLeish ef a l, 1989) and HLA-DR expression (McLeish, 
Wellhausen and Dean, 1987; Wahl et a l, 1987; McLeish et al., 1989) in monocytes 
and, arguably, this may be the early response to a stimulus (increased percentages of 
positive cells) which would be followed by increasing the receptor density per cell 
(increased mean fluorescence). Thus, the percentage of positive cells would be 
expected to be increased by a short exposure or by a low dose stimulus. Indeed, MPL 
increased the percentage of positive cells (CDllb, CD 14) while LPS did not in the 
present experiments, reflecting the initial up-regulation and suggesting that MPL is less 
stimulatory than LPS. In addition, the decreased mean fluorescence in the MPL-treated 
group reflects the low level of expression in a large percentage of cells. The fact that no 
change was seen with the LPS-treated cells may reflect a transitional phenomenon 
because high expression of CD 14 is down-regulated by shedding of the receptors from 
the cell surface, producing sCD14 (Bazil and Strominger, 1991; Birkenmaier, Hong 
and Horn, 1992; Jack et al., 1995; reviewed in Fearon and Locksley, 1996). In 
addition, the initial increase after 12 hours followed by a decrease of HLA-DR 
expression after 24 hours has been observed by Wahl et al., (1987). In the present 
experiments, HLA-DR expression was down-regulated in both LPS- and MPL-treated 
cells, indicating the inhibitory effects of these agents on HLA-DR molecule expression. 
Since an 18-hour incubation was used in these experiments, down-regulation of this 
receptor was to be expected. This finding also agrees with earlier findings that NO 
release is related to HLA-DR expression in human monocytes (Siedlar et al., 1995). 
Thus, it fits.with the model that MPL-stimulated cells showed increased HLA-DR 
expression and increased NO release whereas LPS failed to show a similar effect. The 
MPL-stimulated increase in receptor density, on the other hand, suggests an auto- 
regulatory mechanism of the body's innate immune system. This is in agreement with 
the explanation given for CD 14 expression. It appears that LPS decreases HLA-DR 
expression and cannot respond to stimuli, thus decreasing the antigen presentation 
capacity of MPs, whereas MPL-stimulated cells are competent to carry out this function 
due to increased receptor density. IL^IO has been shown to down-regulate macrophage
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antigen presentation and to suppress both constitutive and IFNy- or IL-4- induced 
expression of HLA-DR (reviewed in Bogdan and Nathan, 1993; Spittler et a l, 1995) 
subsequently inhibiting antigen-specific T-cell proliferation and IFNy production of 
lymphocytes (reviewed in Docke et a l, 1994; de Wahl Malefyt et a l, 1991a).
Because sepsis and septic shock are predominantly caused by bacterial 
infection, it was decided to examine whether the tolerance observed in vitro occurs in 
vivo in patients with these ailments. Monocytes from sepsis and septic shock patients
were shown to spontaneously release increased amounts of Ox  which was down-
regulated upon challenge. Increased release of O2 by human monocytes from surgical
patients has been presented (Tanjoh et a l, 1995) that is in accord with the present 
findings. The authors of the present studies further report that monocytes from sepsis
and septic shock patients down-regulate O2 release in response to a second stimulus.
These findings are consistent with LPS-pretreated and either LPS or PMA-stimulated 
monocytes in vitro (Sections 3.5, Results and 3.6, Results). This phenomenon has 
been demonstrated by cytokine release from monocytes of patients with sepsis and 
septic shock (Munoz et a l, 1991; Ertel et a l, 1995; Randow et a l, 1995) and normal 
subjects infused with LPS (Rodrick et a l, 1992) and confirmed in the present 
experiments (Section 3.8, Results), but here this author reports that ROIs are also
involved in the tolerance phenomenon. The impaired O2 release from monocytes in
response to stimuli suggests a generalized hyporesponsiveness to stimuli in these 
patients that parallels the finding of the LPS-pretreated and challenged monocytes in 
vitro (Section 3.6, Figures 2 ,4  and 5). This finding may explain the higher incidence 
of infections and the development of sepsis and septic shock in patients with trauma, 
even with antibacterial therapy that was recently referred to as compensatory anti­
inflammatory response syndrome (Bone, 1996). Moreover, when the patients
approach recovery, their monocytes regained the (^-producing capacity as evidenced
by the release of significant amounts of O2 in response to different stimuli when
compared to monocytes from normal volunteers (Section 3.6, Figure 8 ). These 
findings parallel those of TNFa and IL-lp release from sepsis and septic shock patients 
in the present experiments (Section 3.8, Figures 1 and 2). This generalized hypo­
responsiveness, which involves various aspects of monocyte activity, is pivotal for 
modulation of the inflammatory response during severe infection. It appears that this 
phenomenon may, in part, be related to the up-regulation of anti-inflammatory 
cytokines and mediators that has been reported earlier (for review please see Bogdan 
and Nathan, 1993; Ziegler-Heitbrock, 1995) and confirmed in the present experiments. 
IL-10, PGE2 and TGFp were found to be increased in vitro and in vivo, in LPS-
stimulated cells, and in patients with sepsis and septic shock, respectively (Haas et a l, 
1990; Takayama, Miller and Szabo, 1990; Ertel et a l, 1991; Miller-Graziano e ta l,  
1991; Bjork et a l, 1992; Marchant et a l, 1994; Gomez-Jimenez et a l, 1995; Randow 
et a l, 1995). It has been indicated earlier that these metabolites down-regulate ROIs
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release (reviewed in Bogdan and Nathan, 1993; Warwick-Davies, Lowrie and Cole, 
1995). The hyporesponsiveness observed in these patients may have been modulated 
through these cytokines. However, the mechanism(s) by which these cytokines are 
regulated is not known, but down-regulation or blockade of the specific receptors and 
inactivation or elimination of the stimulants have been suggested (Ziegler-Heitbrock,
1995). However, this author affirmed that it is not a passive process that occurs in 
exhausted cells and appears to be regulated in a similar fashion to ROIs release
(Abraham, 1996) as described above, possibly by binding of the NF-kB to the
promoter region of the specific genes, thus blocking the transactivation (Ziegler- 
Heitbrock, Frankenberger and Wedel, 1995; Ziegler-Heitbrock, 1995).
In the present experiments, development of hyporesponsiveness was seen with 
both LPS and SEB and the monocytes were tolerant to LPS-, SEB- and PMA- 
challenge. These findings suggest that development of hyporesponsiveness in these 
cells under the present experimental conditions was not specific and agree with earlier 
suggestions (Gonnella, 1994; reviewed in Cavaillon, 1995). The results also show 
that, in addition to the release of pro-inflammatory cytokines, an anti-inflammatory 
cytokine and an anti-inflammatory mediator are also released. These findings are in 
agreement with previous reports (reviewed in Bogdan and Nathan, 1993; Haas et al, 
1990; Ertel et al., 1991; Bjork et al., 1992; Pinsky et al., 1993; reviewed in Bone,
1996). In addition, the data indicate that these changes are not specific for gram- 
negative bacterial infections as has been thought for many years (Greisman, 1983; 
Mathison et al., 1990). Data indicate that the gram-positive bacterial toxin (SEB)
releases higher levels of O2 than LPS, but produces a similar level of tolerance in
response to LPS or SEB challenge, suggesting non-specificity of the tolerance 
phenomenon and cross-tolerization between gram-positive and gram-negative bacteria 
or their toxins. In response to PMA, both LPS and SEB showed hyporesponsiveness
to 0% , further substantiating the non-specificity of the tolerance phenomenon (Section
3.6, Figures 4 and 5). Similar findings were found with monocytes from patients with 
severe sepsis and patients with septic shock during acute infection. This 
hyporesponsiveness did not occur during recovery when monocytes regained the ability
to release O2 in response to either LPS, SEB or PMA. These findings extend our
understanding of the tolerance phenomenon to include ROIs release in addition to 
cytokine release. Analysis of the data based on the type of infection (gram-positive or 
gram-negative) indicate a similarity in cytokine induction by either type of infection 
(Section 3.8, Table 2). These findings suggest that cytokine release is a non-specific 
response that prompting this author to examine if tolerance also exists in gram-positive 
bacterial infections and if the tolerance phenomenon is specific. Non-specificity of the 
tolerance phenomenon and cross-tolerization was demonstrated by cytokine release 
(Section 3.8, Figures 1 and 2). TNFa release was found to be down-regulated in 
response to LPS, SEB and PMA in monocytes from patients with severe sepsis and 
patients with septic shock, confirming the development of tolerance in vivo. A  similar
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result was found with IL-lp release. LPS tolerance is generally described as resistance 
to LPS resulting from a recent prior exposure to LPS and it does not include resistance 
to gram-positive organism or their toxins (Greisman, 1983; Mathison et a l, 1990).
Here this author reports, consistent with recent suggestions (Ziegler-Heitbrock, 1995; 
Cavaillon, 1995) that the tolerance phenomenon can be developed in gram-positive 
toxins and it is not specific for the antigen involved. The underlying mechanism of 
tolerance development in these toxins may be due to the similarity of the inflammatory 
response generated by these toxins despite their structural differences (Pinsky et a l, 
1993; Bjork et a l, 1992). This can be supported by the observations that both groups 
of patients (with gram-negative or gram-positive infections) showed similar levels of 
both pro- and anti-inflammatory mediator release in their serum in the present 
experiments. Thus, these findings will help modify the treatment strategy to accept a 
broader approach and not to confine the treatment against only gram-negative organisms 
and their toxins. In addition, to define a strategy to overcome these obstacles, one must 
realize that tolerance may be detrimental for the host, therefore, a distinction between 
tolerance and immunosuppression must be made. Although not clearly understood, 
available data suggest that, in tolerance, the cells remain potent and down-regulate pro- 
inflammatory functions through an internal homeostatic mechanism(s) to protect the 
host. Arguably, the anti-inflammatory cytokine will maintain a delicate balance with the 
pro-inflammatory components of the cellular functions (Frankenberger, Pechumer and 
Ziegler-Heitbrock, 1995; Ziegler-Heitbrock, 1995; Bone, 1996), but this is yet to be 
determined. It is evidenced by the observations that the tolerance can be broken 
(Henricson et a l, 1992: Matic and Simon, 1992) or preempted (Haas et a l, 1990;
Matic and Simon, 1990; Frankenberger, Pechumer and Ziegler-Heitbrock, 1995) or 
tolerant cells could be stimulated for increased bactericidal activity (Carozzi et a l, 1989) 
using appropriate stimulations in vitro. It is generally believed that tolerance is 
beneficial for the host, however, when induced before sepsis occur and it is non­
specific. On the contrary, immunosuppression is detrimental to the host as it results 
from dysfunctions (immunoparalysis; Volk et a l, 1991) of specific cellular functions 
(Docke et a l, 1994). Nevertheless, if in sepsis and septic shock it is reversible, then 
the determining factors for this condition need to be examined. Since both tolerance 
and immunosuppression are associated with up-regulation of anti-inflammatory 
cytokines and mediators (Miller-Graziano et al., 1991; Docke et a l, 1994; 
Frankenberger, Pechumer and Ziegler-Heitbrock, 1995), a careful consideration should 
be placed on the balance between the pro-inflammatory and anti-inflammatory 
mediators, and other immune regulatory machinery. Unpublished data from our 
laboratory (Mark E. Astiz, unpublished observation) in monocytes from sepsis and 
septic shock patients show two forms of responses in response to a stimulus that could 
be attributed to cellular dysfunction; a), a tolerance-like phenomenon where the cells 
down-regulate pro-inflammatory functions; b). up-regulation of either or both pro- 
inflammatory or anti-inflammatory functions. If the former observation is tolerance, the 
cellular integrity is maintained and the host will respond to appropriate stimulation. 
Intervening at this stage to increase pro-inflammatory function and to down-regulate
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anti-inflammatory function may be beneficial (Docke e ta l,  1994). Human patients 
with pneumonia have been shown to develop tolerance (Dehoux et a l, 1994) and 
human patients with bilobal pneumonia receiving G-CSF have been shown to increase 
bacterial clearance, decrease the incidence of MOF, improve recovery time (Steve 
Nelson, unpublished data from clinical trial). On the other hand, in the latter situation, 
immune stimulation may be detrimental because of the uncertainty of the immune status 
of the host. Because the observed response to a stimulus may reflect breaking of 
tolerance or cellular dysfunction (loss of homeostasis leading to uncontrolled 
expression of some cellular function), immune stimulation in this situation may cause 
loss of the cellular integrity, and thus will be detrimental to the host.
Taken together, it can be summarized that MPL is less toxic than LPS as 
evidenced by the decreased release of pro-inflammatory and anti-inflammatory 
cytokines, ?nd controlled ROIs release in MPL-treated monocytes. Results suggest that 
LPS and MPL stimulate monocytes via similar pathways, but the increased toxicity of 
LPS may be mediated through stimulation of additional pathways, possibly through cell
surface receptors. Data also suggest that O2 and H2O2 release in LPS- and MPL-
stimulated monocytes are differently regulated. MPL-stimulated monocytes are found 
to release NO through a novel mechanism that is yet to be determined. Further evidence 
of the attenuated toxicity of MPL comes from the tolerance experiments which show 
that both LPS and MPL can induce hyporesponsiveness to LPS and PMA whereas 
MPL shows a higher degree of hyporesponsiveness, suggesting that MPL-treated 
monocytes are able to control their own environment while LPS-treated cells cannot. 
Analyses of the variable degrees of phagocytosis-related activities and receptor 
expression suggest the existence of a time- and dose-dependent compensatory 
mechanism. Time-dependent variations in FcyRIII expression and phagocytosis by 
human monocyte-derived macrophages have already been documented (Liao and 
Simon, 1994). The findings of the present experiments support the concept that a 
lower degree of stimulation occurs in MPL-treated monocytes as evidenced by absence 
of phagocytic stimulation and increased expression of HLA-DR molecules in these 
cells. It was found that both LPS and SEB can induce tolerance to specific or non­
specific stimuli. Extension of this study using monocytes from patients with severe 
sepsis and patients with septic shock revealed that sepsis and septic shock induce
hyporesponsiveness in vivo to activating stimuli in vitro that includes O2 , and
cytokines, suggesting a generalized immune suppression in sepsis and septic shock. 
The development of hyporesponsiveness in vivo during sepsis and septic shock is non­
specific and cross-tolerization in vitro occurs in human monocytes. However, 
determining the mechanisms of LPS-, MPL- or SEB-mediated tolerance or if this is 
reversible, warrant further studies.
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APPENDIX
Names and addresses of the manufactures or suppliers of 
instruments and chemicals
BioSource International 
950 Flynn Road, Suite A 
Camarillo, CA 93012 
USA
Abacus Concepts, Inc. 
1984 Bonita Ave. 
Berkeley, CA 94704 
USA
Accurate Chemical Co.
300 Shames Drive 
Westbury, NY 11590 
USA
AMAC Inc.
160B Larrabee Road 
Westbrook, ME 04092 
USA
Baxter Scientific Products 
100 Raritan Center Parkway 
Edison, NJ 08818 
USA
Beckman Instruments 
1050 Page Mill Road 
Palo Alto, CA 94304 
USA
Becton Dickinson 
P.O. Box 243 
Cockeysville, MD 21030 
USA
Bellco Biotechnology 
340 Edrudo Road 
Vineland, NJ 08360 
USA
Bio-Tek Instruments 
Highland Park, Box 998 
Winooski, VT 05404-0998 
USA
CDC Technology 
One Great Hill Road 
Oxford, CT 06478 
USA
Cedarlane Laboratories 
5516 8th Line, R.R. 2 
Hornby, Ontario LOP 1E0 
Canada
Costar
One Alewife Center 
Cambridge, MA 02140 
USA
Coulter Corp.
11800 South West, 147 Avenue 
Miami, FL 33196-2500 
USA
Fisher Scientific 
52 Fadem Road 
Springfield, NJ 07081 
USA 
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GIBCOBRL 
P.O. Box 68
Grand Island, NY 14072-0068 
USA
Hausser Scientific 
935 Horsham Road, Suite C 
Horsham, PA 19044 
USA
Heat Systems 
1938 New Highway 
Farmingdale, NY 11735 
USA
HyClone Labs 
1725 South HyClone Road 
Logan, UT 84321 
USA
ICN
3300 Hyland Ave.
Costa Mesa, CA 92626 
USA
Immunotech International 
160B Larrabee Road 
Westbrook, ME 04092 
USA
Innogenetics
Canadastraat 21, Haven 1009 
B-2070 ZWUNDRECHT 
Belgium
Jouan Inc.
R.R. 12, Box 104 
Winchester, VA 22601 
USA
KPL, Inc.
2 Cessna Court 
Gaithersburg, MD 20879 
USA
New York Blood Bank 
150 Amsterdam Avenue 
New York, NY 10023 
USA
PerSepdve Diagnostics 
735 Concord Ave. 
Cambridge, MA 02138 
USA
Pharmacia
800 Centennial Avenue 
Piscataway, NJ 08855-1327 
USA
Precision Scientific 
3737 W. Cortland. Street 
Chicago, IL 60647 
USA
R & D Systems 
614 McKinley Place N.E. 
Minneapolis, MN 55413 
USA
RIBI Chemicals 
P.O. Box 1409 
Hamilton, MT, 59840 
USA
Sigma Chemical Co.
P.O. Box 14508 
St. Louis, MO 63178 
USA
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Transduction Laboratories Virion
2134 Nicholasville Rd., Suite 18 Wuerzburg
Lexington, KY 40503 Germany
USA
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